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ABSTRACT
This research thesis aimed to explore the apparent dichotomy of ecstasy (MDMA) users who 
report cognitive and psychopathological problems which they attribute to their use of this 
drug ("problematic" users), and those who report no adverse ecstasy-related effects ("non- 
problematic" users). In the first study, possible psychological sequalae linked to past ecstasy 
use were assessed in problematic and non-problematic ecstasy users using the modified Brief 
Symptom Inventory, aspects of the Rivermead Behavioural Memory Test, Tower of London 
and Auditory Verbal Learning Task. Problematic ecstasy users displayed higher 
psychopathological symptoms and a small number of selective cognitive deficits compared to 
non-problematic ecstasy users and polydrug controls. However, problematic ecstasy use did 
not appear to be related to patterns of ecstasy use or polydrug use. Using the same 
assessment measures, a case study based on a heavy problematic ecstasy user (RW), who had 
been abstinent for seven years, was presented. RW displayed cognitive deficits and extensive 
psychological problems suggesting that heavy ecstasy consumption may be associated with 
irreversible problems. The persistence of possible psychological and cognitive problems was 
further investigated in the second group study, using the same battery of tests. However no 
significant differences in cognitive and psychopathological performances were found between 
polydrug controls, current and ex-ecstasy users. It is argued that impairments in performance 
were possibly masked by poor cognitive performance in polydrug controls. The validity of 
the polydrug control group was addressed (in the third study) by assessing 20 drug-naive 
participants on the same measures. The introduction of a drug-naive control group only 
suggested that problematic and non-problematic ecstasy users were exhibiting more errors on 
the Tower of London task compared to polydrug and drug-naive controls. The final study 
assessed psychopathological symptoms in problematic and non-problematic ecstasy users 
relative to drug-naive and polydrug controls, and explored factors which may be integral in 
the development of problematic ecstasy use, including certain pre-existing factors. Users 
were assessed on the BSI and Locus of Control scale. Pre-existing psychiatric histories, the 
intensity of ecstasy dosing and the role of polydrug use in relation to ecstasy use, appeared to 
contribute in higher psychopathological symptoms in problematic ecstasy users. Together 
these studies suggest that only self-reported problematic ecstasy users consistently display 
cognitive and psychopathological problems. For these vulnerable individuals the intensity of 
ecstasy use, patterns of other drug use and pre-existing psychiatric histories are thought to 
contribute to the development of these problems.
Ill
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CHAPTER 1
The History. Culture and Chemistry of MDMA (Ecstasy)
Kirstie Soar Chapter 1
HISTORY OF MDMA/ECSTASY
3,4-methlyenedioxymethamphetamine (MDMA) was first synthesised and patented by Merck 
in 1914. Many believe it was patented as an appetite suppressant, but according to Holland 
(2001) there was no use mentioned for MDMA within this patent application and such claims 
probably arose from MDMA's chemical cousin MDA (3,4-methlyenedioxyamphetamine), 
which was patented by SmithKline French in 1958 and tested as an appetite suppressant in 
humans.
MDMA was never marketed due to the lack of commercial interest and therefore did not 
become available on the public market. It resurfaced briefly during the 1950's, in a 
toxicological and behavioural report from a study conducted by the US Army Chemical 
Centre when they secretly tested a number of psychoactive chemicals for military application 
(Shulgin & Nichols, 1978). It was not until 1976, that Alexander Shulgin synthesised 
MDMA and suggested its potential use in psychotherapy (Holland, 2001). From Shulgin's 
experiences, it was suggested that MDMA's subtle mood modifying characteristics could be 
used as a adjunct to psychotherapy, with the strengthening of the therapeutic alliance by 
enhancing trust, freeing patients from defensive anxiety and making them more emotionally 
open. Its success in fostering introspection and verbalisation during therapy led to a slow 
spread of its use in underground psychotherapeutic work in the late 70s and early 80s (Greer 
and Tolbert, 1986). The drug's ability to alter consciousness and induce such subtle mood 
changes leaked out of the therapeutic community, and as a result MDMA was being used 
amongst students throughout the US under its new name ecstasy.
In 1977 MDMA and other similar psychedelic amphetamines such as MDA and MDEA (3,4- 
methlyenedioxyethylamphetamine) were listed as class A drugs under the Misuse of Drugs 
Act 1971, in the United Kingdom (UK). In the United States (US) the drug was still legal 
until the mid 1980s. However due to numerous reports of misuse in conjunction with a 
widely publicised report of brain damage in rats caused by a similar drug, MDA, the US 
Department of Justice's Drug Enforcement Agency (DEA) followed the British Government 
and placed MDMA and related derivatives on the list of substances under international 
control schedule 1 (equivalent to UK Class A schedule).
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Despite ecstasy's illegality within the UK, towards the end of the 1980s, it started to become a 
popular drug of choice at all-night dance parties, commonly known as 'raves', due to its 
modulation of emotional state; inducing feelings of relaxation, fearlessness and happiness 
which, along with its stimulant properties, enhanced the ability and enjoyment of dancing. 
Since then ecstasy has grown in popularity as a recreational drug and according to Saunders 
(1997), has been used by about one to five million people within Britain.
EPIDEMIOLOGY
Worldwide estimates of ecstasy use within the general population are hard to establish, but 
according to Holland (2001) nearly one million people take ecstasy every weekend. Ecstasy 
along with amphetamine is the second most commonly used drug in Europe (EMCDDA, 
2001). Since the re-emergence of ecstasy in the late 80s, its use increased in the 1990s but 
now appears to be stabilising (EMCDDA, 2001). In 1998 prevalence rates in the general 
population of EU (European Union) adults were 0.5-3% (EMCDDA, 1998) and by 2002 this 
had only risen to 5% (EMCDDA, 2002).
The UK accounts for most of the ecstasy use in the EU, with rates at 11% (EMCDDA, 2002). 
Outside the UK the highest European rates appear in Ireland 8.9% (EMCDDA, 2001) and 
Latvia 6% (ESPAD, 2001). Similar rates to the EU have been reported elsewhere in the 
world. In Australia, for example, the National Drug Strategy Household Survey reports rates 
at 3%, (Commonwealth Department of Health and Family Services, 1996).
In the US, ecstasy has also been reported as the second most frequently tried illicit drug after 
cannabis (Pope et al, 2001). However, despite the prevalence rates stabilising in the EU, 
reports from America indicate a dramatic increase in use in the later part of the 90s amongst 
16-26 year olds (Johnston et al, 2002). Amongst American college students, rates increased 
significantly by 69% between 1997 and 1999, from 2.8% to 4.7% (Strote et al, 2002). Whilst 
one study showed an increase in prevalence rates from 4.1% in 1989 to 10.1% in 1999 (Pope 
et al, 2001), however these rates were based on usage within just the one college.
Prevalence rates are higher in younger more specific age groups, with 6% of 15-34 years olds 
having used the drug. In a school survey 5% of 15-16 year olds reported its usage 
(EMCDDA, 2001). At the end of the 90s there was a marked rise in ecstasy use at the ages of
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16/17 years (Measham et al, 1998), which is thought to reflect the shift in leisure activities of 
the youth as they start reaching the age to attend licensed clubs, bars and pubs. This is 
reflected in the greater use amongst university students at 13% (Webb et al, 1996). 
Additionally, prevalence rates are again much higher amongst youngsters that attend the rave 
or 'party' scene, in which ecstasy is a popular drug of choice; this is fairly consistent across 
the world. Amongst rave attendees in the UK, reported use varied from 82% to 96% (Riley et 
al, 2001; Forsyth, 1996; Winstock et al, 2001). In Australia, reported use amongst people in 
the rave scene has been seen to vary between studies, with Topp et al (1999) reporting 76% 
compared to an earlier report of 89% (Lenton et al, 1997); in the US, Arria et al (2002) 
reported lifetime use by 89% of rave attendees; and in Canada rates were reported as 65.2% 
(Gross et al, 2002).
PATTERNS OF ECSTASY USE
Recreational ecstasy use has been commonly associated with the rave or dance scene, were its 
use has been seen as a dance drug, and has been used in this setting more than any other 
recreational drug (Forsyth, 1996). However, its usage in more recent times has been seen to 
be shifting away from large dance events to more geographically diffuse club, bar and private 
settings (EMCDDA, 2000). In particular, a sub-cultural music preference for house/techno 
music has been shown to be the greatest predictor of ecstasy use (Pederson & Skrondal, 
1999).
The assumption that drug users are unemployed, uneducated and come from socially deprived 
backgrounds does not fit the profile of a common recreational ecstasy user. Ecstasy users are 
not academic underachievers (Strote et al, 2002), but are generally employed or in higher 
education (Riley et al, 2001). In one survey of recreational ecstasy users, 80% reported 
having been in further education (Forsyth, 1996), and another survey reported 65% of users 
were currently employed (Winstock et al, 2001).
The ecstasy user is more than likely to be white (Hammersley, 1999), with surveys reporting 
the average age to be late teens to early twenties (e.g. mean age 18.9 years (Lenton et al, 
1997) and 24 years old (Winstock et al, 2001)). In addition, approximately half to two thirds 
of all users being male (62% - Forysth, 1996; 56% - Boys et al, 2001; 53% - Lenton et al, 
1997).
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The drug is usually consumed orally in multiple tablets (Winstock et al, 2001), but there is a 
subsample of users (16%), mostly found in Australia, that report injection of ecstasy (Topp et 
al, 1999). Boys et al (2001) examined the reasons why a sample of poly-substance users 
chose to use ecstasy, and they discovered that 91% of users reported that the main reason for 
using ecstasy was to 'keep going'. Also, 78% reported using for its euphoric/elation effects, 
80% for its ability to enhance activity, 72% to stay awake and 68% to feel intoxicated.
Recreational ecstasy users rarely report sole use of the drug. In fact, Hammersley (1999) 
failed to find a single interviewee that reported sole use of ecstasy. Instead ecstasy users are 
more likely to be polydrug users, in that they often consume ecstasy in combination with 
other substances, such as tobacco, cannabis, speed, alcohol, d-lysergic acid (LSD), and amyl 
nitrate (Winstock et al, 2001; Topp et al, 1999; Atria et al, 2002). Ecstasy 'polydrug' users 
have also been shown to consume cannabis, alcohol, tobacco, amphetamine, heroin and 
benzodiazepines (BZs) whilst coming off the drug (Topp et al, 1999; Winstock et al, 2001). 
There are a number of potential reasons why people choose to consume ecstasy in the context 
of polydrug use. Firstly, taking several psychoactive compounds together may enhance the 
effects of ecstasy (Schifano, 2004). In particular, the use of alcohol prior to taking ecstasy is 
thought to enhance the 'high' from MDMA (Schifano, 2004), whilst stimulants, such as 
amphetamine and cocaine are thought to maintain the arousal and alertness of the ecstasy 
experience. Sedatives and relaxants, such as opiates, BZs and cannabis, are reported to 
relieve the unpleasant sub-acute effects of ecstasy (Scholey et al, 2004). Secondly, it has been 
repeatedly reported that there is a decrease in the desired effects of ecstasy following repeated 
use (Scholey et al, 2004; Parrott, 2005). This chronic tolerance to ecstasy may lead to the use 
of other stimulants and hallucinogens in order to try and achieve the initial ecstasy effects 
(Schifano, 2004). Some ecstasy users have indeed reported that this is the reason behind the 
need to consume other psychoactive drugs in the context of ecstasy use (Scholey et al, 2004).
ACUTE EFFECTS OF MDMA
The acute effects of MDMA begin approximately 30-60 minutes after ingestion and last for 
approximately 3-5 hours (Liechti & Vollenweider, 2001). Numerous controlled studies using 
single doses of pharmaceutical MDMA have shown consistent behavioural and physiological
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effects in humans. The behavioural and psychological effects include increased positive 
mood, feelings of euphoria, increased physical and emotional energy, heightened sensual 
awareness, depersonalisation, derealisation, fear of loss of control, increased extroversion, 
mild perceptual alterations, increased self-confidence, accelerated thinking, thought blocking, 
difficulty in concentrating and impaired decision making (Downing, 1986; Liechti et al, 
2000a; Liechti et al 2000b; Gamma et al, 2000; Cami et al, 2000; Liechti & Vollenweider, 
2001). Reported physiological effects of MDMA include suppressed appetite, pupil dilation, 
jaw clenching (trismus), enhanced tendon reflexes, increased heart rate and blood pressure, 
increased peripheral body temperature, dry mouth, impaired balance and dizziness (Downing, 
1986; Grob et al, 1996; Liechti et al, 2000a; Gamma et al, 2000; Liechti & Vollenweider, 
2001).
The subjective psychological and physiological effects from pharmaceutical grade MDMA 
are similar to the subjective acute effects of ecstasy. It has been repeatedly reported that 
ecstasy users experience elation, agreeableness, euphoria, increased energy, confidence, 
exhilaration, warmth and friendliness, calmness and relaxation, increased perception of sound, 
colour and touch, confusion, increased heart rate, increased body temperature, sweating and 
dehydration, trismus, sexual arousal, papillary dilation, bruxism, lower back pain and nausea 
(Cohen, 1995; Davison & Parrott, 1997; Parrott & Stuart, 1997; Verheyden et al, 2003).
Following the acute effects of ecstasy, users report subacute effects in the following 24 to 48 
hour period, which tend to be negative effects (Verheyden et al, 2003), characterised by 
symptoms such as muscle aches, lethargy, fatigue, moodiness, depression, anxiety, 
aggression, paranoia, irritability, difficulty in concentrating and headache (Curran & Travill, 
1997; Davison & Parrott, 1997; Verheyden et al, 2002; Verheyden et al, 2003). Which of 
these adverse residual effects individuals experience, and to what degree, has been shown to 
be determined by the age of the user and the length of their ecstasy usage (Verheyden et al, 
2003). Gender has also been shown to determine differences in sub-acute effects, with 
females being more susceptible to the depressive mood effects than men (Verheyden et al, 
2002). This period is often referred to the as 'the come down' or 'crash' stage from ecstasy. 
Again, these subjective, subacute effects of ecstasy are similar to the subacute effects of 
MDMA. Leicht, Gamma and Vollenwider (2001) demonstrated post MDMA-treatment 
effects such as fatigue, muscle ache and headache in approximately half of the participants 
and up to a third reported lowering of mood, including emotional irritability, lack of energy,
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brooding and bad dreams. The fact that the subjective effects of acute and subacute ecstasy 
use are similar to the acute and subacute effects of MDMA administration in placebo 
controlled studies, suggests that in most cases ecstasy contains the active compound MDMA 
more so than any other psychoactive drug.
PSYCHOPHARMACOLOGY OF MDMA
3,4-methylenedioxymethamphetamine (MDMA) is a completely synthetic substance. It is a 
ringed substituted amphetamine derivative, which resembles the structure of the 
hallucinogenic material mescaline. As a result its pharmacological effects are a blend of those 
from amphetamine and mescaline, affecting 5-hydroxytryptamine (Serotonin; 5-HT) and 
dopamine-containing neurons, and also other neurotransmitter systems; hence the frequent 
references to MDMA being a rather 'messy' drug.
MDMA acts as an indirect monoaminergic agonist, stimulating the release of 5-HT from the 
presynaptic neuron (Nixdorf et al, 2001) and inhibiting the reuptake of 5-HT (Iravani et al, 
2000; Mechan et al, 2002), causing the synapse to be flooded with atypically large amounts of 
5-HT. At the same time it also causes the release of dopamine; although this effect is weaker 
than the MDMA-induced efflux of 5-HT (Yamamoto and Spanos, 1988; Gough et al, 1991; 
Nixdorf et al, 2001) and, possibly, norepinephrine (Rothman et al, 2001). Additionally, 
MDMA produces a rapid inactivation of trytophan hydroxylase (Stone et al, 1989; Schmidt 
and Taylor, 1988), an enzyme necessary for the synthesis of 5-HT, thus slowing 5-HT 
replenishment. For a more comprehensive review of the pharmacology of MDMA see Green 
et al (2003).
The acute boost in monoamine activity generates the unique reinforcing effects of the drug. 
Selective blocking studies show that the subjective effects of MDMA (feelings of elation, 
euphoria and well-being, emotional closeness and sensory pleasure; Liechti et al, (2000a & 
2000b) and Cami et al, (2000)), are largely dependent on carrier-mediated 5-HT release, 
whilst the stimulant-like mood effects appear to be related, at least in part, to dopamine D2 
receptor stimulation (see Liechti & Vollenweider, 2001). The mild hallucinogenic like 
perceptual effects appear to be due to serotonergic 5-HT2-receptor stimulation (Liechti & 
Vollenweider, 2001). Because MDMA's dopaminergic actions are similar to those of 
amphetamine, whilst its serotonergic effects are closer to LSD, in behavioural terms MDMA
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displays similarities to both amphetamine and LSD. However, its strong euphoric properties 
appear to be unique to MDMA itself.
MDMA NEUROTQXICITY IN ANIMALS
There is currently a large body of preclinical research, which shows that MDMA has 
neurotoxic effects on brain serotonin neurons in animals (for a comprehensive review see 
Ricaurte et al, 2000 and Green et al, 1995 & 2003). Evidence has arisen from studies using a 
variety of experimental techniques and neurochemical, neuroanatomcial and functional 
measures of 5-HT neurons, which have consistently demonstrated MDMA-induced 
serotonergic injury. These include long-term decreases in levels of 5-HT, the metabolite 5- 
HIAA, 5-HT transporters, tryptophan hydroxylase activity, anterograde transporters and 
vesicular monoamine transporters (VMAT) and histological evidence of 5-HT axon 
degeneration (Ricaurte, 2000). The areas of the rat brain that appear to be the most sensitive 
to these alterations in serotonergic activity are the striatum, hippocampus and prefrontal 
cortex, with smaller but significant effects in the brain stem and hypothalamus (Sabol et al, 
1996).
This selective serotonergic neurotoxicity induced by MDMA has been demonstrated in a 
variety of animals, such as rats (Finnegan et al, 1988; Lew et al, 1996), guinea pigs (Battaglia 
et al, 1988), baboons (Scheffel et al, 1998) and monkeys (Ricaurte et al, 1988). Non-human 
primates have been shown to be considerably more sensitive to the serotonin depleting effects 
than rats (Ricaurte, 1989). The only animal to date that is resistant to this MDMA-induced 
serotonergic neurotoxicity is the mouse. In the mouse dopamine neurons are affected whilst 
serotonin neurons appear to be spared (Battaglia et al, 1988; O'Shea et al, 2001).
Studies have also suggested that regardless of the route of administration and dosage of 
MDMA, serotonin neurotoxicity is still evident. Orally administered MDMA has been seen 
to produce toxic effects that are comparable to those induced by subcutaneous administration 
in rats and monkeys (Finnegan et al, 1988; Ricaurte et al 1988). Serotonergic neurotoxicity 
also appears to be dose-dependent (Battaglia et al, 1988; Finnegan et al, 1988). However, 
even though multiple doses of MDMA are more effective than single doses at depleting 
serotonin, Ricaurte et al (1988) showed that even a single dose of MDMA could produce 
long-lasting depletions in monkey brain 5-HT.
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These effects in animals produced by oral administration and single and multiple dosing of 
MDMA, often at concentrations analogous to MDMA amounts in ecstasy users (Ricaurte, 
2000), has raised legitimate concerns about possible MDMA-induced neurotoxicity in 
humans (Parrott, 2000; Turner and Parrott, 2000). Furthermore, comparative animal data has 
shown that the level of neurotoxicity also increases in high ambient temperatures (Broening et 
al, 1995; Colado et al, 1998; Malberg and Seiden, 1980). However, caution needs to be taken 
in interpreting many of the animal findings and extrapolating to human MDMA use. The 
dosing regimens used in animals vary greatly between studies, and many studies look at 
amounts that actually cause neurotoxic effects, rather than looking at doses that are equivalent 
to those used by human recreational ecstasy users. Many animals employed in these studies 
also have been used in previous studies assessing the acute effects of several other 
psychoactive compounds (Frederick et al, 1995; Frederick et al, 1998; Taffe et al, 2001).
Behavioural consequences of MDMA-induced neurotoxicity in animals
Considering the evidence of MDMA-induced neurotoxicity in animals, it is important to 
determine whether such neurotoxicity has behavioural consequences, and if so, what areas of 
behaviour are affected. Compared to the number of animal studies demonstrating 
neurotoxicity, there is a somewhat limited behavioural data in animals. Studies investigating 
various regimens of MDMA on animal behaviour have consistently failed to find any baseline 
changes in performance across a number of behavioural tests, despite marked reductions in 5- 
HT and 5-HIAA (up to 80% decrease, in the study of Winsaur et al, 2002) in areas including 
the hippocampus, striatum, neocortex, caudate, and thalamus (Ricaurte et al, 1993; Seiden et 
al, 1993; Marston et al, 1999; Dornan et al 1991; Frederick et al, 1995; Winsaur et al, 1993), 
which have, in some studies, lasted up to 4-7 months (Ricaurte et al, 1993; Taffe et al, 2001; 
Frederick et al 1998).
In a majority of the studies that have demonstrated cognitive and behavioural dysfunction 
relative to control animals, this has not persisted longer than 7 days post-MDMA treatment 
(Slikker et al, 1989; McNamara et al, 1995; Robinson et al, 1993; Taffe et al, 2001; 
Maldonado & Navarro, 2001; Navarro et al, 2004). McNamara et al (1995) demonstrated 
behavioural changes in locomotor activity in rats, during the 4 days of MDMA 
administration, but following withdrawal of MDMA no changes were observed compared to
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controls, despite MDMA-induced depletions of 5-HT and 5-HIAA in the frontal cortex and 
amygdala, 7 days after treatment. Similarly, rats who showed 73% depletion in serotonin 
concentrations in the neocortex and 32% in the caudate nucleus relative to controls, only 
demonstrated a mild impairment in developing an efficient search strategy, on a spatial- 
navigation learning set-task, on the first three days of training, after MDMA-treatment. 
However, once learnt, memory performance concerning this location was equivalent to that of 
controls (Robinson et al, 1993). Taffe et al (2001) reported behavioural impairments in 
rhesus monkeys treated with MDMA. Performance in memory, on the delayed non-matching 
to samples test (DNMS) and the self-ordered spatial search task (SOSS); reinforcer efficacy 
and sustained attention on a progressive-ratio (PR) schedule of responding task; fine motor 
control on a bimanual motor task reaction; and reaction time were all impaired relative to 
controls. Task performance returned to pre-treatment baseline levels within one week after 
MDMA treatment, despite reports of a 44% reduction in 5-HIAA concentrations which 
persisted for approximately 3 months after MDMA treatment. However, they did report one 
single animal's behavioural performance to be severely affected which persisted for up to two 
months.
These earlier studies suggest that any cognitive and behavioural dysfunction in MDMA 
treated animals is the result of the acute and sub-acute effects of MDMA, rather than 
functional consequences of neurotoxicity. This evidence also suggests that the neurotoxic 
effects of the drug may not be manifested behaviourally, despite the underlying 
neurochemical changes. However, more recent studies have shown behavioural effects 
related to MDMA-neurotoxicity. Martson et al (1999) reported a selective deficit in 
performance in rats on the delayed non-match to place procedure (DNTMP), 16 days 
following MDMA exposure. MDMA-treated rats did not show the improvement in 
performance at the longer delays, as seen in the control rats. In addition, MDMA treated rats 
showed reductions of 5-HT function upon post-mortem analysis. Memory impairments, on 
object recognition tasks, in MDMA treated rats have also been shown, one week (Piper & 
Meyer, 2004) and 10-12 weeks after drug treatment (McGregor et al, 2003). Taffe et al 
(2002) have showed lasting behavioural sensitivity in monkeys. When pharmacologically 
challenged with l(3-Chlorophenyl)piperazine dihydrichloride (mCPP), vigilance and reaction 
time (5-choice reaction time), and reinforcer efficacy and sustained attention (PR), where 
disrupted in monkeys treated 13-months previously with MDMA . Taffe et al (2002) also
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showed 50% reductions in 5-HIAA, 2-17 weeks post MDMA treatment. However, cognitive 
dysfunction was quite small compared to the magnitude of serotonin depletion.
Studies also indicate that social interaction and anxiety-related behaviours are disrupted in 
MDMA-treated animals, which are lasting after the cessation of MDMA administration. 
McGregor et al (2003) reported that rats pre-treated with MDMA displayed increased anxiety 
in a social interaction test and emergence test; demonstrating a shorter duration of social 
interaction and fewer social interaction bouts, and took longer to emerge in the open field 
compared to control groups 8-10, weeks following drug administration. In addition, rats were 
reported to have shown depressive symptoms in the forced swim test, displaying reduced 
escape attempts and increased immobility. However, these symptoms were only evident on 
the third day of testing. Ho et al, (2004) did not provide indications of anxiety, reduced social 
interaction and depressive symptoms, using similar testing paradigms (open field, plus maze 
and forced swim test). However, Ho et al (2004) only injected animals with a single dose 
(7.5mg/kg) of MDMA compared with a dosing regimen of 5 mg/kg every 4 hours on 2 
consecutive days (20 mg/kg per day) in McGregor et al's study. This, together with the 
animal studies which have demonstrated small, if any, changes in behaviour compared to the 
relatively large amounts of serotonin depletion, suggests that it may be the magnitude of 
neurotoxicity produced by MDMA that is crucial in behavioural studies. The research data 
suggests that there may be a threshold effect of 5-HT, below which no behavioural 
consequences will be observed. In many of the studies which have not demonstrated 
behavioural disturbances or very limited and selective deficits, there may not have been 
sufficient neurotoxic damage over and above that 5-HT threshold, in order to interfere with 
behavioural and cognitive functioning.
The shortage and very selective nature of long-term behavioural dysfunction in these studies 
may be because of the specific tests employed and the differing paradigms: they may not be 
sensitive enough to detect changes in the 5-HT system; and the behaviour in question may not 
be influenced directly by the 5-HT system. What is certain is that the animal behaviour 
research has utilised various behavioural measures, covering numerous behavioural domains 
which are known to be sensitive to small changes in monoamine neurotransmitter 
concentrations (Seiden et al, 1993). One possibility to account for discrepancies in some of 
these tests is that the lasting effects of MDMA may depend on subject-dependent factors.
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Taffe et al (2001) drew attention to one monkey of the six that they assessed, which 
demonstrated marked deficits in performance which lasted for up to 2 months. Ho et al 
(2004) also demonstrated behavioural impairments 3 weeks after MDMA-treatment only in 
animals with low anxiety levels, but not high anxiety levels. This demonstrates certain 
individual vulnerabilities to MDMA-induced effects.
Recovery from MDMA neurotoxicitv in animals
Animal studies have shown that these neurodegenerative effects in the serotonin system are 
long lasting (up to one year). However, there is evidence which shows 'recovery' of this 
serotonergic function; although subsequent reorganisation and/or function may be abnormal. 
Recovery of serotonin reuptake sites has been shown in rats, with the concentration of 5-HT 
reuptake sites returning to control levels after 12 months (Battaligia et al, 1991; Sabol et al, 
1996; Scheffel et al, 1998; Scanzello et al, 1993). Taffe et al (2001) demonstrated a 44% 
reduction in 5-HIAA concentrations and altered peak latencies in brainstem auditory evoked 
potentials in rhesus monkeys, which persisted for approximately 3 months post-MDMA 
treatment, yet in the fourth month both these measures normalised.
Ricaurte at al (1992) showed evidence of partial recovery in some brain regions of nonhuman 
primates (hippocampus, caudate nucleus, frontal cortex). However, after 18 months it was 
evident that recovery did not continue in all regions with the exception of the thalamus and 
hypothalamus. Thus the rate and degree of recovery appears to depend on the brain region 
(Lew et al, 1996; Battaglia et al, 1991; Sabol et al, 1996), with some brain regions showing an 
increase in 5-HT functioning, mainly the hypothalamus, but others showing persistent 
decreases (Ricaurte et al, 1992; Scheffel et al, 1998); also, recovery was not always normal. 
Fischer et al (1995) demonstrated that the pattern of some of the serotonin axonal sprouting in 
both rats and monkeys was abnormal, especially in the amygdala and hypothalamus where 
neuron axons were reinnervated or hyperinnervated, suggesting that MDMA actually lead to a 
reorganisation of the serotonin system. Such abnormal patterns were also evident in monkeys 
seven years after MDMA treatment, although some regions were less severely affected than 
those observed at 18 months (Hatzidimitriou et al 1999). This abnormal reorganisation of 5- 
HT axons and axon terminals is synonymous to the 'pruning effect' seen with a number of 
neurotoxins (Ricaurte et al, 2000), where nerve cells will often grow replacement terminals,
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where there has been damage, resulting in a different dendritic pattern. This pruning effect 
provides further evidence of MDMA's neurotoxicity (Ricaurte, 2000), but also of potential 
attempts of the serotonergic system to recover from such damage.
Serotonergic recovery also depends on the animal treated. On inspection of experimental 
animals, Scanzello et al (1993) revealed a group of rats that did not show signs of recovery, 
whilst others did. Those that did not recover had severe and enduring serotonergic deficits in 
multiple brain regions. Thus, it appears that the recovery of serotonin neurons is region 
dependent and also varies between and within species. Monkeys tend to be more sensitive 
and damage appears to be permanent, whereas with rats there is some indication that recovery 
takes place, but the question is whether this is sustained? Such differences in recovery may 
be due to the severity of damage sustained from MDMA; the more severe the damage, or 
more highly arborized, the lower the probability of recovery (Fischer et al, 1995). Disparity 
may also be due to genetic differences, individual vulnerabilities and other parameters like 
age, health status, diet and fluid supply etc.
Whilst studies have demonstrated the potential for animals to show a certain level of recovery 
from neurotoxic effects of MDMA, this recovery is not always normal and there is a paucity 
of research indicating the behavioural consequences this has. As tests for neurotoxic effects 
become more refined, then the assessment of behavioural recovery should become possible.
HUMAN NEUROTOXITICY
That fact that nearly all animal species tested are sensitive to the neurotoxic potential of 
MDMA (with the exception of the mouse), suggests that humans too will be sensitive to the 
toxic effects. Applying the well-established principles of interspecies scaling also strengthens 
the case for human sensitivity to MDMA-induced serotonergic neurotoxicity. The principle 
of interspecies scaling is that smaller animals require higher doses of a psychoactive drug to 
achieve the equivalent effect. As demonstrated in the animal literature, rodents require higher 
doses of MDMA to produce the same neurotoxic effect as in non-human primates. Using this 
technique, the dosages of MDMA known to be neurotoxic in animals falls squarely in the 
range of dosages typically used by recreational ecstasy users: between 75-125mg of MDMA 
(Ricaurte et al, 2000). The fact that most recreational ecstasy users consume more than one
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dose of ecstasy on one occasion (Winstock et al, 2001), and that the acute effects of ecstasy 
mimic these controlled effects of pharmaceutical MDMA (Leicht & Vollenweider, 2001), 
strongly suggests that recreational ecstasy users are ingesting neurotoxic doses of MDMA.
A number of lines of evidence to support the notion that MDMA-induced serotonergic 
neurotoxicity occurs amongst recreational ecstasy users has emerged in the last 10 years (see 
table 1). Methods of assessing serotonin neurotoxic changes in the living human brain 
include analysis of cerebrospinal fluid (CSF) 5-hydroxyindoleacetic acid (5-HIAA - a major 
metabolite of serotonin) concentrations and pharmacological challenges using 5-HT agonists. 
Less invasive methods of assessing changes have included Positron Emission Tomography 
(PET), Single Photon Emission Computed Tomography (SPECT), Proton Magnetic 
Resonance Spectroscopy (H-MRSI), Electroencephalograms (EEG) and assessment of 
auditory evoked potentials.
1. CSF Assessment
The first study which measured the concentration of 5-HIAA in cerebrospinal fluid (CSF) did 
not find any significant indication of neuronal alteration in ecstasy users compared to age- 
matched controls (Peroutka et al, 1987). However, subsequent studies using the same 
technique and larger participant numbers have consistently demonstrated significantly 
reduced concentration levels of CSF 5-HIAA in human ecstasy users compared to controls 
(Ricaurte et al, 1990; McCann et al, 1994; Bolla et al, 1998; McCann et al, 1999). Bolla et al, 
(1998) demonstrated a dose-response effect, with the concentration of 5-HIAA decreasing as 
the dose of reported ecstasy use increased. However, other studies which have looked at this 
correlation, have not found a significant relationship between the concentration levels of 5- 
HIAA and number of ecstasy exposures (Ricaurte at al, 1990; McCann et al, 1994). 
Measuring levels of CSF does not indicate which areas of the brain are potentially affected by 
ecstasy, if at all; because CSF can also be a consequence of psychological changes; (e.g CSF 
5-HIAA is lower in depressed individuals (Becker et al, 1995)).
2. Pharmacological Challenges
Pharmacological challenges using 5-HT modulators, such as L-tryptophan, d-fenfluramine 
and M-chlorophenylpiperazine, have also been used to assess possible MDMA-induced
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neuronal alterations but with less consistency in their findings. Price et al (1989) first 
demonstrated altered 5-HT functioning compared to healthy controls, using the precursor L- 
tryptophan. Ecstasy users showed blunted responses to the effects of L-tryptophan, as 
measured by prolactin concentration, yet the difference compared to healthy controls failed to 
reach significance. A subsequent study using L-tryptophan also did not find any significant 
differences in prolactin concentration between ecstasy users and controls (McCann et al,
1999). A more recent study by Curran & Verheyden (2003) showed that only ex-ecstasy 
users (who had used more than 20 tablets, but not within the last year), and not current ecstasy 
users (who had used more than 20 tables within the last year), showed significantly higher 
levels of total and free plasma tryptophan following tryptophan manipulation compared to 
polydrug controls. However, such differences in these ex-users may reflect pre-morbid 
differences in their 5-HT function.
The studies by Gerra et al (1998 & 2000) and Verkes et al (2001) have indicated alterations in 
serotonin functioning in ecstasy users compared to control participants using the agonist d- 
fenfluramine, with ecstasy users showing significantly reduced prolactin and cortisol 
responses compared to controls. Gouzoulis-Mayfrank et al (2002) failed to find any 
significant effects of d-fenfluramine. However, one of their control groups consisted of heavy 
cannabis users, which is thought to be an important confound in endocrinological studies of 
ecstasy users.
McCann et al (1999) also found evidence of possible serotonergic neurotoxic change using 
another 5-HT agonist, M-chlorophenylpiperazine, which caused significant blunting of both 
prolactin and cortisol responses in heavy ecstasy users compared to non-using controls. It 
therefore appears that differences in the studies involving pharmacological challenges are 
related to the 5-HT activating drug used, with L-tryptophan appearing to be the least sensitive 
probe for demonstrating brain serotonergic alteration induced by MDMA. None of these 
pharmacological challenge studies have demonstrated any significant correlation between 
prolactin responses and the amount of ecstasy used (Price et al, 1989; Gerra et al 1998 &
2000), such that in summary pharmacological challenge techniques seem a somewhat crude 
and indirect assessment measure of MDMA neurotoxicity in humans.
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3. Neurological Assessment
More recently less invasive methods of evaluating the neurotoxic effects of MDMA in 
humans have been developed, using measurements of biological markers by in vivo imaging 
techniques (see Table 1; for a comprehensive review see Reneman et al, 2001). PET studies 
using the 5-HT transporter ligand McN-5652 have shown decreases in both global and 
regional 5-HT transporter binding in ecstasy users, compared with ecstasy-naive controls 
(McCann et al, 1998) and polydrug controls (Thomasius et al, 2003). This would appear to 
indicate actual structural changes in the serotonin neurons within the brain. Also the 
decreases observed in the 5-HT labelled transporter sites correlated with the degree of 
previous MDMA exposure (McCann et al, 1998), indicate dose-related 5-HT neurotoxicity. 
Further, using the same transporter ligand, Buchert et al (2003) showed that ecstasy users had 
significantly reduced distribution volume ratios of SERT (presynaptic serotonin transporter) 
availability in the mesencephalon and thalamus, compared to drug naive controls. However, 
Gamma et al (2001) did not find any indication of neuronal alterations using the same 5-HT 
ligand; although this method only used PET to detect possible deviant patterns of rCBF, not 
SERT densities or availability.
Neuronal activity using PET has also been studied by Obrocki et al (2000). They assessed 
alterations to the brain cerebral glucose metabolic rate using the ligand 2-[(18)F]-fluro-2- 
deoxy-D-glucose (FDG). They demonstrated lasting reductions in the metabolic uptake rate 
within the amygdala, hippocampus and Brodmann's area 11 in ecstasy users, compared to 
controls. However, no correlations were found between FDG uptake rates and cumulative 
ecstasy dosage. One further limitation of this study was that FDG PET does not selectively 
display activity of the serotonergic system; rather it reflects total neuronal activity and thus 
the possible effects of MDMA on other neurotransmitters in these areas, can not be 
established. In addition, it is as yet impossible to conclude whether any disruption to 5-HT or 
other neurotransmitters, is due to MDMA and/or other drug use.
SPECT has also been used to demonstrate selective serotonin neurotoxicity, using a number 
of different radioactive ligands; in particular [ 123I]p-CIT and [ 123I]R91150 which are good in 
vivo tracers for 5-HT transporters (Reneman et al, 2001). Using these markers, ecstasy users 
were shown to have significantly reduced cortical SERT, particularly in the primary sensory 
cortex, compared to polydrug controls, but there were no correlations between lifetime dose
16
Kirstie Soar Chapter 1
and reductions in SERT binding (Semple at al, 1999). Such effects on cortical 5-HT receptor 
densities have been replicated by Reneman and colleagues (2000, 2001a, 2001b), who 
demonstrated significantly lower binding ratios in recent ecstasy users compared to controls. 
This suggests down-regulation of receptors caused by MDMA-induced 5-HT release. 
Reductions in receptor densities have also been demonstrated in all areas studied within the 
cerebral cortex (Reneman et al, 2002), but with no correlation between the level of cortical 
binding and extent of previous ecstasy use.
These alterations in SERT densities only appear to occur in heavy ecstasy users. In all of the 
above studies, reported lifetime consumption of ecstasy is above 140 tablets. Reneman et al 
(2001) only found significant decreases in overall binding ratios in heavy users (who had used 
over 50 ecstasy tablets) compared to non-ecstasy users, but not between binding ratios of 
moderate users (who reported use of a maximum of 50 ecstasy tablets) compared with non- 
users. This could be taken to suggest a possible dose-response effect shown in the previously 
discussed animal data. However, this could also be indicative of a neurotoxic 'threshold'. 
Below this threshold neurons can manage or self-protect against (or perhaps recover from) the 
neurotoxic effects of MDMA, but above this threshold neurons may sustain damage.
Magnetic resonance spectroscopic imaging (1H-MRSI) has also provided evidence for 
neuronal abnormality in human recreational ecstasy users. Reneman et al (2002) evaluated 
the MDMA-related alterations in metabolite ratios: N-Acetylaspartate (NAA) / creatine (Cr), 
NAA/Choline (Cho) and myo-inositol (MI)/Cr ratios (markers associated with neuronal loss 
or dysfunction) in the frontal cortex of ecstasy users. Neuronal abnormalities significantly 
correlated with the degree of ecstasy use: the higher the amount of ecstasy exposure the lower 
the metabolite ratios. Chang et al (1999) also demonstrated metabolic alterations in ecstasy 
users compared to normal controls using the same method. Cumulative lifetime dose showed 
significant effects on MI (a glial marker) in the parietal white matter and the occipital cortex 
of ecstasy users. However, using the same technique, Obergeisser et al (2001) failed to find 
any group differences in neuronal functioning in the hippocampus, between ecstasy users and 
controls, although they only assessed a small number of users (5) and also a differing region 
of the brain to that assessed by Reneman et al (2002), which might account for the difference 
in findings.
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Neuroimaging techniques are not without their criticism, especially when it comes to data 
interpretation as evidence for MDMA neurotoxicity. The binding specificity of ligands has 
been questioned, potentially causing an under or overestimation of binding density (see Cole 
et al, 2003 for further discussion). Also, the loss of markers indicated in these neuroimaging 
techniques does not necessarily equate to actual cell loss. Certain polymorphisms in the 5-HT 
transporter gene have shown to have reduced 5-HT transport activity. As such, these possible 
pre-existing differences in ecstasy users in previous studies are unknown (Kish, 2002). 
Whilst there are limitations to neuroimaging studies, the converging line of evidence, using 
different techniques in conjunction with the preclinical animal data, does allow for a certain 
level of assessment of the potential effects of ecstasy.
4. Electrophysiological Assessment
Other evidence of MDMA-induced depletion of 5-HT functioning is provided by studies 
using electrophysiological assessment, involving the auditory evoked potentials and the 
intensity dependence paradigms. The intensity dependence of auditory evoked potentials is 
thought to be one index of 5-HT integrity. High intensity dependence has found to be 
associated with a low functioning of serotonergic neurotransmission (Hegerl and Juckel, 
1993). Croft et al (2001) and Tuchtenhagen et al (2000) have both demonstrated serotonin 
neuronal alterations via this method in ecstasy users. Ecstasy users exhibited significant 
increases in amplitude of the tangential N1/P2 source activity with higher stimulus intensities 
compared to drug-naive and cannabis users, indicating diminished serotonergic activity 
specifically in ecstasy users. In addition, Croft et al (2001) demonstrated a significant 
positive relation between ecstasy users' N1/P2 slopes and total ecstasy consumption 
independent of cannabis use, suggesting a causative link between ecstasy and 5-HT 
dysfunction.
Further evidence for dose-related neuronal alterations is provided by Dafters et al (1999). 
They investigated whether there was a correlation between quantitative EEG variables 
(Spectral power and coherence) and the level of prior ecstasy use. Reported ecstasy use 
positively correlated with absolute power in alpha and beta frequency bands and negatively 
correlated with EEG coherence.
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Dopaminergic functioning
Most of the previously discussed studies addressing neurotoxicity have focused on the levels 
of serotonin within the brain of human recreational ecstasy users. Two further studies 
focused primarily on the long-term effects, MDMA exposure may have, on the dopamine 
system. Gerra et al (2002) investigated dopaminergic function in ecstasy users compared to 
control subjects. In a pharmacological challenge study using bromocriptine (a specific D-2 
receptor agonist), they found a negative correlation between dopamine receptor sensitivity 
and ecstasy exposure. This suggested possible reduced dopaminergic receptor sensitivity in 
heavy ecstasy users. Within the same study, there were no significant group differences on 
prolactin response, but there was a significant difference in growth hormone (GH) responses. 
Ecstasy users showed significantly reduced GH response compared to controls. However, 
such alterations in dopamine could be related to the use of other drugs, which are known to 
affect dopaminergic neurons. Reneman et al (2002) demonstrated that the sole use of ecstasy 
was not related to dopaminergic neurotoxicity, but rather that the combined use of ecstasy and 
amphetamine were associated with reduced dopamine transporter densities. This appears to 
suggest that MDMA is not associated with human dopaminergic neurotoxicity; but rather it is 
a selective serotonergic neurotoxin.
Strength of evidence for neurotoxicity in ecstasy users
With the development of in vivo imaging in the human brain, there is now extensive evidence 
which suggests that MDMA may cause neuronal injury in some recreational ecstasy users. 
However, these human studies employ a retrospective design and thus evidence is indirect and 
based on associations. Experimental and/or longitudinal designs are needed to establish 
whether there is actually a causal link between neurotoxic changes and MDMA. There are a 
number of methodological flaws with the neuroimaging studies. Kish (2002) argues that 
evidence employing the radioligands used to bind to the serotonin neuron, over-rely on one 
component, that of the serotonin transporter (SERT). He questions the reliability and validity 
of the SERT measure and whether this is actually proof of brain damage; since it has been 
established that drug-induced changes in the levels of brain neurotransmitter transporters can 
occur independently of any changes in the number of serotonin neurones. As such, brain 
levels of SERT might change following exposure to some drugs independently of any 
changes in levels of nerve terminals. It is also suggested that SERT levels can also vary as a
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function of oestrogen status, gender and variations in a SERT promoter gene polymorphism, 
which may be unrelated to the actual number of serotonin neurons. Thus studies involving 
measurement of brain SERT might be confounded to some extent.
However, there is other evidence, as discussed, which suggests there are alterations in 
neuronal functioning which have been associated with MDMA exposure, which mirrors 
findings found in the animal data. The notion that cell loss of markers equates to real 5-HT 
cell loss, within the human brain can be obtained from post-mortem brain examination and to 
date there is only one published study that has done this. Kish et al (2000) reported that 
striatal (putamen, caudate, nucleus accumbens) levels of serotonin and of its metabolite 5- 
HIAA were severely depleted by 50 to 80% in the brain of an ecstasy user compared to 
controls, but that there were generally normal dopamine concentrations. However, it still can 
not be determined whether 5-HT depletion was caused by ecstasy use or other polydrug use. 
Though all methodologies described are flawed, taken together with the animal data there is 
an increasingly compelling case for the theory of MDMA-induced 5-HT injury in recreational 
ecstasy users. Thus taken together the evidence strongly supports the earlier animal findings 
of reductions in brain serotonin in ecstasy users as a result of MDMA-induced neurotoxicity.
Recovery from MDMA neurotoxicity in humans
As outlined above there is strong evidence to suggest that recreational ecstasy use can cause 
serotonergic injury within the human brain. This also raises the question as to whether 
recovery of brain neurons can occur after continued abstinence from the drug or whether such 
changes are persistent. Theses questions have only been addressed in the last 5 years. Chang 
et al (1999) did not find a significant relationship between the recent timing of MDMA use 
and the concentration of any metabolites, nor did Reneman et al (2002). McCann et al (2000) 
also found no significant correlation between the duration of abstinence from MDMA and the 
extent of 5-HT transporter binding. However, Semple et al (1999) and Reneman et al (2002) 
observed a significant positive correlation between SERT binding and the duration of 
abstinence; suggesting possible recovery from serotonergic neurotoxic injury over time. 
Obrocki et al (2000) also focused on the reversibility of PET FDG uptake on brain glucose 
metabolism and found a correlation between uptake and the time since ecstasy was last 
ingested; though as mentioned before, PET FDG only reflects total neuronal activity levels
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not selective serotonergic activity. The evidence of possible reversibility of MDMA 
neurotoxicity, is only based on associations using correlational analyses. Other studies 
though, have actually looked at group differences between current ecstasy users, former or ex- 
ecstasy users and controls.
Using SPECT, Reneman et al (2000a and b) compared ecstasy users and ex-ecstasy users who 
reported using similar amounts of ecstasy but had not used in the last 2 months, and controls. 
Cortical binding ratios were lower in current ecstasy users compared to ex-users and controls. 
There was also a significant correlation between cortical binding and duration of abstinence 
from ecstasy; suggesting possible neuronal recovery in ex-ecstasy users. They also 
demonstrated that there was higher cortical binding of the 5-HT ligand [ 123I]R91150 in the ex- 
ecstasy users compared to controls (though not a significant effect), possibly suggesting an 
up-regulation of postsynaptic receptors. Reneman et al (2002) replicated these findings in a 
later study, but only in female ecstasy users. Binding ratios were significantly higher in ex- 
female users compared to current female users, but not controls; again suggesting that in 
several brain regions, MDMA-induced decreases in serotonin transporters could be reversible. 
This study also suggested a possible gender difference in recovery as this reversal was not 
observed in the male ecstasy users. Buchert at al (2003) have also indicated the reversibility 
of MDMA-induced SERT availability as measured by PET. Former users showed levels 
close to that of drug-nai've controls in all brain regions assessed. However, using a tryptophan 
challenge, as an indirect measure of central 5-HT function, Curran & Verheyden (2003) 
showed evidence of altered 5-HT functioning in ex-ecstasy users, but not current users, 
compared to controls. This indicates that neuronal alterations could further develop after 
cessation of ecstasy use. However, in light of previous research showing possible recovery, it 
is more than likely that such differences in 5-HT functioning in these users could reflect pre- 
morbid differences in 5-HT function.
When considering the persistence or reversibility of MDMA-induced neurotoxicity, there is a 
need for more longitudinal studies like that of Gerra et al (2000) who investigated possible 
reversibility of changes in the 5-HT system. They found that prolactin rises were 
significantly impaired in ecstasy users compared to controls both 3 weeks after discontinuing 
ecstasy use and after prolonged abstinence (12 months). But in contrast, cortisol rises in 
ecstasy users were significantly impaired compared to controls at 3 weeks, but were restored 
after 12 months. Thus, the restored responses of cortisol after 12 months may represent the
21
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expression of an initial recovery of serotonergic functioning after MDMA-induced 
neurotoxicity.
Whether MDMA leads to irreversible or partly reversible impairment of serotonergic neurons 
within humans still remains controversial. The current studies do not allow for definite 
conclusions but do indicate that there are delayed changes in 5-HT function after abstinence 
of MDMA.
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CHAPTER 2
Possible Functional Consequences of Ecstasy-Induced
Serotonergic Neurotoxicity
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The previous chapter highlighted a substantial body of evidence that supports the idea that 
recreational ecstasy use induces neurotoxic effects on serotonergic neurons and alters brain 
serotonergic functioning. The fundamental question then, is whether or not this MDMA- 
induced neurotoxicity results in alterations in human behaviour.
The role of serotonin has been implicated in the regulation of mood (Young et al, 1985), 
depression (Delgado et al, 1990), anxiety (Garvey et al, 1995), aggression and impulsiveness 
(Brown et al, 1979; Coccaro, 1989; Reist et al, 1996; Askenazy et al, 2000), sexual activity, 
appetite (Fernstrom, 1987), sleep (Oswald et al, 1964), pain (Messing et al, 1977; Akunne and 
Soliman, 1994), circadian and seasonal rhythms (Penev et al, 1995), motor activity 
(Loubinoux et al, 2002) and body temperature (Blier et al, 2002). It is also thought to play a 
role in cognitive processes (Hunter, 1988), although the place of 5-HT in cognition is poorly 
understood. However, it has been proposed that serotonin may play an important modulating 
role in memory and attention and so it is possible that extreme deviations of 5-HT activity 
could result in biases in cognitive processing. Evidence to date suggests that 5-HT is 
involved in learning, visuo-spatial memory, visual discrimination, associative functions and 
aspects of planning and general memory.
The consequences, therefore, of alterations in serotonergic functioning in recreational ecstasy 
users are expected in these psychological and behavioural domains, which are related to 
serotonergic processes. This current chapter summarises the growing number of research 
reports which lend support to this notion, in particular concerning psychiatric, 
psychobiological, and also cognitive effects in recreational ecstasy users. The idea that these 
psychological effects are associated with altered serotonergic functioning is also discussed, 
along with a discussion regarding evidence concerning the reversibility or permanence of 
these effects.
Long-term psychopathological consequences associated with ecstasy use
The first evidence which indicated that ecstasy might lead to chronic psychiatric symptoms 
came from individual case studies, where psychiatric complaints were reported to have 
appeared to develop in the context of ecstasy use (see Table 2 for a summary of case reports 
from the last 15 years). These clinical reports suggest that certain individuals appeared to 
have developed psychopathological symptoms, which manifested in a range of psychiatric
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conditions, including panic attacks (Whitaker-Azmitia & Aronson, 1989), depression (Cohen, 
1996), flashbacks (Creighton et al, 1991), psychosis (Vaiva et al, 2001), paranoid ideation 
(McGuire & Fahy, 1991) and suicidal ideation (Benazzi & Mazzoli, 1991). As table 2 
indicates the most common symptoms thought to be associated with ecstasy use appear to be 
psychoticism, panic attacks and depression; behavioural domains that are putatively 
influenced by brain serotonin. In most cases individuals who reported these problematic 
effects of ecstasy had previous experience of using the drug (Cohen, 1996; McGuire & Fahy, 
1991; Cassidy & Ballard, 1994; Keenan et al, 1993; Bone et al, 2000; Creighton et al, 1991; 
Schifano, 1991; Schifano & Magni, 1994; Alciati et al, 1999; McGuire et al, 1994; Pallanti & 
Mazzi, 1992; Windhaber et al, 1998) and thus these sequalae could not be considered to be 
acute reactions to the drug. Additionally, many of the individuals reported symptoms which 
persisted after the acute ecstasy withdrawal effects, and were also exacerbated or reoccurred 
after further ecstasy use (Series et al 1994; McGurie et al, 1994; Milas, 2000). Creighton et al 
(1991) reported a patient who was free of psychiatric symptoms for 8 months, but after taking 
a further 4 doses of ecstasy the psychological symptoms returned. Similarly, the individual 
reported by Cassidy and Ballard (1994) stated a close relationship between symptom 
improvement and ecstasy cessation.
The main limitation of using individual case studies as evidence for the possible 
neuropsychiatric effects of ecstasy is that such individual abreactions may be viewed as 
idiosyncratic or atypical. However, additional support for psychiatric consequences of 
ecstasy use comes from a clinical survey conducted by Schifano et al in 1998. This study 
examined the possible psychopathological consequences of ecstasy use in 150 patients who 
had taken ecstasy on at least one occasion. 53% of the sample were found to be affected by 
one or more psychopathological problems as diagnosed using the criteria of DSM-III-R (the 
diagnostic manual of the American Psychiatric Association version III Revised.). These 
patients specifically denied the presence of these psychiatric disturbances prior to ecstasy 
usage. The most frequent psychopathological problems were depression, psychotic disorders, 
cognitive disturbances, bulimic episodes, impulse control disorders, panic disorders and social 
phobia. Again these are areas of behaviour/pathology thought to be influenced by serotonin 
and, in addition, parallel the disorders seen in the individual case study reports. The key 
limitation of this study is that participants were all clients at a clinical unit. This self-referred 
psychiatric group may not have been typical recreational ecstasy users, since many reported 
high use of cocaine and heroin; drugs which when used in isolation can cause long-term
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psychiatric complications. There was nonetheless a significant correlation between severity 
and extent of symptoms and level of ecstasy use. Those that had used larger doses of ecstasy, 
both acutely and cumulatively were found to have more severe symptoms.
The notion of ecstasy-related psychiatric symptoms and disorders has not only been shown in 
a clinical sample. Recent research suggests that there may be other ecstasy users who 
experience milder psychiatric disturbances who do not contact health professionals. There is 
a growing body of evidence to suggest this from studies employing recreational users that do 
not present themselves to clinicians, but show evidence of psychopathological symptoms on 
numerous measures of clinical indicators compared to people who do not use illicit drugs 
and/or participants who have used other illicit drugs but not ecstasy (see table 3 for a 
summary of these studies). The method of comparing ecstasy users to other drug using 
groups has been used in order to try to eliminate the confounding effects of these other drugs 
on psychological performance. It is difficult to ascertain which, if any, of the drugs 
previously used by recreational ecstasy users is responsible for the manifestation of 
psychological problems. Epidemiological studies have failed to identify sole ecstasy users. 
Instead ecstasy users are more likely to be polydrug users (Webb et al, 1996; Pederson & 
Skrondal, 1999; Topp et al, 1999; Winstock et al, 2001; Strote et al, 2002; Arria et al, 2002). 
All of the drugs reported in these studies are capable of producing strong psychoactive effects 
and may also have longer-term psychological effects if used alone (Rodgers & Robbins, 
2001). Thus interpretation of the findings from many of the empirical studies into the 
functional effects of MDMA-induced neurotoxicity, is limited. The solution of employing a 
research design that incorporates valid control groups with matched levels of drug use other 
than ecstasy (often referred to in the literature as polydrug users) and/or cannabis use, 
addresses this interpretative difficulty. Any findings in group differences can then be 
attributed more to ecstasy and not polydrug or cannabis use. Also, evidence for any dose- 
related* effects between levels of ecstasy consumption and levels of reported 
psychopathology can further strengthen the associations with ecstasy use and potential 
psychological effects.
* The term "dose-related" (response) will be used in a loose fashion throughout this thesis to allude to possible 
relationships between consumption of ecstasy and possible effects. This differs from the stricter use of this 
terminology which is normally applied in psychopharmacology (i.e. in controlled trials).
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One of the first studies to report long-term psychological effects in recreational ecstasy users 
was Cohen (1995) who surveyed 500 ecstasy users. The most frequently reported 
psychological effects pertaining to the long-term effects of ecstasy were depersonalisation, 
insomnia, depression and flashbacks. However, findings were purely reliant on participant's 
subjective reports, with no supportive objective psychological assessment or any comparison 
to other non-drug/drug using groups. Additionally, he did not find any relationship between 
an individual's number of exposures to ecstasy and recurring symptomatology.
Curran and Travill (1997) reported one of the first studies showing elevated psychopathology 
in ecstasy users compared to a control group. They found elevated levels of depression as 
measured by the BDI (Becks Depression Inventory) in ecstasy users five days after ecstasy 
consumption compared to alcohol controls. Further still, Verheyden et al (2002) suggested 
that females may be more susceptible to this low mood effect than males, and in addition they 
demonstrated that aggression ratings, in both males and females, were increased 4 days after 
ecstasy use. Further support for these sub-acute psychopathological effects have been shown 
in a later study by Curran et al (2004) who reported that ecstasy users displayed higher scores 
on the BDI compared to polydrug controls on day 5, but by day 7 there were no differences in 
levels of depression. Together, these studies would appear to identify a number of sub-acute 
effects of ecstasy rather than the long-term effects of ecstasy (at least two weeks post-ecstasy 
use).
Long-term changes in psychopathological symptomatology in ecstasy users have been 
reported in studies such as that by Parrott, Sisk & Turner (2000). Using the SCL-90 they 
showed elevated psychopathological scores on a number of dimensions including 
somatisation, psychoticism, phobic anxiety, obsessive-compulsive symptoms, paranoid 
ideation, anger/hostility and altered appetite. Also, they demonstrated that heavier ecstasy 
users reported significantly higher scores on several of these dimensions compared to 
polydrug users. Light ecstasy users also scored significantly lower than heavy ecstasy users 
on anxiety, paranoid-ideation and appetite, but significantly higher on paranoid-ideation 
compared to polydrug users. It was suggested that this may be evidence that heavier ecstasy 
users exhibit a greater range of psychobiological problems, as a result of their greater 
exposure to the drug. Dugherio et al (2001) have also shown ecstasy users to exhibit higher 
psychopathological scores, on the same assessment measure, compared to drug-naive and 
polydrug controls, but failed to find any differences between 'ecstasy abusers', experimental
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users and controls; despite their definition of 'ecstasy abuser' being similar to that of a 
'heavy' ecstasy user in Parrott, Sisk & Turner's (2000) study ('abusers' being those who took 
> 27.5 tablets in their lifetime, 'heavy' users taking 30+ tablets). One possible reason for the 
discrepancy in these studies is that whilst they used similar criteria for defining 'heavy' or 
'abuser' ecstasy use, mean ecstasy use in the two studies could have differed considerably. In 
Parrott, Sisk & Turner's study, mean ecstasy use in 'heavy' users was 371 times, where as 
mean usage of 'abusers' in Dugherio's study was not specified. Another possible account for 
the discrepancy in findings could be due to polydrug use, which has also been found to 
influence psychopathological profiles of ecstasy users (Parrott et al, 2001).
From a large-scale survey involving 768 volunteers from Italy and the UK, Parrott et al 
(2001) demonstrated that heavier ecstasy polydrug use was associated with higher 
psychopathology scores on the SCL-90. Whilst the heavy ecstasy using group was the most 
problematic and to a lesser extent the light ecstasy users, ecstasy users also displayed the 
heaviest polydrug use. Thus the high pathology scores for the heavier ecstasy users could 
simply be a profile of polydrug use in general. However, evidence to further suggest that 
higher psychopathology is associated with heavy ecstasy use, comes from a study by Milani 
et al (2000). They showed there was a significant positive correlation between the amount of 
ecstasy pills consumed and the scores on the anxiety, phobic anxiety and psychoticism scales 
of the SCL-90. A further study reported that of 234 ecstasy-polydrug users, 'problematic' 
users had higher pathology scores on several sub-scales of the SCL-90 compared with the 
'non-problematic' users. These perceived problems were related to greater lifetime 
consumption of ecstasy and the number of pills taken in a single occasion (Milani et al, 2001).
Other studies have also shown elevated psychopathology in ecstasy users compared to drug- 
naive and/or polydrug users (Gamma et al, 2001; Wareing et al, 2001; Daumann et al, 2001; 
Morgan et al, 2002 and Thomasius et al, 2003). Simon and Mattick (2002) also reported 
elevated levels of general psychopathology in ecstasy users compared to drug-naive and 
polydrug controls, as measured by the SCL-90-R Global Severity Index, but they failed to 
identify any specific psychopathological symptoms in these ecstasy users compared to 
cannabis users. However, this particular study has been criticised for its design in comparing 
ecstasy users with heavy concomitant use of cannabis, with cannabis users that also reported 
some use of ecstasy (Parrott et al, 2003).
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Which areas of psychopathology are affected?
Areas of psychopathology which have consistently been shown to be elevated in ecstasy users 
include psychoticism (Parrott, Sisk & Turner, 2000; Parrott et al, 2001; Dugherio et al, 2001; 
Daumann et al, 2001), phobic anxiety (Parrott, Sisk & Turner, 2000; Parrott et al, 2001; 
Dugherio et al, 2001; Daumann et al, 2001; Morgan et al, 2002), obsessive-compulsive 
symptomatology (Parrott, Sisk & Turner, 2000; Parrott et al, 2001; Dugherio et al, 2001; 
Daumann et al, 2001; Thomasius et al, 2003) and sleep (Dugherio et al, 2001; Morgan et al, 
2002). Table 3 summarises these findings.
Depression and anxiety have been the most extensively studied psychopathological symptom 
amongst ecstasy users, however, findings have not always been consistent. Maclnnes et al 
(2001) reported elevated levels of depression as measured by the BDI in ecstasy users 
compared to drug-naive controls. Further still, they reported that these levels of depression 
positively correlated with the maximum amount of ecstasy consumed in 12 hours (i.e. binge 
consumption). Other studies have shown long-term changes in depression in ecstasy users 
relative to drug-naive controls (Morgan et al, 2002) and compared to polydrug controls 
(Gamma et al, 2001; Morgan et al, 2002). Thomasius et al (2003) found significant 
differences in depression between ecstasy users and drug-naive controls but not between 
ecstasy users and polydrug users. However, it is notable that other studies did not find any 
significant group differences in levels of depression (Parrott, Sisk & Turner, 2000; Parrott et 
al, 2001; Dugherio et al, 2001; Daumann et al, 2001). As for anxiety, using the STAI, 
Morgan et al (1998) did not find any significant group differences between ecstasy users, 
polydrug controls, drug naive controls and cannabis users. However, in later studies assessing 
state anxiety, Wareing et al (2001) and Daumann et al (2001) found ecstasy users to have 
elevated anxiety scores compared to drug-naive controls, although they did not differ from 
cannabis users (Daumann et al, 2001). Using the SCL-90 and SCL-90-R, several studies have 
reported ecstasy users to exhibit significantly higher anxiety scores compared to drug naive 
and polydrug controls, but not cannabis users (Parrott, Sisk & Turner, 2000; Parrott et al, 
2001; Daumann et al, 2001; Morgan et al, 2002). However, Thomasius et al (2003) and 
Dugherio et al (2001) did not replicate this finding despite heavier use of ecstasy in their 
participants.
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Other areas of psychopathology, which have shown less consistent findings in ecstasy users, 
include somatisation, paranoia, aggression, anger/hostility and interpersonal sensitivity (see 
Parrott, Sisk & Turner, 2000; Parrott et al, 2001 and Morgan et al, 2002; Dugherio et al, 2001; 
Daumann et al, 2001; Thomasius et al, 2003; Curran & Veryheyden, 2003 and Curran et al, 
2004; Table 3). Such inconsistencies in the research could be partly related to the variation in 
the assessment measures used. For example, both studies by Parrott's group (Parrott el al, 
2001 and Parrott, Sisk & Turner, 2000) used the older version of the SCL-90 and 
demonstrated elevated anger/hostility scores in ecstasy users compared to polydrug controls 
and/or drug-nai've controls. This version of the SCL-90 has been criticised for its 
psychometric properties (see Cole et al, 2002). Conversely, Thomasius et al (2003) used the 
newer revised version of this scale (the SCL-90-R) and only found elevated anger/hostility 
scores compared to drug-nai've controls, but not the polydrug controls. Further still, Daumann 
et al (2001) assessed anger using the State-Trait Anger Expression Inventory (STAXI) and 
found that anger levels did not differ in ecstasy users compared to cannabis and drug-nai've 
controls.
Ecstasy use or polydrug use ?
Whether or not the elevated psychopathological symptoms in these ecstasy users are due to 
ecstasy use or general polydrug use has still to be fully addressed. Many differences in 
ecstasy user's psychopathological symptoms have only been shown relative to drug-nai've 
controls. Maclnnes et al (2001) reported elevated depression in ecstasy users relative to drug- 
nai've controls. Thomasius et al (2003) report elevated levels of depression, anger/hostility, 
obsessive-compulsive and interpersonal sensitivity symptoms compared to drug-nai've, but not 
polydrug controls. Daumann et al (2001) reported elevated phobic anxiety, obsessive- 
compulsive symptoms, anxiety, paranoia and aggression in ecstasy users relative to cannabis 
and drug-nai've controls, but not polydrug controls. This could suggest that 
psychopathological symptomatology in these ecstasy users may be more an artefact of 
polydrug use in general.
Studies such as Parrott et al (2001), Gamma et al (2001) and Parrott, Sisk & Turner (2000) 
have shown elevated psychopathological symptoms in ecstasy users compared to polydrug 
controls. Morgan et al (2002) showed that ecstasy users displayed significantly elevated
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scores on a majority of the scales of the SCL-90-R compared to drug-naive controls as well as 
polydrug controls, who were matched on levels of other drugs besides ecstasy. This suggests 
that the group differences were a result of ecstasy use rather than polydrug use. However, no 
measure of past ecstasy use predicted the psychopathology scores in these ecstasy users, 
whereas measures of cannabis use and some other drug use (e.g. poppers, speed, cocaine) did 
significantly predict psychopathological levels. Similar confounding effects of cannabis on 
psychopathological scores were found by Daumann et al (2001). Parrott et al (2001) also 
confirmed that psychological problems were not specific to ecstasy users, since higher 
psychopathology scores were evident in heavy polydrug users who had not consumed ecstasy, 
and that as the amounts of drug use increased, so too did the levels of psychopathology. This 
strongly suggests that drug use in general, in particular cannabis, is associated with 
psychopathology rather than ecstasy alone.
Perhaps the strongest evidence to date for psychological effects linked to ecstasy is from the 
only longitudinal study into the effects of ecstasy functioning on humans. Gerra et al (2000) 
assessed a group of ecstasy users over a period of a year compared to a group of control 
subjects. Levels of aggression/hostility, as measured by the Buss Durkee Hostility Inventory, 
were significantly higher in ecstasy users compared to controls after three weeks of abstinence 
from ecstasy. After 12 months of abstinence the ecstasy users no longer showed higher scores 
on aggression, and such a reduction in scores was significant compared to levels of aggression 
at 3 weeks. However, this study was limited in numbers and by the absence of a control 
group; this work also only measured one aspect of behaviour.
Interim Summary
In summary it appears that studies demonstrate elevated levels of psychopathology in ecstasy 
users compared to drug-naive controls and polydrug users. Dose-related findings between 
levels of psychopathology and levels of ecstasy use further suggest that there may certainly be 
an association between ecstasy use and psychopathological symptoms. The 
psychopathological symptoms that appear to be the most consistently elevated in ecstasy users 
are: - psychoticism, phobic anxiety, obsessive-compulsive symptoms and often anxiety and 
depression. All of these psychopathological dimensions, highlighted in these recreational 
ecstasy users are those which are prevalent in the individual case studies reported earlier. 
However, there is evidence to suggest that drug use in general is associated with
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psychopathology, in particular cannabis use. As such, interpreting any association or 
specifically any causative link between ecstasy use and psychopathology should be made with 
caution.
Long-term cognitive consequences associated with ecstasy use
In contrast to individual case study reports of psychiatric complaints associated with ecstasy 
use, there are a limited number of case studies focusing on adverse neurological and cognitive 
effects associated with ecstasy consumption. Teggin (1992) reported a 32-year-old female 
who developed an hysterical dissociative state followed by mild expressive aphasia, which 
lasted up to six weeks after ingesting a single tablet of ecstasy. Spatt et al (1997) also 
reported a case of a female aged 26 who developed a pure amnestic syndrome after exposure 
to ecstasy. Following a psychotic episode, which resolved, she was left with ongoing 
memory problems which persisted for two months. Nine months later there was only a slight 
improvement in her memory performance. A neurological examination showed bilateral 
hyperintense lesions, in the globus pallidus, which partly disappeared 2 months later. This is 
an area rich in serotonin releasing neurons and intimately connected to the basal ganglia 
(Feldman et al, 1997) and to basal structures of forebrain mnemonic systems (Dunnett et al, 
2001).
More recently Kopelman et al (2001) reported severe and persisting cognitive and 
neurological abnormalities in a 26-year-old female after she had consumed two ecstasy tablets 
on a single occasion. There was no known history of adverse reactions to ecstasy use from 
previous occasions when she took the drug. She exhibited severe anterograde memory 
problems, with evidence of executive/frontal lobe impairments, whilst immediate memory 
span, card sorting performance and various aspects of semantic memory remained intact. 
Kopelman and colleagues observed some improvement during an 8-year follow-up period, 
particularly in verbal recognition memory and performance IQ, but severe deficits still 
remained. However, with this case, and others of its nature, it is impossible to be certain 
whether the patient's brain damage and subsequent cognitive problems resulted directly from 
neurotoxic effects of ecstasy. For example, in this study, damage could have arisen indirectly 
from a disseminated intravascular coagulation and brief respiratory arrest that the woman
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suffered at the initial time of the adverse reaction to ecstasy. In addition, such adverse 
reaction case studies are, by their very nature, highly atypical.
The most extensive body of research concerning the long-term cognitive effects associated 
with ecstasy are from empirical studies. A brief summary of findings by specific area of 
cognitive processing can be found in Table 4.
Memory deficits are the most consistently reported long-term cognitive problem associated 
with ecstasy use. Parrott et al (1998) was one of the first to show memory deficits in ecstasy 
users compared to drug-naive controls. Since then, numerous studies have supported this 
finding, demonstrating memory impairments in ecstasy users relative to drug-naive controls 
(Wareing et al, 2000; Milani & Schifano, 2000; Reneman et al, 2000; Reneman et al, 2001; 
Gouzoulis-Mayfrank et al, 2000; Croft et al, 2001), cannabis users (Rodgers, 2000) and also 
polydrug controls (Morgan, 1998; Morgan, 1999; McCann et al, 1999; Bhattachary & Powell, 
2001; Fox et al, 2001b; Fox et al, 2001c; Verkes et al, 2001; Heffernan et al, 2001).
However, there are studies which do not demonstrate memory impairments in ecstasy users 
relative to polydrug controls or even cannabis users. For example, Semple at al (2001) 
showed relatively heavy ecstasy users (average lifetime consumption of 672 ecstasy tablets) 
performed at comparable levels to that of polydrug controls on CANTAB working memory 
tasks and the FAS word generation task. Simon and Mattick (2002) also failed to find any 
differences in memory between ecstasy and cannabis users on immediate and delayed 
memory recall, and also on a working memory test (WASI III). Again, interpretation of this 
finding should be made with caution because of the methodological flaws previously 
mentioned.
Even with those studies that show memory deficits in ecstasy users, the consistency of 
memory impairments differs considerably between and within studies (see Table 4). The 
inconsistencies between studies may, in part, be due to the wide range of assessment methods 
that have been employed and the type of memory being assessed. Everyday memory, 
including prospective memory has been consistently shown to be impaired in ecstasy users 
relative to drug-naive and polydrug controls (Schifano et al, 1998; Milani & Schifano, 2000; 
Rodgers, 2000; Heffernan et al, 2001; Rodgers et al, 2001).
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Less consistent findings have been found regarding immediate and delayed memory, and 
working memory. Reneman et al (2000 & 2001) have shown immediate and delayed memory 
impairments on the AVLT compared to drug-naive controls. Similar deficits have also been 
shown relative to polydrug controls, using the same and different methods of assessment (Fox 
et al, 2001c; Morgan, 1999; Morgan et al, 2002; Bhattachary & Powell, 2001; McCann et al, 
1999). However, these findings have not always been supported. Parrot and Lasky (1999) 
did not find any significant differences in word recall between ecstasy and polydrug users. 
This finding was supported by Thomasius et al (2002) who also did not find any differences 
in ecstasy users compared to polydrug controls or even drug-naive controls on prose and word 
recall, despite their ecstasy users having reported considerably large amounts of ecstasy use 
(average lifetime consumption was reported as 600 for females and 1034 for males).
Executive functioning/working memory deficits in ecstasy users have also been inconsistent. 
A number of studies have demonstrated significant deficits in ecstasy users relative to drug- 
naive controls (Wareing et al, 2000; Milani & Schifano, 2000; Croft et al, 2001) and also 
polydrug controls (Verkes et al, 2001; Morgan, 1998; Fox et al, 2001b & 2001c; Bhattachary 
& Powell, 2001; Fox et al, 2002). Nonetheless, other studies have not found any working 
memory deficits in ecstasy users (Morgan et al, 2002; McCann et al, 1999; Gouzoulis- 
Mayfrank et al, 2000). Even within the same studies impairments in working memory depend 
on the assessment measure employed. For example, Fox et al (2002) showed ecstasy users to 
be impaired on a spatial working memory task and semantic and letter category task, but not 
on the CANTAB Tower of London test. Likewise, Morgan et al (2002) showed working 
memory performance decrements in ecstasy users on the MMF20 and Subtracting Serial 
Sevens task, but not on the Controlled Oral Word Association Test. These studies clearly 
demonstrate that research showing memory deficits in ecstasy users is dependent on the type 
of memory being assessed and also the assessment measures used. These outcomes appear to 
demonstrate that memory problems are clearly not profound, but are instead more subtle 
phenomena.
Research findings demonstrating learning deficits in ecstasy users have been relatively more 
consistent. Croft et al (2001) and Gouzoulis-Mayfrank et al (2000) have reported learning 
deficits in ecstasy users compared to drug-naive controls but not cannabis users. Deficits 
have also been shown relative to polydrug controls (Fox et al, 2001c & McCann et al, 1999). 
However, Croft et al (2001) showed that learning deficits may again be task dependent. In
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their study, ecstasy users were impaired on visuo-spatial learning as measured using a design 
learning task, but not on verbal learning using the Coughlan list.
More consistent cognitive deficits have been shown in relation to attention/motor abilities. 
Ecstasy users have demonstrated impaired performances on a number of attentional tasks 
relative to drug-naive controls (Gouzoulis-Mayfrank et al, 2000; Croft et al, 2001; Milani & 
Schifano, 2000; Wareing et al, 2000; Morgan et al, 2002), cannabis users (Gouzoulis- 
Mayfrank et al, 2000) and polydrug controls (Zakzanis et al, 2002; Fox et al, 2002; Parrott & 
Lasky, 1998; Morgan et al, 2002; Verkes et al, 2001). Semple et al (1999), Gamma et al 
(2001) and Parrott et al (1998) did not show ecstasy users to be impaired on similar tasks, 
even though most of these studies actually employed heavier ecstasy users. Once again the 
discrepancy in findings between these and the former studies could be due to the differing 
measures employed in assessing this cognitive ability. Even within the same study, 
performance was dependent on the type of attention looked at and the assessment measure. 
For example, Gouzoulis-Mayfrank et al (2000) demonstrated deficits in ecstasy users on 
divided attention, selective visual attention and intermodal attention, but not on tonic and 
phase attention and visual scanning, nor on the Stroop test.
Ecstasy use or polydrug use ?
Amongst the studies discussed, a number of cognitive deficits in ecstasy users have been 
shown relative to polydrug users, suggesting that these deficits are associated with ecstasy use 
rather than just general polydrug use. However, further clarification of the potential 
confounding effect of polydrug use, especially cannabis use, on cognitive performance is 
necessary.
Fox et al (2001c) found that ecstasy users were still cognitively impaired, even after 
covarying for other drugs such as cannabis, cocaine, LSD and magic mushrooms. Similar 
findings were also shown by Morgan (1999) and Bhattachary & Powell (2001). However, in 
a study by Croft et al (2001), they found that cannabis was an important confound in studies 
of ecstasy-induced cognitive impairments, because covarying for indices of cannabis 
consumption removed most of the significant cognitive differences previously evident in their 
sample of ecstasy users.
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Further evidence suggests that there are certain cognitive deficits that are more pronounced or 
unique to ecstasy users. Rodgers (2000) found that deficits in logical memory were a feature 
of both ecstasy and cannabis use rather than ecstasy use alone. However, the ecstasy using 
group experienced additional impairments over and above those witnessed in the cannabis 
only control group. Rodgers et al (2001) tried to isolate the contribution of individual drugs 
to the overall variance in prospective memory performance scores in groups of ecstasy and 
cannabis users. They found a double dissociation between the impact of cannabis and 
ecstasy. Cannabis, but not ecstasy, was found to be associated with short-term and internally 
cued prospective memory; whilst ecstasy use, but not cannabis, was associated with long-term 
memory deficits. Thus, it appears that some selective cognitive deficits can be attributed to 
ecstasy use, but other drug use, specifically cannabis use, is certainly an important confound 
in these studies. Even though cannabis use alone is not sufficient to impair the performance 
in many of these tasks, the concomitant use of cannabis can certainly contribute to a cognitive 
impairment (Gouzoulis-Mayfrank et al, 2000).
Dose-related Effects
Further support for the role of ecstasy use and associated cognitive deficits, and an attempt to 
infer causation between ecstasy and its possible long-term cognitive effects, comes from 
studies which have reported dose-related type effects. This has been attempted, within 
cognitive studies, in one of two ways: Firstly, by employing different ecstasy using groups 
dependent on the level of drug use. For instance, assessing novice users who had only 
consumed ecstasy on 1-9 occasions, compared to regular ecstasy users who had used the drug 
on ten or more occasions (Parrott et al, 1998; Parrott & Lasky, 1998). Or comparing low 
ecstasy users (0-100 occasions), to medium (100-500 occasions) and high (500+ occasions) 
ecstasy users as well as polydrug controls (Fox et al, 2001b). The second method employed is 
to use statistical techniques such as regression, correlation or co-variant analysis to control for 
levels of ecstasy consumption and thus demonstrate possible dose-related findings (Morgan et 
al, 2002; Fox et al, 2001c; Morgan, 1999)
Parrott et al (1998) were one of the first research teams to employ a research design involving 
ecstasy groups with varying levels of drug use, as defined above. Despite finding significant 
cognitive deficits in immediate and delayed recall compared to drug-naive controls, they 
failed to find any differences in recall between novice and regular ecstasy users. However,
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they did find a difference between these two ecstasy-using groups on reaction time as 
measured by the Sternberg task. A further study by Parrott & Lasky (1998), which employed 
the same criteria for their novice and regular ecstasy using groups, found regular ecstasy users 
displaying the worst memory scores; though they did not differ significantly from the novice 
users.
A similar research design was used by Bhattachary & Powell (2001), comparing novice users, 
(1-5 occasions and never more than once a month), with regular ecstasy users (at least 5 times 
and twice in the last 21 days). Again, despite finding differences in performance between 
both ecstasy using groups and non-users, they did not find any differences between novice 
and regular users. However, statistically controlling for the amounts of ecstasy use, they 
found that heavier ecstasy use predicted poorer memory scores, with lifetime use emerging as 
the strongest predictor for immediate and delayed recall performance.
Level of ecstasy use was also found to influence performance on word recognition (Verkes et 
al, 2001), with heavy ecstasy users (defined as using on at least 48+ occasions, but had used 
on average 741 times), being affected significantly more than moderate ecstasy users (12-48 
occasions). Executive functioning decrements as a function of the level of ecstasy have also 
been demonstrated. Fox et al (200Ib) found that their higher user group (500+ occasions) 
demonstrated significantly poorer performance on an executive functioning task compared to 
low ecstasy users (0-100 occasions).
There is a greater amount of evidence demonstrating dose-related effects shown by 
statistically controlling for levels of ecstasy consumption. Bolla et al (1998) were one of the 
first research teams to demonstrate that impairments in immediate and verbal memory recall 
were associated with higher doses of ecstasy. Support for this dose-related effect on verbal 
memory recall also comes from Morgan et al (2001) and Reneman et al (2001), who both 
showed that greater lifetime use of ecstasy, negatively correlated with verbal memory 
performance. More recently, Thomasius et al (2003) demonstrated that the average number of 
words recalled on the AVLT was best predicted by the typical number of ecstasy tablets 
consumed in a year.
Other areas of cognitive performance deficits shown to be associated with ecstasy dosage 
include spatial working memory (Semple et al, 1999), working memory (McCann et al,
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1999), reaction times (Gouzoulis-Mayfrank (2000), attentional abilities (Gouzoulis-Mayfrank 
et al, 2000; Zakzanis et al, 2002) and executive functioning (Zakzanis & Young, 2001). The 
latter study also showed that the frequency and duration of ecstasy use was also associated 
with lower scores on many subtests of the Behavioural Assessment Dysexecutive Syndrome 
test. Collectively, these results suggest that increasing ecstasy consumption may lead to more 
pronounced impairment in cognitive functioning.
However, Simon and Mattick (2002) did not show any significant effects between the 
relationship of lifetime exposure and memory performance on the WMS-II. More recently, a 
meta-regression analysis did not indicate support for a linear relationship between the mean 
effect size and total lifetime consumption (Verbaten, 2003). However, there was the 
possibility of a stepwise relationship which may account for most of the research findings 
discussed earlier.
Interim Summary
There is a fairly large amount of empirical research into the possible cognitive impairments 
associated with ecstasy use. Areas of relatively consistent cognitive dysfunction in current 
ecstasy users compared to non-ecstasy using groups are immediate and delayed memory, 
executive functioning, working memory, including prospective memory, and attentional 
abilities. Whilst cannabis use is thought to have a potential confounding effect on some of 
these cognitive functions, there are some selective cognitive deficits found to be associated 
with ecstasy alone. Conclusions concerning dose-related effects of ecstasy on cognitive 
impairments are more difficult to come to because of the inconsistencies in research findings 
and the differences in approaches in trying to demonstrate dose-related findings. It is possible 
that such inconsistencies and discrepancies between research studies may indicate that 
ecstasy-induced effects are very subtle, rather than overtly profound global impairments in 
cognition.
Cognition and altered serotonin functioning
In addition to dose-related effects between cognitive impairment and levels of ecstasy 
consumption, further support for the association between ecstasy and its possible functional 
consequences, on cognitive functioning, comes from studies which have measured alterations
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in serotonin functioning, as well as corresponding cognitive performance in ecstasy users 
compared to controls.
Cognitive deficits in ecstasy users have been shown to be correlated with decreases in the 
concentration of 5-HIAA (McCann et al, 1999; Bolla et al, 1998). Bolla et al (1998) also 
showed an additional negative association between ecstasy dosage and 5-HIAA 
concentrations. This suggests that the higher the dose of ecstasy the greater the subsequent 
decrement in memory function and the lower the level of CSF-5-HIAA (an indirect measure 
of central 5-HT function).
Other markers of serotonergic neuronal injury and corresponding cognitive deficits have also 
been demonstrated. Krystal et al (1992) found a correlation between ecstasy user's 
performance on the delayed figural subtest of the Wechsler memory scale, and prolactin 
response to an L-tryptophan pharmacological challenge. However, there is a limit concerning 
the degree to which one can derive conclusions from this finding since there were no age- 
matched controls and the sample size was small. Curran & Verheyden (2003) found elevated 
levels of plasma tryptophan following an L-tryptophan pharmacological challenge, which 
strongly correlated with performance on a prose recall task. However, this was only found in 
ex-ecstasy users (those who had not used for at least one year) and not current ecstasy users. 
Verkes et al (2001) found that following a d-fenfluramine challenge, cortisol levels in 
moderate and heavy users significantly differed to that of polydrug controls. This study also 
showed cognitive deficits in both ecstasy using groups on a variety of tasks.
Further still, Reneman et al (2000) demonstrated that 5-HT cortical binding significantly 
correlated with verbal recall on the AVLT in ecstasy users. In a follow-up study they also 
showed significant group differences in cortical 5-HT neuron binding and also immediate and 
delayed recall on AVLT; though here memory performance was not associated with the 
extent of cortical binding and they failed to replicate the dose-related findings from the 
previous study (Reneman et al, 2001).
Although most of these studies addressing cognitive dysfunction and altered serotonergic 
activity are limited in someway or another (i.e. small sample sizes, cross reference 
comparisons only), they at least suggest an intriguing relationship between markers of 
serotonergic brain damage and memory performance in ecstasy users. This pattern of
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cognitive decrement is consistent with the animal data illustrating serotonin neurotoxicity in 
the frontal cortex and hippocampus; brain areas that are important for planned actions and 
memory functioning (see chapter 1).
Recovery of cognitive abilities
Despite extensive empirical evidence suggesting serotonergic alterations and associated 
cognitive dysfunction as a result of recreational ecstasy use, there has been very little research 
into whether these cognitive deficits remain after abstinence from ecstasy, or if ex-users show 
signs of functional recovery. The recovery, if any, of cognitive functioning in humans might 
suggest a recovery of central 5-HT functioning, as documented in the case of animals.
Tentative evidence of the recovery of memory performance was shown in a small group of 
ecstasy users who had abstained from the drug for more than 6 months (Morgan, 1998). 
However, further evidence suggests that cognitive deficits are more persistent, as shown by 
Wareing, et al (2000). In their study, current and previous ecstasy users (defined as those 
who had stopped taking ecstasy at for at least six months), were found to have deficits on 
some aspects of central executive functioning compared to a control group of non-ecstasy 
users. Thomasius et al (2003) showed impairments on immediate and delayed verbal recall 
that were persistent in ex-ecstasy users. However, they had only been abstinent for at least 5 
months (males on average 485.4 + 533.09 days and females 545.13 + 470.74 days), and their 
current ecstasy users failed to show any impairments relative to controls. Curran & 
Verheyden (2003) showed ex-ecstasy users demonstrated a number of cognitive impairments 
in working and episodic memory a year after ecstasy cessation compared to current ecstasy 
users and polydrug controls. However, like Thomasius et al (2003), their current ecstasy 
users did not show any impairments on the same tasks relative to controls. Further support 
for the persistency of selective cognitive impairments, come from a study by Morgan et al, 
(2002). Here ex-ecstasy users showed significant impairments on the RBMT story recall task 
and committed a significant number of errors on the MFFT-20 relative to polydrug users. 
These deficits remained after an average of two years of abstinence (Morgan et al, 2002).
It is also worth noting here that the data on the persistency of cognitive impairments in 
abstinent ecstasy users, does not necessarily reflect that serotonergic recovery does not occur. 
Reneman et al (2001) demonstrated that the neurotoxic effects on 5-HT in the cortex may be
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reversible in ex-ecstasy users, yet despite these indications of recovery in cortical binding, 
cognitive impairment still remained in ex-ecstasy users compared to controls. AVLT 
performances showed that both ecstasy and ex-ecstasy users differed to that of controls. This 
suggests that although the neurotoxic effects may appear reversible at the neurological level, 
the effects on memory function may be long-lasting. This would tie in with the animal data 
(Fischer et al, 1995; Hatzidimitriou et al, 1999) showing 'sprouting' of serotonin axons i.e. 
serotonergic recovery, but not necessarily normal organisation or functioning. As such, it 
could be argued that memory testing is a more valid indicator of injury or recovery than 
measuring ecstasy effects on SERT densities, though this still remains to be proven.
Other important confounds/contributory factors
Caution is needed when interpreting some of the research findings discussed, as sequalae 
reported as long-term effects of ecstasy could instead be the subacute effects. Parrott et al 
(1998), Morgan et al (1999), Croft et al (2001), Heffernan et al (2001), Verkes et al (2001), 
Bhattachary and Powell (2001) and Daumann et al (2001), all reported effects of ecstasy after 
a short abstinence period of only 1-7 days. Therefore any effects could potentially be acute 
partial residual effects or drug withdrawal effects of the ecstasy, rather than the long-term 
effects. Also, many studies do not even report any abstinence criteria for ecstasy use before 
testing or the time since the last ecstasy ingestion (e.g. Schifano et al, 1998; Parrott et al, 2000 
& 2001; Dughiero et al, 2001; Morgan et al, 2002). Again making it difficult to infer whether 
the findings are about the long-term effects of the drug. However, support suggesting that 
these problems are long-term effects associated with ecstasy use comes from studies which 
did utilise a minimum two-week abstinence period prior to assessment (e.g. Bolla et al, 1998; 
Zakzanis & Young, 2001; Zakzanis et al, 2002; Renemen et al, 2001; McCann et al, 1999).
In trying to interpret a causative link between recreational ecstasy use and the development of 
cognitive and psychological problems there is always the confounding variable of pre-existing 
problems that ecstasy users may have prior to their ecstasy use. Most empirical research into 
the long-term effects of ecstasy is retrospective and thus baseline (premorbid) levels of 
function, both cognitively and psychologically, are difficult to establish. Any differences 
between ecstasy users and control groups could reflect a number of pre-existing 
neurochemical, genetic and personality differences between the two groups rather than the
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effects of using ecstasy. It has been repeatedly shown that, in a number of studies, ecstasy 
users display higher scores on impulsiveness, venturesomeness, sensation seeking and novelty 
seeking scales, compared to controls (Morgan et al, 1998; Parrott et al, 2000; Morgan et al, 
2000; Montgomery & Butler, 2001a; Daumann et al, 2001; Dugherio et al, 2001). It is well 
established that childhood problems and personality traits such as sensation seeking and 
impulsivity, are associated with an increase risk of experimenting with controlled drugs and 
developing substance abuse problems (Bardo et al, 1996; Hawkins et al, 1992; Zuckerman et 
al, 1994; Hatzitaskos et al, 1999; Clark et al, 1998). These secondary personality factors are 
also associated with lower serotonergic functioning (Linnoila et al, 1993; Virkkunen et al, 
1995) and alone may account for the psychopathological scores and cognitive deficits in the 
ecstasy users, since many of these personality traits, independent of drug use, are also 
associated with poorer cognitive performance and increased risk of developing adult 
psychopathology (Zuckerman & Neeb, 1979; Hawkins & Trobst, 2000). Thus, premorbid 
states, especially ones that are known to be related to low 5-HT function, could contribute to a 
misleading impression that cognitive deficits and increased psychopathology are caused by 
ecstasy use or, at the very least, may limit the interpretation of the functional effects of 
ecstasy.
There is also the confounding factor of the individuals having a pre-existing diathesis, 
especially concerning studies assessing the psychopathological status of ecstasy users. The 
classic diathesis model for mental health, proposes that the combined impact of genetic 
predisposition and an environmental stressor, produces a given negative mental health 
outcome (Gabbard & Goodwin, 1996). However, it may be that in ecstasy using individuals, 
their ecstasy use may have constituted this significant external stressor by negatively 
modulating normal brain function. Even though many empirical studies exclude participants 
with current or past psychiatric and medical illnesses (e.g. Verkes et al, 2001; Bolla et al, 
1998; Reneman 2000; Zakzanis et al, 2002; Fox et al, 2002; Simon & Mattick, 2002), few 
studies actually report family psychiatric history, which might suggest a possible genetic 
predisposition to psychiatric illness in participants. Thus, evidence in terms of any causative 
link between ecstasy and MDMA-induced neurotoxicity from psychiatric reports and 
experienced psychopathology following ecstasy use, is therefore the weakest, because of the 
mediating factor of a pre-existing diathesis. Therefore interpretation should be limited to
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mere associations between ecstasy use and these cognitive and psychological effects which 
have been discussed.
Finally, another pre-existing genetic difference that could possibly account for differences in 
ecstasy users, and/or determine possible individual vulnerabilities in ecstasy users, is the 
individual metabolic handling of certain drugs. Polymorphic enzyme cytochrome P450 2D 
(CYP2D6) is involved in the metabolism of a broad array of drugs. Kreth et al (2000) and 
Ramamoorthy et al (2002) have shown that individuals who lack fully functioning CYP2D6 
enzymes have a reduced ability to metabolise MDMA. Since about 5-9% of Caucasians are 
deficient in this enzyme (Tucker et al, 1994), it has been suggested that this genetic 
polymorphism may explain some of the inter-individual differences in MDMA toxicity 
(Schifano, 2004). Additionally, the enzyme COMT is also involved in the metabolism of 
MDMA and its metabolites, and approximately 25% of the Caucasian population have low 
COMT activity (Zhu, 2002). Thus a reduced ability to metabolise MDMA and its metabolites 
due to genetic differences, may contribute to the toxic effects of MDMA in some individuals, 
and potentially long-term ecstasy-related neurotoxicity and its cognitive and psychological 
consequences (Schifano, 2004).
Problematic ecstasy use
To date there is an extensive body of research that demonstrates the possible functional 
consequences of ecstasy-induced serotonergic neurotoxicity, with supportive dose-related 
type effects and associated alterations in serotonergic functioning. The literature suggests that 
ecstasy is associated with long-term cognitive and psychopathological effects, but little 
attention has been given to establishing whether these effects develop to such an extent that 
ecstasy users consider them to be problematic. Clinical case studies demonstrate that these 
effects of ecstasy can be problematic. However, these are limited in number compared to the 
numbers of people reported using ecstasy. Research concerning the extent of ecstasy-related 
effects in non-clinical ecstasy users has been limited.
According to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA; 
2001), ecstasy use is the main drug of those in treatment in only a few cases. However, 
reports focusing solely on ecstasy users demonstrate a different picture. In an Australian
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survey, Topp et al (1999) showed that one fifth of ecstasy users had received treatment for an 
ecstasy-related problem, mainly from a GP or a natural therapist, 7% were currently in 
treatment and a further 15% wanted formal treatment for difficulties perceived to be related to 
ecstasy use.
In a UK survey of ecstasy users, 55% reported continuing to use ecstasy despite reporting 
problems (Winstock et al 2001). In the same study 15% of ecstasy users fell into the 
problematic range, as defined by using the severity of dependence scale. These studies 
indicate that there are recreational ecstasy users that are developing chronic problems 
associated with their ecstasy use, but do not indicate what specific type of problems these 
ecstasy users are exhibiting. Hammersley et al (1999) noted that the heaviest users of ecstasy 
were more likely to report having experienced paranoia and memory problems, but were also 
more likely to report having been an inpatient in the last year, making it difficult to determine 
whether their problems were a result of their ecstasy use.
To try and establish whether the effects of ecstasy develop to such an extent that users 
considered the effects to be problematic, Parrott et al (2002) aimed to assess the incidence of 
ecstasy-attributed problems in relation to the level of ecstasy use. Volunteer ecstasy users (n 
= 763) were divided into novice (n = 109), moderate (n = 136) and heavy users (n = 36), 
depending on their lifetime ecstasy consumption (1-9 occasions, 10-99 occasions and 100+ 
occasions respectively). They were asked to indicate whether or not they had experienced a 
list of problems 'off-drug' that they attributed to ecstasy; these included psychological, 
cognitive, medical and physiological problems. Depression, memory problems, anxiety, 
mood fluctuations, poor concentration, infections, tremors/twitches and weight loss were all 
significantly associated with the extent of ecstasy use. One limitation of this study is that it 
was web-based, which potentially means that these problematic ecstasy users are self-selected 
and are an unrepresentative cohort of ecstasy users. However, despite the reliance on self- 
report data, with no objective measure of these problems, it does argue that the diversity of 
problems experienced by these particular ecstasy users and their incidence, is a direct function 
of the number of occasions on which the drug has been consumed.
However, Fox et al (200 Ib) reported that psychological symptoms in "problematic" ecstasy 
users were unrelated to ecstasy use. This study examined the differences between self- 
reported problems (psychological, emotional and somatic problems) and "non-problem"
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ecstasy users in relation to both consumption and premorbid life adjustment variables. Those 
problem ecstasy users who reported problems which they attributed to their ecstasy use, had 
significantly higher scores on all scales of the SCL-90 compared to the non-problem group. 
Yet their self-perceived problematic use was not related to their drug use but to negative 
interpersonal relationships prior to taking the drug and less socially orientated motivations for 
using the drug. Winstock et al (2001) argues that it is speculative to suggest that ecstasy per 
se can cause such problems or even an ecstasy dependence syndrome, because of social and 
behavioural constructs, which are key issues. This is supported by the findings of Fox et al 
(200la), in that the role of premorbid data and self-perception of problematic drug use is 
integral to issues relating to cause and effect in the ecstasy use/pathology relationship. 
There are inconsistencies in the literature focusing on the problematic nature of these ecstasy- 
related effects, but evidence does suggest that some ecstasy users do consider themselves to 
have developed problems which are associated with past ecstasy use. This issue of 
problematic ecstasy use lends support to the MDMA induced serotonergic neurotoxicity 
model; in that, these ecstasy users have incurred serotonergic injury and are displaying the 
functional impairments associated with such damage. Individuals, who are not considered as 
problematic, may not have experienced sufficient neurotoxic injury for the effects to have 
developed to such an extent that they have become behaviourally problematic. However, 
there are inconsistencies in the evidence for this model, since not all ecstasy users become 
problematic. Not all deficits become problematic, some are more subtle than others and other 
behavioural capacities seem to be spared.
Taken together with anecdotal evidence, it is clear that many ecstasy users are not 
problematised by their ecstasy use. The question is, whether this is because the effects in 
these ecstasy users are so subtle they are not perceived as being problematic? Or, that they 
have not taken enough ecstasy to have incurred serotonergic damage to have caused 
behavioural problems? Or even, that there are some ecstasy using individuals who are 
impervious to the potential harmful effects of the drug, be that for genetic, biological and/or, 
personality reasons. It is for this reason that further empirical research is needed into the 
extent and nature of problems associated with ecstasy use and whether such problems are a 
result of ecstasy per se and/or a combination of other behavioural and social issues.
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SUMMARY
This chapter provides an overview of the current research which demonstrates the possible 
cognitive and psychological effects associated with ecstasy use. It appears that there is 
evidence from both clinical and empirical studies to suggest that ecstasy users demonstrate 
elevated psychopathology and cognitive impairments. Studies have consistently shown that 
ecstasy has been associated with elevated levels of psychoticism, phobic anxiety, and 
obsessive-compulsive and anxiety symptoms. Whilst there is evidence to suggest that ecstasy 
users show elevated levels of interpersonal sensitivity, paranoia, aggression and anger, and 
depression, not all studies have shown consistent significant group differences. Research 
concerning cognitive abilities in ecstasy users, points to selective deficits: in particular verbal 
memory, prospective memory, working memory and executive functioning, and attentional 
abilities; even in studies which have accounted and controlled for polydrug use. However, 
not all findings have been consistent, with some studies only showing impairments in one of 
these cognitive domains and not others. Some studies have only indicated deficits relative to 
drug-naive controls and not cannabis and/or polydrug users and some cognitive deficits are 
dependent on the specific cognitive task employed. Dose-related effects of ecstasy in relation 
to both cognitive impairment and psychopathology, strengthens the association with ecstasy 
use and these functional consequences, as well as associated alterations in serotonergic 
functioning. The question pertaining to whether or not any of these long-term problems 
develop to an extent that they become problematic to the user, and are a direct function of 
their past ecstasy use has yet to be resolved.
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RATIONALE
Animal research strongly suggests that MDMA (ecstasy) induces serotonergic neurotoxicity. 
Human research, whilst less consistent, also provides support for possible serotonergic 
neurotoxicity, by showing altered brain serotonergic functioning in recreational ecstasy users. 
The possible psychological consequences of these neuronal alterations therefore are thought 
to be within areas that are regulated by serotonin. These include:- mood, anxiety, aggression, 
appetite, sleep, motor activity and areas of cognition such as learning, visuo-spatial memory, 
associative functions and aspects of planning and general memory consolidation and retrieval. 
Whilst a number of case studies and empirical evidence strongly point to this proposition, 
there still remain inconsistencies concerning which areas of cognition and which specific 
psychopathological domains are affected. More importantly, research concerning the extent 
of these problems is limited. Clinical case studies demonstrate that these effects of ecstasy 
can be problematic. However, these are limited in number compared to the numbers of 
people reported using ecstasy. There is also a paucity of literature on problematic ecstasy use 
in non-clinical population samples, with little attention given to establishing whether there are 
differences in ecstasy users who develop problems, to those ecstasy users who do not. Little 
research has addressed personality factors in relation to problematic ecstasy use. It may be 
that perceived problems relate to certain personality factors. In response to this shortage of 
research differentiating between problematic and non-problematic ecstasy use, the broad aim 
of this thesis was to corroborate and expand upon prior research, by identifying ecstasy users 
who have developed problems which they attributed to their past ecstasy and compare them to 
ecstasy users who do not report problems attributable to their ecstasy use, in order to identify 
any potential differences between these two distinct ecstasy using groups. In order to achieve 
this aim, this thesis intends on focusing on the two main areas which, in the current literature, 
have shown to be affected in ecstasy users relative to non-ecstasy users - that of cognitive 
problems and psychological health. To assess potential differences in problematic and non- 
problematic ecstasy users in relation to one another and compared to polydrug controls within 
these two areas, tests known to demonstrate ecstasy-related impairments will be used, these 
include the AVLT, TOL, RBMT and a measure of psychopathology using the brief version of 
the SCL-90-R; the BSI.
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CHAPTER 3
Cognitive and psychological profiles of non-problematic and
problematic ecstasy users
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INTRODUCTION
This study aimed to assess whether ecstasy polydrug users are more susceptible to cognitive 
and psychopathological 1 problems compared to polydrug controls. More specifically, 
whether there are relationships between the cognitive and psychopathological effects, drug 
dosage and problematic ecstasy use (adverse psychological problems attributed to past ecstasy 
use).
To date a few studies have addressed the issue of problematic ecstasy use in relation to 
cognitive and psychological functioning. Schifano et al (1998) conducted a large scale 
clinical survey examining 150 patients who had used ecstasy on at least one occasion, and 
who had presented themselves, for various reasons, to an addiction treatment unit. Seventy- 
nine patients were diagnosed as problematic, with the presence of one or more 
psychopathological disorders as assessed by the DSM-III-R. Those individuals that had used 
ecstasy for a longer period of time, and had consumed a greater amount in their lifetime were 
more likely to show co-morbidity and/or present with more severe symptoms.
A sub-sample of these problematic ecstasy users (n=10) were assessed for cognitive 
impairment, by comparison with a group of 20 (age and education matched) normal subjects 
who did not report any lifetime consumption of illegal drugs (Milani, 1997). The problematic 
ecstasy users showed significant cognitive impairments compared to these drug-naive 
controls. However, interpretation of the cognitive impairments in these problematic ecstasy 
users was limited since no comparison was made with ecstasy users that were not diagnosed 
with psychopathological disorders, or with age-matched drug-naive psychiatric patients. 
Additionally, cognitive abilities were compared with a control group that consisted of drug- 
naive subjects. Since 78% of the problematic ecstasy users reported opiate use and 30% 
reported other drug use (nitrates, LSD); cognitive deficits might be the result of polydrug use 
rather than ecstasy per se.
These limitations were addressed in the first non-clinical study to examine the interaction 
between ecstasy use and self-reported problematic drug use in relation to cognitive
1 Psychopathology will be used as a term to refer to the manifestation of behaviours and experiences which may 
be indicative of mental distress / illness or psychological impairment.
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impairment. Fox et al (2001b) assessed whether cognitive deficits in recreational ecstasy 
users were related to the awareness of problematic ecstasy use or actual drug dosage, by 
comparing problematic ecstasy users, non-problematic ecstasy users and polydrug controls on 
a number of cognitive tests. Despite the fact that the two ecstasy groups differed markedly in 
reported problems attributed to ecstasy use, both groups (problematic and non-problematic) 
showed similar cognitive impairments compared to polydrug controls on two executive tasks, 
as well as similar drug consumption profiles, duration and lifetime consumption of ecstasy 
use. Thus there were differences in perceived problems between groups yet they exhibited 
similar cognitive deficits and patterns of drug use. To further assess the interaction of drug 
dosage and cognitive functioning, Fox et al (200Ib) combined both ecstasy-using groups 
together and further divided them into low, medium and high users. High ecstasy users 
exhibited significantly greater cognitive impairment than medium and low ecstasy users. 
Hence, decrements in cognitive functioning were demonstrated as a function of drug dosage 
rather than problematic ecstasy use, which further suggests that individual's awareness of 
problematic ecstasy use may not be necessarily dose-related. However, this study did not 
formally assess the psychopathological status of these recreational ecstasy users. Rather 
subjects were just asked to indicate whether they had or had not experienced problems which 
they attributed to their past use of ecstasy.
This current study aimed to expand and improve upon prior research into the cognitive 
functioning and psychopathological status in relation to drug dosage in problematic ecstasy 
users, by employing a non-problematic ecstasy using group and also looking at a clinical 
sample of problematic ecstasy users. In order to achieve this, the current study employed 
recreational ecstasy users who reported psychobiological problems that they attributed to their 
past ecstasy use (problematic ecstasy users) and a second group of recreational ecstasy users 
who were problem free (non-problematic ecstasy users), in addition to a polydrug control 
group. Problems in the 'problematic' ecstasy group were defined as problems that were 
clinically recognised and/or interfered sufficiently in their life functioning that they had 
sought some form of help for.
All three groups were assessed and compared on a battery of cognitive tasks which consisted 
of the Auditory Verbal Learning Task (AVLT), Tower of London (TOL) and Rivermead 
Behavioural Memory Test (RBMT). These tasks have previously demonstrated sensitivity to 
ecstasy-induced effects (see literature review). The AVLT assesses problems specifically
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with immediate and delayed verbal recall. Ecstasy users have been shown to perform 
significantly worse than drug naive and polydrug controls on the immediate recall component 
of this task (Reneman et al, 2001 and Fox et al, 2001c) and the delayed recall component 
(Reneman et al, 2001, Reneman et al, 2000 and Fox et al, 2001c). Additionally, AVLT verbal 
recall has been shown to significantly correlate with 5-HT cortical binding (Reneman et al, 
2000). Ecstasy users may also be susceptible to frontal executive problems (Verkes et al, 
2001; Morgan et al, 2002; Fox et al 2002). The TOL measures planning abilities, one aspect 
of executive functioning. This assessment measure has also revealed impairments in ecstasy 
users (Fox et al, 2001b; Schifano et al, 1998). The RBMT was employed because it is an 
ecologically valid battery of psychological tests which indicate impairments in everyday 
memory functioning and has also been used previously in this research area (Schifano et al 
1998). The aim of the study was therefore to try and identify cognitive deficits in ecstasy 
users compared to polydrug controls and, more specifically, whether those that reported 
problematic ecstasy use were more sensitive to detrimental cognitive effects compared to 
ecstasy users that did not report problems.
Psychopathological status was assessed in all three groups, using a modified version of the 
Brief Symptom Inventory (BSI) (Derogatis & Melisaratos, 1983). This is a self-report 
clinical rating scale, covering nine distinct subscales; including somatisation, obsessive- 
compulsive-like behaviour (OCD), interpersonal sensitivity, depression, anxiety, 
anger/hostility, phobic anxiety, paranoid ideation and psychoticism (see appendix for further 
detailed definitions of these subscales). The BSI is a shortened version of the SCL-90-R 
(Derogatis et al, 1976), designed to assess the psychological symptom status across nine 
primary dimensions in psychiatric and medical patients, as well as individuals who are not 
patients (Derogatis & Melisaratos, 1983). This shortened version of the SCL-90-R seemed 
suitable to employ in conjunction with other assessment measures as psychometric evaluation 
has shown it to be an acceptable, reliable and valid alternative to the longer complete scale 
(Derogatis & Melisaratos, 1983). The use of this scale was to establish whether ecstasy users 
reported higher psychopathological scores than polydrug controls. Previous studies using the 
SCL-90-R have demonstrated elevated psychopathology compared to controls (Parrott et al, 
2001; Morgan et al, 2002, Parrott et al, 2000; Daumann et al, 2001; Dugherio et al, 2001). 
Further still the BSI allows for formal assessment of psychopathology in the 'problematic' 
ecstasy users, to establish whether they do exhibit psychopathological problems, or whether
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there is just a difference in awareness and perception of problematic ecstasy use as 
demonstrated previously by Fox et al (200Ib).
The scale was modified with the addition of items reflecting sexual functioning, cognitive 
failures; known MDMA side effects and the addition of four positive dimensions: feeling 
content with life, positive psychobiology, sociability and mood state (items previously added 
to the SCL-90 in the studies by Parrott et al (2001) and Milani et al (2001)). The cognitive 
failures subscale was added to allow subjective assessment of cognitive performance, whilst 
the sexual functioning and MDMA side effects dimensions were added to tailor the scale to 
areas specifically related to ecstasy problems (Cohen, 1995). The four positive items were 
added in answer to criticism from advocates of recreational ecstasy use who frequently state 
that researchers are biased and focus solely on the negative effects rather than the positive 
effects of the drug (Parrott et al, 2001).
Another objective to the study was to examine whether there were any cognitive and 
psychological dose response effects of ecstasy use, in order to confirm previous findings (e.g. 
Schifano et al, 1998; Parrott, Sisk & Turner, 2000; Maclnnes et al, 2001; Fox et al, 2001b; 
Reneman et al, 2001). In order to achieve this psychopathological and cognitive test scores in 
all ecstasy users (both problematic and non-problematic) were correlated with ecstasy use 
patterns; including lifetime consumption, average dose consumed on any one occasion and 
largest dose consumed on one occasion. To date a number of conclusions have been drawn 
relating to the total level of ecstasy consumption (Fox et al, 200Ib; Parrott et al, 2001), the 
number of pills taken in a single occasion (Milani et al, 2001) or maximum amount of ecstasy 
consumed in 12 hours i.e. binge consumption (Maclnnes et al, 2001). This will hopefully 
help to establish further which aspects of ecstasy consumption are important in inducing 
cognitive and/or psychopathological problems.
The study also aimed to explore further, a number of other variables such as, patterns of 
ecstasy use and levels of polydrug use and other self-rating variables, focusing on perceived 
positive and negative effects of ecstasy, which have been briefly examined in previous 
investigations (Liechti et al 2000b; Gamma et al, 2000; Cami et al, 2000; Liechti & 
Vollenweider, 2001; Cohen et al, 1995; Parrott et al, 2002). The study also explored a record 
of individual and family psychiatric histories. 'Ecstasy' problems may be influenced in whole 
or part by pre-existing pathology or predisposition, which in turn, might be reflected from
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such individual and family histories, or more intense ecstasy use in combination with heavier 
polydrug use.
There is a multiple of case reports involving ecstasy induced toxicity that exhibit features and 
in some cases fit the diagnostic criteria for the serotonin syndrome2 (Demirkan et al, 1996; 
Mueller & Korey, 1998). It has been argued that the serotonin syndrome represents a 
continuum of responses from mild to severe (Gillman, 1998), with the greater the elevation of 
5-HT concentration the greater and more severe the symptoms (Gillman, 1997). Thus it has 
been proposed that the mechanism of ecstasy intoxication produces the serotonin syndrome 
(Gillman, 1997). Some individuals develop severe responses, as demonstrated by reported 
case studies and others reporting a milder version of the syndrome. Many of the negative 
acute effects of ecstasy (e.g. reduced body temperature, excessive sweating, confused thought, 
dilated pupils), are in part, mild symptoms that constitute the serotonin syndrome. 
Susceptibility to the long-term neurotoxic effects could be reflected by, or be a direct result of 
acute negative effects (Parrott, 2002). There is very little data on this relationship, therefore 
the current study also aims to explore whether this is possibly the case, by comparing 
problematic and non-problematic ecstasy user's scores on a self-rating questionnaire based on 
the acute physiological and psychological effects of ecstasy (Cohen, 1995; Davison and 
Parrott, 1997).
The working hypotheses were as follows: Firstly, ecstasy using individuals would 
demonstrate cognitive deficits and higher psychopathology compared to polydrug controls. In 
addition, it is predicted that there will be a significant difference in cognitive and 
psychopathological status between the two more 'clinically' defined ecstasy using groups; 
those who reported problems from ecstasy use and those who did not. Secondly, it is 
predicted that patterns and levels of ecstasy use would vary between the problematic and non- 
problematic ecstasy user groups. It is expected that problematic ecstasy users would report 
greater lifetime consumption and average use than non-problematic ecstasy users, and thirdly
2 The serotonin syndrome is produced in the setting of the recent concurrent use of a serotonergic agent. It is 
characterised by alterations in cognition, behaviours, CNS function and neuromuscular activity. Diagnosis is 
usually established by a constellation of symptoms; confusion, shivering, diaphoresis, ataxia, hyperreflexia, 
diarrhoea, myoclonus, rigidity, agitation, restlessness, coma, autonomic instability, low-grade fever, nausea, 
flushing and rarely rhabdomyolysis and death (Sternbach, 1991; LoCurto, 1997).
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the cognitive and psychopathological effects of the drug will vary with dose, i.e. the greater 
the dose the greater the impairment.
67
Kirstie Soar Chapter 3
METHOD 
Participants
Participants were recruited via the 'snowball' method (6%) (Solowij et al. 1992), word of 
mouth (35%), self-referrals from psychiatrists and clinical psychologists (3%), advertisements 
(appendix O) in a London based magazine called the Big Issue (15%) and posters (appendix 
Q) around the University of East London (28%). First year undergraduate psychology 
students, who volunteered for the study, did so as part of a course requirement (13%). All 
participants were assessed for ratings of health, age and number of years in education.
Fifty-four subjects participated in this study: 20 (13 male, 7 female) recreational ecstasy users 
who had used ecstasy on at least 20 occasions in their lifetime and had not experienced any 
long term problems attributable to its use, 14 (8 male, 6 female) recreational ecstasy users 
who reported problems which they attributed to past ecstasy use. These problems had to be 
clinically defined (e.g. clinical depression, psychosis, schizophrenia), and/or interfere 
sufficiently in the participants life functioning to the degree that they had sought some form 
of help. Finally, there were 20 (8 male. 12 female) polydrug controls that had no history of 
ecstasy exposure but otherwise had used other illicit drugs. Given that the half-life of MDMA 
in animals is between 1 and 2 hours, it was deemed appropriate to have a 2-week abstinence 
period of ecstasy prior to assessment, in order to rule out any withdrawal or possible residual 
effects of the drug. Participants were required to abstain from other drug use for 24 hours 
prior to assessment.
All participants were required to give details of personal history regarding their own and their 
immediate family's psychiatric history and details of their past drug history (appendix A). 
Ecstasy users were required to provide further information concerning, patterns of ecstasy 
use: including information on the duration of ecstasy use, the last time taken, the average 
number of ecstasy tablets consumed in one occasion, the largest number consumed in one 
occasion, whether they increased the number of ecstasy tablets taken on each successive 
occasion, whether they thought the effects of ecstasy had changed the more it was taken, 
whether they suffered if they went without ecstasy for sometime, whether they needed to take 
ecstasy regularly, whether they felt addicted or dependent on ecstasy, whether they considered 
themselves to be a stable user of ecstasy, whether they continued to use ecstasy and whether 
they used other drugs to alleviate any known ecstasy side effects (appendix B).
68
Kirstie Soar Chapter 3
Both ecstasy-using groups were also asked to complete two additional sets of questions. The 
first consisted of a 4-point Likert scale on the acute effects of ecstasy (appendix C). 
Participants were asked to indicate which, of seventeen acute effects of ecstasy they had 
experienced, and if so, to what extent the acute effects were, from slightly too strongly. A 
mean acute effects score was calculated for each user. The list of acute effects was compiled 
from a review of empirical and subjective reports of the effects that were experienced whilst 
using ecstasy. The second set of questions ecstasy-using groups completed consisted of a 4- 
point self-report Likert scale on the positive and negative effects ecstasy has had on their 
experiences of life (appendix D). The scale comprised of twenty-eight long-term effects of 
ecstasy, seven positive effects and twenty-one negative effects. These effects were compiled 
from a review of empirical and subjective reports into the long-term effects of the drug. 
Ecstasy-users were asked to rate which, of these effects, they had noticed in their lives, from 
'not at all' to 'strongly'. A separate mean positive and negative score was calculated for each 
ecstasy user. Participants were further asked whether any of these changes had led them to 
seek help and/or advice from a professional or organisation and to indicate which particular 
service (e.g. GP, Clinical psychologist, psychiatrist, drugs clinic/services or counselling) they 
sought this from. Participants were asked to abstain from using ecstasy for at least 2 weeks 
and any other drug for 24 hours prior to testing. The University of East London ethics 
committee approved the study (see appendix for application and confirmation of approval). 
All participants gave written informed consent (see appendix V) and were paid £10 each for 
participating.
Assessment Measures
Following completion of the above, psychopathological status and cognitive performance was 
then assessed using the following measures in the order presented below:
Modified Brief Symptom Inventory (BSI, Derogatis & Melisaratos. 1983). This scale is 
comprised of 53 items, each rated on a standard 5 point Likert Scale: not at all (0), a little bit 
(1), quite a bit (2), moderately (3) and extremely (4). The distinct items reflect nine primary 
symptom dimensions or subscales: somatisation, obsessive-compulsive behaviour (OCD), 
interpersonal sensitivity, depression, anxiety, anger/hostility, phobic anxiety, paranoid 
ideation and psychoticism. Additional items reflected sexual functioning, cognitive failures,
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known MDMA side effects, and four positive dimensions: feeling content with life, positive 
psychobiology, sociability and mood state (Parrott et al, 2001 and Milani et al, 2001). See 
appendix for the full modified version and subscale definitions.
National Adult Reading Test fNART; Nelson, 1982). This test was a measure of premorbid 
verbal IQ, which involved participants reading out 50 words. These words allowed for 
assessment of the familiarity with the words rather than the ability to phonetically decode 
unfamiliar words (i.e. intelligent guess work alone would not result in a correct response). 
The number of correct pronunciations was recorded.
Choice reaction time tasks. A computerised choice reaction time task was utilised. 
Participants were presented with a fixation point that changed to either an X or Y, subjects 
had to press the corresponding key. Reaction time to each presentation was recorded in 
milliseconds (ms). There were 20 presentations and the mean latency response (ms) across all 
20 trials was recorded along with the number of correct responses.
Auditory Verbal Learning Test (AVLT: Rev, 1964). The AVLT test was used as an 
assessment of immediate and delayed verbal recall. It began as immediate word span recall, 
with the participant recalling as many words from a 15-word list (list A) read aloud to them 
by the examiner at a rate of one word per second. The same list was read and immediately 
recalled for a further 4 trials. After trial 5, recall was then measured for a second new 
distractor word list (list B) - interference trial. After list B recall, the participant was then 
asked to recall as many words from the first list (list A), but without presentation - trial 6. 
Retention of the first word list was then measured after a 20-minute delay - delayed recall. 
All responses were taped for subsequent scoring. The score for each trial was the number of 
words correctly recalled. The number of repetitions and intrusion errors from list A and list B 
were also recorded.
Tower of London (TOL; Shallice, 1982). The TOL measures participants planning abilities, 
which is one aspect of executive functioning. Participants were instructed to arrange three 
different coloured balls (blue, green and red) on an abacus from a starting position to a "goal" 
position (as demonstrated on a second identical abacus) in a specified minimal number of 
moves. Participants were instructed to complete each trial in their own time and if they were 
to make a mistake they could start the trial again from the starting position, or move on to the
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next trial. However, trials were terminated if problem solving exceeded one minute or if the 
participant was unable to solve the trail after 4 attempts. The test comprised of twelve trials 
which were tape recorded in order to calculate the "planning times" and "solution times" for 
each trial. Planning time represented the interval between the last verbalisation of the 
investigator to the first "click" of the apparatus. Solution time represented the duration of 
moves until completion of that particular trial. The mean total number of errors and total 
number of trials completed was also scored and then planning time and solution times were 
averaged across all completed trials.
Rivermead Behavioural Memory Test (RBMT; Wilson et al. 1991). The RBMT is a test 
battery consisting of a number of components that assess everyday memory functioning. 
Each component is described below.
Remembering a name. The subject was shown a photographic portrait and asked to 
remember the first and second name of the person in the photograph immediately after 
presentation of the name and after a delay. The duration of this delay was determined 
by the time it takes for the remaining RBMT components to be completed, and was 
tested at the end of the RBMT test.
Remembering a belonging. A possession belonging to the subject was borrowed and 
placed out of view of the participant. They were then requested to ask for their 
belonging when cued by the experimenter saying "that is the end of the test" and to 
remember where it had been hidden.
Remembering an appointment. The participant was required to ask a particular 
question relating to the near future (e.g. When will our next appointment be?) when an 
alarm sounded during the experiment.
Picture recognition. Line drawings of 10 common objects were shown one at a time, 
for approximately 5 seconds each. The participant was required to name each drawing 
and after a delay of a few minutes they were shown 20 pictures (the original 10 and 10 
distractors) and asked to select which ones they had seen previously. 
Remembering a story (immediate and delayed). After listening to a short prose 
passage read aloud by the experimenter, the participant was required to recall as much 
as possible immediately after the reading and again after a delay of approximately 10 
minutes.
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Face recognition. The participant was shown 5 portrait photographs, one at a time, 
for approximately 5 seconds. After a filled delay, the participant was required to 
select the original 5 from a set of 10 portraits (5 original and 5 distractors). 
Remembering a new route (immediate and delayed). The experimenter traced a short 
path around the room. The path was composed of five sections. The participant was 
required to copy the route immediately after the experimenter and again after a 10- 
minute delay.
Delivering a message (immediate and delayed). When tracing a short route around the 
experimental room the participant was requested to pick-up an envelope marked with 
a message at one particular stage (e.g. when at the table) and leave it at the location 
indicated by the experimenter (e.g. ....) on both immediate and delayed routes. 
Orientation. The participants were asked 10 questions regarding orientation in both 
time and place e.g. what month is it? What day of the week is it? What place are we in 
now?
For each component two scores were produced, a screening score (pass or fail) and a 
standardised profile score depending on the degree of deficit (0 = abnormal; 1 = borderline; 2 
= normal). Thus, participant's scores on the RBMT were summarised by a total screening 
score of all components, ranging from 0-12, and a total Standardised Profile score, for all 
components, ranging from 0-24.
Statistical Analysis
Data analysis was conducted using the Statistical Package for the Social Sciences (SPSS) 
version 10 for windows. One-way between groups analysis of variance (ANOVA) tests were 
performed for all measures of the AVLT and TOL to assess whether there were any group 
differences between polydrug controls, non-problem ecstasy users and problematic ecstasy 
users. Post Hoc analysis included paired comparisons between groups using the Tukey's 
HSD range statistic.
ANOVAs were performed on the RBMT screening score, profile score and individual 
component scores. Where there were violations of homogeneity of variance on the individual 
component scores of the RBMT the non-parametric Kruskall-Wallis test was employed. Post 
Hoc analysis included paired comparisons between groups using the Tukey's HSD range
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statistic and Mann-Whitney tests as the non-parametric equivalent; with a correction 
employed, to limit Type 1 errors, by dividing the standard 0.05 probability by the number of 
groups compared, in this case cx/3 = 0.017. The more usual Bonferroni adjustment was not 
employed as, with the large number of potential comparisons, this would have produced a p- 
value threshold that would have been difficult to estimate given the limitations of SPSS (ie. 
values of p < 0.0001 are presented as p=0.000). It is recognized however that the correction 
used here may have produced some Type 1 errors; so that although these results may be 
indicative of possible relationships between variables, such conclusions must be treated with a 
degree of caution.
The data from the BSI was positively skewed and had heterogeneous variances. As a result 
the square-root transformation was applied to stabilize the variances, allowing for an ANOVA 
to be performed assessing any differences in psychopathology between the three groups.
Drug use data violated the assumption of homogeneity of variance, despite attempts at 
transforming the data; therefore the Kruskall Wallis test was employed (with the exception of 
current tobacco and alcohol use in which an ANOVA was employed). An independent 
samples t-test was used to assess differences in patterns of ecstasy use between the two 
ecstasy groups (problematic and non-problematic). Chi-squared tests were used to establish 
any significant differences in responses to questions regarding the effects of ecstasy, gender, 
reported psychiatric history and family psychiatric histories.
After collapsing the two ecstasy using groups into one, Pearson correlational analyses were 
conducted to assess the association between patterns of ecstasy use and scores on the BSI, 
acute effects scale, negative and positive effects of ecstasy and cognitive performance. Where 
there were group differences in performance (between problematic and non-problematic 
ecstasy users), within group correlations were conducted; for example, for the 'remembering a 
name' component of the RBMT and certain subscales of the BSI. Additional analyses were 
conducted to assess whether the acute effect scores and the positive and negative effect scores 
correlated with scores on the BSI.
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RESULTS
Group characteristics and drug data Tables 5-8
As part of the inclusion criteria to the problematic ecstasy-using group, participants had to 
have sought some form of help for their attributed problems. As shown in table 5, a majority 
of problematic ecstasy users sought help from either a GP, 93% (n = 13), a psychiatrist, 71% 
(n = 10) or a clinical psychologist, 57% (n = 8), whilst only 21% (n = 3) had approached a 
drugs service and 21% (n = 3) a counselling service.
There were no significant group differences for gender, education, verbal IQ, health and 
family psychiatric history. However, there was a significant group effect of age [F(2,51) = 
4.02, p = 0.024]; problematic ecstasy users were significantly older than controls (p=0.026). 
There was a significant difference in reported psychiatric history Oc2(2) = 11.31, p = 0.004), 
with a greater number of problematic ecstasy users reporting a psychiatric history compared 
to non-problematic ecstasy users and controls.
Table 5: Professional organisations where help/advice was sought by problematic 
ecstasy users
% of problem users reported
_______________________contacting organisation 
General Practitioner 93
Clinical Psychologist 57
Psychiatrist 71
Drugs clinic/services 21
Counselling 21
Other 21
There were no group differences with regard to alcohol and tobacco consumption, but there 
were significant group differences in other categories of illicit drug consumption (with the 
exception of GHB, solvents, opiates and crack). Polydrug controls reported using 
significantly less amphetamine, cocaine, cannabis, benzodiazepines, LSD, magic mushrooms,
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poppers, ketamine and Prozac compared to non-problematic and problematic ecstasy users. 
Both ecstasy groups reported similar consumption of illegal drugs, with the exception of 
lifetime Prozac use (non-prescribed) and monthly cannabis use, where the problematic ecstasy 
group reported a significantly greater consumption (p = 0.005 and p = 0.008 respectively). 
There was no reported usage of any current prescription medicine in any of the participants.
Patterns of ecstasy use were similar across the two ecstasy using groups with the exception of 
'continued use', whereby more problematic ecstasy users reported discontinued use compared 
to non-problematic ecstasy users. Other than this both ecstasy-using groups showed similar 
lifetime consumption, used similar amounts of ecstasy on each occasion, reported similar 
maximum dosage on any one occasion and had used for a similar period of time. Also both 
ecstasy-using groups reported similar acute effects from ecstasy. However, the two groups 
differed in their long-term self-reported positive and negative effects experienced from 
ecstasy (table 6). Problematic ecstasy users scored significantly higher on the questions 
regarding the positive effects of ecstasy [t(80) = -4.56, p<0.001] and scored significantly 
higher on the questions regarding the negative effects of ecstasy [t(80) = -9.74, p<0.001] 
compared to non-problematic ecstasy users.
Group differences
Measures of psychopathological symptoms Table 9.
For the modified BSI scores, there were significant group differences on a number of negative 
symptoms, including somatisation [F(2,52) = 6.09, p = 0.004] (figure 1), interpersonal 
sensitivity [F(2,52) = 7.11, p = 0.002] (figure 2), depression [F(2,52) = 6.76, p = 0.002] 
(figure 3), anxiety [F(2,52) = 7.52, p = 0.001] (figure 4), phobic anxiety [F(2,52) = 9.43, 
p<0.001] (figure 5), paranoid ideation [F(2,52) = 9.33, p<0.001] (figure 6) and psychoticism 
[F(2,52) = 8.27, p = 0.001 ] (figure 7) subscales3 . Post hoc analysis revealed that problematic 
ecstasy users scored significantly higher than non-problematic ecstasy users and polydrug 
controls in all of these subscales. An adjusted ANCOVA was conducted on these BSI scores, 
with age entered as a covariate, as there was a significant age difference in groups (see
3 The same group differences were found when analysing non-transformed data, and the addition of significant 
group differences on the anger/hostility [F(2,51) = 4.124, p = 0.022] and sexual dysfunction [F(2,51) = 4.123, p 
= 0.022] subscales.
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above). This analysis revealed no change in the main effect of group on somatisation, 
interpersonal sensitivity, anxiety, phobic anxiety and psychoticism after co-varying for age 
(see table 43, appendix V for individual statistics).
Table 6; Participant demographics, levels of illicit drug use and patterns of ecstasy use
consumption in polvdrug controls.
(means and standard
Age
Education (number of
years)
Verbal IQ
Current rating of health
Patterns of ecstasy use:
Average dose
Maximum dosage
Total consumption
Duration of ecstasy use
(months)
Acute effect score
Positive effect score
Negative effect score
Other lifetime drug use:
Amphetamine
Cocaine
Crack
Opiates
Cannabis
Benzodiazepines
LSD
Magic Mushrooms
Solvents
Poppers
Ketamine
Prozac
GHB
Tobacco (per day)
Alcohol (units per week)
Cannabis (per month)
deviations).
Polydrug 
Controls
(C)
25. 15 ±3.87
16.0 + 2.13
11 1.65 ±6.53
3.45 ±0.83
-
-
2. 10 ±6.94
0.85 ±1.79
-
-
59.3 ±165. 19
non-problematic
Non- 
problematic 
Ecstasy
users
(E)
25.70 ±3.45
16.60±1.14
113.35 ±4.52
3.05 ±0.76
2.43 ±1.37
5.33 ±2.63
263.55 ±299.54
83.7 ±34.13
2.24 + 0.42
1.51 ±0.38
1.39 ±0.37
84.05 + 104.72
88.35 ±127.61
1.10±4.47
182.85 ±816.08
1733 ±1636.13
and problematic ecstasy
Problematic 
Ecstasy users
(P)
28.93 ±4.94
15.36±2.41
11 3. 07 ±6.40
2.86 ±1.03
2.86 ±2.51
7.50 ±7.36
367.36 ±557.62
61.29± 35.15
2.49 ±0.52
2.05 + 0.69
2.41 ±0.58
258.36 + 566.75
208.71 ±529.17
1.50±3.16
1.14 ±2.25
2658.93 +
5156.27
3.70 ±11.20 354.07 ±1196.34
0.05 + 0.22
0.05 + 0.22
0.05 + 0.22
0.30±1.13
0.10 ±0.45
-
3.85 ±7.71
10.45 ±7.52
0.20 ±0.52
23.55 ±46.10
9.20 ±13.36
4.10 ±10.93
62.25 ±22 1.29
3.70 ±7.26
0.35 ±1.09
9.40 + 6.67
17.35 ±13.22
14.95 ±12.85
86.21 ±263.71
8. 14 ±26.47
3. 00 ±5. 74
78.93 ±195.20
40.50 ±132.80
86.57 ±189.21
0.14±0.36
8.50 ±11. 45
10.50 ±12.92
19.36 ±54.39
Group 
effect
0.024
0.183
0.624
0.125
0.522
0.306
0.533
0.072
0.119
0.006
0.000
0.000
0.000
0.109
0.055
0.000
0.008
0.000
0.000
0.072
0.000
0.008
0.002
0.269
0.102
0.109
0.000
users
Post Hoc 
Comparisons
(p<0.05)
P>C
P>E
P>E
C<P&E
C<P&E
C<P&E
C<P&E
C<P&E
C<P&E
C<P&E
C<P&E
P>C&E
C<E<P
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Table 7; Percentages of non-problematic and problematic ecstasy users reporting
changes in ecstasy use consumption
% of participants in each group
Increase number of tablets
Effects of ecstasy changed
Not Suffer without usage
Did not need to take ecstasy
Felt dependent/addicted to ecstasy
Considered stable user
Continue to use
Use drugs to alleviate ecstasy side
effects
and perceptions of their
Non-problematic 
Ecstasy Users 
(n=20)
30
75
100
100
5
80
70
10
patterns of use
Problematic 
Ecstasy users 
(n=14)
43
71
93
93
7
50
24
29
Chi-square 
group effect
0.440
0.816
0.225
0.225
0.794
0.066
0.005
0.162
Table 8; Number of psychiatric disorders reported in polydrug, non-problematic and
problematic ecstasy users of those who reported individual psychiatric and family
psychiatric histories
Participants
Disorder
Anxiety
Depression
Schizophrenia
Phobia
Panic Attacks
Eating Disorder
Alcohol and/or drug 
dependency
Polydrug 
Controls
n = 5
3
3
0
0
2
1
0
Ecstasy 
users
n = 6
0
4
0
0
0
2
1
Problem 
users
n = 11
7
9
5
1
5
0
3
Immediate family
Polydrug 
Controls
n = 10
3
9
0
0
3
0
2
Ecstasy 
users
n = 10
1
5
2
0
0
1
2
Problem 
users
n = 7
4
7
1
0
2
0
1
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Table 9 : Modified BSI subscale scores for oolvdrue controls, non-problematic and
problematic ecstasy users. (Means
Symptom
Negative Symptoms
Somatisation
Obsessive-compulsive
Interpersonal sensitivity
Depression
Anxiety
Anger/hostility
Phobic anxiety
Paranoid ideation
Psychoticism
Negative psychobiology
MDMA side effects
Sexual functioning
Cognitive failures
Positive Symptoms
Feeling content with life
Mood state
Sociability
Positive psychobiology
Polydrug 
Controls
(C)
0.41+0.37
1.10 + 0.66
0.81+0.68
0.58 + 0.64
0.68 + 0.66
0.46 + 0.33
0.29 + 0.33
0.67 + 0.45
0.45 + 0.54
0.55 + 0.39
1.05 + 0.62
0.39 + 0.36
1.22 + 0.70
2.28 + 0.82
2.21+0.74
2.28 + 0.52
2.06 + 0.62
and standard deviations)
Non- 
problematic 
Ecstasy Users
(E)
0.52 + 0.38
1.31 ±0.99
0.59 ±0.54
0.44 + 0.51
0.44 ±0.36
0.65 ± 0.65
0.14 ±0.39
0.68 ±0.57
0.40 ±0.41
0.64 ±0.51
1.04 ±0.72
0.38 ±0.34
1.69 ±0.94
2.38 ±0.76
2.24 ± 0.69
2.44 + 0.77
2.23 ±0.63
Problem 
Ecstasy users
(P)
1.11 ±0.78
1.64 ±0.88
1.75+1.07
1.63 ±1.30
1.67 ±1.23
1.13 ±1.02
1.00 ±1.07
1.73 ±0.97
1.29 ±0.82
0.77 ±0.39
1.56 ±0.80
0.81 ±0.74
2.01 ±1.20
1.99 ±0.99
1.71 ±0.87
2.07 ± 0.94
1.92+1.13
Group 
effect
0.004
0.396
0.002
0.002
0.001
0.118
0.000
0.000
0.001
0.308
0.087
0.226
0.135
0.322
0.056
0.297
0.316
Post Hoc 
Comparisons 
(p<0.05)
P>C&E
P>C&E
P>C&E
P>C&E
P>C&E
P>C&E
P>C&E
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Measures of cognitive assessment All cognitive task data are displayed in table 10.
There were no significant group differences on the reaction time task, AVLT recall across all 
trials or the number of word repetitions for this task. There were no significant differences 
between the three groups for planning and solution times across all trials on the Tower of 
London, nor where there any significant differences between the numbers of errors made and 
the number of incomplete trails. There were no significant group differences on the screening 
and standardised profile scores for the RBMT. However, when analysing the data of 
individual RBMT components, there were significant group differences in 'remembering to 
deliver a message (immediate)' [%2(2) = 13.85, p = 0.001], with problematic ecstasy users 
scoring significantly worse than ecstasy users, p<0.001 (figure 8); and in the 'remembering a 
name' component [%2(2) = 8.62, p = 0.013], with the problematic ecstasy users scoring 
significantly worse than polydrug controls (p = 0.012: figure 9). An adjusted ANCOVA 
model was conducted on these significant RBMT component scores, with age entered as a 
covariate, as there was a significant age difference in groups (see earlier). This adjusted 
model revealed no change in the significant main effect of group on 'remembering to deliver a 
message' (immediate) [F(2,52) = 7.62, p = 0.001] after co-varying for age [F(l,54) = 0.010, p 
= 0.923]; and no change in the significant main effect in the 'remembering a name' 
component [F(2,52) = 3.298, p = 0.045], after co-varying for age [F(l,54) = 0.081, p = 0.777].
Correlational analyses 
Dose-response effects of ecstasy
The estimated lifetime consumption of ecstasy negatively correlated with delayed recall on 
the AVLT (r = -0.393, p = 0.022), and positively correlated with the positive subscale 
'content' on the BSI (r = 0.517, p = 0.002).
The reported average dose consumed negatively correlated with trial 6 (post-interference 
recall trial) and delayed recall on the AVLT (r = -0.0388, p = 0.023; r = -0.361, p = 0.036 
respectively) The reported average dose consumed negatively correlated with, 'remembering 
a name' from the RBMT (r = -0.860, p = 0<0.001), but only in the problematic ecstasy users. 
Whilst interpersonal sensitivity significantly correlated with the average dose consumed (r = 
0.481, p = 0.032), but only in the non-problematic ecstasy users. Additionally the average
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dose consumed also positively correlated with scores on the acute effects of ecstasy 
questionnaire (r = 0.443, p= 0.009).
The largest dose of ecstasy on any one occasion negatively correlated with RBMT immediate 
story recall (r = -0.352, p = 0.041) and with trials one (r = -0.368, p = 0.032), two (r = -0.381, 
p = 0.026), four (r = -0.359, p = 0.037), post-interference trial six (r = -0.364, p = 0.034) and 
the total words recalled from the first 5 trials (r = -0.375, p = 0.029) on the AVLT. The 
largest dose of ecstasy on any one occasion positively correlated with the 'remembering a 
name' component of the RBMT in problematic ecstasy users (r = -0.810, p = 0.001), but not 
in non-problematic ecstasy users (r = -0.029, p = 0.903). Additionally, the largest dose 
consumed in one occasion positively correlated with the scores on the acute effects of ecstasy 
questionnaire (r = 0.551, p = 0.001) and with the scores on the questions regarding the 
negative effects of ecstasy,; although this latter finding was only in problematic ecstasy users 
(r = 0.538, p = 0.047), and not non-problematic ecstasy users (r = 0.075, p = 0.755).
Measures of acute effects and long-term effects
Scores on the questionnaire scale regarding the acute effects of ecstasy positively correlated 
with the scores on the long-term negative effect questions (r = 0.461, p = 0.006) and the 
somatisation (r = 0.397, p = 0.020) and phobic anxiety (r = 0.358, p = 0.038) subscales of the 
BSI.
Scores to the 7 positive questions on the long-term experiences from ecstasy questionnaire 
positively correlated with the negative effect score on the same questionnaire (r = 0.514, p = 
0.002) and the following scales of the BSI: somatisation (r = 0.340, p = 0.049), paranoid 
ideation (r = 0.369, p = 0.032), psychoticism (r = 0.358, p = 0.037), negative psychobiology (r 
= 0.356, p = 0.039) and sexual dysfunction (r = 0.422, p = 0.013). Scores to the 21 negative 
questions on the long-term experiences from ecstasy questionnaire positively correlated with 
somatisation (r=0.584, p<0.001), obsessive-compulsive disorder (r = 0.367, p = 0.033), 
interpersonal sensitivity (r = 0.641, p<0.001), depression (r = 0.549, p = 0.001), anxiety (r = 
0.592, p<0.001), anger/hostility (r = 0.485, p = 0.004), phobic anxiety (r = 0.536, p = 0.001), 
paranoid ideation (r = 0.543, p = 0.001), psychoticism (r = 0.512, p = 0.002), MDMA side 
effects (r = 0.490, p = 0.003) and sexual dysfunction (r = 0.567, p<0.001).
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Table 10; RBMT component and test scores, reaction times, TOL times and AVLT
scores bv trial for polvdrue controls, non-problematic and problematic ecstasv users.
(Means and standard deviations)
RBMT
SCREENING SCORE
PROFILE SCORE
Story recall 
Immediate
Delayed 
Pictures
Faces
Route
Immediate
Delayed 
Message 
Immediate
Delayed 
Orientation & date
Remembering an
appointment 
First & second name
Remembering a belonging
REACTION TIME
Reaction time
Reaction time errors
TOWER OF LONDON
Total Planning times
Total Solution times
No. of errors
No. of incomplete trials
AVLT
Immediate Recall
Trial 1
Trial 2
Trial 3
Trial 4
Trial 5
Total Recall
Interference Trial
Trial 6
Delayed Recall
Number of repeats
Intrusion from list A
Intrusion from list B
Polydrug 
Controls
(C)
9. 45 ±1.05
20.85+1.57
7.65 + 2.44
6.73 + 2.70 
9.95 + 0.22
3.80 ±0.41
5. 00 ±0.00
5. 00 ±0.00
2.85 + 0.37
2.75 ± 0.44 
9.45 ±0.89
1.80 ±0.41
4.00 ± 0.00
3.70 + 0.47
471.79 ±51.55
18.45 ±1.64
6.95 ±2.17
4.07 + 0.89
2.80 ±3.21
0.20 ±0.41
6.30 ±1.79
8.80 ±2.24
10.80 ±2.67
10.80 ±2.46
11. 55 ±2.26
48.25 ±9.95
5.70 ±2.64
9.10±2.81
6.05 ±5.60
5. 00 ±5. 48
0.05 ± 0.22
0.10±0.31
Non- 
problematic 
Ecstasy Users
(E)
9.15 ±1.35
20.50 ±1.88
9.18±2.75
7.83 + 3.14 
9.90 ±0.31
3.75 ±0.55
4.95 ±0.22
4.90 + 0.31 
3. 00 ±0.00
2.90 ±0.31 
9.40 ±0.88
1.65 ±0.49
3.95 ±0.22
3.45 ±0.76
488.09 ±85.76
18.20 ±1.28
6.07 ±2.59
3.91 ±0.73
5. 15 ±3.79
0.20 ± 0.70
6.75 ±1.48
9.50 ±1.88
10.35 ±2.32
11.70+1.95
11.60 ±1.73
49.95 ±7.36
4.80 ±1.58
10.50 + 2.95
9.15 ±3.45
6.55 ±4.98
0
0.10 ±0.45
Problem 
Ecstasy users
(P)
8.71 ±1.49
20.07 + 2.17
7.64 ±1.99
6.86 ±1.86 
10.00 ±0.00
3.64 ±0.63
5. 00 ±0.00
5. 00 ±0.00 
2.43 ±0.65
2.64 ±0.63 
9.71 ±0.47
1.86 ±0.36
3.57 + 0.85
3.29 ±0.61
530.92 ± 77.94
17.50 ±2.71
8.08 + 3.72
4.27 ±1.30
4.43 ±2. 14
0.64 ±0.74
5.93 ±1.77
8.57 + 2.41
9.43 ±2.95
11. 00 ±2.08
11. 00 ±2.72
45.21 ± 10.60
4.86 ±2.25
9.79 ±2.69
8.29 ±3.32
6.29 ±15.59
0.43 ± 0.76
0
Group 
effect
0.269
0.486
0.098
0.391 
0.459
0.692
0.427
0.177 
0.001
0.324 
0.502
0.336
0.013
0.147
0.070
0.340
0.129
0.551
0.072
0.081
0.368
0.414
0.329
0.406
0.705
0.347
0.372
0.303
0.079
0.851
i
i
Post Hoc 
Comparisons 
(p<0.05)
E>P
C>P
1 No analyses were conducted due to floor effects
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DISCUSSION
The results of the present study indicate that non-problematic ecstasy users are not 
demonstrating any profound deficits in cognitive abilities compared to polydrug controls, 
despite polydrug controls having used significantly lower amounts of most other drugs (table 
6). This is inconsistent with previous empirical research where ecstasy users were shown to 
have selective deficits on the same cognitive assessment measures compared to non-ecstasy 
using controls. This previous research showed that ecstasy users recalled significantly fewer 
words on the initial three recall trials and delayed recall trial on the AVLT (Fox et al, 200la); 
displayed longer planning times on the TOL (Fox et al, 2001b and Schifano et al, 1998); and 
showed significant memory impairment on the RBMT (Schifano et al, 1998).
Problematic ecstasy users did show some cognitive deficits, but only in one subtest of the 
RBMT (remembering a first and second name); compared to polydrug controls (figure 9). 
This lends only tentative evidence to support the cognitive findings found in the sub-sample 
of problematic ecstasy users assessed by Schifano et al (1998). The only cognitive difference 
between problematic and non-problematic ecstasy users was poorer performance in the 
remembering to deliver a message component of the RBMT (immediate; figure 8). The fact 
that problematic and non-problematic ecstasy users displayed similar cognitive performance 
on most of the tasks supports the findings of Fox et al (2001), who demonstrated similarities 
in cognitive performance between problematic and non-problematic ecstasy users despite 
differences in perceived problems attributable to their ecstasy use.
In the current study the psychopathological status of non-problematic ecstasy users does not 
appear to differ from polydrug controls (table 9). However, as expected problematic ecstasy 
users do appear to report higher psychopathological scores on a number of subscales 
compared to polydrug controls and non-problematic ecstasy users; namely somatisation 
(figure 1), interpersonal sensitivity (figure 2), depression (figure 3), anxiety (figure 4), phobic 
anxiety (figure 5), paranoid ideation (figure 6) and psychoticism (figure 7). These differences 
in psychopathology appear to be independent of ecstasy dosage and other patterns of ecstasy 
use since both ecstasy-using groups showed similar drug consumption profiles, (Soar & 
Parrott, 2002). This confirms the finding from Fox et al (2001) who concluded that 
perceived problematic ecstasy use was not dose-related and also independent from other 
patterns of ecstasy use. Both these findings are in contrast to that of Parrott, Sisk and Turner
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(2000), who demonstrated that heavy ecstasy users reported significantly higher scores than 
controls on paranoid ideation, psychoticism somatisation, obsessionality, anxiety, hostility, 
phobic anxiety, altered appetite and restless sleep. However, this study only addressed dosage 
and psychopathology, not whether users perceived themselves to be problematic or not. This 
later point is also true of other studies that have demonstrated psychopathology in ecstasy 
users (Parrott et al, 2001; Dugherio et al, 2001; Morgan et al, 2002).
The lack of cognitive differences between groups may be due to the performance of the 
polydrug control group. Evidence to suggest this comes when comparing the AVLT scores 
from this study with normative data. Normative data indicates that immediate recall appears 
to run within the range of 6.3 to 7.8 (Lezak, 1995). Even though the control group is 
performing within these limits, scores are at the very bottom end of the range. Delayed recall 
is also poor in this group compared to normative data. There should be little loss between 
recall on trial 6 and the delayed recall trial, yet the control group demonstrate a dramatic drop 
in recall score between these two trials (9.1 on trial 6 and 6.05 on the delayed recall trial). It 
appears that the polydrug controls themselves may show signs of memory dysfunction, such 
that any existent cognitive deficits exhibited by the ecstasy using groups would not 
necessarily be visible because of this poor cognitive performance by the control group 
masking the effect.
When looking at the ecstasy user's performance for immediate recall, the non-problematic 
ecstasy users are actually performing slightly better than polydrug controls on the story recall 
of the RBMT and on most trials of the AVLT, though such differences did not reach 
statistical significance. However, ecstasy users performance on the AVLT are at the lower 
end of the score range for normative data, whereas problematic ecstasy users are performing 
worse than normative scores thus indicating memory dysfunction. Recall for trial 5 in non- 
problematic and problematic ecstasy users (11.60 and 11.00 respectively) is also lower than 
normative data, which typically indicates a range of 12 to 14 (Lezak, 1995). Additionally, 
delayed recall scores on story recall of the RBMT and AVLT, are slightly better in non- 
problematic ecstasy users compared to polydrug controls and problematic ecstasy users; 
though once again delayed recall is lower in both ecstasy using groups compared to normative 
data. It appears therefore that both ecstasy-using groups are showing poorer cognitive 
performance on the AVLT compared to normative data.
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On the TOL test, non-problematic ecstasy users were seen to perform better than polydrug 
controls, exhibiting quicker planning and solution times; though this effect failed to reach 
statistical significance. The validity of the control group could again be questioned; however 
there is no normative data available for the manual version of the TOL to make valid 
comparisons. However, direct comparisons can be made, with TOL performances, with 
similar groups from the study by Fox et al (200 Ib). Planning times demonstrated by the 
control group in the current study do not appear to differ greatly from the performance of Fox 
et al's (2001b) control group (6.95 seconds and 6.5 seconds, respectively); however the 
planning and solution times for ecstasy users seem to differ markedly between the two 
studies. Fox et al (2001b) demonstrated planning and solution times twice that of the non- 
problematic ecstasy users in this current study (13.3 seconds and 6.07 seconds, respectively 
for planning times and 6.4 and 3.91 seconds respectively for solution times). This could 
suggest that non-problematic ecstasy users are not demonstrating impairments relative to 
other ecstasy using sub-groups. This is only speculative since comparisons can only be made 
with the one study; ideally comparisons need to be made with standardised normative data.
It may appear that non-problematic ecstasy users are performing better than polydrug controls 
on the TOL, by exhibiting decreased planning and solution times; however this could be at the 
expense of making more errors. The number of errors made in the non-problematic ecstasy 
users were higher than polydrug controls (table 10), though this effect did not reach statistical 
significance. These results would support similar findings by Morgan et al (2002) who 
demonstrated significantly quicker first responses in the MFF20 in ecstasy users compared to 
controls and polydrug controls. These ecstasy users committed more errors however, 
suggesting a trade-off between greater speed and accuracy (Morgan et al, 2002).
Further support for the issue of a poorly performing control group arises from the dose-related 
cognitive findings in ecstasy users. It appears that the greater the amount of ecstasy 
consumed in a lifetime and the larger the dose consumed on any one occasion, were 
associated with an impaired ability to remember a name (RBMT) and also poorer delayed 
recall (AVLT). This latter finding supports the dose-response effects on delayed recall found 
by Morgan (2002) and Fox et al (2001c). However, it is important to note that any dose- 
related findings within this study should be treated with extreme caution, since no statistical 
corrections were made to the correlational analyses to control for type 1 errors.
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Another reason for lack of group differences in cognitive abilities may be due to the lack of 
sensitivity to ecstasy-induced effects in the test procedures used. This applies specifically to 
the RBMT, since previous research using the AVLT and the manual version of the TOL have 
been shown to indicate deficits in ecstasy users (Fox et al, 2001b; Fox et al, 2001c; Schifano 
et al, 1998; Milani & Schifano, 2000; Reneman et al, 2000; Reneman et al, 2001). A potential 
problem with the RBMT is that when used on individuals with intact cognitive abilities it can 
demonstrate ceiling effects. It has been argued that ecstasy-induced cognitive effects are 
selective and thus any mild cognitive deficits exhibited by these individuals may not be 
detected with such a test, since it is not thought to be suitable for detecting subtle memory 
deficits; whether due to brain damage or the introduction of a drug (Wall et al, 1994; Wills et 
al, 2000). Based on the standardised profile score of the RBMT there was a hypothesised 
trend for problematic ecstasy users to score lower than ecstasy users, who in turn scored lower 
than polydrug controls, however these differences did not reach statistical significance.
It has been suggested that the ecstasy users may experience a mild form of the serotonin 
syndrome whilst under the influence of the drug (Parrott, 2002). Tentative support for this 
notion has been shown, with higher levels of ecstasy consumption being associated with an 
increased chance of experiencing those acute effects of ecstasy that are representative of the 
serotonin syndrome (Gillman, 1997). Additionally, this study suggests a link between 
experiences of these acute effects of ecstasy and the long term effects. Those ecstasy users 
who reported higher symptoms whilst 'on drug', also reported higher psychopathological 
scores and higher ratings of long term effects attributed to ecstasy use. However, problematic 
and non-problematic ecstasy users did not differ on their subjective ratings on these negative 
acute effects, as such; the extent of acute effects of ecstasy does not appear to be a defining 
feature of problematic ecstasy use.
Assessing the reported long-term positive and negative effects attributed to the consumption 
of ecstasy, it appears that whilst ecstasy users reported experiencing negative effects from 
ecstasy, these are probably outweighed by the greater reported positive effects also 
experienced. However, problematic ecstasy users report both significantly higher positive 
and negative life experiences compared to non-problematic ecstasy users (table 6). Thus, the 
negative effects reported by the problematic ecstasy users may be exacerbated, but their 
perceptions of the positive effects are also much stronger than non-problematic users. It may 
be that certain problematic ecstasy users are just more emotionally reactive than other ecstasy
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(non-problematic) users, which may account for both of these findings. Enhanced sensitivity 
to both the positive and negative long term effects of MDMA, in some of these problematic 
ecstasy users, could also be accounted for by certain genetic and neurochemical differences. 
There is evidence from both animal and human research, to suggest that there may be a 
critical threshold of serotonergic activity below which functional sequalae develop. It is 
possible that problematic ecstasy users may be more vulnerable to the MDMA neurotoxicity 
by virtue of a lower serotonergic 'injury' threshold. Individual 5-HT neurons may be more 
robust in non-problematic ecstasy users and thus this injury threshold is not reached and 
functional problems do not develop. Alternatively, and perhaps more likely, some individuals 
may have lower levels of 5-HT to begin with and less severe serotonergic injury is needed to 
reach a critical threshold, and thus develop the functional psychological and cognitive 
problems demonstrated in these problematic ecstasy users. Additionally, this vulnerability to 
the long-term effects of MDMA- induced serotonergic neurotoxicity could also be due to 
differences in individual's abilities to metabolise MDMA. Kreth et al (2000) and 
Ramamoorthy et al (2002) have shown that individuals who lack fully functioning 
cytochrome P450 2D (CYP2D6 - the polymorphic enzyme involved in the metabolism of 
MDMA) have a reduced ability to metabolise MDMA. Since unexpected adverse effects of 
drugs are often related to their metabolism, it is possible that the differences in the capacity to 
metabolise ecstasy, specifically MDMA, may determine or modulate inter-individual acute 
toxic reactions (Schifano, 2004) and, potentially, long-term ecstasy-related neurotoxicity, and 
this could modulate the development of ecstasy-related problems in particular individuals. 
Thus it could be speculated that the problematic ecstasy users demonstrating psychological 
difficulties in the current study, had a predisposing genetic risk to the long term effects of 
MDMA exposure.
In addition to the methodological issues discussed in the literature review (chapter 2), there 
are also a number of related points that need to be addressed which are specific to this study. 
Firstly, any significant cognitive and psychopathological differences found between polydrug 
controls and the ecstasy using groups cannot be solely attributed to ecstasy use, since the 
polydrug control group used significantly less illicit drugs than both ecstasy groups (table 6). 
Previous research has attempted to control for other drug use using statistical techniques such 
as regression models or analysis of covariance for other drug use. Daumann et al (2001) and 
Morgan et al (2002) found that concomitant use of other drugs, specifically cannabis, 
influenced the levels of psychopathology in ecstasy users. Rodgers et al (2001) assessed the
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influence of cannabis use further using a regression design to try to isolate the contribution of 
individual drugs to the variance in prospective memory performance scores in groups of 
ecstasy and cannabis users. They found a double dissociation between the impact of cannabis 
and ecstasy. Cannabis, but not ecstasy, was found to be associated with short-term and 
internally cued prospective memory, whilst ecstasy use, but not cannabis, was associated with 
long-term memory deficits. However, they also reported that cannabis and ecstasy use were 
significantly correlated. This is a problem that is consistently found when trying to control 
for other drug use via statistical techniques: the extent and duration of ecstasy use tends to be 
highly correlated with other drug use and this multicolinearity poses statistical limitations in 
producing any meaningful analysis on its own. Additionally, co-varying for drug use does not 
account the for possible drug-drug interactions that occur. Since ecstasy users predominantly 
use other drugs in combination with Ecstasy (Strote et al, 2002; Riley et al, 2001; Winstock et 
al, 2001) it is likely that administering such drugs together produce different effects compared 
to using ecstasy alone (Hernandez-Lopez et al, 2002). A recent study has also suggested an 
additive effect nicotine has on neurocognitive functioning in ecstasy users (Friend et al, 
2004). Thus, co-varying for different drug use does not address these additive and/or drug 
interaction effects, and it is for this reason that such analyses were deemed inappropriate in 
this research.
What is more important in respect of the cognitive and psychopathological findings here is 
that the amounts of illicit drug use was matched between ecstasy using groups, with the 
exception of monthly cannabis use and Prozac. There is the possibility that the 
psychopathological status of the problematic ecstasy users could be confounded by their 
monthly cannabis use, which was higher in this group compared to both polydrug controls 
and non-problematic ecstasy users. This confounding effect would be consistent with that of 
Morgan et al (2002) who concluded that cannabis use predicted most measures of the SCL- 
90-R, whereas ecstasy consumption did not. Whilst other drug use was matched between the 
two ecstasy using groups, this match is a rather crude measure, since reported lifetime drug 
use did not take into account potential differences between groups in the period of time and 
subsequently the intensity of drug use.
The explicit selection process for this study allowed ecstasy users to allocate themselves into 
one of three groups, depending upon their past ecstasy experiences. This selection process of 
overtly advertising for problematic and non-problematic ecstasy users may have influenced
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demand characteristics and thus affected the outcome of the study. Non-problematic ecstasy 
users may have a vested interest in defying the negative opinion surrounding the long-term 
effects of ecstasy and therefore be more motivated to perform to the best of their ability. This 
may have contributed to a paucity of statistical cognitive effects found and also the 
performance on the TOL, as discussed earlier. In addition, self-selecting problematic ecstasy 
users may have been influenced by the pessimistic attention surrounding ecstasy portrayed by 
the public and media and also be more likely to volunteer to participate in order to 'find out 
what's wrong with them' (Turner & Parrott, 2000). For such reasons caution should be made 
in extrapolating results to other ecstasy users. Ideally future studies should perhaps be refined 
to use post hoc methods of group allocation to avoid such confounds.
No formal psychiatric assessment was conducted to assess whether self-perceived problematic 
users actually demonstrated /exhibited psychological problems. However, the fact that they 
had sought some help, mostly from a GP, clinical psychologist and psychiatrist (table 5), 
strongly suggests that their problems may have been clinically defined at some point. The 
significantly high scores on the BSI also provided some data to indicate that they were 
experiencing problems. However, labelling users 'problematic' or 'non-problematic' on the 
basis of a single question relating to the experience of 'problems' which users attribute to 
ecstasy is a somewhat crude classification system. This effectively replicates the method used 
in Fox et al (2001), although this study did also ask participants to give some qualitative 
information regarding the nature of problems. The problems most commonly reported were 
related to low mood, depression and anxiety, and to experiences of cognitive difficulties (Fox, 
2002). However, limiting assessment to a single question may have missed some important 
information as the word 'problem' is of course open to wide interpretation. Additionally, 
asking users to self-identify themselves as problematic could be argued to be an approach that 
may produce some response bias. As participants were defining themselves by their 'help- 
seeking' behaviour, it is perhaps not surprising that they will have differed on self-reports of 
psychological distress. However it could be argued that this would be demonstrated by 
evidence of systematic responding on a questionnaire, in this case the BSI. The current data, 
however, show a selective pattern of decrements on this scale; i.e. the problematic ecstasy 
users did not score higher than non-problematic ecstasy users in all the subscales (table 9).
An additional problem is that distinguishing between the two groups just on the basis of 
labelling them as 'problematic' or 'non-problematic', does not address the potential confound
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of whether the ecstasy users continued to use or not. From table 7, it is clear that a 
considerably higher number of the problematic ecstasy users, were in fact ex-users (only 24% 
continued to use the drug), compared to the non-problematic group (70% reported continued 
ecstasy use). Therefore, conceptually, these problematic ecstasy users not only differ on their 
self-reported problems, but also whether they are current or ex-ecstasy users. Verheyden et al 
(2003) reported that there were two different types of ex-ecstasy users: those who stopped 
using for mental health reasons and those who stopped for circumstantial reasons (e.g. 
changes in circumstances, boredom, a fall in the quality of ecstasy). Of those ecstasy users 
that stopped using because of mental health reasons, 62% reported having received 
professional help for these problems, which was significantly higher that those who had 
stopped in the circumstantial group (27%). These two groups, 'circumstantial' and 'mental 
health', did not differ on any measure of ecstasy use or other drug use, which is consistent 
with the findings from this study. This suggests, as with the current study, that some users 
may be more vulnerable to the long-term effects of ecstasy.
The issue of causality is also complex to address within this study. Whether ecstasy use 
actually caused the problems reported by the problematic ecstasy users is difficult to 
ascertain. There is the suggestion that the basis of these problems could have already existed 
prior to ecstasy use, since poor premorbid adjustment is associated with increased drug use 
(Fox et al, 2001a). In a prospective-longitudinal study in a non-clinical sample, Lieb et al 
(2002) found that in a majority of cases, ecstasy and other polydrug use was actually 
secondary to the onset of mental disorders and psychological problems. However, there was 
only a difference in individual, but not family psychiatric between the two ecstasy using 
groups, which could argue against a vulnerability to a predisposition to psychopathological 
problems.
To conclude, this study has shown that contrary to previous research, ecstasy users do not 
exhibit the selective cognitive deficits relative to polydrug controls. Problematic ecstasy 
users did display a few significant deficits in cognitive performance compared to polydrug 
controls, but compared to non-problematic ecstasy users, problematic ecstasy users generally 
displayed similar cognitive performance, despite differences in perceived problems. The 
findings suggest that cognitive problems are dose-related rather than due to accurate self- 
attribution of ecstasy-adverse effects. Problematic ecstasy users were found to exhibit higher 
psychopathological symptoms across a number of dimensions compared to non-problematic
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and polydrug controls, which objectively verifies their subjective awareness of clinical 
problems. These reported problems do not appear to be related to patterns of ecstasy use or 
polydrug use. It could be that this sub-sample of problematic users is simply more vulnerable 
to ecstasy-induced psychological effects, both positive and negative, than non-problematic 
ecstasy users, and/or that they are predisposed to psychiatric disturbances. Another issue that 
needs to be explored concerns the length of abstinence from ecstasy consumption, this was 
not addressed in the current study and may have important implications concerning the 
presentation of problems related to ecstasy use.
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CHAPTER 4
Case Study of Persistent Psvchobiological Problems Attributed to
Ecstasy After Seven Years Abstinence1
1 A brief summary paper of this case study can be seen in Soar et al (2004), a copy of which is 
included in the appendix
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INTRODUCTION
The current chapter focuses on a case study concerning a problematic ecstasy user who 
approached the researcher during the previous study into the cognitive and psychological 
status of ecstasy and problematic ecstasy users (chapter 3). This individual (RW) was unique 
in his profile compared to other problematic ecstasy users, in that he had developed an 
extensive number of psychiatric and psychological problems which he attributed to having 
taken high amounts of ecstasy and that remained troublesome despite remaining abstinent 
from ecstasy for seven years. Because of this unique profile and length of abstinence from 
ecstasy use he was deemed inappropriate to include in the previous study and instead was 
assessed separately in order to document his current cognitive and psychological status after 
seven years of abstinence from ecstasy, using the same battery of cognitive assessment 
measures used in the previous study, with documented sensitivity to ecstasy-induced effects 
(Fox et al, 2001b & c; Parrott et al, 2000).
There are numerous case studies and empirical research data suggesting that recreational 
ecstasy users demonstrate psychopathological problems (see Soar et al (2001) and chapter 2 
for a review). Despite the large body of empirical evidence demonstrating cognitive deficits 
in recreational ecstasy users, only two case studies have reported severe cognitive problems. 
The first case was by Spatt et al (1997); this involved a 26-year-old woman who developed a 
pure amnestic syndrome after ecstasy use, with ongoing memory problems up to nine months 
after presentation. Secondly, Kopelman et al (2001) presented a 26 year old woman who was 
left with severe anterograde memory problems and evidence of executive/frontal lobe 
impairments and although there were cognitive improvements eight years after ecstasy 
consumption, severe deficits remained. In both cases MRI or PET scans indicated brain 
abnormalities in regions rich in serotonin releasing neurons.
These two case studies also demonstrated that cognitive problems are persistent in nature. 
Other case studies suggesting that psychiatric symptomatology is persistent have also been 
reported (Cohen, 1996; McCann & Ricaurte, 1992, Windhaber et al, 1998). In one particular 
case a 24-year old male who had been taking ecstasy for 4 years and reported use on about 
150 occasions was diagnosed with chronic atypical psychosis. However, symptoms in this 
individual, such as hallucinations, loss of appetite, weight loss, reduced sexual activity, mood 
swings, paranoia and aggressive outbursts, were reported to have begun 4 years prior to
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diagnosis (Schifano, 1991). Schifano and Magni (1994) also presented a number of case 
studies where psychological problems were strongly associated with ecstasy use, and still 
evident on presentation to a clinic from 6 months to 30 months after discontinued ecstasy 
consumption.
However, there is relatively little empirical research to show whether psychological or 
cognitive deficits remain after abstinence from ecstasy, or show signs of recovery. Tentative 
empirical evidence for the persistence of cognitive deficits has been shown by Wareing et al 
(2000). In this study, current and previous ecstasy users were tested on measures of central 
executive functioning and on self-reported levels of anxiety. Both groups were found to have 
deficits on some aspects of central executive functioning and measures of anxiety compared 
to a control group of non-ecstasy users, suggesting that the neuropsychological effects 
persisted after the cessation of ecstasy use. Morgan et al (2002) found evidence for selective 
cognitive impairments remaining after an average of two years of abstinence. Ex-ecstasy 
users showed significant impairments on the RBMT recall measure and committed 
significantly more errors on the MFF20 relative to polydrug users (who did not use ecstasy).
Evidence of the persistence of psychiatric symptoms after abstinence of ecstasy use has also 
been shown by Maclnnes et al (2001). They reported higher levels of depression in former 
ecstasy users compared to matched controls. However, the 'drug free status' in these former 
ecstasy users was somewhat ambiguous, since abstinence was reported for an average of 6 
months, but some ecstasy users reported use as little as 2 weeks before testing.
In light of the discussed case studies and limited empirical research documenting persistent 
effects of cognitive or psychological problems associated with past ecstasy use, the main 
objective in this study was to assess the cognitive abilities and current psychopathological 
status, of RW in light of his reported psychiatric and psychological problems, seven years 
after abstaining from ecstasy use. Cognitive performance and current psychopathological 
states were measured using the same assessment employed in the previous study (chapter 3). 
This was to compare RW's cognitive and psychopathological status with non-problematic 
ecstasy users, problematic ecstasy users and polydrug controls from the previous study 
(chapter 3), to establish the extent of his problems in relation to a group of non-clinical 
recreational drug users. The study also aimed to assess RW's current status with available 
normative data (Geffen et al, 1990 and Derogatis & Melisaratos, 1983, respectively).
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METHOD
Participant Characteristics and drug use
a
RW contacted the researcher at the University of East London by telephone. He described 
himself as having severe problems, which he attributed to past ecstasy use. We arranged for 
semi-structured interview at the University of East London along with the completion of 
standard drug use questionnaires, which included specific questions on experiences and 
patterns of ecstasy usage (the same questionnaires given to ecstasy using groups in the 
previous empirical study (appendix A-D)).
RW was a 26-year-old Caucasian male, who reported no history of psychiatric illness prior to 
his ecstasy use, but a history of anxiety and depression amongst first-degree relatives. After 3 
years of heavy ecstasy use (1991-1994) he started to develop problems, which he attributed 
solely to ecstasy consumption. These problems consisted of depression, suicidal thoughts, 
visual disturbances, panic attacks, social phobia, sexual impotence and severe sleeping 
difficulties. The severity of these problems increased to such an extent that by 1994 he 
decided to cease taking the drug. However, with no alleviation of these symptoms on 
cessation, he approached the local health services. At various times he was seen by his local 
GP (general medical practitioner), a clinical psychologist and a psychiatrist, in addition to 
gaining some help and advice from a local drug clinic. He was diagnosed has having a 
constellation of psychiatric disorders including anxiety, depression, phobia and panic attack 
disorders, which were related to drug dependency. RW was prescribed various medications 
including fluoxetine, all of which proved ineffective. However he was eventually placed on 
15mg of oral trifluoperazine, which reduced the severity of some symptoms. However, the 
remaining symptoms were and still are distressing enough that this individual often consumes 
illicit diazepam, which he claims reduces the symptoms further.
Between 1991 and 1994, RW took approximately 750 ecstasy tablets, initially taking 1-2 
tablets on each occasion, but this increased to an average of 10 per night. On some evenings 
he would take 25 tablets, stating "...they were like sweeties, 1 just kept popping them in my 
mouth one after the other...". The most he claimed to have taken in one overnight session was 
25 tablets. He claimed that during the course of this 3-year period, he needed to take ecstasy
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and felt psychologically dependent and addicted to the drug, despite not suffering if he 
sometimes went without it. In addition, he also reported using amphetamine (10 occasions), 
cocaine (25 occasions), crack cocaine (6 occasions), LSD (35 occasions), solvents (20 
occasions) and nitrates or poppers (20 occasions), during the same 3 year period of ecstasy, 
use. During this period he smoked cannabis on a daily basis, and continued using it for a year 
after the onset of these psychological symptoms. Since 1994, he reported using 
benzodiazepines (BZs) on approximately 300 occasions, with the sole purpose of self- 
medication to relieve the psychiatric symptoms mentioned above. Currently he reported 
consuming an average 18 units of alcohol/week, and smoked an average of 30 cigarettes/day. 
Current daily medication consists of 15mg of trifluoperazine. He stated that he was currently 
not using BZs on the day he attended the University of East London for testing.
After RW gave written informed consent to take part in the study, which was approved by the 
University of East London Ethics Committee (appendix S), he was given a battery of 
assessment measures to empirically determine his cognitive and psychopathological status 
after seven years of abstinence from ecstasy (MDMA). Other than his daily medication of 
15mg of trifluoperazine, RW reported being drug free on the day of testing.
Assessment Measures
Current psychopathological status was assessed using the same modified version of the Brief 
Symptom Inventory (BSI) as in the previous study. Cognitive performance was also assessed 
using the same battery of tasks as in the former study, in the following order: Auditory Verbal 
Learning Task (AVLT; Rey 1964), Tower of London (TOL; Shallice 1982) and the Version A 
of the Rivermead Behavioural Memory Test (RBMT; Wilson, Cockburn, Baddley & Hiorns, 
1991), hence the methodology for each task being identical to that used in the previous study 
(see methodology section, chapter 3)
Statistical Analysis
The individual score for each cognitive test was converted to a 'z' score, and compared with 
group values for polydrug controls (n = 20), non-problematic ecstasy users (20) and 
problematic ecstasy users (14) from the previous study. Also, AVLT comparisons were made
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with normative data taken from Geffen et al (1990). Individual RBMT scores were assessed 
using the standardised profile scoring criteria depending on the degree of deficit, with '0' 
indicating abnormal performance; T indicating borderline; and '2' indicating normal 
performance. The total standardised profile score was assessed against the cut-off points 
established by Wilson et al (1991). RW's scores on the BSI were also compared to 3 
published norms: a sample of heterogeneous outpatients (n = 1002), psychiatric inpatients (n 
= 3130) and a sample of non-patient normal subjects (n = 685) (Derogatis and Melisaratos, 
1983).
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RESULTS 
Task Data
Brief Symptom Inventory [Modified Version]
Table 11 shows RW scores on all dimensions of the BSI compared to the drug using groups 
from the previous study. Compared to polydrug controls RW scored higher on all negative 
subscales and lower on all positive subscales. Scores were significantly higher on 
somatisation (z = 5.84, p<0.001), interpersonal sensitivity (z = 3.96, p = 0.001), depression (z 
= 4.83, p<0.001), anxiety (z = 4.53, p<0.001), anger/hostility (z = 9.73, p<0.001), phobic- 
anxiety (z = 9.72, p<0.001), paranoid ideation (z = 4.76, p<0.001), MDMA side effects (z = 
2.50, p = 0.006), sexual function (z = 5.58, p<0.001) and cognitive failures (z = 3.11, p = 
0.001) subscales. Scores were, significantly lower on positive mood (z = -2.54, p = 0.006), 
sociability (z = -2.13, p = 0.017) and psychobiology (z = -2.40, p = 0.008) sub-scales.
Compared to non-problematic ecstasy users, RW also scored higher on all negative subscales 
and lower on all positive subscales. Scores were significantly higher on somatisation (z = 
5.39, p<0.001), interpersonal sensitivity (z = 5.39, p<0.001), depression (z = 6.33, p<0.001), 
anxiety (z = 8.97, p<0.001), anger/hostility (z = 4.65, p<0.001), phobic-anxiety (z = 8.62, 
p<0.001), paranoid ideation (z = 3.72, p<0.002), psychoticism (z = 1.95, p = 0.026), negative 
psychobiology (z = 2.02, p = 0.022), sexual functioning (z = 5.94, p<0.001) and cognitive 
failures (z = 1.82, p = 0.034) subscales. Scores were also significantly lower on positive 
mood state (z = 2.77, p = 0.003), sociability (z = 1.65, p = 0.05) and positive psychobiology (z 
= -2.63, p = 0.004) subscales.
Compared to problematic ecstasy users, RW scored higher on nearly all negative subscales 
(the exception being on the psychoticism scale) and lower on all positive subscales. 
However, scores were only significantly higher on somatisation (z = 1.87, p = 0.031), 
interpersonal sensitivity (z = 1.64, p = 0.05), anxiety (z = 1.63, p = 0.05), anger/hostility (z = 
2.49, p = 0.006), phobic anxiety (z = 2.34, p = 0.01) and sexual functioning (z = 2.15, p = 
0.016) subscales and none of the scores reached significance on the positive scales.
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Table 12 illustrates RW's scores on 9 dimensions of the BSI in comparison to normative data 
taken from non-patient subjects, psychiatric in-patients and psychiatric out-patients (Derogatis 
and Melisaratos, 1983). Compared to non-patient normals RW scored significantly higher on 
all of the nine subscales: somatisation (z = 5.7, p<0.001), obsessive-compulsive (z = 3.27, 
p<0.002), interpersonal sensitivity (z = 6.63, p<0.001), depression (z = 7.37, p<0.001), 
anxiety (z = 7.38, p<0.001), anger/hostility (z = 7.90, p<0.001), phobic anxiety (z = 9.25, 
p<0.001), paranoid ideation (z = 5.47, p<0.001) and psychoticism (z = 3.39, p<0.006). In 
comparison to psychiatric in-patients RW scored higher on all of the nine subscales, reaching 
significance on the somatisation (z = 1.71, p = 0.044), interpersonal sensitivity (z = 1.82, p = 
0.03), anxiety (z = 1.71, p = 0.04), anger/hostility (z = 2.75, p = 0.003) and phobic anxiety (z 
= 2.19, p = 0.014) subscales. Compared to psychiatric out-patients RW scored higher in all 
nine dimensions and in nearly all reaching significance: somatisation (z = 2.18, p=0.01), 
interpersonal sensitivity (z = 1.83, p = 0.03), depression (z = 1.73, p = 0.04), anxiety (z = 1.97 
p = 0.02), anger/hostility (z = 2.70, p = 0.004), phobic anxiety (z = 3.00, p = 0.001) and 
paranoid ideation (z = 1.75, p = 0.04).
Auditory Verbal Learning Task
Table 13 shows RW's AVLT scores for each trial compared to drug using groups and 
normative data. Despite the fact that RW recalled fewer words than the three drug using 
groups on most of the AVLT trials, none of them were significantly lower. However, 
compared to normative data, RW scored significantly lower for retention of newly learned 
information on trial 1 of immediate recall (z = -2.83, p = 0.002) and its loss due to retroactive 
interference, shown by trial six (z = -2.41, p = 0.008), see figure 10.
Tower of London
Table 13 shows RW's planning and solution times compared to polydrug controls and ecstasy 
using groups. RW exhibited longer planning (figure 11) and solution times (figure 12), 
compared to all drug using groups. Planning times were significantly longer compared to 
polydrug controls (z = 3.03, p<0.001), non-problematic ecstasy users (z = 3.56, p<0.002), and 
problematic ecstasy users (z = 1.94, p = 0.026). Solution times were significantly longer
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compared to polydrug controls (z = 2.84, p = 0.002), non-problematic ecstasy users (z = 3.68, 
p<0.002) and problematic ecstasy users (z = 1.79, p = 0.04).
Rivermead Behavioural Memory Test
RW demonstrated normal functioning (scores of 2) on the following items: delayed article 
recall, remembering a belonging, remembering an appointment, immediate route recall, 
delayed route recall, orientation for time & place and picture recognition. Borderline 
performances (scores of 1) were found on immediate article recall and message delivery. A 
poor performance (score of 0) was found in aspects of face recognition. According to cut-off 
points established by Wilson et al, (1991), the total memory score of this individual (=16) 
indicates moderately impaired memory function, but normal expressive language ability and 
perceptual functioning. Compared to the drug using groups from the previous study RW's 
memory profile score (table 13) was significantly lower than all the experimental groups.
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DISCUSSION
Like many ecstasy users RW reported that with continued ecstasy use he reported the need to 
increase his self-dosing, but this dosage escalation is typical of regular users (Parrott, 2002). 
However the maximum number of tablets taken on one occasion, twenty-five, is considered to 
be very high, although high rates of ten tablets/occasion or more have been described 
previously (McGurie & Fahy, 1991; Winstock et al, 2001; Janssen, 1999). RW stated that it 
was during this period of heavy usage that he started to develop psychological problems, 
including poor sleep, depression, phobic anxiety, memory/concentration difficulties, and 
sexual impotence. He attributed this constellation of problems to his increasing use of 
ecstasy, and therefore decided to stop taking it. Nevertheless cessation did not lead to a 
resolution of the problems, but instead they have continued unabated for the past seven years. 
It was against this biographic profile that RW was assessed on the cognitive and psychiatric 
symptom test battery, used in the previous study.
The cognitive test results confirmed that RW had various deficits, with a significant 
impairment in immediate memory compared to normative data in addition to everyday 
memory and executive functioning (as measured by the TOL), compared with polydrug 
controls, current non-problematic ecstasy users and problematic ecstasy users (see table 13). 
This was consistent with previous reports of selective cognitive problems in heavy ecstasy 
polydrug users, on similar and in some cases the same cognitive tests (Fox et al, 200Ib; 
2001c; Morgan et al, 2002). RW's subjective complaints of memory/cognitive problems were 
also consistent with the verbal reports of other recreational users. For example, Parrott et al 
(2002) found in their sample that 73% of heavy ecstasy polydrug users complained of 
memory difficulties which they attributed to ecstasy.
The adverse scores on the BSI were also indicative of severe problems and difficulties (table 
11). On some subscales RW indicated scores in the clinical range for psychiatric patients 
(table 12); somatisation, interpersonal sensitivity, depression, anxiety, anger/hostility, phobic 
anxiety and paranoid ideation. This profile was unsurprisingly consistent with RW's reports 
of depression, suicidal thoughts, panic attacks, social phobia, sexual impotence and sleeping 
problems, which he had been reporting for seven years. Surveys have revealed that 
recreational ecstasy polydrug users often report raised psychiatric symptom profiles (Schifano 
et al, 1998; Parrott et al, 2000; 2001). Interestingly though, the extreme BSI scores reported
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by RW were much higher than the raised group means apparent in the above surveys (table 
11) but were consistent with many of the published case studies of severe clinical problems in 
ecstasy users: e.g. paranoia (McGurie and Fahy, 1991), panic attacks (Windhaber et al, 1998), 
delirium (Alciati et al, 1999) and psychosis (Bone et al, (2000). For a comprehensive review 
of this extensive literature of individual case studies, see Soar et al (2001).
The importance of this current case study was that RW had been abstinent from ecstasy for 
seven years, yet was still suffering severe psychobiological problems. It is well documented 
that ecstasy use can be associated with cognitive and psychiatric deficits. However, there is 
little empirical evidence on whether these effects endure over time. Wareing et al (2001) 
found deficits on executive functioning and measures of anxiety in previous ecstasy users, and 
Maclnnes et al (2001) found higher levels of depression in former ecstasy users up to 6 
months after drug cessation. Morgan et al (2002) found ex-ecstasy users exhibited 
significantly impaired RBMT recall performance and committed significantly more errors in 
the MFF20 test than polydrug users, despite being tested at least 6 months after their last 
ecstasy experience. They also showed that ex-ecstasy users exhibited elevated 
psychopathology scores on the SCL-90-R relative to polydrug users on a subset of measures: 
positive symptom distress index, inter-personal sensitivity and altered appetite/restless sleep. 
The above studies demonstrate that anxiety, depression, altered sleep patterns and 
impairments in executive functioning and verbal recall can persist for up to 6 months to 2 
years after the cessation of ecstasy. The present case study suggests that such effects may 
persist for considerably longer and that spontaneous recovery might never occur. Deficits of 
this magnitude, seen here after seven years of abstinence are consistent with the case 
presented by Kopelman et al (2001).
However, as with any retrospective case study, there are always numerous interpretative 
difficulties and limitations (Schifano & Magni, 1994; Pallanti & Mazzi, 1992). Firstly, there 
was no psychiatric data prior to the onset of ecstasy use. Poor premorbid adjustment has been 
associated with increased drug use and since there were no formal psychiatric assessments 
performed prior to the onset of his problems, it is difficult to rule out psychiatric disturbance 
of some degree existing prior to ecstasy use. Also RW may have had a genetic predisposition 
towards neuropsychiatric illness. This possibility is supported by the history of anxiety and 
depression in his first-degree relatives. The latter point cannot be ruled out but it is important
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to note the RW did not report to his GP with any previous psychological disturbances prior to 
ecstasy use. In addition, RW stated that his symptoms gradually developed over a period of 
time during which his ecstasy use was escalating.
A second, similar problem is that there is no objective measure of pre-morbid cognitive 
capacity, and so it is possible that RW exhibited this cognitive profile prior to ecstasy use. 
Previous studies have found cognitive deficits in ecstasy users screened to exclude those with 
clinical-psychiatric distress (Fox et al, 2001b; Fox et al, 2001c; Morgan et al, 2002). 
However in the present case study it might be that the psychiatric symptoms exacerbated the 
cognitive difficulties, or that these impairments could have been entirely secondary to the 
psychiatric problems. However, as with the psychological problems, RW did not report 
cognitive problems prior to taking ecstasy and his symptoms were described as developing 
over the period when ecstasy was being used at markedly escalating levels. Thus the high 
doses of ecstasy seem to be the crucial releasing factor, whether or not there was any 
premorbid predisposition. Of course, this interpretation of the development of both 
psychopathological symptomatology and cognitive impairments is solely based on the 
assessment from RW himself.
The use of other psychoactive drugs was another important potential confounding factor, 
since cannabis, amphetamine, LSD, or other polydrug use, may have contributed to these 
psychobiological problems (Parrott et al, 2001; Morgan et al, 2002) and cognitive deficits 
(Rogers and Robbins, 2001). However, McGuire et al (1994), Series et al (1994), Creighton 
et al. (1991) and Schifano (1991) all concluded there was an association with ecstasy and 
adverse symptomatology, despite occasional and sporadic use of other drugs (LSD, heroin, 
amphetamines, and cannabis). Also similar adverse symptomatology (paranoia, anxiety, 
aggression, depersonalisation, panic attacks, melancholia, suicidal ideation and repetitive 
thought patterns) was reported in an individual who had taken ecstasy over the course of 6 
years with no other drug use except ecstasy and cannabis (Cohen, 1996). These case studies 
all show similar sporadic polydrug use profiles comparable to that of RW.
It is possible that cannabis could have contributed to the development of RW's problems, 
since it was regularly taken during the time of ecstasy use and this would also be consistent
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with the idea that cannabis is an important contributor to elevated psychopathological profiles 
(Morgan et al, 2002). However, as with other case studies that report adverse reactions to 
ecstasy with concurrent cannabis use (Williams et al, 1993, McCann & Ricaurte, 1992; 
Creighton et al, 1991; McGuire et al, 1994; Cassidy & Ballard, 1994), no reported adverse 
reactions were attributed by the individual to cannabis. Regarding the possible confounding 
effects of previous use of cannabis on RW's cognitive profile, it is difficult to dissociate the 
contributions of ecstasy and cannabis in any empirical research to date.
BZ use may also have contributed to RW's cognitive deficits, since BZs can impair memory, 
particularly on complex tasks and/or those involving episodic aspects. However, tasks which 
involve remembering a few verbal items for a period of seconds, e.g. cued-recall and 
recognition, are not generally affected by BZs (Curran, 2002). However, the use of BZs may 
have contributed to the poor performance of AVLT recall and story recall in the RBMT. 
However, it would not necessarily account for the poor performance of face recognition 
within the RBMT or Tower of London planning times since benzodiazepines do not seem to 
affect performance on traditional tests of frontal functioning (Curran, 2002). Rather this 
profile is more akin to that suggested by current literature to be characteristic of that induced 
by ecstasy use.
It could be argued that RW's cognitive profile may be accounted for by his current use of 
trifluoperazine. Typical antipsychotic drugs, such as trifluoperazine, have been found to 
impair memory (Goldstone et al, 1979; Tune et al, 1982; Medalia et al, 1988; Cassens et al, 
1990; Cleghorn et al, 1990) however, this is possibly attributable to the conjunctive use of 
other anticholinergic medication (Mishara & Goldberg, 2004). On the contrary Eitan et al 
(1992) showed that whilst there was no impairment on immediate memory, long-term 
memory and visual short-term memory, trifluoperazine was shown to improve short-term 
verbal memory. Wickert et al (2003) has also shown significant cognitive performance 
improvements with the administration of atypical agents compared to placebo controls. A 
more recent meta-analysis (Mishara & Goldberg, 2004) of typical antipsychotic medication 
suggests that modest-to moderate gains are seen in multiple cognitive functions: attention, 
language function, intellectual and perceptual function, memory, and executive function.
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Therefore, RWs cognitive impairments are very unlikely to be a result of his current 
medication.
There are a number of methodological limitations, which need to be addressed. The first is 
the reliance on subjective reports of drug use. Objective assessment of past ecstasy and other 
drug consumption is difficult, since in this case as in most case studies the individual stops 
taking the ecstasy before presentation. It would be useful in future cases such as this to use 
the hair analysis technique (Kikura et al, 1997; Alien & Oliver, 2000) to have an objective 
measure of drug use. However, this could only really assess relatively recent drug use, not 
drug use seven years previously. Additionally, it is difficult to infer that these cognitive and 
psychobiological problems are the result of serotonin neurotoxicity incurred from past ecstasy 
use without support from neurological evidence: for example from brain MRI scans. The two 
case studies concerning severe cognitive deficits related to ecstasy use, as discussed in the 
introduction to this chapter (Kopelman et al, 2001 and Spatt et al, 1997), were supported by 
MRI and PET scans indicating brain abnormalities in regions rich in serotonin releasing 
neurons, indicating that ecstasy possibly contributed to such abnormalities and subsequent 
functional consequences. Despite the absence of scan data for RW it is nonetheless 
significant that his behavioural profile is akin to those in the latter two studies.
In summary, RW displayed clear cognitive deficits and extensive psychological problems 
which he attributes to his former heavy use of ecstasy, which are consistent in nature and 
magnitude to data in many empirical studies of current and former ecstasy users (Parrott et al, 
2001; Morgan et al, 2002; Wareing et al, 2001; Maclnnes et al, 2001). There was some 
evidence of psychiatric predisposition (family history), which did not appear to be producing 
symptoms prior to ecstasy use, that may explain to some degree in combination with ecstasy 
use, the problems experienced by RW. That these problems are still evident seven years after 
cessation of the drug suggests that heavy ecstasy consumption may be associated with 
irreversible long-term psychological and cognitive problems. It may be that having a 
psychiatric predisposition, it may be more likely that one suffers from the long term effects 
and/or have reduced ability to recover following cessation of ecstasy. Thus, further studies 
are needed to assess the persistence of ecstasy-induced psychopathological and cognitive 
effects and the role of premorbid factors.
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CHAPTER 5
Persistency of cognitive and psychological effects 
of recreational ecstasy use
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INTRODUCTION
Several studies have indicated the persistence of what are thought to be ecstasy-induced 
effects. These include case study reports where psychiatric symptomatology has been 
associated with ecstasy long after discontinued use (Cohen, 1996; McCann & Ricaurte, 1992, 
Windhaber et al, 1998; Schifano, 1991). Schifano and Magni (1994) presented a number of 
individual case studies with psychiatric symptomatology, present for 6 months to over 2 years 
after ecstasy cessation. The case study in the previous chapter (4) showed cognitive deficits 
in immediate memory, everyday memory and executive functioning and psychological 
problems thought to be attributable to ecstasy consumption 7 years previously. As discussed 
in the previous chapter there are a number of methodological limitations with such case 
studies, which restricts interpretation concerning the persistency of ecstasy-induced effects. 
This study aims to investigate the persistence of these psychological deficits using the same 
battery of tasks used in the previous two studies, by assessing ecstasy users who have 
abstained from using the drug for at least a year.
Recently, neuroimaging studies have demonstrated possible recovery from ecstasy induced 5- 
HT neurotoxicity (Reneman et al, 2001; Reneman et al, 2001) which have considerable 
implications regarding whether or not the behavioural and cognitive effects associated with 
recreational ecstasy use are reversible or persistent in nature. Empirical studies involving 
non-clinical samples have specifically addressed the issue of persistency of psychological 
effects associated with ecstasy; with varying results. Maclnnes et al (2001) reported higher 
levels of depression in former ecstasy users compared to matched controls, though the 'drug 
free' status in these former ecstasy users was somewhat ambiguous, since abstinence was 
reported for an average of 6 months, but some ecstasy users reported use as little as 2 weeks 
before testing. Gerra et al (2000) actually found an improvement in hostility scores on the 
Buss Durkee Hostility Inventory, in ecstasy users 12 months after ecstasy discontinuation. 
However, these findings are limited since there were no control group comparisons. In 
contrast, Morgan et al (2002) failed to find any differences on the SCL-90-R or IVE, between 
current and ex-ecstasy users.
Persistency of cognitive deficits has been explored in a few studies, again with varying 
results. Tentative evidence for the persistence of neurocognitive deficits has been shown by 
Wareing et al (2000). Current and previous ecstasy users were tested on measures of central
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executive functioning in addition to self-reported levels of anxiety. Both groups were found 
to have deficits on some aspects of central executive functioning and raised levels of anxiety 
compared to a control group of non-ecstasy users, suggesting that the neuropsychological 
effects persisted after the cessation of ecstasy use. Morgan et al (2002) found selective 
cognitive impairments to remain after an average of two years of abstinence, with ex-ecstasy 
users showing significant impairments in recall on the RBMT and committing significantly 
more errors on the MFF20 relative to 'non-ecstasy' polydrug user controls. Zakzanis and 
Young (2001) demonstrated impairments in abstinent ecstasy users on aspects of the 
Behavioural Assessment of Dysexecutive Syndrome (BADS) compared to controls. 
However, these findings are questionable since the length of abstinence varied in the ecstasy 
user group from 2 to 156 weeks, with no current ecstasy user group comparison. 
Additionally, Reneman et al (2001) showed that whilst ecstasy and ex-ecstasy users 
demonstrated impairment on the AVLT compared to controls, ex-users still showed 
impairment. Together these studies indicate that whilst it is difficult to ascertain empirically 
whether psychological symptoms associated with ecstasy are persistent in nature, the effects 
on some aspects of memory function certainly appear to be prolonged.
The present study sought to extend understanding of which psychological and cognitive 
impairments associated with ecstasy use might be persistent in nature, by assessing the 
cognitive and psychopathological profiles of ex-ecstasy users who had not used ecstasy for a 
period of at least a year. There scores were compared with current ecstasy users and also with 
a polydrug control group. 'Ex-ecstasy' use was defined by a one year period of abstinence. 
This one year cut off point for ex-ecstasy users was chosen based on the criteria used in 
Reneman et al's study (2001) as discussed above.
All three groups were assessed and compared on the same TOL and AVLT tasks used in the 
previous two studies, but not the complete RBMT. Instead of using the complete version of 
the RBMT, only the story recall and prospective memory components were used. This 
methodological alteration was made since the complete RBMT is not thought to be suitable 
for detecting subtle memory deficits (Wall et al, 1994; Wills et al, 2000) and also because any 
cognitive effects in ex-ecstasy users are likely to be more even more subtle than current 
ecstasy users because of hypothesised cognitive recovery. The prose recall component was 
used since numerous studies employing this component have demonstrated impaired 
performance in ecstasy users (Morgan, 1999; Morgan et al, 2002; see chapter 2). The two
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prospective memory components from the RBMT (remembering to ask for a belonging and 
remembering to ask a particular question relating on future cues), were used since recent 
research has shown that prospective memory is impaired in ecstasy users (Heffernan et al, 
2001; Rodgers et al, 2001) and also to validate the self-reported cognitive failure questions 
included in the BSI. Based on previous research and the employment of more sensitive tests, 
it is hypothesised that current ecstasy users will display cognitive deficits compared to 
polydrug controls. Whether or not ex-ecstasy users will display cognitive deficits to the 
extent of current ecstasy users or whether they indicate similar cognitive profiles compared to 
polydrug controls will be addressed.
As in the previous studies, psychopathological status was assessed in all three groups using 
the same modified version of the BSI. Again this was used to establish whether ecstasy users 
displayed higher self-reported psychopathological profiles than polydrug controls, as has been 
repeatedly shown (Parrott et al, 2000; Parrott et al, 2001; Daumann et al, 2001; Dugherio et 
al, 2001), and also to indicate whether these psychopathological symptoms were persistent or 
if they recovered to the level of polydrug controls after a period of abstinence from ecstasy. 
Based on the findings of this previous research it is hypothesised that current ecstasy users 
will display different psychopathological profiles to ex-ecstasy users. A further objective of 
this study is to explore whether the potential problems and deficits in ex-ecstasy users are 
simply weaker versions of the same problems reported in the problematic ecstasy users in the 
first study (chapter 3) and the individual case study or different problems altogether.
The usage of other drugs, patterns of ecstasy consumption and self-reported positive and 
negative effects associated with ecstasy, were also assessed using a similar questionnaire as in 
the previous two studies, to try and establish any possible differences between the two ecstasy 
using groups. The drug use questionnaire differed slightly from that used in the previous 
studies, with the omission of questions focusing on the acute effects of ecstasy. This was to 
shorten the questionnaire, but at the same time to focus more on the main objective of the 
thesis (i.e. the 'long-term' effects associated with ecstasy), rather than the acute effects.
Another objective of the study was to replicate the cognitive and psychological dose-related 
findings from the initial study (chapter 3) and to confirm previous findings (e.g. 
Schifano et al, 1998; Parrott, Sisk & Turner, 2000; Maclnnes et al, 2001; Fox et al, 2001b; 
Reneman et al, 2001). In order to achieve this, the psychopathological and cognitive test
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scores in all ecstasy users (both current and ex-ecstasy users) will be correlated with ecstasy 
use; factors include:- lifetime consumption, average dose consumed on any one occasions and 
largest dose consumed on a single occasion. Correlation analyses involving the 
psychopathological and cognitive test scores and 'duration since last used ecstasy' should 
help validate any significant group effects between current and ex-ecstasy users.
The fact that the methodology used in this present study is nearly identical to that used 
previously, may also allow for confirmation of the results found for ecstasy users and 
polydrug users in the first study. This partial replication will help determine whether ecstasy 
users demonstrate cognitive and psychological deficits compared to polydrug controls, and 
thus establish whether the lack of findings in the first study were partly due to a poorly 
performing polydrug control group, as discussed previously (chapter 3).
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METHOD
Participants
Subjects were recruited via the 'snowball' technique' (28%) (Solowij et al, 1992), word of 
mouth (44%) and posters around the University of East London (28%). First year 
undergraduate psychology students, who volunteered for the study, did so as part of a course 
requirement (n=20). All participants were assessed for ratings of health, age, number of years 
in education and premorbid verbal IQ, as measured by the NART (Nelson, 1982). 
Participants were excluded from the study if they reported any of the following conditions: 
head injury, current or previous asthma, depression, anxiety, obsessive compulsive disorder, 
schizophrenia or paranoia, panic attacks, eating disorders, alcohol or drug dependency.
Sixty-one subjects participated in this study: 21 (13 male, 8 female) current recreational 
ecstasy users who had used ecstasy at least 20 occasions in their lifetime, but had not used 
within the last 2 weeks; 20 (14 male, 6 female) recreational ecstasy users who had used 
ecstasy on at least 20 occasions in their lifetime, but had been abstinent for at least 1 year; and 
20 (6 male, 14 female) polydrug controls who had no history of ecstasy exposure but 
otherwise used other illicit drugs. Those participants that did not meet the exclusion criteria 
were then formally assessed with a questionnaire. This comprised of questions concerning 
their own and immediate family psychiatric history and details of past illicit drug use. The 
University of East London ethics committee approved the study (see appendix U for the 
application for ethical approval and confirmation of approval. All participants gave written 
informed consent (see appendix Y) and were paid £10 each for participating.
Assessment Measures
Participant's drug usage patterns were assessed using the same drug use questionnaire as the 
previous study for assessing their history of drug use (Appendix A). Individuals in the 
ecstasy group were asked to complete the additional questionnaire used in the previous study 
regarding patterns of ecstasy use (Appendix B). In addition they were asked to indicate when 
they last consumed ecstasy and also whether they used other drugs in conjunction with 
ecstasy and to indicate what these were. They were also asked to complete the same 4-point
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self-report Likert scale on the long-term positive and negative effects of ecstasy on life 
experiences (Appendix B).
Psychopathological status was assessed using the same modified version of the Brief 
Symptom Inventory (BSI) as in the first study. Cognitive performance was assessed using 
the following tasks in the order presented below:
Prospective Memory tasks: The two prospective memory test components were taken from 
the RBMT (Wilson et al, 1991). The first of these was 'Remembering an appointment'. 
Participants were required to ask a particular question relating to the near future when an 
alarm sounds during the experiment. The second was 'Remembering a belonging', where 
participants were requested to ask for a belonging, which had previously been hidden by the 
experimenter, on the cue of the experimenter saying "that is the end of the test" and to 
remember where it has been hidden. These two test items were scored using the standardised 
profile scoring system for the RBMT (see methodology, chapter 3): 2 points awarded for each 
task if completed successfully, 1 point awarded for each task if they completed the tasks after 
a prompt and 0 points if they failed to remember to complete the task, even after prompting.
Prose recall (immediate and delayed). After listening to a short passage read aloud by the 
experimenter, each participant was required to recall as much as possible immediately after 
the reading and again after a period of delay. The story was taken from the prose recall 
component of the RBMT (Wilson et al, 1991) and comprised five sentences containing 65 
words and 21 'ideas'. Recall was scored with one point given to each of the 21 ideas recalled 
perfectly or a close synonym and half a point for partial recall or partial synonym.
Auditory Verbal Learning Test (AVLT; Rey, 1964). The methodology for this task is identical 
to that in the first study (see methodology section, chapter 3).
Tower of London (TOL): The methodology for this task is identical to that in the first study 
(see methodology section, chapter 3).
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Statistical Analysis
Data analysis was conducted using SPSS 10 for windows. ANOVA tests were performed for 
all cognitive tasks (AVLT, TOL, prose recall and prospective memory) and the BSI data to 
assess whether there were any group differences between polydrug controls, ecstasy users and 
ex-ecstasy users. Post Hoc analyses comprised of paired comparisons between groups using 
the Tukey's range statistic.
As drug use violated parametric assumptions, Kruskall Wallis was employed to assess 
differences in drug use between the three experimental groups. Post hoc analysis comprised 
of paired comparisons between groups using the Mann Whitney test. Bonferroni corrections 
were employed by dividing the standard error rate (a = 0.05) by the number of groups in the 
analysis, in this case o/3 = 0.017, to minimise the risk of type 1 errors.
There was no need to conduct further separate analyses of covariance, since age did not differ 
between experimental groups. Again co-variation for other drug use was not carried out for 
the reasons given in the discussion of chapter 3.
The independent samples t-test was used to assess differences between current and ex-users, 
in the patterns of ecstasy use as well as reported positive and negative effects of ecstasy. Chi- 
squared tests were used to establish any significant differences between these groups in 
response to questions regarding both the positive and negative effects of ecstasy on life 
experiences and gender.
After collapsing the two ecstasy groups, Pearson Product Moment Correlational Analyses 
were conducted to assess whether there were any associations between patterns of ecstasy use 
and BSI data, negative and positive effects of ecstasy and cognitive performance; and whether 
data from the positive and negative effects of ecstasy were associated with data from the BSI. 
There were no statistical corrections made to the correlational analyses to control for type 1 
errors, thus it is important to note that significant findings should be treated with extreme 
caution due to the large number of correlations and potential chance occurrences.
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RESULTS
Personal characteristics and drug data
Tables 14 to 16 show the demographic and drug use data. There were no significant group 
differences for age, rating of health and verbal IQ. However, there was a significant group 
difference of gender ratios [^2 (2) = 7.23, p = 0.027] with significantly more males than 
females in the control group than in the current and ex-ecstasy using groups.
With regard to drug consumption (see table 14), polydrug controls reported significant less
*j
drug use than the ecstasy groups for a number of compounds: amphetamine [x, = 24.46, 
p<0.001], cocaine ft2 = 20.56, p<0.001], crack cocaine [%2 = -6.48, p=0.039, opiates [%2 = 
10.01, p=0.004], cannabis fe2 = 19.29, p<0.001], LSD [%2 = 20.04, p<0.001], magic 
mushrooms [%2 = 15.14, p<0.001], poppers ft2 = 23.10, p<0.001], ketamine [%2 = 8.10, p =
0.017], tobacco [%2 = 9.74, p = 0.008] and monthly cannabis [%2 = 22.05, p<0.001].
As expected, current ecstasy users reported a significantly shorter duration since they last 
consumed ecstasy [t(38) = -4.54, p<0.001]. They also reported a significantly higher 
maximum dosage compared with ex-ecstasy users [t(39) = 2.54, p = 0.016] (table 14). There 
were no differences on the reported long-term positive and negative effects scale that ecstasy 
had had on life experiences between the two ecstasy using groups (table 14).
Regarding use of other drugs specifically on occasions when using ecstasy (see table 16), a 
greater percentage of current ecstasy users reported use of cannabis (65% vs. 43%), cocaine 
(65% vs. 24%), alcohol (25% vs. 14%) and poppers (15% vs. 10%) in conjunction with 
ecstasy compared to ex-ecstasy users; who reported greater use of amphetamine (43% vs. 
30%) and LSD (10% vs. 5%) in conjunction with ecstasy.
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Table 14; Participant demographics, levels of illicit drug use and patterns of ecstasy use
consumption in polvdrue controls, current and ex-ecstasv users (means and SDs).
Age
Verbal IQ
Current rating of health
Patterns of ecstasy use:
Average dose
Maximum dose
Total consumption
Duration of ecstasy use 
(months) 
Weeks since last used
Positive effect score
Negative Effect Score
Other drug use:
Amphetamine
Cocaine
Crack
Opiates
Cannabis
Benzodiazepines
LSD
Magic Mushrooms
Solvents
Poppers
Ketamine
Prozac
GHB
Tobacco (Per day)
Alcohol (Units per week)
Cannabis (Per month)
Polydrug 
Controls
(C)
27.95 + 6.12
112.05 ±7.48
3.5 ±0.69
11. 55 ±44.62
12.25 + 44.70
-
0.05 + 0.224
175.90 ±338.90
0.10 ±0.45
10.60 + 44.64
1.60 + 6.69
0.30±1.18
-
0.10 ±0.45
-
3.30 ±6.91
9.60 ±10.15
0.3 + 0.57
Current 
Ecstasy Users
(E)
24.48 + 3.4
111.57 + 5.16
3.29 + 0.46
2.14 ±0.91
5.83 + 3.13
238.95 ±286.92
87.42 + 41.86 
11.55 +14.79
12.10±4.53
31.90 + 7.91
56.86 + 70.84
130.86 ±233.56
I A3 ±4.42
0.90+1.92
1436.52 ±1753.93
3.67 + 10.93
21.57 ±48.99
4.19 ±7.55
1.43 + 3.17
59.90 ±216.00
3.19±7.79
-
0.48 ±1.12
8.00 ± 6.46
14.43 ±14.48
12.43 ±11.96
Ex-Ecstasy Users 
(Ex)
27.1 + 3.78
113.15±4.36
3.45 + 0.69
1.73 + 0.57
3.75 + 2.03
185.25 ±148.86
75.40+37.01 
146.45 ±132
14.10 ±4.56
30.30 ±.8.46
75.25 + 83.42
40.95 ±58. 10
0.55 ±1.05
4.05 ±11. 07
1590.25 ± 1453.34
3.40 ±11.32
35.00 ±49.44
14.00 ±17. 89
3.65 ±10.8
12.39 + 23.31
4.40 ±8.57
0.25 ±0.91
12.25 ±11.88
11.30+11.62
11.65 ±12.77
Group 
Effect
£
0.063
0.675
0.286
0.088
0.016
0.460
0.348 
<0.001
0.166
0.535
<0.001
<0.001
0.039
0.004
<0.001
0.067
<0.001
0.001
0.088
<0.001
0.017
0.359
0.128
0.008
0.660
<0.001
Post Hoc
Comparisons
-
-
C < E & Ex
C < E & Ex
C < E & Ex
C<Ex
C < E & Ex
C < E & Ex
C < E & Ex
C < E & Ex
C < E & Ex
_
-
C < E & Ex
C < E & Ex
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Table 16: Reported drug use whilst using ecstasy, for current and ex-ecstasv using 
groups
% of participants in each group Current
Ecstasy Users
(n=21)
Ex-Ecstasy Users
(n=20)
Cannabis
Amphetamine
Cocaine
Alcohol
Nicotine
Caffeine
Poppers
LSD
Magic Mushrooms
Opiates
65%
30%
65%
25%
5%
0%
15%
5%
0%
0%
43%
43%
24%
14%
10%
5%
10%
10%
5%
0%
Table 17; Modified BSI subscale scores for polvdrug controls, current ecstasy and ex- 
ecstasv users (means and SDs).
Polydrug Current Ex-Ecstasy Users ANOVA 
Controls Ecstasy Users Group Effect
___________________________________________________E____ 
Negative symptoms
Somatisation 0.37 ±0.34 0.63 + 0.56 0.57 + 0.50 0.200
Obsessive-compulsive 1.05 + 0.75 1.09 + 0.73 1.28 + 0.72 0.567
Interpersonal sensitivity 0.71+0.70 0.69 + 0.59 0.79 + 0.60 0.876
Depression 0.53 ±0.64 0.45 ±0.63 0.65 ±0.68 0.619
Anxiety 0.55 ±0.68 0.56 ±0.45 0.62 ±0.56 0.927
Anger/hostility 0.49 ±0.47 0.60 ±0.49 0.67±0.7T 0.600
Phobic anxiety 0.25 ±0.30 0.13 + 0.22 0.11 ±0.21 0.167
Paranoid ideation 0.51 ±0.38 0.58 ±0.52 0.68 ±0.73 0.632
Psychoticism 0.39 ±0.56 0.41 ±0.53 0.46 ±0.46 0.907
Negative psychobiology 0.51 ±0.38 0.49 ±0.33 0.46 ±0.42 0.915
MDMA side effects 0.99 ±0.71 0.98 ±0.68 1.04 ±0.53 0.952
Sexual functioning 0.38 ±0.34 0.59±0.55 0.52 ±0.48 0.313
Cognitive failures 1.14±0.79 1.30±0.76 1.51 ±0.82 0.336
Positive Symptoms
Feeling content with life 2.40 ± 0.95 
Mood state 2.30 ± 0.87 
Sociability 2.22 ± 0.64 
Positive psychobiology 2.22 ± 0.72
2.41 ±0.94 
2.32 ±0.87 
2.45 ±0.77 
2.28 + 0.88
2.49 ±0.86 
2.37 ±0.63 
2.43 ±0.67 
2.36 + 0.81
0.943
0.963
0.493
0.853
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Table 18: Cognitive assessment data for oolvdrus controls, current and ex-ecstasv users
(means and SD's)
Story recall
Immediate
Delayed
Prospective memory
Remembering an appointment
Remembering a belonging
Tower of London
Planning times
Solution times
Number of errors
Number of incomplete trials
AVLT
Immediate Recall
Trial 1
Trial 2
Trial 3
Trial 4
Trial 5
Total Recall
Interference Trial
Trial 6
Delayed Recall
Number of Errors
Number of Repeats
Intrusion from list A
Intrusion from list B
Polydrug 
Controls
7.87 + 2.95
7. 15 ±3.23
1.95 ±0.22
3.35 ±0.67
7.48 ±3.57
4.11 ±0.96
3.60 ±3.71
0.15 ±0.37
6.40 ±1.79
8.65 ±2.62
10.95 ±2.58
11.10±2.65
11. 60 ±2.44
5.45 ±2.67
9.70 ±2.94
10.30 ±2.75
2.25 ±2.59
5.25 ±4.39
0
0.10 + 0.31
Current 
Ecstasy 
Users
8. 33 ±2.46
7.88 ±2.91
2.00 ±0.32
2.90 ±0.89
8.20 ±4.23
3.78 ±0.68
3.90 ±3.77
0.05 + 0.22
6.19 ±1.72
9.48 ±2.14
10.33 ±2.27
11 .43 ±2.29
11.62 ±1.91
4.14+1.28
10.43 + 2.62
9.90 ±2.13
1.57 ±1.89
4.43 + 4.09
0.0476 ± 0.22
0.19 ±0.60
Ex-Ecstasy 
Users
7.38 ±2.50
6.33 ±2.12
1.80 ±0.52
3.25 ±0.72
9.31 ±4.42
4.13±1.81
3.75 ±2.97
0.15 ±0.37
6.10 ±2.00
8.30 ±1.92
9.55 ±2.16
11.10±1.65
11.15+1.98
4.40 ±1.47
10.1 ±2.07
9.25 ±3.35
2.75 ±3.26
4.2 ±3.76
0.10 + 0.31
0.15 ±0.37
Group Effect 
P
0.514
0.213
0.281
0.157
0.370
0.600
0.962
0.505
0.869
0.233
0.176
0.863
0.730
0.075
0.664
0.490
0.360
0.695
0.811
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Group differences
Measures of psychopathology
Table 17 shows the group scores for all the subscales of the modified version of the BSI. 
Despite the ex-ecstasy users scoring higher on most of the negative scales (obsessive- 
compulsive, interpersonal sensitivity, depression, anxiety, anger/hostility, paranoid ideation, 
psychoticism, MDMA side effects, and cognitive failures) compared to polydrug controls and 
current ecstasy users, these differences did not reach statistical significance.
Measures of cognitive performance
Table 18 shows the group scores for all task data. There were no significant group 
differences on the prose recall task or prospective memory components of the RBMT. Ex- 
ecstasy users performed lower on all trials of the AVLT compared to current ecstasy users 
and polydrug controls; and polydrug controls demonstrated greater delayed recall compared 
to current and ex-ecstasy users (illustrated in figure 14). However, none of these differences 
approached significance. On the TOL, polydrug controls also showed quicker planning times 
(figure 15) and fewer errors (figure 16) compared to current and ex-ecstasy users. Again, 
these did not approach significance, nor were there any significant group differences in 
solution times or the number of incomplete trials.
Correlational analyses 
Dose-response relationships
There were no significant correlations between total ecstasy consumption, average and 
maximum number of ecstasy tablets consumed on one occasion and any subscale of the BSI 
and TOL. Lifetime ecstasy consumption positively correlated with delayed story recall (r = 
0.337, p = 0.031) and recall on trial three of the AVLT (r = 0.346, p = 0.027) and negatively 
correlated with recall on trial six of the AVLT (r = -0.343, p = 0.028).
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Duration of use
Duration of ecstasy use negatively correlated with interpersonal sensitivity (r = -0.318, p = 
0.05) and depression (r = -0.401, p = 0.011) and positively correlated with positive 
psychobiology (r = 0.42, p = 0.008). In addition, there were significant positive correlations 
between the number of weeks since ecstasy use and obsessive-compulsive (r = 0.328, p = 
0.039) and depression scores (r = 0.383, p = 0.015), as well as scores on the positive effects 
attributable to ecstasy scale (r=0.530, p = 0.001).
Measure of drug use
Estimated lifetime consumption positively correlated with the average (r = 0.340, p = 0.029) 
and maximum (r = 0.370, p = 0.017) number of tablets consumed in one occasion, and the 
duration of ecstasy use (r = 0.347, p = 0.030). Regarding other drug use, total lifetime 
consumption positively correlated with lifetime cannabis consumption (r = 0.355, p = 0.023), 
cocaine (r = 0.423, p = 0.006), benzodiazepines (r = 0.621, p<0.001) and monthly cannabis 
consumption (r = 0.384, p = 0.013). Duration of ecstasy use positively correlated with 
lifetime consumption of cannabis (r = 0.385, p = 0.015), cocaine (r = 0.355, p = 0.027) and 
GHB (r = 0.328, p = 0.041).
Measure of long-term psychological effects
The total score for the long-term negative effects attributable to ecstasy positively correlated 
with most of the negative subscales of the BSI: somatisation (r = 0.420, p = 0.006), 
obsessive-compulsive (r = 0.485, p = 0.001), depression (r = 0.385, p = 0.013), anxiety (r = 
0.590, p < 0.001), anger/hostility (r = 0.472, p = 0.002), phobic anxiety (r = 0.416, p = 0.007), 
paranoid ideation (r = 0.337, p = 0.031), psychoticism (r = 0.516, p = 0.001), negative 
psychophysiology (r = 0.414, p = 0.007), MDMA side effects (r = 0.438, p = 0.004), sexual 
functioning (r = 0.494, p = 0.001) and cognitive failures (r = 0.312, p = 0.050). Scores on the 
long-term positive effects attributable to ecstasy positively correlated two of the positive 
subscales of the BSI: feeling content with life (r = 0.336, p = 0.032) and sociability (r = 0.331, 
p = 0.035) and also sexual functioning (r = 0.379, p = 0.015).
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Kirstie Soar Chapter 5
DISCUSSION
The current study indicates that current ecstasy users do not differ in cognitive abilities and 
psychopathological status compared to ecstasy users that have abstained from ecstasy use for 
over a year (ex-users). These findings are inconsistent to that of Maclnnes et al (2001) and 
Gerra et al (2000) who demonstrated recovery from psychopathology e.g. depression and 
hostility. However, both studies have methodological limitations, in the ambiguity of 
abstinence in the ex-ecstasy users (Maclnnes et al, 2001) and due to a lack of appropriate 
control comparisons (Gerra et al, 2000). The current findings are however, also consistent 
with the previous empirical research which avoid these methodological limitations (Morgan et 
al, 2002; Wareing et al, 2000; Reneman et al, 2001: Zakzanis & Young, 2001), indicating 
further evidence that ex-ecstasy users do not differ from current ecstasy users in cognitive and 
psychological abilities.
However, the current ecstasy and ex-ecstasy users do not seem to be displaying cognitive 
deficits or psychological impairments compared to the polydrug controls employed within 
this study; despite the fact that the polydrug controls had used significantly lower amounts of 
most other illicit drugs (table 14). These results replicate those found in the first study 
(chapter 3), which demonstrated that ecstasy users had similar cognitive abilities and 
psychopathological profiles to polydrug controls. However, they are inconsistent with 
previous research studies, which have demonstrated that current ecstasy users display 
cognitive deficits and psychopathology compared to non-ecstasy using controls (Parrott et al, 
2000; Morgan et al, 2002; Fox et al, 2001b; Fox et al, 2001c).
There were a number of possible dose-related effects in relation to cognitive and 
psychopathological status. Recall scores on trial 6 of the AVLT, were shown to worsen with 
higher lifetime consumption, suggesting that it is the cumulative amount of ecstasy that 
affects some aspects of cognitive function, an idea which is supported in some previous 
literature (Morgan et al, 2001; Reneman et al, 2001; Thomasius et al, 2003). However, in 
surprising contrast to previous research, the current study demonstrated a significant positive 
correlation with lifetime consumption of ecstasy and delayed story recall on the RBMT. The 
results also suggested that interpersonal sensitivity and depression scores are higher in 
individuals who have be using ecstasy for a much shorter time period, this may be accounted 
for by individuals becoming tolerant to these negative symptoms the longer they use ecstasy.
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However, a degree of caution needs to be exerted in drawing conclusions from these 
correlational analyses due to the high chance that such significant findings occurred by 
chance, since there was no control for type 1 errors and also because of the collapsed data for 
what are arguably two distinct ecstasy using groups into one. Apart from the expected 
difference in the time each of the two groups last consumed ecstasy, evidence to suggests that 
these two groups are different in relation to their ecstasy use is shown by current ecstasy 
user's using significantly higher amounts on one occasion than ex-ecstasy users (table 14) and 
also their reports of using other drugs in combination with ecstasy. Another difference 
highlighted in the correlational analyses, is that it appears that the longer you abstain from 
using ecstasy, the more likely you are to report obsessive-compulsive and depressive 
symptoms. This may constitute as tentative evidence that ecstasy use may be a form of self- 
medication for psychological problems in some individuals. This self-medication hypothesis 
postulates that "drug users seek to self-administer substances that correct or compensate for 
discomforting features of their biology and usual emotional state" (Gunnarsdottir et al, 2000). 
This has been shown in certain cocaine users with dysphoric moods (Gunnarsdottir et al, 
2000) and drug using schizophrenics (Batel, 2000). Therefore ecstasy users may be using the 
drug to alleviate obsessive-compulsive and depressive symptomatology, as evidenced from a 
case study of one ecstasy using individual, who met the diagnostic criteria for Post-traumatic 
Stress disorder (PTSD; Jansen, 1999).
In summary, it appears there were no group differences in cognitive and psychopathological 
performances, and specifically no evidence of any persistent effects of ecstasy. However, on 
closer inspection of the results there may be differences between the two ecstasy using 
groups, as indicated to by the correlational analyses involving the 'time since last consumed 
ecstasy', but these differences are being masked by poor performance of the control group.
As with the first study, the lack of statistically significant cognitive differences between 
polydrug controls and ecstasy using groups brings into question the validity of the polydrug 
control group. The polydrug controls performed within the levels of normative data for 
immediate recall on the AVLT (6.3 to 7.8, Lezak, 1995) but, again, they performed at the 
lower end of the scale (6.4). When examining the ecstasy users performance for immediate 
recall compared with normative data, both current and ex-ecstasy users scored lower than 
normative data (6.19 and 6.10 respectively); indicating signs of memory dysfunction. 
Delayed recall performance was much better in the polydrug controls than the previous study
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and there is an expected trend of polydrug controls showing better delayed recall than both 
ecstasy using groups. However, once again, polydrug controls performed lower than 
normative data, so any memory deficits in ecstasy users are not pronounced enough to 
produce a significant effect. Comparing AVLT scores to those of Fox et al (2001c), the 
ecstasy users, in this study, are displaying poorer recall across all trails, including delayed 
recall, compared to polydrug controls, as well as, short- and long-term ecstasy users from Fox 
et al's study; indicating that the control group in the present study is impaired, in addition to 
the current and ex-ecstasy users.
Similar comments could be made with regard to the findings from the TOL. There was a 
trend for ecstasy users to show increased planning times (figure 15), indicative of deficits in 
central executive functioning. However, these times were not significantly longer compared 
to polydrug controls, since the polydrug controls here demonstrated higher planning times 
relative to the polydrug controls in the first study and also compared to the control group used 
in the study by Fox et al (200Ib - a study which did demonstrate significant differences in 
planning times between polydrug controls and ecstasy using groups). However, it is 
important to note that this later study only showed poorer planning abilities in heavy ecstasy 
users and not low ecstasy users (this will be discussed in more detail later).
The poor cognitive performance by the polydrug control group could also explain the lack of 
significant findings in prospective memory ability between groups. But, there were no 
distinct trends in this data and it is more likely that it is the task's inability to detect subtle 
memory deficits (Wall et al, 1994; Wills et al, 2000) which explains the lack of findings.
Concerning the group psychopathological scores, polydrug controls were actually reporting 
higher psychopathology across all subscales compared to normative data (Derogatis & 
Melisaratos, 1983). For example, depression scores for non-patient norms are 0.28 compared 
to the 0.55 score in polydrug controls here, and anxiety scores for norms are 0.35 compared to 
0.55 in the polydrug controls. Looking at the current and ex-ecstasy users, they too 
demonstrate higher psychopathology scores across all BSI subscales, relative to normative 
data (for example; depression scores of 0.45; anxiety scores of 0.56). It is reasonable to 
conclude therefore, that whilst the ecstasy users show signs of psychological dysfunction, this 
is quite possibly being masked by a control group who are actually showing signs of 
psychopathology.
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An alternative explanation for the lack of cognitive and psychological deficits in the ecstasy 
users in the current and first study (chapter 3) is that participants might not be exhibiting 
ecstasy-induced neurotoxicity. The fact that participants do not show any signs of cognitive 
and psychological dysfunction, could be evidence that they have not consumed ecstasy in the 
dosages required to produce neurotoxic injury to 5-HT (or other) systems. Current ecstasy 
users and ex-ecstasy users in this present study reported lifetime ecstasy consumption of 239 
and 185 respectively. This is consistent with the number used by the low ecstasy users in the 
study by Fox et al (200Ib). This group of ecstasy users reported using between 100 and 500 
ecstasy tablets and did not differ from polydrug controls on TOL planning times. It was only 
in the heavy ecstasy users (500-1000 tablets) that executive problems were seen. This is 
demonstrated in the former case study of RW who had an estimated lifetime total use of 750 
ecstasy tablets. The cognitive deficits seen in RW, as well as the increased psychopathology 
scores, taken together with the results from Fox et al's heavy users and the lack of effects in 
the ecstasy groups in this current study, could be taken to suggest that large quantities are 
required to induce significant, observable compromisation of 5-HT function.
However, this argument is brought into refute when considering other's research findings. 
Bolla et al (1998) found impairments on the AVLT in ecstasy users with a lifetime 
consumption of as little as 60 tablets, whilst Reneman et al (2000) and Fox et al (200Ic) 
showed AVLT deficits in ecstasy users with similar lifetime consumption levels as the current 
study (218 and 224 respectively). Deficits on the prose recall of the RBMT were also found 
in ecstasy users with an average of 50 tablets (Morgan, 1999) and 55 tablets per lifetime 
(Zakzanis and Young, 2001). Evidence from these previous studies therefore would suggest 
that the lack of cognitive and behavioural findings in this current study is unlikely to be 
because of the levels of ecstasy consumption, and more likely to be due to methodological 
reasons (i.e. an inappropriate control group). Having a poor control group then, may suggest 
that there are actually problems in the ecstasy users here, with no remittance after a period of 
abstinence (i.e. in ex-users).
The nature of a control group is of particular importance, considering ecstasy users are 
notoriously polydrug users, hence the need to use a control group consisting of individuals 
who have also used other drugs, as in the case of this study. There were no differences in 
cognitive performance and psychopathological status between polydrug controls and ecstasy
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groups in the current study (tables 17 & 18). Since all experimental groups displayed some 
level of impairment compared to normative data or previous research, it may suggest that 
cognitive and psychological problems could be a general profile for polydrug use rather than 
ecstasy per se. However, the level of polydrug use in the control group shows they used 
significantly less of most other drugs compared to current and ex-ecstasy users (table 14). 
Levels of polydrug use are also considerably lower than those reported in other polydrug 
control groups in previous studies, which have demonstrated differences from ecstasy user 
groups. For example, the polydrug control groups employed by Morgan et al (2002) actually 
reported smoking cannabis 590 times in the year prior to the study, where as the polydrug 
controls within this study only reported smoking 175.9 times in their lifetime. Similarly, 
other drug use here (including cocaine, LSD, magic mushrooms and amphetamine) was 
similar to levels reported by non-ecstasy using polydrug controls in the study by Parrott et al 
(2001), but they still demonstrated significant differences in psychopathology between 
groups. Thus, it would be expected that any effects of ecstasy over and above those produced 
by polydrug use, would have been detected.
The present study also allowed for the exploration of the patterns of drug use amongst ecstasy 
users, by collapsing the two ecstasy using groups into one group (current and ex-users 
combined). It appears that the greater the lifetime consumption of ecstasy the greater the 
consumption of cannabis, cocaine and benzodiazepines. In addition, the longer ecstasy had 
been used, the more likely was the use of cannabis, cocaine and GHB. This provides support 
for the notion that ecstasy users are more likely to be polydrug users (Strote et al, 2002; Arria 
et al, 2002; Webb et al, 1996; Riley et al, 2001; Winstock et al, 2001). The fact that ecstasy 
users also reported using high rates of cannabis, amphetamine and cocaine in conjunction 
with ecstasy supports the idea that stimulants and hallucinogens are the most likely drugs to 
be used in combination with ecstasy (Riley et al, 2001; Winstock et al, 2001).
In the same combined group of ecstasy users, there was also evidence to suggest that the 
reported long-term negative effects experienced from ecstasy correlated with the majority of 
the negative psychopathological scales of the BSI. These include somatisation, obsessive- 
compulsive, depression, anxiety, paranoid ideation, psychoticism, anger/hostility, MDMA 
side effects and sexual dysfunction. The higher the reported negative effects, the higher the 
psychopathological status. These findings replicate those found in the first study (chapter 3). 
There was also an association between the positive effects experienced from ecstasy and two
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of the positive subscales of the modified BSI (feeling content with life and sociability). 
Together these findings validate the 'negative and positive life experiences, attributed to 
ecstasy questionnaire'. In addition, these results suggest that there is some association 
between the effects attributed to ecstasy and psychopathological profiles measured by the 
BSI. It appears that many individuals, who attribute more of their negative life experiences to 
their ecstasy use, also display higher levels of psychopathology. This could be due a 
cognitive bias concerning attributions of events, or a general predisposition in individuals 
who already have psychopathological tendencies, and/or recall the negative effects as more 
significant. As a result, the consumption of ecstasy is less likely to produce positive effects 
and more likely to produce ill-effects. Another possibility could be that some individuals may 
be more susceptible to the 'toxic' effects of ecstasy: both acute and chronic, as suggested 
from the correlation between scores on the 'MDMA side effects' subscale and negative life 
experiences. This could possibly suggest that short-term ill-effects of ecstasy might be a 
predictor of neurotoxic injury, as was found in the first study concerning higher acute 
symptoms which were related to higher psychopathological scores and long term effects 
attributable to ecstasy use (chapter 3).
To conclude, this study has shown that, contrary to some previous research, ecstasy users and 
ex-ecstasy users did not exhibit any selective cognitive deficits or report differential 
psychopathological profiles relative to polydrug controls. The ecstasy using groups may be 
showing cognitive deficits on tasks such as the AVLT and the TOL, (allowing for poor 
controls), but if so there does not appear to be performance differences between current 
ecstasy users and ex-ecstasy users. This is consistent with previous research, but again 
because of the probable methodological constraints here, it was difficult to gauge whether 
these potential problems were persistent. Thus there are some potentially important 
phenomena indicated here. However, overshadowing these notions, this study highlights the 
need to address the issue of a reliable control group for valid comparisons to establish the 
nature and persistency of the cognitive and behavioural effects of ecstasy and also the role of 
ecstasy in the context of polydrug use.
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CHAPTER 6
Addressing the Methodological Issue of a Valid and Reliable
Control Group: 
Comparisons with a Drug-Naive Control Group
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INTRODUCTION
Findings from studies one and two (chapters 3 & 5) highlight some of the difficulties of using 
polydrug control groups in research, assessing the cognitive and psychopathological status of 
current and ex-ecstasy users. This has raised the question of the validity and reliability of the 
polydrug control group. Evidence to suggest that polydrug controls are exhibiting raised 
levels of psychopathology comes from comparisons in a number of subscales with normative 
data; polydrug controls showing elevated levels (chapter 5). Concerning cognitive 
performance, the polydrug control groups in both these studies (chapters 3 and 5) show subtle 
impairments. Evidence to suggest that polydrug controls may be showing slight cognitive 
impairments, comes from comparisons of memory recall scores on the AVLT with normative 
data, which indicate cognitive performance at the lower end of the normative performance 
spectrum (chapter 3 & 5). Additional evidence to suggest that the reason for the lack of 
statistical cognitive findings may be due to a poorly performing control group, is that, in the 
previous study (chapter 5), ecstasy users were actually showing signs of memory dysfunction 
on the delayed recall trial of the AVLT, since performances were lower than normative data 
(see chapter 5 for further details).
Past research assessing the cognitive effects associated with recreational ecstasy use, suggests 
that selective cognitive deficits occur in ecstasy users. However, many researchers highlight 
the possible effects of concomitant use of other drugs, especially cannabis, on cognitive 
performance (Gouzoulis-Mayfrank et al, 2002; Rodgers, 2000; Croft et al, 2001; Rodgers et 
al, 2001). For example, in a study by Morgan et al (2002) current ecstasy users were shown 
to have impairments in working memory and recall compared with drug-naive controls, but 
not polydrug controls.
Similarly, research into the psychopathological profiles of ecstasy users also suggests that 
concomitant use of other drugs, specifically cannabis, may be crucial. Daumann et al (2001) 
found significant group differences on many subscales of the SCL-90-R (i.e. obsessive- 
compulsive disorder, anxiety, phobic anxiety, paranoid ideation) and its global severity index, 
between ecstasy users and drug-naive controls, but not between ecstasy users and cannabis 
users. Also, any further differences in psychopathology between all three groups no longer 
remained after statistically controlling for cannabis. Morgan (1998) found differences in 
psychological measures between ecstasy users and non-drug users, but not polydrug controls.
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Psychopathology in regular ecstasy users is even thought to be associated more with polydrug 
use generally. Morgan et al (2002) showed that no measure of past ecstasy use predicted 
psychopathological scores as measured by the SCL-90-R, whereas cannabis use did, and in 
some cases, so too did other drug use (e.g. poppers, amphetamine and cocaine). Whilst 
Parrott et al (2001) showed that psychological problems were evident in heavier ecstasy users, 
these users also reported the heaviest polydrug use, and psychopathological symptoms were 
also evident in polydrug users that had not used ecstasy.
It is apparent that polydrug use, and specifically cannabis use, is an important confound in 
studies concerning the cognitive impairments and psychological effects associated with 
recreational ecstasy use. Even though in previous studies within this thesis polydrug controls 
had used significantly less drugs than the ecstasy using groups, they still reported use of other 
drugs, specifically cannabis, amphetamine, cocaine and LSD. It is therefore possible that the 
use of these drugs contributed to cognitive impairment and possibly to the psychological 
symptoms in these polydrug controls, and as a result, any deficits in performance exhibited by 
the ecstasy using groups, would not have been statistically apparent compared to these control 
groups.
The present study sought to address this last issue by running a separate and additional control 
group consisting of drug naive participants and statistically comparing their cognitive and 
psychological profiles, with the cognitive and psychological profiles of the ecstasy and 
polydrug using groups in the previous two empirical studies (i.e. data from chapters 3 and 5). 
The same cognitive test battery (AVLT, TOL, prose recall and prospective memory 
components taken from the RBMT) and BSI used in the previous study were employed for 
direct cognitive and psychopathological profile comparisons. Essentially this would provide 
two new sets of results. Firstly, this would allow exploration of any cognitive and 
psychological differences, between the new drug naive controls, the polydrug controls and 
non-problematic and problematic ecstasy users from the first study (chapter 3; now to be 
referred to as comparison A). Secondly, it will be possible to make comparisons on 
performance between the new drug-naive controls and the polydrug controls, current and ex- 
ecstasy users from the second empirical study (chapter 5; now to be referred to as comparison 
B). If the lack of any significant effects in the previous studies is due to impairments within 
polydrug controls, then it would be expected that ecstasy-using groups would exhibit higher 
psychopathological scores and cognitive deficits compared to the drug-naive controls. If this
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were the case, then it would support the notion that the cognitive and psychological effects 
associated with ecstasy are confounded by polydrug use. If significant differences are found 
between drug naive and polydrug controls, this would provide evidence to suggest that 
polydrug use per se is problematic; contributing to cognitive deficits and elevated 
psychopathological symptoms.
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METHOD
Participants
Subjects were recruited through an advertisement sent via e-mail around the University of 
East London. All participants were assessed for ratings of health, age, number of years in 
education and verbal IQ, as measured by the NART (Nelson, 1982). Participants were 
excluded from the study if they were first year undergraduate psychology students and those 
participants who reported any of the following: past history of any illicit drug use, head 
injury, depression, anxiety, obsessive compulsive disorder, schizophrenia or paranoia, panic 
attacks, eating disorders, alcohol or drug dependency.
Twenty subjects participated in this study (10 male, 10 female) all of whom had no current or 
past history of illicit drug use including cannabis.
Participants were formally assessed with a questionnaire, which consisted of personal details 
regarding their psychiatric history and that of their immediate family. The University of East 
London ethics committee approved the study. All participants gave written informed consent 
and were paid £10 each for participating.
Assessment Measures
Participant's alcohol and nicotine patterns were assessed using the relevant questions from the 
drug use questionnaire used in the previous studies.
Psychopathological status and cognitive performance were assessed using the same battery of 
assessment measures and in the same order of presentation as those used in chapter 5. This 
included the modified version of the BSI, the Prospective Memory tasks (RBMT, Wilson et 
al, 1991), the Auditory Verbal Learning Test (AVLT; Rey, 1964), Prose recall (immediate 
and delayed; RBMT, Wilson et al, 1991) and the Tower of London (TOL; Shallice, 1982), 
(see methodology section, chapter 5 for further detail).
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Statistical Analysis
Data analysis was conducted using the Statistical SPSS 10. Data from the current drug naive 
controls were combined with data from polydrug controls, problematic and non-problematic 
ecstasy users from chapter 3, to provide a new data set consisting of 4 experimental groups 
(comparison A). Data from the current drug naive controls were also combined with the data 
from polydrug controls, current ecstasy and ex-ecstasy users from chapter 5, to provide 
another new data set, also consisting of 4 experimental groups (comparison B).
Prior to analysis the BSI data for comparison A were subjected to a square root 
transformation, since the data was markedly skewed with heterogeneous variances. All other 
data was used in is original form.
One-way ANOVAs were performed for all cognitive tasks (AVLT, TOL, prose recall and 
prospective memory), the BSI data, demographic and tobacco and alcohol data to assess 
whether there were any group differences between the four experimental groups in each 
study. Where there were violations of homogeneity of variance, the non-parametric Kruskall 
Wallis test was employed. Post Hoc analysis comprised of paired comparisons between 
groups using the Tukey's range statistic and the Mann-Whitney test for the non-parametric 
equivalent. For such pairwise tests a partial error correction was made, by dividing the 
standard error rate (a = 0.05) by the number of groups in the analysis, in this case o/4 = 
0.013, to minimise the risk of type 1 errors. The Chi-squared test was used to establish any 
significant gender differences between groups.
Finally, to control for the significant group differences in age, data was re-analysed using 
analysis of covariance, to determine whether age was a statistically significant covariate, and 
if so, what effect this had on the statistical significance on any group differences. Again, co­ 
variation for other drug use was not carried out for the reasons given in the discussion of 
chapter 3.
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RESULTS
Comparison A: Drug naive controls and data from chapter 3
Personal characteristics and drug data
Table 19 shows the demographic data and levels of tobacco and alcohol use for the current 
drug naive control group as well as the data from chapter 3. Significant group differences 
were found with age [F(3,70) = 3.19, p = 0.029], with the drug-naive controls and polydrug 
controls being significantly younger than problematic ecstasy users. Differences were also 
evident with current rating of health [F(3,70) = 6.04, p = 0.001J, with drug-naive controls 
reporting significantly better health than ecstasy and problematic ecstasy users. There were 
no significant group differences in gender and verbal IQ.
There were also significant group effects of tobacco use and alcohol consumption, [%2 = 
23.17, p <0.001J and [^2 = 10.38 p = 0.016] respectively. Drug-naive controls reported 
significantly lower levels of tobacco consumption compared to ecstasy and problematic 
ecstasy users. Polydrug controls also reported significantly lower levels of tobacco use 
compared to non-problematic ecstasy users. Drug-naive controls also reported significantly 
less alcohol consumption than non-problematic ecstasy users.
Measures of psychopathology
Table 20 shows data for all the subscales of the modified version of the BSI for the current 
drug naive control group and alongside the data from chapter 3. There were significant group 
differences on the following subscales: somatisation [F(3,70) = 9.02, p = <0.001], 
interpersonal sensitivity [F(3,70) = 6.23, p = 0.001], depression, [F(3,70) = 6.90, p <0.001], 
anxiety [F(3,70) = 7.92, p< 0.001], phobic anxiety [F(3,70) = 9.95, p = <0.001], paranoid 
ideation [F(3,70) = 6.88, p <0.001], psychoticism [F(3,70) = 9.35, p <0.001], MDMA side 
effects [F(3,70) = 4.47, p = 0.006], cognitive failures [F(3,70) = 6.56, p = 0.001] and positive 
mood [F(3,70) = 3.00, p = 0.036].
Adjusted ANCOVA analyses were conducted on these significant BSI subscales, with age 
entered as a covariate, as there was a significant age difference in groups (see table 19).
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These analyses revealed no change in the significant main effect of group on somatisation, 
interpersonal sensitivity, depression, anxiety phobic anxiety, psychoticism, MDMA side and 
cognitive failures (see table 44, appendix V for individual statistics). There was no change in 
the significant main effect of group on paranoid ideation subscale [F(3,70) = 8.98, p <0.001], 
despite age showing a significant covariate [F(l,73) = 5.34, p = 0.024]. Finally, the adjusted 
ANOCVA model revealed that there was no longer a significant group effect on positive 
mood [F(3,70) = 2.35, p = 0.08), but this was change was not accounted for by age [F(l,73) = 
0.199, p = 0.657].
Post hoc analyses showed that problematic ecstasy users scored significantly higher on 
interpersonal sensitivity, depression, anxiety, paranoid ideation and psychoticism compared to 
drug-naive controls, polydrug controls and problem free ecstasy users. They also scored 
significantly higher on MDMA side effects compared to drug-naive controls (figure 17); 
significantly higher than polydrug controls on somatisation (figure 19); and scored 
significantly higher on cognitive failures (figure 18) compared to polydrug controls and drug- 
naive controls. On the positive mood subscale, problematic ecstasy users scored significantly 
lower than drug-naive controls (figure 21).
Non-problematic ecstasy users scored significantly higher on somatisation (figure 19) and 
cognitive failures compared to drug-naive controls, but not polydrug controls. However, non- 
problematic ecstasy users scored significantly lower than drug-naive controls and problematic 
ecstasy users on the phobic anxiety subscale.
Measures of cognitive performance
Table 21 shows all the cognitive assessment data for the current drug naive control group 
together with the cognitive data from chapter 3. There were no significant group differences 
in prose recall (immediate and delayed), prospective memory, planning and solution times of 
the TOL. There were significant group differences with the number of errors made on the 
TOL [F(2,70) = 2.89, p = 0.043], with a trend showing both ecstasy using groups to have 
made more errors than drug naive and polydrug controls, but these failed to reach significance 
on post hoc tests (figure 22).
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On the AVLT there were significant group differences in the delayed recall trial [F(3,73) = 
3.22, p = 0.028]. Polydrug controls were significantly impaired on delayed recall compared 
to drug-naive controls (figure 23). Adjusted ANCOVA analyses were conducted on the 
AVLT delayed recall trial data, with age entered as a covariate, as there was a significant age 
difference in groups (see table 19). This adjusted model revealed no change in the significant 
main effect of group on the delayed recall trial [F(3,73) = 3.169, p = 0.03], after co-varying 
for age [F(l,73) = 0.002, p = 0.964].
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Kirstie Soar Chapter 6 
Comparison B: current drug naive controls and data from chapter 5
Personal characteristics and drug data
Table 22 shows the demographic data and levels of alcohol and tobacco consumption for the 
current drug naive controls, as well as the same data from the experimental groups in chapter
?\
5. Significant group differences were found in current rating of health [% = 11.64, p = 0.009], 
with drug-naive controls reporting significantly better health than current ecstasy users; and 
tobacco consumption [x,2 = 25.31 p<0.001] with drug-naive and polydrug controls consuming 
significantly lower amounts of tobacco per day compared to current and ex-ecstasy users. 
There were no significant group differences in age, gender and verbal IQ and alcohol 
consumption.
Measures of psvchopathology
Table 23 shows data for all BSI subscales, for current drug naive control group together with 
BSI data from chapter 5. Significant group differences were found on somatisation [F(3,77) = 
3.71, p = 0.015] (figure 24), phobic anxiety [F(3,77) = 10.03, p = <0.001] (figure 25) and 
cognitive failures [F(3,76) = 3.76, p = 0.014] (figure 26) subscales. Drug-naive controls 
exhibited significantly lower scores on somatisation compared to current ecstasy users, 
significantly higher scores on phobic anxiety compared to polydrug controls, current and ex- 
ecstasy users; and significantly lower scores on the cognitive failures subscale.
Measures of cognitive performance
Table 24 indicates data for all cognitive assessment measures for the current drug naive 
control group compared with the data from chapter 5. There were no significant group 
differences in any of the cognitive tasks.
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Kirstie Soar Chapter 6
DISCUSSION
The results of the current study concerning cognitive performance, indicates that with the 
introduction of a new drug-naive control group, ecstasy users from the first empirical study 
(both non-problematic and problematic; chapter 3) were exhibiting trends of impairment in 
performance on the TOL; they were making more errors whilst completing the TOL 
compared to polydrug and drug-naive controls. This may suggest that such impairments are 
selective problems of ecstasy use, since polydrug users did not show increased errors. This is 
consistent with previous evidence, where ecstasy users exhibited significantly more errors on 
completing a questionnaire than cannabis users (Rodgers et al, 2001), and significantly more 
errors on a spatial working memory task compared to polydrug users (Fox et al, 2002), and 
made significantly higher number of errors on the MFFT20 task compared to polydrug and 
drug-naive controls (Morgan, 1998; Morgan et al, 2002). The fact that ecstasy users produce 
more errors on such cognitive tasks may indicate a lack of reflection (Rodgers et al, 2001) and 
be a manifestation of greater impulsivity in these users. Support for this later explanation 
comes from a study by Morgan (1998). Not only were an increased number of errors made by 
ecstasy users on the MFFT20 compared to polydrug and non-drug users, but ecstasy users 
also showed signs of elevated impulsivity on the Impulsivity, Venturesomeness and Empathy 
Questionnaire (IVE).
In the same comparison (A), it appears that polydrug controls from chapter 3 were also 
showing deficits on the delayed recall trial of the AVLT compared to drug-naive controls 
(figure 23). This supports the suggestion that polydrug use may contribute to cognitive 
impairments. However, there were no impairments in any ecstasy user group compared to the 
drug-naive controls, which suggests that in this case deficits may not be an artefact of 
polydrug use; especially since both ecstasy using groups used significantly higher amounts of 
other drugs than the polydrug controls. It is more likely that such deficits are caused by a 
factor independent to drug use. This finding does however support the notion that the 
polydrug control group in chapter 3, were showing memory deficits and this may account for 
the lack of evident memory deficits between the polydrug control group and ecstasy using 
groups. As such, this evidence strengthens the suggestion that the polydrug control group in 
that study (chapter 3) was not a reliable experimental group compared to previous research.
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Concerning comparison B, the introduction of a new drug naive control group did not 
demonstrate any statistical deficits in cognitive performance for both the polydrug and the 
ecstasy using groups from chapter 5. However, ex-ecstasy users reported significantly more 
cognitive failures than the drug naive controls (figure 26). This subjective reporting of 
cognitive deficits is not supported by the objective measures of cognitive performance. Ex- 
ecstasy users did not show signs of impairment on any of the cognitive tests. This disparity 
between subjective and objective measures of cognition, highlights the need to be cautious in 
relation to the reliability of self-report data concerning cognitive abilities in ecstasy users.
For the BSI data the results of the present study indicate that, that problematic ecstasy users 
(chapter 3 data) are now showing elevated symptoms on the MDMA side effects scale 
compared to drug-naive controls. These problematic users, who attributed their problems to 
ecstasy, also seemed to be showing increased reports of cognitive failures compared to 
polydrug and drug-naive control groups. More importantly, non-problematic ecstasy users 
were displaying higher levels of somatisation and reported more cognitive failures compared 
to drug naive controls only. This suggests that polydrug use causes somatisation symptoms, 
but only when used in conjunction with ecstasy, since there were no significant differences in 
this subscale between polydrug and drug naive controls.
With the introduction of the new drug-naive control group to the second empirical study 
(chapter 5; comparison B), current ecstasy users showed signs of elevated somatisation scores 
compared to drug naive controls only. Again, this provides some evidence to suggest that 
polydrug use in conjunction with ecstasy causes significant somatisation effects, but not 
polydrug use alone. The second set of comparisons also showed that cognitive failures are 
perhaps more of an artefact of polydrug use, since polydrug users, current and ex-ecstasy 
users scored significantly higher numbers of cognitive failures than the drug-naive controls, 
but did not differ from one another.
What is interesting to note is that the drug-naive controls are themselves showing signs of 
phobic-anxiety, when compared to the groups from the first empirical study (chapter 3); they 
scored significantly higher than both ecstasy using groups and polydrug controls on this 
subscale of the BSI. This could be taken to suggest that ecstasy and polydrug use actually 
reduce the symptoms of phobic-anxiety, yet this is contrary to previous research where drug-
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naive controls have been shown to have reduced phobic-anxiety compared to ecstasy users 
(Parrott et al, 2001; Dugherio et al, 2001; Daumann et al, 2001 and Morgan et al, 2002).
The consistent new finding within the two new comparisons (A & B) of this chapter is that 
scores in (some) ecstasy users showed elevated somatisation scores (from both chapter 3 & 5) 
compared to drug-naive controls. This is consistent with findings of Parrott et al (2002), 
Morgan et al (2002) and Thomasius et al (2003). However, these studies also found ecstasy 
users to differ on other subscales of the SCL-90 and SCL-90-R compared to controls. The 
only ecstasy using group to show elevated signs of psychopathology in most scales of the 
BSI, within this current research programme, were those that reported problems from their 
ecstasy use. Thus, the psychopathological profile of problematic ecstasy users is actually 
closer to these previous findings, than is the case with the data from non-problematic users. 
This raises an important issue concerning the nature of those who choose to participate in 
'ecstasy' research and whether participants perceive themselves to have problems or not, 
which they attribute to their ecstasy use (see chapter 8 for further discussion); such questions 
have not been addressed in previous research demonstrating elevated psychopathology in 
ecstasy users.
This study also highlights the effect ecstasy polydrug use has on reported ratings of health. 
Across both comparisons (A & B); ecstasy users (and problematic ecstasy users in 
comparison A) reported significantly poorer health compared to drug-naive controls. Drug- 
naive controls reported an average 3.85 on a rating scale from 1 to 4 (1 being bad health and 4 
indicating good health). These findings support that of Morgan (1998) who found ecstasy 
users to display poorer health compared to non-drug users. Also, weight loss, infections, 
tremors and twitches (Parrott et al, 2002), lower back pain, headaches and stomach cramps 
(Cohen, 1995) have all been attributed to ecstasy use. Whether these health issues are a result 
of drug use or more to do with the lifestyle involved in recreational drug use is impossible to 
determine from this study, but this certainly warrants further investigation.
This current study attempted to address the validity of data in chapter 2 by determining 
whether ecstasy users showed signs of memory dysfunction and psychopathology. However, 
this has not been the case (with the exception of the somatisation symptoms - see above). 
The lack of significant findings between non-problematic ecstasy users and both polydrug 
controls and drug-naive controls could suggest that regular ecstasy use is not always
163
Kirstie Soar Chapter 6
associated with cognitive performance and psychopathology. There are other researchers that 
have failed to find cognitive deficits in ecstasy users compared to controls (Simon and 
Mattick, 2002; Gamma et al, 2001; Turner at al, 1998). One suggestion for this is that the 
MDMA content of ecstasy tablets has fallen and as a result ecstasy users are not necessarily 
consuming neurotoxic doses of MDMA, and hence are not showing any functional sequalae 
(Parrott, 2000). However, this is unlikely to be the case. Whilst acknowledging that the 
amounts of MDMA may be lower in ecstasy tablets compared to 10 years ago (Cole et al, 
2002), ecstasy users within this research had consumed large amounts of the drug. In chapter 
3, non-problematic ecstasy users reported a mean lifetime consumption of 264 tablets, and 
problematic ecstasy users reported 367 tables. In chapter 5, ecstasy users reported a mean 
lifetime consumption of 239 tablets, and ex-ecstasy users 185. In both these data sets, users 
had consumed similar amounts of ecstasy, and in some cases a lot more, compared to recent 
studies which have shown cognitive impairments in ecstasy users compared to drug naive and 
polydrug controls (see, or example: Fox et al, 2001b & c; McCann et al, 2001; Reneman et al, 
2001; Reneman et al, 2000; Gouzoulis-Mayfrank et al, 2000 and Morgan et al, 2002). It is 
therefore more likely that there is an alternative explanation for the non-significant findings in 
this study.
One explanation that could account for the lack of cognitive findings may lie in the reliability 
of the cognitive tests and the differences in administration between this study and other 
research. For example, with the AVLT administration, there is little uniformity in various 
procedural aspects, with varying rates of delayed recall from 15 to 40 minutes. There is also 
variation in filler activities between the last immediate recall trial and the delayed recall trial. 
In the studies detailed here (chapters 3 and 5) there was a large cognitive demand placed on 
participants between trial 6 and the delayed recall trial (with participants performing the prose 
recall task of the RBMT, the TOL and the NART in the interim), which may have affected 
consolidation of previously learnt material and hence produced difficulties in delayed recall. 
Such cognitive demands may be less in other studies which demonstrate deficits in delayed 
recall in ecstasy users compared to polydrug controls (e.g. Morgan, 1999; Fox et al, 2001c; 
Reneman et al, 2001).
The manual version of the TOL was used throughout this research. This is not a standardised 
test and is less commonly used within psychology research today, since more reliable 
computerised versions are available (e.g. CANTAB), which avoid variations in manual
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dexterity. Finally, it has already been discussed in chapter 5 that the prospective memory 
components of the RBMT may not be sensitive enough alone as a measure for prospective 
memory, and it may have been more suitable to have used a graded measure of prospective 
memory; such as the PMQ which has previously been shown to indicate differences in ecstasy 
users compared to polydrug controls (Heffernan et al, 2001; Rodgers, 2000).
However, it is more likely that the inconsistent cognitive and psychobiological findings 
between ecstasy users, polydrug and drug naive controls are due to atypical experimental 
group characteristics and performance. As previously discussed the drug naive control group 
was actually showing higher symptom ratings related to phobic anxiety compared to ecstasy 
users. At the same time this drug naive control group was actually performing lower than 
normative data on immediate recall of the AVLT, with immediate recall of 6.1 items out of 
15: normative data suggests immediate recall should fall between the range of 6.3 and 7.8 
(Lezak, 1995). Also, on recall scores of trial 5 of the AVLT, normative data indicates this 
should be between 12 and 14. However, drug naive controls recalled at the low end of this 
spectrum with 12.1 words. Together, this data suggests the possibility that this drug naive 
control group is not performing normally, or is, at least, at the very lower end of the 
normative spectrum. Thus any performance deficits in ecstasy user groups may be masked by 
poor cognitive performance in the drug-naive control group. The question then arises, why 
are the control groups performing worse than expected?
One possible reason for the poor performance in the polydrug and drug-naive controls found 
in this research could be due to sampling errors. Most of the polydrug control groups in the 
chapters 3 and 5, comprised predominantly of first year undergraduate psychology students. 
As part of a first year course requirement these students have to provide evidence of 
participating in three research studies in the academic year. Hence the reasons for taking part 
in this research differed to a majority of those who were allocated to the ecstasy using groups. 
This same issue was highlighted by Fox (2002) in her research, who also found such sampling 
errors. Those students who took part in the research as part of a course requirement were 
described as being far less motivated and focused than many of the ecstasy users who 
contributed. With this additional study incorporating a new control group of drug naive 
participants, a concerted effort was made to avoid using these first year undergraduate 
psychology students, but the group was still made up of undergraduate students, who 
appeared more interested in taking part in research as a means to earning some money rather
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than the research subject area itself. In contrast a majority of the ecstasy users were external 
volunteers, who had a vested interest in the study. Such motivational issues could, in these 
instances, have accounted for the discrepancies found in cognitive performance.
Therefore the most likely explanation for the atypical findings in the research conducted so 
far within this thesis, lies within methodological issues; specifically sampling errors with the 
control groups. As a result of the poor cognitive performance demonstrated by these groups 
(polydrug controls and drug naive controls), cognitive deficits are not statistically evident in 
the ecstasy using groups. This is a more likely explanation to that originally proposed, which 
was that polydrug use in general produces cognitive deficits rather than ecstasy use. This 
raises the interesting possibility that the importance of controls is a testament to the relatively 
subtle deficits produced by ecstasy and other drug use. On one hand it could be argued that 
the subtle effects of ecstasy are not that important or more worryingly that the cognitive 
effects of ecstasy can easily go unnoticed.
The atypical findings with regard to psychopathological status are harder to account for using 
the explanation of an impaired control group. It is perhaps more likely, that polydrug use 
accounts for some of the discrepancies in the data. But most importantly, the individual's 
self-perception of problematic ecstasy use plays an important role, since the highest 
psychopathological symptoms have been found in ecstasy users who report problems which 
they specifically attribute to ecstasy use.
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CHAPTER 7
Differences in Attributionai Style Between Problematic and 
Non-Problematic Ecstasy Users: Locus of Control and
Drug Attributions
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INTRODUCTION
According to the data from these empirical studies, non-problematic ecstasy users do not 
appear to be demonstrating any significant cognitive differences compared to polydrug 
controls or drug-naive controls. Non-problematic ecstasy users only displayed elevated levels 
of somatisation when compared to a group of drug-naive controls (chapter 6), but no signs of 
psychopathology compared to polydrug controls. In these studies, the only sample of ecstasy 
users that appear to be showing any signs of psychopathological symptoms, are those that 
reported problems which they attributed to their ecstasy use (chapter 3 & chapter 4). The fact 
that these reported problems and their psychopathological status were independent of their 
patterns of ecstasy consumption highlighted the need for further investigation into the 
possible reasons underlying problematic ecstasy use. The aim of this current study therefore, 
is to explore one possible personality trait, which may contribute or help us understand the 
reporting of such problems, specifically in this group of ecstasy users.
In the first study, individuals were self-selecting themselves into problematic or non- 
problematic ecstasy using groups, on the basis that they experienced problems, which they 
attributed to their ecstasy use. This has lead to the suggestion that premorbid personality 
characteristics may play a role in attributing problems to ecstasy use. In a study by Dughiero 
et al (2001), psychopathological characteristics of ecstasy users were assessed with respect to 
premorbid personality traits as measured by the Cloninger Tridimensional Personality 
Questionnaire. Ecstasy users showed higher novelty-seeking scores compared to controls and 
in addition, showed higher scores than controls on the obsession-compulsion, phobic anxiety, 
psychoticism and sleep disturbance subscales of the SCL-90. Maclnnes et al (2001) showed 
higher levels of depression, as measured by the Beck's Depression Inventory, in ecstasy users 
compared to non-drug using controls. These levels of depression were positively correlated 
with an external locus of control and self-report measures of life stress. Both these studies 
demonstrated differences in certain measures of personality, between ecstasy users and 
controls. However, neither studies addressed whether the ecstasy users self-perceived 
themselves as being problematic or not, or whether high levels of certain personality traits 
were more of less associated with possible ecstasy-induced problems.
Fox et al (2001a) addressed the issue concerning the self-perception of problems attributable 
to past ecstasy use, by examining differences in a group of problematic and non-problematic
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ecstasy users in relation to both drug consumption and premorbid life adjustment variables. 
As with chapter 3, they found no group differences in relation to quantity and pattern of 
ecstasy use or in personal and family psychiatric history, yet problematic ecstasy users 
reported experiencing a greater number of negative interpersonal experiences prior to taking 
ecstasy. This finding suggests the need for the assessment of premorbid criteria when looking 
at problematic ecstasy use.
The present study sought to establish whether certain premorbid personality factors were 
important in contributing towards whether ecstasy users report problems, which they attribute 
to past ecstasy use. One particular personality characteristic that may be of importance is 
whether individuals attribute events to factors outside of their control e.g. externally, or 
attribute events to factors with their own control e.g. internally. This personality construct is 
referred to as the locus of control (LOG). It is thought to be a stable attribute of an 
individual's personality (Rotter, 1966) and is derived from the Social Learning Theory of 
personality (Rotter, 1954). He argues that for behaviour to occur in any specific 
psychological situation, there needs to be an expectancy that that behaviour will lead to a 
particular reinforcement in that situation. External LOG individuals believe reinforcers to be 
controlled by outside forces, such as luck, fate, the environment, powerful others or other 
factors outside their own control. Whereas, internal LOG individuals believe that reinforcers 
are controlled from within, contingent on their own actions or enduring personality 
characteristics (Rotter, 1966).
There has been considerable interest in the role of this personality construct and psychological 
distress, with the belief that individuals who have more of an external control orientation are 
likely to report higher levels of psychopathology and maladjustment than those with an 
internal control orientation. Amongst psychiatric inpatients, external LOG has been seen to 
be related to greater psychopathology (Archer, 1980). Amongst non-patient populations, 
studies have shown that LOG has tended to be positively correlated with psychological 
distress (D'Arcy & Siddique, 1984; Young & Washburn, 1992) and psychopathology (Hale & 
Cochran, 1987; Young & Washburn, 1992; Petrosky & Birkimer, 1991; Hoehn-Saric & 
McLeod, 1985; Archer, 1980). O'Leary et al (1976) examined the role of this personality 
construct amongst alcoholics. Alcoholics with an internal LOG exhibited the least 
psychopathology, whilst the greatest levels of psychopathology were found amongst 
alcoholics with an external LOG. A more recent study on inpatients, demonstrated that an
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external LOG orientation for substance use behaviour was related to more days in treatment 
and a general external locus of control for life events; whilst an internal LOG was related to 
high self-efficacy for avoidance of drug use (Malin & Fordham, 2002). Taken together this 
research suggests that individuals, who exhibit psychological distress and drug using 
individuals, tend to have more of an external LOG orientation.
Fox et al (200la) appears to support this notion in some respect by showing a difference 
between individual's perceptions of problems compared to the actual experience of problems. 
They suggested that problematic ecstasy users are attributing symptoms to their ecstasy usage, 
despite reporting a greater number of negative interpersonal experiences prior to taking 
ecstasy. Thus the main aim of the current study was to assess the relationship between self- 
reported problematic ecstasy use and the potential issue as to whether these individuals are 
attributing these problems to factors that are outside of their personal control (e.g. their 
ecstasy consumption), rather than attributing their problems to something that they have 
personal control over, i.e. LOG.
The present study also sought to investigate further the issue of polydrug use with regard to 
long term psychological effects reported by recreational drug users. Previous research 
suggests that the heavier the polydrug use alongside ecstasy, the higher the level of self- 
reported psychological symptoms as measured by the SCL-90 (Parrott et al, 2001). In 
addition, Morgan et al (2002) reported that psychopathology amongst ecstasy users was more 
associated with polydrug use rather than ecstasy per se. Thus, the present investigation was 
also an exploratory study, which sought to determine which drugs, if any, were associated 
with the long-term effects reported by some ecstasy-polydrug users. This was achieved by 
asking volunteers to indicate which drug or drug combinations, if any, they attributed to 
changes in their life experiences. These long-term changes in life experiences, where those 
that were used in the positive and negative effects scale in chapter 3.
The current study comprised a large scale survey, which included the personal history and 
drug use questionnaires used in the previous studies. The drug use questionnaire was slightly 
amended to include two new questions covering the frequency of ecstasy use and problematic 
use. The response options for the questions concerning the positive and negative changes in 
life experiences were also amended to allow for individuals to indicate which other drugs they 
attributed these changes too, if any, rather than just ecstasy use. The extent, to which
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individuals attribute control to themselves, or to external factors, was assessed using the 
Locus of Control Scale (Rotter, 1966). This scale was used, based on the established 
literature concerning psychopathological symptoms and drug using population samples. 
Psychopathological status was assessed using the BSI, as used in previous studies. However, 
the subscale concerning MDMA effects was omitted, since it was seen that these items are 
associated more with the acute effects of ecstasy rather than the long-term effects and thus 
deemed as unnecessary for the aim of this particular study.
The grouping criteria used, within this study, consisted of ecstasy users who reported 
psychobiological problems that they attributed to their past ecstasy use (problematic ecstasy 
users), ecstasy users that did not report any problems from their usage (non-problematic 
ecstasy users), a polydrug group who had not used ecstasy (polydrug controls) and a non-drug 
using group who had not used any illicit substances (drug-naive control group). A non-drug 
using group was included in this study, because conclusions from the previous study 
concerning polydrug and ecstasy using groups are flawed. The drug-naive group did not 
follow exactly the same experimental protocol as many of the experimental groups they were 
subsequently compared to. As such, some group differences or lack of them may, in part, 
have been due to different demand characteristics and the different paradigms.
It is predicted that ecstasy users who report problems attributable to their past ecstasy use will 
report significantly higher psychopathological symptom scores than non-problem ecstasy 
users, who will also report greater psychopathological symptoms compared to polydrug 
controls and non-drug users. It is also predicted that problematic ecstasy users will differ 
significantly to non-problematic ecstasy users on the Locus of Control Scale (indicating a 
differing attributional style); demonstrating a higher external locus of control. The study also 
aims to explore which drugs, if any, are attributed to differing positive and negative life 
experiences,
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METHOD 
Participants
Participants were recruited through a number of techniques 1 , including recruitment notices 
throughout the University of East London's e-mail system, posters around the University of 
East London and various clubs throughout London, and via an advertisement in the 'Big 
Issue' magazine (appendix P). First year undergraduate psychology students, who 
volunteered for the study, did so as part of a course requirement.
Two-hundred and eighty-eight volunteers participated in the study: 111 (37 male, 74 female) 
drug naive participants, who reported no past drug use other than alcohol and nicotine; 62 (27 
male, 35 female) polydrug users who had no history of ecstasy use but otherwise had used 
other illicit drugs; 62 (33 male, 29 female) ecstasy users, who reported ecstasy and other 
polydrug use but did not report problems from their past ecstasy use; and 53 (25 male, 28 
female) problematic ecstasy users, who reported ecstasy and other polydrug use and also 
indicated that they had experienced problems which they attributed to ecstasy use. All 
participants were allocated to these groups using a post hoc method. Problematic ecstasy 
users were distinguished from non-problematic users by answering 'yes' to the question, 
'Have you experienced any problems, which you attribute to your ecstasy use?' All 
participants gave written informed consent (see appendix Z) and The University of East 
London ethics committee approved the study (see appendix U for the application for ethical 
approval and confirmation of approval).
Assessment Measures
Drug Use
Each volunteer completed a questionnaire using either a hard copy (n= 46) or accessed and 
submitted on-line (n=242) via http://homepages.uel.ac.Uk/K.Soar/ecstasv qa.htm (part of the
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University of East London's web-site). This questionnaire consisted of the same questions 
used in chapters 3, 5 and 6 linked to drug, alcohol and tobacco use. It was slightly modified 
to assess volunteers' current cannabis use and also address volunteers' past cannabis use. 
Questions regarding levels and patterns of ecstasy use were also taken from the previous 
studies in this thesis, with the addition of two new questions: the first assessing the frequency 
of ecstasy use and the second which allowed post hoc group allocation to problematic or non- 
problematic ecstasy groups (see above for question). All participants were then asked to 
indicate whether or not they had experienced a list of 7 positive and 21 negative changes in 
their life and which, if any, of six drugs (ecstasy, amphetamine, cocaine, LSD, cannabis and 
alcohol), they attributed this change to (appendix F).
Brief Symptom Inventory
Psychopathological status was assessed using the modified version of the BSI as used in 
previous studies, with the omission of the MDMA side effects subscale.
Locus of Control Scale (LOC; Rotter, 1966).
This scale is a 29-item, forced-choice test including 6 filler items, where participants had to 
select one statement of each pair (and only one), which they strongly believed to be the case. 
In some instances, both statements or neither statement may be believed in, in which case 
participants were instructed to select the one that they most strongly believed to be the case. 
The total score is the number of external choices made.
Statistical Analysis
Data analysis was conducted using SPSS 10. One-way ANOVAs were performed on the BSI 
data, demographic data and LOC scores to assess whether there were any group differences 
between drug-naive, polydrug controls, ecstasy users and problematic ecstasy users. Where 
there were violations of homogeneity of variance (e.g. age and rating of health) the Kruskall 
Wallis test was employed. Post hoc analyses comprised of paired comparisons between
1 The proportion of participants recruited by each source is unknown, due to the majority of participants 
completing the on-line questionnaire; which did not require individuals to indicate the manner in which they had 
heard about the study.
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groups using the Tukey's HSD range statistic and Mann-Whitney test for the non-parametric 
equivalent. For these pairwise comparisons error corrections were employed by dividing the 
standard error rate (a = 0.05) by the number of groups in the analysis, in this case a/3 = 
0.017, to reduce the risk of type 1 errors. Chi-squared was used to investigate any significant 
group differences with questions regarding gender, ethnicity, reported psychiatric history and 
family psychiatric history.
Drug use data violated the assumption of homogeneity of variance, despite attempts at 
transforming the data. Therefore Kruskall Wallis tests were employed. The independent 
samples t-test was used to assess differences in patterns of ecstasy use between the two 
ecstasy using groups.
To control for the significant group differences in age, data was re-analysed using analysis of 
covariance, to determine whether age was a statistically significant covariate, and if so, what 
effect this had on the statistical significance of any group differences. Again, co-variation for 
other drug use was not carried out for reasons given in the discussion of chapter 3.
After collapsing the two ecstasy using groups into one group named 'ecstasy users', Pearson 
Product Moment Correlational Analyses were conducted to assess the association between 
patterns of ecstasy use and scores on the LOG questionnaire and scores on the BSI. There 
were no statistical corrections made to these analyse to control for type 1 errors, thus it is 
important to note that significant findings should be treated with extreme caution due to the 
large number of correlations and potential chance occurrences.
Data concerning the positive and negative changes to life experiences and which, if any, drugs 
they attributed these changes to, are reported as percentages (tables 31-34; appendices). It 
was deemed inappropriate to conduct detailed inferential analyses on all of this data for a 
number of reasons. The first was that levels of drug use differed considerably across all four 
drug using groups. Secondly, respondents sometimes indicated more than one drug for each 
dimension on the questionnaire, yet it was difficult to establish whether they were referring to 
polydrug use as contributing to this change or whether individual drugs per se contributed to 
this change. Thirdly, not all cells were independent. Finally, if a chi squared test was 
conducted the expected frequency would be less than 5 on more than 20% of cases; therefore 
it would not have been statistically viable. However, data concerning the number of
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respondents, in each of the four groups, who indicated they had experienced a change were 
analysed using a 4 x 2 Chi Squared test. Separate 2x2 Chi Square tests were used to 
establish between, which of the four groups, any statistical significant differences were. A 
significant level of 0.008 was used, in order to limit the possibilities of type 1 errors. For 
those respondents in the drug using groups who did indicate a change attributable to drug use, 
a 3 x 2 Chi Squared test was utilised to establish whether there were any significant 
differences between the number of respondents in each group who indicated more than one 
drug as indicative of positive and negative changes. Separate 2 x 2 chi square tests were used 
to establish which groups differed with the significance level set at 0.02 to limit any type 1 
errors.
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RESULTS
Group characteristics and drug data
Tables 25 and 26 show the demographic data for the participants, patterns of drug use and 
reported psychiatric history. There were no significant group differences for gender or health. 
However, there was a significant group effect of age tx2(3) = 19.51, p<0.001], as non- 
problematic ecstasy users were significantly older than drug-naive controls (p=<0.001). 
There was a significant difference in reported psychiatric history (x2(3) = 30.71, p<0.001) and 
family psychiatric history (%2(3) = 18.84, p<0.001), with a greater number of problematic 
ecstasy users reporting a psychiatric history compared to controls and ecstasy users (table 26). 
There was also a significant difference in ethnicity between groups (x2(12) = 45.78, p<0.001), 
with drug naive participants showing greater ethnic diversity than non-problematic ecstasy 
and problematic ecstasy users (see table 42 in appendix).
There were significant group differences on most levels of reported illegal drug consumption, 
amphetamine (x2(2) = 69.05, p<0.001), cocaine (x2(2) = 68.97, p<0.001), crack (x2(2) = 13.08, 
p = 0.001), LSD (x2(2) = 60.93, p<0.001), magic mushrooms (x2(2) = 43.37, p<0.001), 
poppers (x2(2) = 57.01, p<0.001), ketamine tf(2) = 37.39, p<0.001) and current (x2(2) =
1 1.42, p = 0.003) and past cannabis use (x2(2) = 12.84, p = 0.002), see table 25. Specifically, 
polydrug controls reported using significantly less amphetamine, cocaine, LSD, magic 
mushrooms, poppers, ketamine and current cannabis use, compared to non-problematic 
ecstasy and problematic ecstasy users; and significantly less crack and past cannabis use 
compared to problematic ecstasy users. Non-problematic ecstasy and problematic ecstasy 
users reported similar consumption of illegal drugs, with the exception of LSD and magic 
mushrooms, where the problem ecstasy group reported a significantly greater consumption of 
both drugs.
Drug naive participants reported significantly less tobacco and alcohol use compared to 
polydrug controls, non-problematic ecstasy and problematic ecstasy users (%2(3) = 78.23, 
p<0.001). Polydrug controls also reported significantly less tobacco use compared to non- 
problematic ecstasy and problematic ecstasy users, as well as significantly less alcohol use 
compared to ecstasy users (x2(3) = 75.04, p<0.001).
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Patterns of ecstasy use differed between the two ecstasy using groups. Problematic ecstasy 
users reported significantly higher lifetime consumption levels of ecstasy [t(113) = -2.31, p = 
0.0251 , average dosage levels [t(109) = -3.09, p = 0.003] and maximum dosage levels [t(109) 
= -2.90, p = 0.005] compared to non-problematic ecstasy users. However, there were no 
significant differences in duration of ecstasy use and length of abstinence periods from 
ecstasy use between the two ecstasy using groups (see table 25).
Problematic ecstasy users were also asked to indicate whether they had sought some form of 
help for their attributed problems (table 27). 32.1% (n = 17) reported that they had and, as 
shown in table 27, the most common help sought was from a GP (26.4%). 11.3% sought help 
from a psychiatrist and 9.4% sought help from a clinical psychologist or drugs service. The 
final 11.3% sought help from a variety of other organisations, which included counselling 
services.
Group differences
Locus of Control
Figure 27 illustrates the scores obtained on the LOG questionnaire for all four groups. 
Problematic ecstasy users scored lower than drug-naive, polydrug controls and non- 
problematic ecstasy users, indicating a higher external LOG. However, this difference did not 
reach statistical significance [F(3,284) = 1.226, p = 0.300]. In order to further assess whether 
LOG was associated with problematic attributions, rather than ecstasy use, a post hoc 
ANOVA was conducted on LOG scores, using five groups by separating the problematic 
ecstasy users into two groups; those who reported problems and those who reported problems 
but had sought some form of help for them (consistent with the criteria from chapter 3). Data 
(see appendix; table 40) indicated that those problematic ecstasy users who had sought help 
for their attributed problems, reported a higher external locus of control compared to all other 
groups, including problematic ecstasy users who just self-reported problems and had not 
sought help. Again, these differences did not reach statistical significance [F (4, 284) = 0.994, 
p = 0.411], (see appendix; figure 33).
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Kirstie Soar Chapter 7
Measures of psychopathology
Table 28 shows the group scores for all the subscales of the modified version of the BSI. 
With the negative subscales; problematic ecstasy users reported significantly higher levels of 
somatisation [F(3,284) = 4.35, p = 0.005] and negative psychobiology [F(3,284) = 5.96, p = 
0.001J compared to drug naive, polydrug controls and non-problematic ecstasy users (figures 
28 & 29). Adjusted ANCOVA analyses, with age as a covariate (since age has shown to 
differ between groups - see table 25) showed there were no changes to the main effect of 
group on somatisation [F(3,284) = 4.58, p = 0.004], after co-varying for age [F(l,286) = 1.68, 
p = 0.197); and no change to the main effect of group on negative psychobiology [F(3,284) = 
6.33, p <0.001], after co-varying for age [F(l,286) = 1.78, p = 0.183].
Problematic ecstasy users reported significantly higher levels of depression [F(3,284)=3.60, 
p=0.014] and anxiety [F(3,284) = 5.94, p = 0.001] compared to drug-naive and non- 
problematic ecstasy users (Figures 30 & 31). These main effects of group on depression 
[F(3,284) = 3.68, p = 0.013] and anxiety [F(3,284) = 5.95, p = 0.001] remained after co- 
varying for age.
Problematic ecstasy users and polydrug controls reported significantly higher obsessive- 
compulsive scores [F(3,284) = 4.65, p = 0.003] and cognitive failures [F(3,284) = 5.09, p = 
0.002] compared to drug naive participants. These main effects of group on obsessive- 
compulsive scores [F(3,284) = 4.49, p = 0.004] and cognitive failures [F(3,284) = 5.05, p = 
0.002] remained after co-varying for age.
All drug using groups (polydrug controls; problematic and non-problematic ecstasy users) 
reported higher levels of sexual dysfunction compared to drug-naive controls [F(3,284) = 
9.16, p<0.001] (figure 32). Adjusted ANCOVA analyses showed that despite the covariate, 
age being significant [F(l,286) = 5.26, p = 0.023], the main effect of group on sexual 
dysfunction remained [F(3,284) = 10.27, p <0.001].
Finally, there were significant group differences on the anger subscale [F(3,284) = 2.70, p = 
0.046], with drug-naive controls showing lower scores than polydrug, non-problematic and
180
K
ir
st
ie
 S
oa
r 
C
ha
pt
er
 7
Sy
m
pt
om
N
eg
at
iv
e 
Sy
m
pt
om
s
So
m
at
isa
tio
n
O
bs
es
siv
e-
co
m
pu
lsi
ve
In
te
rp
er
so
na
l s
en
sit
iv
ity
D
ep
re
ss
io
n
A
nx
ie
ty
A
ng
er
/h
os
til
ity
Ph
ob
ic
 a
nx
ie
ty
Pa
ra
no
id
 id
ea
tio
n
Ps
yc
ho
tic
ism
N
eg
at
iv
e 
ps
yc
ho
bi
ol
og
y
Se
xu
al
 fu
nc
tio
ni
ng
Co
gn
iti
ve
 fa
ilu
re
s
Po
sit
iv
e 
Sy
m
pt
om
s
Fe
el
in
g 
co
nt
en
t w
ith
 li
fe
Po
sit
iv
e 
M
oo
d 
sta
te
So
ci
ab
ili
ty
Po
sit
iv
e 
ps
yc
ho
bi
ol
og
y
D
ru
g 
N
ai
ve
[N
]
0.
46
 ±
0.
53
1.0
5 
±0
.7
7
0.
98
 +
 0
.8
9
0.
69
 ±
0.
78
0.
63
 ±
0.
65
0.
65
 ±
 0
.6
9
0.
37
 ±
0.
56
0.
88
 ±
0.
78
0.
58
 ±
0.
68
0.
86
 ±
0.
70
0.
47
 ±
0.
41
1.1
8 
+ 
0.
98
2.
33
 ±
0.
91
1.
92
 ±
0.
79
2.
12
 +
 0
.8
0
2.
17
±0
.8
2
Po
ly
dr
ug
 
C
on
tro
ls
[C
]
0.
48
 ±
0.
56
1.4
1 
±0
.9
2
1.
14
 ±
0.
96
0.
83
 ±
0.
82
0.
83
+0
.8
7
0.
95
 ±
 0
.8
9
0.
47
 ±
0.
71
1.0
3 
±0
.8
6
0.
65
 ±
 0
.7
4
1.0
5 
±0
.8
4
0.
73
 ±
0.
55
1.
66
 ±
1.
04
2.
22
 ±
0.
75
1.9
4 
±0
.7
3
2.
28
 ±
0.
96
2.
07
 +
 0
.6
6
N
on
- 
pr
ob
le
m
at
ic
 
Ec
st
as
y 
us
er
s
[E
]
0.
45
 ±
 0
.4
9
1.2
1 
±0
.7
4
1.
04
 ±
0.
88
0.
74
 ±
 0
.6
9
0.
63
 ±
 0
.6
5
0.
81
 ±
0.
83
0.
36
 ±
0.
55
0.
85
 ±
0.
75
0.
66
 ±
 0
.7
0
0.
99
 ±
0.
67
0.
76
 ±
 0
.4
4
1.4
5 
±1
.0
0
2.
47
 +
 0
.7
1
2.
34
 ±
0.
63
2.
47
 ±
 0
.7
2
2.
37
 ±
0.
70
Pr
ob
le
m
at
ic
 
ec
sta
sy
 u
se
rs
[P
]
0.
77
 ±
 0
.6
4
1.
47
 +
 0
.7
6
1.3
8 
±0
.9
2
1.1
1 
±0
.8
9
1.
11
±0
.8
2
0.
97
 +
 0
.9
1
0.
54
 ±
 0
.6
9
1.
06
 ±
0.
75
0.
83
 ±
0.
77
1.
39
 ±
0.
84
0.
82
 ±
0.
58
1.7
3 
±0
.9
4
2.
23
 ±
0.
75
2.
07
 ±
0.
83
2.
29
 ±
0.
71
2.
17
 ±
0.
73
G
ro
up
 E
ff
ec
t
0.
00
5
0.
00
3
0.
06
2
0.
01
4
0.
00
1
0.
04
6
0.
28
5
0.
30
6
0.
21
6
0.
00
1
<0
.0
01
0.
00
2
0.
30
4
0.
00
4
0.
03
0
0.
16
4
Po
st
 H
oc
 
C
om
pa
ris
on
s
N,
 C
 &
 E
 <
 P
N
<
C
&
P
N
&
E
<
P
N
&
E
<
P
N
, C
 &
 E
 <
 P
N
<
C
, E
&
P
N
<
C
&
P
N
&
C
<
E
N
<
E
18
1
K
irs
tie
 S
oa
r
C
ha
pt
er
 7
Fi
gu
re
 2
7:
 M
ea
n 
sc
or
es
 o
n 
th
e 
LO
G
 s
ca
le
 fo
r a
ll 
fo
ur
 
gr
ou
ps
. (
Ba
rs
 in
di
ca
te
 1 
sta
nd
ar
d 
er
ro
r o
f m
ea
n)
Fi
gu
re
 2
8;
 M
ea
n 
BS
I s
om
at
is
at
io
n 
sc
or
es
 fo
r a
ll 
fo
ur
 g
ro
up
s.
( B
ar
s 
in
di
ca
te
 1 
sta
nd
ar
d 
er
ro
r o
f m
ea
n)
0
D
ru
g-
na
iv
e
Po
ly
dr
ug
 
Ec
st
as
y 
U
se
rs
 
Pr
ob
le
m
at
ic
 
C
on
tro
ls
 
Ec
st
as
y 
U
se
rs
0.
9
D
ru
g 
Na
i'v
e
Po
ly
dr
ug
 
Ec
st
as
y 
U
se
rs
 
Pr
ob
le
m
at
ic
 
C
on
tro
ls
 
Ec
st
as
y 
U
se
rs
18
2
K
irs
tie
 S
oa
r
C
ha
pt
er
 7
Fi
gu
re
 2
9;
 M
ea
n 
BS
I n
eg
at
iv
e 
ps
vc
ho
bi
ol
og
y 
sc
or
es
 fo
r 
al
l 
fo
ur
 g
ro
up
s 
(B
ar
s 
in
di
ca
te
 1 
sta
nd
ar
d 
er
ro
r o
f m
ea
n)
Fi
gu
re
 3
0:
 M
ea
n 
BS
I d
ep
re
ss
io
n 
sc
or
es
 fo
r 
al
l f
ou
r 
gr
ou
ps
 (B
ar
s 
in
di
ca
te
 1 
sta
nd
ar
d 
er
ro
r o
f m
ea
n)
1.
4 1.2 0.
8
0.
6
0.
4
0.
2 0
D
ru
g 
N
ai
ve
Po
ly
dr
ug
 
Ec
st
as
y 
U
se
rs
 P
ro
bl
em
at
ic
 
C
on
tro
ls
 
Ec
st
as
y 
U
se
rs
D
ru
g 
N
ai
ve
 
Po
ly
dr
ug
 
Ec
st
as
y 
U
se
rs
 
Pr
ob
le
m
at
ic
C
on
tro
ls
 
Ec
st
as
y 
U
se
rs
18
3
K
irs
tie
 S
oa
r
C
ha
pt
er
 7
Fi
gu
re
 3
1;
 M
ea
n 
BS
I a
n
x
ie
ty
 sc
or
es
 fo
r 
al
l f
ou
r 
gr
ou
ps
.
(B
ar
s 
in
di
ca
te
 1 
sta
nd
ar
d 
er
ro
r o
f m
ea
n)
Fi
gu
re
 3
2;
 M
ea
n 
BS
I S
ex
ua
l f
un
ct
io
ni
ng
 sc
or
es
 fo
r 
al
l 
gr
ou
ps
 (B
ar
s 
in
di
ca
te
 1 
sta
nd
ar
d 
er
ro
r o
f m
ea
n)
1.4 1.
2
0.
8
0.
6
0.
4
0.
2 0
0.
9 0
D
ru
g 
N
ai
ve
 
Po
ly
dr
ug
 
Ec
st
as
y 
U
se
rs
 
Pr
ob
le
m
at
ic
Co
nt
ro
ls 
Ec
st
as
y 
U
se
rs
D
ru
g 
N
ai
ve
 
Po
ly
dr
ug
 
Ec
st
as
y 
U
se
rs
 
Pr
ob
le
m
at
ic
Co
nt
ro
ls 
Ec
st
as
y 
U
se
rs
18
4
Kirstie Soar Chapter 7
problematic ecstasy users. However, these no longer remained significant following post hoc 
analyses.
With respect to the positive subscales of the modified BSI, there were significant group 
differences on positive mood F(3,284) = 4.56, p = 0.004], with non-problematic ecstasy users 
scoring significantly higher than drug naive and polydrug controls. In the adjusted ANOCVA 
analyses the covariate, age, was significant [F(l,286) = 7.78, p = 0.006], however, the main 
effect of group on positive mood remained [F(3,284) = 4.24, p = 0.006]. Non-problematic 
ecstasy users also scored significantly higher than drug-naive participants on the sociability 
subscale [F(3,284) = 3.03, p = 0.030]. This main effect of group on the sociability subscale 
remained in the adjusted ANCOVA analyses, [F(3,284) = 2.79, p = 0.041] after co-varying 
for age [F(l,286) = 0.999, p = 0.318].
Changes in Life Experiences Questionnaire
Tables 31-34 (appendices) show the percentages of drug naive, polydrug controls, non- 
problematic and problematic ecstasy users who reported which positive and negative changes 
they have experienced in their life and which, if any, drug(s) they attributed these changes to.
Table 29 shows the number and percentage of drug-naive, polydrug controls, non-problematic 
and problematic ecstasy users who reported that they had experienced positive and negative 
life changes. There were highly significant differences between groups for all life changes. A 
significantly higher number of people in the polydrug, non-problematic and problematic 
ecstasy user groups reported experiencing changes in empathy, a decrease in defensiveness, 
improved social functioning, increased feelings of well-being, obsessive thoughts, mood 
swings, less sociable, anxiety, paranoia, panic attacks, aggression, breathlessness, loss of 
organisation skills, motivational, memory and concentration loss, compared to drug-naive 
controls. Polydrug users reported significantly less life experience changes compared to non- 
problematic and/or problematic ecstasy users in areas of spiritual enlightenment, enhanced 
sensations, obsessive thoughts, mood swings, depression, anxiety, paranoia, hallucinations, 
panic attacks, weight loss, sleep disruptions, but a greater number of polydrug controls 
reported memory problems compared to both non-problematic ft2 = 25.05, p<0.001] and 
problematic ecstasy users [%2 =11.43, p = 0.001]. A significantly greater number of 
problematic ecstasy users reported life changes on all positive and negative items compared to
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drug-naive and/or polydrug controls and/or non-problematic ecstasy users. A greater number 
of problematic ecstasy users reported changes in panic attacks [%2 = 11.28, p = 0.001], 
depression ft2 =11.46, p = 0.001], paranoia [%2 = 7.60, p = 0.006] and general illness [%2 
=11.29, p = 0.001], compared to non-problematic ecstasy users
Single drug attributions versus multiple drug attributions to changes in life experiences
Comparing percentages alone (see tables 31-34 in the appendix), polydrug users who did 
indicate changes, attributed them more to other factors than their drug use. Those ecstasy 
users who reported both positive and negative changes in their life, attributed these more to 
drug use than other non-drug factors. Non-problematic ecstasy users attributed use of a 
greater range of drugs to their changes, compared to problematic ecstasy users.
Chi squared results indicate that there were significant groups differences in the number of 
people who reported attributing life changes to more than one drug on a majority of life
_ -^
changes (table 30). These included the positive changes of increased empathy [% =12.36, p 
= 0.002], a decrease in defensiveness [%2 = 9.84, p = 0.007], improved social/interpersonal 
functioning ft2 = 12.09, p = 0.002], increased feelings of well-being ft2 =13.79, p = 0.001], a
0 ^decrease in fear [% = 15.40, p<0.001] and enhanced sensations [x, = 6.02, p = 0.05]. They 
also included the negative changes of obsessive thoughts ft2 = 9.91, p = 0.007], aggression [%2 
= 8.26, p = 0.016], mood swings [%2 = 10.09, p = 0.006], less sociability [%2 = 8.69, p = 
0.013], confidence loss [%2 = 7.69, p = 0.021], anxiety [%2 =15.50, p<0.001], paranoia ft2 
=13.36, p = 0.001], hallucinations [£ = 7.96, p = 0.019], backache fe2 = 4.48, p = 0.034], 
sexual problems ft2 =10.76, p = 0.005], general illness ft2 = 9.13, p = 0.010], weight loss [%2 
= 6.23, p = 0.044], loss of organisational skills ft2 = 8.92, p = 0.012], and memory ft2 =17.67, 
p<0.001] and concentration loss ft2 =15.21, p<0.001].
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Table 29; Number and percentage of drug-naive, polvdrug controls, non-problematic
and problematic ecstasy users that reported that thev had experienced
negative life changes
n/%
Positive life changes
Increased empathy
Decrease in defensiveness
Improved social/interpersonal 
functioning 
Increased feelings of well being
Decrease in fear
Spiritual enlightenment
Enhanced sensations
Negative life changes
Obsessive thoughts
Aggression
Mood swings
Less sociable
Confidence loss
Depression
Anxiety
Paranoia
Hallucinations
Panic attacks
Phobias
Breathlessness
Backache
Sex problems
General illness
Weight loss
Sleep problems
Loss of organisational skills
Motivational problems
Memory loss
Concentration loss
Drug
n =
28
20
47 
40
37
21
30
22
33
37
31
41
35
21
13
5
4
10
16
32
12
32
27
35
19
32
16
34
•naive
111
25%
18%
42% 
36%
33%
19%
27%
20%
30%
33%
28%
37%
32%
19%
12%
5%
4%
9%
34%
29%
11%
41%
24%
32%
17%
29%
14%
31%
Polydrug Users
n=62
32
32
49
47
38
21
26
25
31
37
32
29
29
29
21
8
13
6
25
21
13
27
18
28
27
33
60
36
52%
52%
79% 
76%
61%
34%
42%
40%
50%
60%
52%
47%
45%
47%
34%
13%
21%
10%
40%
34%
21%
44%
29%
45%
44%
53%
97%
59%
Non- 
problematic 
Ecstasy Users
n = 62
44
32
53 
44
33
30
40
35
29
42
36
30
33
40
34
21
14
7
21
18
17
16
31
37
27
36
37
38
71%
53%
83% 
36%
53%
48%
65%
57%
47%
68%
58%
48%
53%
65%
55%
34%
23%
11%
34%
29%
28%
26%
50%
60%
44%
58%
60%
61%
positive and
Problematic 
Ecstasy Users
n=53
35
36
44 
38
28
33
40
36
29
45
34
33
44
39
42
25
28
13
25
28
21
30
38
38
31
37
40
54
66%
68%
83% 
72%
53%
62%
76%
68%
55%
66%
64%
62%
83%
74%
79%
47%
53%
25%
47%
53%
40%
57%
72%
72%
59%
70%
76%
86%
P
<0.001
<0.001
<0.001 
<0.001
0.002
<0.001
<0.001
<0.001
0.006
<0.001
<0.001
0.024
<0.001
<0.001
<0.001
<0.001
<0.001
0.032
<0.001
0.016
<0.001
0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
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Of those polydrug users who did indicate life changes attributable to drugs, they were 
significantly more likely to attribute these changes to just one drug rather than a combination 
of drugs, compared to non-problematic and/or problematic ecstasy users (table 30). This 
finding was relatively consistent across positive and negative life changes, except for spiritual 
enlightenment, confidence loss, backache and sexual problems. In addition, a significantly 
higher number of problematic ecstasy users attributed more than one drug to increased 
empathy ft2 = 7.01, p = 0.008], decrease in fear ft2 = 6.62, p = 0.01], obsessive thoughts ft2 = 
6.19, p = 0.013], aggression ft2 = 5.75, p = 0.016], anxiety [%2 = 10.8, p = 0.001], paranoia [%2 
= 7.82, p = 0.005], hallucinations [£ = 5.37, p = 0.02], sexual problems [%2 = 9.96, p = 0.002], 
general illness fr2 = 9.13, p = 0.003], loss of organisational skills ft2 = 7.25, p = 0.007],
f\ T
memory loss [/, = 10.89, p = 0.001], concentration loss [jf = 11.93, p = 0.001] compared to 
non-problematic ecstasy users. A significantly higher number of non-problematic ecstasy 
users attributed more than one drug to improved social/interpersonal functioning [^2 = 10.94,
<~* ^
p = 0.001], increased feelings of well-being [% = 10.75, p = 0.001] and mood swings [x = 
5.36, p = 0.021], compared to polydrug controls.
Specific Drugs Attributions to Positive Life Experience Changes
In establishing which specific drugs changes were attributed to, comparisons can only be 
made by comparing percentages (tables 31-34 in the appendix). Positive life experience 
changes, such as improved social/interpersonal functioning was strongly attributed to alcohol 
compared to any other drug across all four groups, with 18% of drug naive participants, 
45.2% polydrug controls, 43.5% non-problematic ecstasy users and 28.3% problematic 
ecstasy users attributing this change to alcohol. However, amongst non-problematic ecstasy 
users, ecstasy (35.5%) and cocaine (33.9%) also played a strong part, whilst amongst 
problematic ecstasy users this life change was attributed more to ecstasy than alcohol (45.3% 
vs. 28.3% respectively). A decrease in fear was also attributed mostly to alcohol compared to 
any other drug, amongst drug naive (12.6%), polydrug controls (32.3%) and non-problematic 
ecstasy users (32.3%).
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Table 30: Number of polvdrug, non-problematic and problematic ecstasy users who
attributed life changes to more than one
n/%
Positive life changes
Increased empathy
Decrease in defensiveness
Improved social/interpersonal functioning
Increased feelings of well being
Decrease in fear
Spiritual enlightenment
Enhanced sensations
Negative life changes
Obsessive thoughts
Aggression
Mood swings
Less sociable
Confidence loss
Depression
Anxiety
Paranoia
Hallucinations
Panic attacks
Phobias
Breathlessness
Backache
Sex problems
General illness
Weight loss
Sleep problems
Loss of organisational skills
Motivational problems
Memory loss
Concentration loss
drug
Polydrug 
Users
5
4
10
5
5
2
6
2
3
3
1
1
3
2
2
0
1
0
0
0
1
3
0
1
4
5
2
7
23%
18%
28%
18%
20%
22%
30%
17%
19%
18%
6%
11%
25%
14%
13%
0%
20%
0%
0%
0%
20%
43%
0%
13%
29%
33%
12%
32%
Non- 
problematic 
Ecstasy 
Users
11
12
28
18
11
15
23
8
6
17
9
4
11
8
9
4
2
1
2
0
1
1
8
14
6
8
9
11
34%
46%
65%
60%
41%
65%
59%
27%
23%
52%
46%
20%
44%
25%
27%
20%
25%
50%
13%
0%
7%
7%
29%
42%
26%
26%
25%
32%
Problematic 
Ecstasy 
Users
21
18
19
16
15
15
23
21
13
28
11
14
20
22
24
13
13
5
7
8
9
14
17
18
19
12
24
29
68%
62%
59%
62%
79%
54%
62%
60%
57%
63%
36%
52%
49%
65%
60%
54%
54%
63%
33%
40%
64%
54%
50%
50%
63%
35%
63%
73%
P
0.002
0.007
0.002
0.001
<0.001
0.09
0.049
0.007
0.016
0.006
0.013
0.021
0.343
<0.001
0.001
0.019
0.187
0.747
0.097
0.034
0.005
0.010
0.044
0.152
0.012
0.699
<0.001
<0.001
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Increased feelings of well-being were also attributed to alcohol amongst polydrug controls 
(21%) and non-problematic ecstasy users (25.8%), but also to cannabis (24.2%) in polydrug 
controls, whilst amongst non-problematic ecstasy users, ecstasy (25.8%) and cocaine (27.4%) 
were strongly implicated. Ecstasy was the strongest drug implicated (35.8%).in feelings of 
well-being with problematic ecstasy users.
Cannabis was reported as the reason behind enhanced sensations, by 22.6% of polydrug 
controls, yet ecstasy appeared to be the drug that non-problematic (54.8%) and problematic 
ecstasy users (56.6%) attributing enhanced sensations to the most, with LSD, cocaine and 
cannabis also being implicated in these two ecstasy using groups. Ecstasy use was a strong 
attributional factor for changes in spiritual enlightenment, with 27.4% of non-problematic 
ecstasy users and 30.2% problematic ecstasy reporting as such. Although non-problematic 
ecstasy users reported LSD to have been an equally contributing factor to changes in spiritual 
enlightenment. As expected, increased empathy was also attributed to ecstasy more than any 
other drug (45.2% and 45.3% respectively) amongst non-problematic and problematic ecstasy 
users, as was a decrease in defensiveness amongst problematic ecstasy users (35.8%).
Specific Drugs Attributions to Negative Life Experience Changes
Aggression appeared to be strongly associated with alcohol compared to any other drug and 
across all groups, with 24.2% of polydrug controls, 32.3% ecstasy users and 26.4% 
problematic users attributing this change to alcohol. Paranoia was most strongly associated 
with cannabis, compared to other drugs and across groups, with 21% of polydrug controls, 
25.8% ecstasy users and 49.1% problematic ecstasy users implicating cannabis in this change. 
However, problematic ecstasy users also attributed paranoia quite highly to ecstasy (34%) and 
amphetamine (30.2%) use.
Cannabis use also appeared to be a strong factor compared to any other drug for motivational 
problems and loss of sociability in both ecstasy (30.6% and 22.6% respectively) and 
problematic ecstasy users (32.1% and 39.6%). Cannabis was also implicated in perceptions of 
concentration loss amongst problematic ecstasy users (24.5%) and also with memory loss 
amongst non-problematic ecstasy users (27.4%) compared to a low implication of ecstasy
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attributed to memory loss in this non-problematic and problematic ecstasy users (only 4.8% 
and 13.2% respectively).
Hallucinations were mainly reported by problematic ecstasy users but were equally attributed 
to ecstasy and LSD use (24.5%). This is probably because this group reported significantly 
greater consumption levels of both ecstasy and LSD compared to the other drug using groups.
Ecstasy was a very strong attributional factor linked to depression (62.3%), anxiety (37.7%), 
panic attacks (34%), general illness (39.6%) and weight loss (39.6%) amongst problematic 
ecstasy users. Amongst this group, ecstasy was also implicated in obsessive thoughts, 
alongside cannabis use (30.2%). Whilst in the non-problematic user group, far fewer 
participants linked their ecstasy use to these negative symptoms. Mood swings were also 
strongly attributed to ecstasy, amongst ecstasy and problematic ecstasy users (25.8% and 
54.7% respectively), but so too were the other stimulants, cocaine and amphetamine. 
Similarly both ecstasy using groups reported similar drug attributions with sleep problems.
Dose-related relationships
The self-reported lifetime consumption of ecstasy did not correlate with any measure on the 
BSI or locus of control scales. The reported average dose consumed, positively correlated 
with obsessive compulsive scores (r = 0.210, p = 0.027), anger (r = 0.208, p = 0.029), phobic 
anxiety (r = 0.190, p = 0.046) and psychoticism (r = 0.193, p = 0.043). But reported average 
dose consumed negatively correlated with the feeling content with life (r = -0.262, p = 0.005), 
positive mood (r = -0.223, p = 0.019) and sociability (r = -0.196, p = 0.040) subscales on the 
modified version of the BSI.
The largest dose of ecstasy on any one occasion positively correlated with obsessive 
compulsive scores (r = 0.210, p = 0.027), anger (r = 0.246, p = 0.009) and psychoticism (r = 
0.222, p = 0.019), whilst it negatively correlated with the feeling content with life (r = -0.302, 
p=0.001) and positive mood (r = -0.222, p = 0.019) subscales on the modified version of the 
BSI.
Estimated lifetime consumption positively correlated with the average ecstasy dosage (r = 
0.597, p<0.001), maximum number of ecstasy tablets that users reported consuming on a
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single occasion (r = 0.548, p<0.001) and negatively correlated with the duration of ecstasy use 
(r = -0.269, p = 0.005).
Lifetime consumption of ecstasy also positively correlated with reported lifetime consumption 
of other drug use, including:- amphetamine (r = 0.675, p<0.001), cocaine (r = 0.710, 
p<0.001), LSD (r = 0.713, p<0.001), magic mushrooms (r = 0.301, p = 0.001), ketamine(r = 
0.484, p<0.001), GHB (r = 0.208, p = 0.026), solvents (r = 0.682, p<0.001) and current 
cannabis use (r = 0.193, p = 0.039). Average dose consumed in one occasion correlated with 
usage levels of amphetamine (r = 0.250, p = 0.008), ketamine (r=0.549, p<0.001), GHB (r = 
0.218 p = 0.021), tobacco (r = 0.301, p = 0.001) and alcohol (r = 0.272, p = 0.004). Whilst 
maximum dosage consumed in one occasion correlated with amphetamine (r = 0.248, p = 
0.009), ketamine (r = 0.447, p<0.001), tobacco (r = 0.287, p = 0.002) and alcohol (r = 0.272, p 
= 0.004) use.
Duration of drug use
The duration of ecstasy use was found to negatively correlate with the paranoia subscale (r = - 
0.250, p = 0.010) and positively correlate with the sociability subscale (r = 0.212, p = 0.029) 
of the modified BSI.
Locus of Control and drug use
LOG did not correlate with any measure of ecstasy use (maximum dosage, average dose, 
lifetime consumption, duration of use, time since last used), nor did LOG correlate with any 
lifetime consumption use of any other drug. However, LOG negatively correlated with the 
number of years cannabis had been consumed for (r = 0.187, p = 0.005)
Locus of control and the BSI
Scores on the LOG questionnaire positively correlated with depression (r = 0.225, p = 0.016) 
and psychoticism (r = 0.224, p = 0.016) subscales, indicating that a greater external attribution 
is associated with higher levels of depression and psychoticism. A more internal attribution 
style was associated with greater levels of contentment (r = -0.220, p = 0.018) and sociability 
(r = -0.206, p = 0.027).
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DISCUSSION
The current study supports one of the main hypotheses, with problematic ecstasy users 
demonstrating significantly higher levels of psychopathology compared to non-problem 
ecstasy users, polydrug users and drug-naive controls on a number of the BSI subscales. 
Problematic ecstasy users reported higher scores for symptoms associated with somatisation, 
depression, anxiety, negative psychobiology and sexual dysfunction compared to non- 
problematic ecstasy users (table 28). However, despite similar patterns of other drug use 
between these two ecstasy using groups, problematic ecstasy users did report higher levels of 
ecstasy use (a significantly higher average dose, maximum dose and lifetime consumption), 
compared to non-problem ecstasy users (table 25). What is perhaps even more important, is 
that there were no differences in the duration of ecstasy use between the two ecstasy using 
groups, which suggests that problematic ecstasy use may be a function of the levels and 
intensity of ecstasy use. This is somewhat contrary to the initial suggestion in this thesis that 
problems associated with ecstasy use and psychopathological status were independent of 
patterns of ecstasy consumption, and also contrary to the findings of Fox et al (200 Ib), who 
found that problematic ecstasy use may not necessarily be dose-related.
The idea that it is the intensity of ecstasy use that possibly contributes or causes 
psychobiological problems is further supported by the dose-related effects found in this study. 
Higher average doses of ecstasy where associated with higher scores on the obsessive- 
compulsive, anger, phobic anxiety and psychoticism subscales, than lower average doses, in 
ecstasy users. Also, the higher the maximum amounts of ecstasy consumed on any one 
occasion the higher the scores on the obsessive-compulsive, anger and psychoticism 
subscales, in ecstasy users. This supports findings by Parrott et al (2002), who found that 
self-reported psychobiological problems attributed to ecstasy, were a direct function of the 
amount of times it was taken. However, these correlations need to be interpreted with caution 
because analyses have been conducted on ecstasy users as one large collapsed group 
(problematic and non-problematic) and not analysed as separate groups. As a result, the 
correlations might largely be a product of the very different ecstasy users. Additionally, there 
was no control for type 1 errors on what is arguably a large number of correlations, hence 
there is a higher probability that these significant findings were by chance.
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This present study did not find any significant differences in the locus of control personality 
trait between the ecstasy using groups (table 25). Problematic ecstasy users demonstrated a 
trend towards lower external locus of control compared to non-problem ecstasy users (figure 
27). However, this difference did not reach statistical significance, suggesting that this 
personality construct was not an important influence over whether or not some ecstasy users 
report more problems than other ecstasy users, which they attribute to their ecstasy use. 
There are, however, many other personality factors which could possibly contribute to or be 
associated with problematic ecstasy use. One important possible variable that has been 
highlighted within this study is psychiatric history. Problematic ecstasy users reported 
significantly greater personal and family psychiatric histories compared to non-problematic 
ecstasy users (table 26), suggesting a vulnerability to the development of psychological 
problems. Whether their ecstasy use contributes to or exacerbates the development of 
psychopathology is still to be determined. It may be the case that some, perhaps even all of 
these individuals, would have developed psychological problems independent of ecstasy use.
A limitation of this study is that these problematic ecstasy users were not asked to indicate 
details of the problems they attributed to their ecstasy use. Specific problems were only 
assessed indirectly via the questions pertaining to the changes in life experiences. Isolating 
the specific problems is difficult, based on the fact that problematic ecstasy users tended to 
implicate more of all other drugs when attributing negative long-term problems. It is 
interesting to note at this point, that whilst 58 participants self-perceived themselves as being 
problematic, only 17 (32.1%) reported having sought some form of help for their problems 
(table 27). These individuals tended to seek help via primary care services (GP, psychiatrists, 
clinical psychologists), with the GP being the first port of call. This is consistent with 
findings of Topp et al (1999) who found one fifth of their ecstasy using sample had received 
formal assistance from a health practioner for an ecstasy-related problem; and this was 
predominantly from a GP (11%). This help-seeking behaviour in ecstasy users has 
implications for health services; for example, GPs may benefit from the dissemination of 
ecstasy-related information.
The present study also lends some support to Maclnnes et al (2001) who found higher levels 
of depression in ecstasy users compared to non-drug using controls, and that the levels of 
depression positively correlated with scores indicating an external LOG. In the present study, 
non-problematic ecstasy users showed higher levels of depression than drug-naive controls,
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though this did not reach significance, but problematic ecstasy users did show significantly 
higher levels of depression compared to drug-naive controls. In addition, correlational 
findings show that higher depression levels were associated with a greater external LOG. 
Therefore, there is support for the idea that ecstasy users tend to have higher levels of 
depression and thus a higher external LOG, but it must be made clear that external LOG is 
associated with the level of depression and not ecstasy use.
Parrott et al (2001) suggested that psychiatric symptoms and psychobiological problems are 
associated not only with ecstasy use but also with recreational polydrug use. The current 
study lends support to this, since ecstasy using groups exhibited higher levels of 
psychopathology on a number of subscales compared to polydrug controls, who also 
exhibited higher psychopathology on some subscales compared to drug-naive controls. In 
addition both ecstasy using groups had used significantly more other recreational drugs 
compared to polydrug controls who, in turn, had obviously used significantly more substances 
than drug naive controls. It could be concluded that this indicates that as polydrug use is 
increased so too is the risk of psychopathology. It appears that increasing use of other drugs 
is strongly associated with the increasing use of ecstasy, since the lifetime consumption of 
ecstasy use positively correlated with other common recreational drug use: i.e. amphetamine, 
cocaine, magic mushrooms, ketamine, GHB, solvents and cannabis.
Further support for the role of polydrug use in changes in life experiences, comes from the 
exploratory part of this study into positive and negative life changes attributed to differing 
recreational drug use. Ecstasy and problematic ecstasy users reported more positive and 
negative changes in life experiences (tables 29, 33 & 34) compared to polydrug and drug 
naive controls (tables 29, 31 & 32). They also attributed these, more to drug use than 'other 
factors'. However, a greater number of polydrug controls reported changes compared to 
drug-naive controls and also attributed these changes more to drug use than 'other factors', 
suggesting that polydrug use certainly plays a role in attributions related to life experiences 
(table 32). However, a greater number of ecstasy users appear to experience more life 
changes over and above those reported by polydrug users, with problematic ecstasy users 
experiencing the most (table 29). Ecstasy users (both non-problematic and problematic) also 
report life changes more to a combination of drugs than one specific drug, suggesting 
polydrug use in these ecstasy users has an impact on their life experiences. Ecstasy use plays 
a strong attributional role with regard to depression, anxiety, panic attacks, general illness and
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mood swings, which is consistent to previous research. However, other drugs such as alcohol, 
amphetamine and cocaine also seem to be reported as playing a role; especially cannabis, 
which appears to play a strong attributional role with negative changes such as paranoia, 
memory loss, concentration loss, motivational problems and obsessive thoughts, (consistent 
with the findings of Morgan et al, 2002). This all lends support to the idea that research into 
the psychological effects of ecstasy clearly should not underestimate the contribution of other 
drug use/polydrug use.
Caution should also be taken in interpreting differences in 'drug attributions' between 
problematic and non-problematic ecstasy users. Even though a higher percentage of 
problematic ecstasy users attributed changes in life experiences to a greater range of drugs 
compared to non-problematic ecstasy users. A significantly higher number of problematic 
ecstasy users reported these changes to more than one drug (table 30) It is difficult to 
determine whether this is as a result of their 'problematic use' or the fact that they used 
significantly more hallucinogens and reported different patterns of ecstasy consumption. 
Problematic ecstasy users did report more negative changes related to ecstasy use, but they 
did also report having used significantly more ecstasy than non-problematic users (table 25).
LOG is well established as being linked to mental health related problems (Hale & Cochran, 
1987; D'Arcy & Siddique, 1984; Young & Washburn, 1992; Petrosky & Birkimer, 1991; 
Hoehn-Saric & McLeod, 1985; Archer, 1980), even amongst drug using populations (O'Leary 
et al, 1976; Malin & Fordham, 2002) with higher rates of psychopathology relating to an 
external locus of control. The dose-related findings from this study supports this, since a 
greater external LOC orientation was associated with higher levels of depression and 
psychoticism. An internal LOC orientation was associated with higher levels of feeling 
content with life and sociability, indicating signs of psychological well-being (D'Arcy & 
Siddique, 1984). However, the hypothesis that problematic ecstasy users would demonstrate 
a more external locus of control orientation compared to non-problematic ecstasy users, may 
explain why they report higher psychopathology compared to non-problematic users. This 
hypothesis was not supported in this study. On the contrary, problematic ecstasy users 
reported a lower external locus of control to non-problematic ecstasy users (figure 27) and 
problematic ecstasy users who reported having sought help for their problems, reported an 
even lower external locus of control; although neither scores reached statistical significance
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(figure 33, appendix). Therefore the LOG does not appear to be important in determining 
whether individuals report problems attributable to ecstasy within this study.
The higher percentage of problematic ecstasy users reporting life changes attributable to 
ecstasy, still suggests that attributional style may play some role in whether ecstasy users 
define themselves as problematic or not. This difference in attributional style may not 
necessarily be detected by the Locus of Control Scale (Rotter, 1966). The scale was chosen 
because of the extensive and consistent findings concerning psychopathology and externality 
LOG, and that the measure allows for the prediction of behaviour across a wide range of 
potential situations (Rotter, 1975). Whilst this later point was originally seen as a beneficial 
reason for using the LOG Scale, with hindsight it may have been beneficial to use a measure 
which would allow for a high prediction of behaviour in more specific situations, more 
closely related to the topic in question, for example the Multidimensional Health Locus of 
Control Scale (Wallston et al, 1978), which measures the degree to which an individual 
perceives that they themselves have control over their health or whether it is determined by 
chance.
The LOG is thought to be a stable personality variable based on behaviour focusing on future 
expectations. Hence is one premorbid psychosocial construct worth exploring in light of 
previous literature into its association with psychopathology. The fact that this study 
demonstrated an association with external LOG and some psychopathological dimensions 
strengthens the importance of such a personality factor in relation to psychological problems. 
However, its relationship with problematic ecstasy use is less clear. From this study, 
reported levels of psychiatric history (both personal and family) were higher in problematic 
ecstasy users, which does suggest that such traits are necessary factors for consideration when 
assessing problematic ecstasy use. In conclusion, the current study suggests that it is certain 
pre-existing factors, the intensity of ecstasy dosing and the role of polydrug use in relation to 
ecstasy use, which contributes to problematic ecstasy experiences.
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CHAPTER 8
Overview of Thesis Research Findings
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There is sufficient evidence from both clinical and empirical studies to suggest that ecstasy 
users demonstrate elevated psychopathology and cognitive impairments compared to non- 
ecstasy users, even when allowing for some of the many methodological confounds inherent 
in long-term recreational ecstasy research (see chapter 2 for details). In these studies it has 
been shown that ecstasy has been associated with elevated levels of psychoticism, phobic 
anxiety, obsessive-compulsive and anxiety symptoms. In addition, research points to 
selective cognitive deficits: in particular verbal memory (both recall and recognition), 
executive functioning, attentional abilities and working memory, including prospective 
memory. Many of these cognitive and psychological differences have also been shown to be 
related to altered brain serotonin functioning and in addition, further evidence suggests that 
cognitive impairments and psychopathology are dose-related.
However, there is currently a shortage of empirical evidence concerning whether or not any of 
these problems develop to an extent that they become problematic to the user. Topp et al 
(1999) reported that one fifth of ecstasy users had received treatment for an ecstasy related 
problem. Hammersley et al (1999) found that the heaviest users of ecstasy were more likely 
to report having been an inpatient in the last year. Further still the question pertaining to 
whether or not any of these problems are a direct function of their past ecstasy use has still to 
be resolved. Parrott et al (2002) reported that ecstasy-attributed problems were a direct 
function of the number of occasions on which the drug has been consumed. Alternatively, 
Fox et al (200 Ib) reported that psychological symptoms in "problematic" ecstasy users were 
unrelated to ecstasy use, but related to negative interpersonal relationships prior to taking the 
drug and less socially orientated motivations for using the drug.
This research thesis aimed to explore this issue of problematic ecstasy use and whether or not 
the role of premorbid issues and levels of drug use were integral to issues relating to the cause 
and effect of problematic drug use. The current chapter aims to provide an overview of the 
whole research programme, concerning the psychopathological and cognitive functioning of 
the problematic ecstasy users. The overview will be discussed in terms of the main 
differences, in terms of "premorbid" variables and levels of drug use between 'problematic' 
and 'non-problematic' ecstasy users. This will be followed by the main group differences in 
psychopathology and possible dose-related effects. It will also include an overview of group 
differences in cognitive functioning in terms of short term memory, executive functioning, 
everyday memory and reaction time, as well as dose-related effects. Interpretation of these
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findings is also discussed in light of methodological constraints; highlighting potential 
improvements and the need for specific informative research.
OVERVIEW OF PROBLEMATIC AND NON-PROBLEMATIC ECSTASY USER 
PROFILES
The current thesis referred to 'problematic' ecstasy users as recreational ecstasy users who 
reported problems which they attributed to past ecstasy use; and which had developed to the 
extent that they had become problematic to the user. In the case of chapter 3, these problems 
were either clinically defined and/or had interfered with the individual's life to the extent that 
they had sought some form of help. Only 14 problematic ecstasy users could be recruited for 
this particular study, based on this 'problematic' criteria. In order to generate a larger sample 
of problematic ecstasy users, this definition was slightly changed in chapter 7, to those 
individuals who had developed problems which they strongly attributed to their past ecstasy 
use. With this slightly different inclusion criteria for 'problematic users', 53 problematic 
ecstasy users were identified, but only 17 of these (32% of problematic ecstasy users) had 
sought help for their problems. The most common sources of help that these individuals (in 
both groups; chapters 3 & 7) appear to have drawn upon was primarily from their local GP 
(93% in study 1 and 26% in study 4); although in a number of cases help was also reported to 
have been sought from clinical psychologists and psychiatrists, suggesting that they were 
clinically defined problems.
Problematic ecstasy users did not differ greatly on their levels of drug consumption compared 
with non-problematic ecstasy users. All ecstasy users reported using a wide range of drugs, 
including amphetamine, cocaine, LSD and cannabis use. Those problematic ecstasy users in 
the first study (chapter 3) tended to report more use of Prozac and monthly cannabis use than 
non-problematic ecstasy users. In the last study (chapter 7), problematic ecstasy users tended 
to have used more hallucinogens (LSD and magic mushrooms) compared to non-problematic 
ecstasy users. The individual from the 'problematic' case study (chapter 4), also reported 
consuming similar types of drugs to the problematic and non-problematic ecstasy users, but 
also reported quite an extensive use of benzodiazepines (post-ecstasy use). However, in 
general, within this research thesis, there were no consistently distinct patterns of drug use 
which enabled a clear differentiation to be made between problematic and non-problematic 
ecstasy users.
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Concerning the levels of ecstasy consumption, in problematic and non-problematic ecstasy 
users, there was little difference between the two groups in the first study. However, there 
were significantly different patterns of ecstasy use between problematic and non-problematic 
ecstasy users in chapter 7. Here problematic ecstasy users reported significantly higher 
lifetime consumption levels of ecstasy, higher average dosage levels and higher maximum 
dosage levels compared to non-problematic ecstasy users. This provides some evidence to 
indicate that the problems reported by ecstasy users may be a function of their past ecstasy 
use.
Another issue which may play a contributory role in the development of problematic ecstasy 
use are possible premorbid factors such as psychiatric history. This is suggested by the 
evidence that problematic ecstasy users reported a more extensive level of psychiatric history 
(in both studies 1 and 4) and family psychiatric history (study 4) compared to non- 
problematic ecstasy users. However, there was no objective measure of psychiatric status of 
these users and it is difficult to establish from this thesis whether reported psychiatric histories 
occurred prior to ecstasy polydrug use, whether or not ecstasy use may have caused and/or 
contributed to more severe symptoms in pre-existing psychiatric problems and even whether 
they developed in the context of their drug use. However, the higher levels of family 
psychiatric history in some of these problematic ecstasy users, suggests that there may have 
been a predisposition to psychological problems. Finally, another factor which was explored 
within this research thesis was that of self-perception and whether or not individuals have a 
certain attributory style. Whilst the research did not indicate this was a significant 
contribution to problematic ecstasy use, problematic ecstasy users did indicate a slightly 
higher external locus of control compared to non-problematic ecstasy users. This trend was 
strengthened by an even higher external locus of control in a sub-sample of problematic 
ecstasy users (chapter 7) that had sought help for their attributed problems, compared to those 
who had not (appendix, figure 34). Whilst these differences in LOC did not reach statistical 
significance, the trends suggest that such personality factors may influence the development 
or certainly the reporting of problems related to ecstasy use, though this area warrants further 
investigation.
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OVERVIEW OF PSYCHOPATHOLOGY FINDINGS
BSI and negative scales
Based on the current research programme it appears that problematic ecstasy users are 
consistently reporting significantly elevated scores on somatisation, depression and anxiety 
compared to polydrug drug controls and/or drug-naive controls across all studies. Other areas 
of psychopathology that are elevated in problematic ecstasy users, compared to control groups 
include interpersonal sensitivity, phobic anxiety; paranoid ideation and psychoticism 
(chapters 3, 6 & case study). However, the current programme did not find any strong 
support for elevated scores on the psychobiological subscales (including poor appetite, 
overeating and difficulties in getting to sleep), sexual dysfunction, obsessive compulsive 
symptoms and anger/hostility in problematic ecstasy users.
Problematic ecstasy users also displayed consistently higher psychopathology scores 
compared to non-problematic ecstasy users (particularly for somatisation, depression, anxiety 
and negative psychophysiology) across all studies. In addition, scores were elevated in these 
individuals compared to non-problematic ecstasy users for interpersonal sensitivity, phobic 
anxiety, paranoid ideation and psychoticism in chapter 3 and in the case study.
The psychopathology evident in these problematic ecstasy users is consistent with many 
clinical case studies which have reported, in individual ecstasy users, anxiety related 
symptoms (Series et al, 1994; Creighton et al, 1991), depression (McGuire et al, 1994; 
Benazzi and Mazzoli, 1991; Cohen, 1996; Teggin, 1992; Schifano and Magni, 1994), panic 
attacks (Whitaker-Azmitia & Aronoson, 1989; Schifano and Magni, 1994; Pallanti & Mazzi, 
1992; Windhaber et al, 1998; McCann & Ricaurte, 1992; McGuire et al, 1994); psychosis/ 
delusions and paranoid symptoms (e.g. Cassidy & Ballard, 1994; Series et al, 1994; Kennan et 
al, 1993; Van Kampen & Katz, 2001; Alciati et al, 1999). In addition, the elevated 
psychopathology in these problematic ecstasy users are also consistent with a large scale 
clinical survey, which identified 53% of its sample as being affected by one or more 
psychopathological problems, which included depression, psychotic disorders, and panic 
disorders (Schifano et al, 2000); and is also consistent with Parrott et al's (2002) report of 
raised levels of depression, mood fluctuation and anxiety reported by ecstasy users.
202
Kirstie Soar Chapter 8
On first inspection of the data from this research thesis, it appears that there is a necessity to 
identify the 'problematic' and 'non-problematic' ecstasy user factor, within ecstasy-related 
research. The non-problematic data from the studies within this thesis do not appear to be 
consistent with the majority of the existing literature concerning cognitive and psychological 
deficits in ecstasy users. Conversely the data from the problematic ecstasy does fit in with the 
existing literature; i.e. problematic ecstasy users showing elevated signs of psychopathology, 
(see Parrott et al, 2001; Dugherio et al, 2001; Morgan et al, 2002; Daumann et al, 2001; 
Parrott, Sisk & Turner, 2000; Gamma et al, 2001; Maclnnes et al, 2001; Thomasius et al, 
2003 and Wareing et al, 2001). Few existing studies have addressed this factor of 
'problematic' ecstasy use, thus any inconsistencies between the literature and comparisons 
made within this research programme could be explained by the general absence of attention 
to a distinction between problematic and non-problematic ecstasy users.
In order to help establish whether this issue does contribute to some of the inconsistencies 
between the data and the existing literature, data for all groups were compared to normative 
data. There are currently three published norms available for the BSI: based on 1) a sample of 
1002 heterogeneous psychiatric out-patients; 2) a sample of 719 non-patient normal subjects; 
and 3) a sample of 313 psychiatric in-patients (Derogatis & Melisaratos, 1983). Comparing 
the non-problematic ecstasy users mean scores on the BSI from this current research 
programme, with those of normative data (table 36), it was seen that, with the exception of 
phobic anxiety in two studies, non-problematic ecstasy users are consistently reporting higher 
psychopathology compared to non-patient norms, but lower than psychiatric in-patients and 
out-patients. This possibly suggests that these non-problematic ecstasy users are showing 
elevated psychopathology relative to norms, but not compared to the current controls within 
this research programme. This suggests that the inconsistent findings between this group and 
existing ecstasy research may not just be because of the lack of distinction in prior research 
concerning problematic and non-problematic ecstasy use. Instead, it raises an important 
question about the nature and validity of the polydrug control groups used throughout this 
research. It could suggest that polydrug use may produce mild problems, and for many, these 
problems remain unnoticeable, but when comparing non-problematic ecstasy users with these 
polydrug users, elevated psychopathological scores in the non-problematic ecstasy users may 
be masked by the mild problems in polydrug users. This is further supported when comparing 
the non-ecstasy polydrug users with the normative data (table 35). These polydrug controls 
are consistently reporting higher psychopathology scores across all studies and dimensions
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compared to the non-patient population norms, though lower scores than psychiatric in- and 
out-patients. Therefore polydrug controls themselves appear to be showing signs of 
psychopathology.
In response to the question about the validity and reliability of polydrug controls, a new drug- 
naive control group was employed. Their cognitive and psychological profiles were 
statistically compared with those ecstasy and polydrug using groups in the previous two 
empirical studies (studies one and two), essentially providing two additional data sets (see 
chapter 6). However, the introduction of a new drug naive control group only indicated 
elevated somatisation in non-problematic ecstasy users and no other psychopathological 
dimension. In study 4 (chapter 6), which also employed a drug naive control group, non- 
problematic ecstasy users, still did not show any signs of elevated psychopathology, with the 
exception of sexual functioning. Again, when comparing the psychopathological scores of 
the drug naive controls with normative data (table 37), with the exception of somatisation 
levels in study 3, drug naive controls were also consistently reporting higher mean 
psychopathology scores compared to non-patient norms. This does raise the possibility that 
perhaps higher scores here are, to a degree, a function of the sample cohort and testing 
environment (i.e. they are different to patient norms in terms of a number of possible factors - 
setting, expectations, motivation etc.).
Regardless of whether or not ecstasy users score within the clinical range or not, the BSI is 
still only a self-report method of clinical measurement. Self-report clinical measures are 
thought to have significant utility in that they can access exclusive information not ordinarily 
available through other methods of assessment. They reflect information derived directly 
from the patient or individual in question, with ease, which can be scored and interpreted with 
regard to clinical decisions (Derogatis & Melisaratos, 1983). There are problems, however, 
with relying on self-report data, which could be affected by personality characteristics, 
attitudes, values and other traits at the time of completion. It would be interesting therefore, 
in future research, to include a more objective assessment of psychopathology, such as the 
DSM-IV or equivalent, to validate those self-report data.
Another possible methodological confound which may account for some of the 
inconsistencies concerning psychopathological findings between ecstasy users in this research 
programme and the majority of the literature, concerns the differences in assessment of
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psychopathology status. In the previous literature demonstrating elevated psychopathology 
scores in ecstasy users, the SCL-90 and SCL-90-R had been employed with fairly consistent 
results across some of its subscales (Parrott et al, 2000; Parrott et al, 2001; Dugherio et al, 
2001; Daumann et al, 2001; Morgan et al, 2002; Thomasius et al, 2003). In the current 
research programme psychopathology was assessed using the BSI (Derogatis & Melisaratos, 
1983), a shortened version of the SCL-90 and SCL-90-R, which has not been previously used 
to assess recreational ecstasy users. Yet other measures have been used to assess depression 
such as the Beck Depression Inventory (Maclnnes et al, 2001), Hamilton Rating Scale 
(Gamma et al, 2001), D-S [Depression Scale] (Daumann et al, 2001) and anxiety - State-Trait 
Anxiety Inventory (Daumann et al, 2001) and have still shown ecstasy users to have elevated 
depression and anxiety compared to controls. However, with the exception of the final study 
(chapter 7) the BSI was modified to include additional items reflecting sexual functioning, 
cognitive failures, MDMA side effects and four positive dimensions. Adapting the scale in 
this manner, or any modification of any scale, raises questions concerning the reliability and 
validity of the changed measure (Bradley, 1994; Cole et al, 2002). It is possible that these 
additions may have disrupted the factorial dimensions of the scale. Therefore, each 
questionnaire item may not be measuring what it pertained to measure in the original 
questionnaire. As such the inventory might not be truly reflecting the psychopathological 
dimensions it aims to identify and the potential subtle selective differences in 
psychopathological symptoms between experimental groups.
The psychometric properties of the scale could have remained unchanged but this cannot be 
assumed. Parrott et al (2001) adapted the SCL-90 in the same manner, including additional 
subscales reflecting sexual functioning, cognitive failures, MDMA side effects and the same 
four positive dimensions and presented a number of reasons why they did not believe this to 
be a problem (see Parrott et al, 2002 for further detail). Their data on this modified SCL-90 
was later subjected to factor analysis (Milani, personal communication). It was found that the 
original nine dimensions of the SCL-90 remained unchanged. It is suggested that the 
additional scales added to the BSI have also remained unchanged, as the two measures (SCL- 
90 and BSI) have been shown to measure essentially the same symptom constructs. Derogatis 
& Melisaratos (1983) demonstrated that the BSI strongly correlates with the SCL-90-R, with 
correlations being uniformly very high across all of the nine dimensions.
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Milani (personal communication) did demonstrate that the four positive subscales of the 
modified version positively correlated with one another and failed to constitute as separate 
robust factors which separate from one another. Therefore the validity and reliability of the 
findings relating to these positive subscales are seriously questioned and interpretation is 
limited. However, the implications of this, on the overall findings of this research thesis are 
limited, since there were no consistent group differences on these positive subscales across all 
studies.
The psychometric properties of the original BSI subscales also need to be considered based on 
the same pattern of data across groups in both chapter 3 (see figures 1-7) and chapter 6 (see 
figures 17-19). Whilst it has been suggested that these are group trends it does raise the issue 
concerning the validity of the individual subscales within this measure. Previous research 
using the SCL-90 (Parrott et al, 2001; Dugherio et al, 2001) and the SCL-90-R (Daumann et 
al, 2001) only demonstrated differences between groups in selective subscales. In retrospect, 
it would have been better to look at the correlations between subscales of the BSI, within this 
thesis, and possibly reduced the number of psychopathological variables to be analysed. This 
may have allowed for more specific areas of psychopathology to be identified in the ecstasy 
using groups and also account for some of the inconsistent findings in symptoms between 
these studies and studies which have used specific measures such as the Beck Depression 
used by Maclnnes et al (2001) or the State-Trait Anxiety Inventory used by Daumann et al 
(2001). Additionally, having one single measure, like the BSI and SCL-90R, that assesses 
different pathologies could also be problematic, in that systematic negative responding could 
possibly inflate the severity of some of the factors or maybe lessen the severity of others; a 
further argument for using separate questionnaires/measures to measure specific pathologies, 
in future research.
It is possible that differences in the findings for the non-problematic ecstasy users compared 
to the majority of data in previous studies could be due to methodological issues. However, 
whilst these arguments may account for inconsistencies in the findings between non- 
problematic ecstasy users and controls, it does not account for the fact that problematic 
ecstasy users showed elevated psychopathology compared to non-problematic ecstasy users 
for somatisation, depression and anxiety, (in both studies one and four) and phobic anxiety, 
paranoid ideation, psychoticism and interpersonal sensitivity (study one). It therefore appears 
that there could feasibly be two distinct ecstasy using groups which differ to the extent of
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presented psychopathology. Possible accounts for this difference will be presented later in 
this chapter.
Positive effects
The four separate positive dimensions were introduced to the BSI to address the criticisms 
from advocates of recreational ecstasy use, who have stated that researchers are biased and 
focus solely on the negative effects rather than the positive effects of ecstasy use (Parrott et al, 
2001). These positive dimensions included: feeling content with life, positive mood states, 
sociability and positive psychobiology (for example, feeling healthy and proficient, enjoying 
dancing or music and feeling full of energy). Problematic ecstasy users consistently reported 
similar positive symptoms, in all dimensions, compared to drug naive controls and polydrug 
controls. The only exception was in chapter 6, with problematic ecstasy users reporting lower 
levels of positive mood states compared to drug naive controls; which was consistent with the 
increased levels of depression seen in these users.
The non-problematic ecstasy users from chapter 7 displayed significantly higher levels of 
positive mood state compared to drug-naive and polydrug controls, and higher levels of 
sociability compared to drug naive controls. Considering that this group of ecstasy users did 
not show any obvious or consistent signs of psychopathology suggests that they have received 
positive benefits from taking ecstasy. This finding in this particular group of ecstasy users 
(i.e. non-problematic users) appears to conflict with that of Parrott et al (2001), who 
demonstrated slightly lower scores for positive mood for all three polydrug using groups 
(non-ecstasy polydrug users, light ecstasy polydrug users and heavy ecstasy polydrug users). 
The current findings are, however, consistent with the frequent reports of reasons why 
individuals use the drug in the first instance; for increased positive mood, feelings of 
euphoria, increased physical and emotional energy and heightened sensual awareness 
(Downing, 1986; Liechti at al, 2000a; Liechti et al 2000b; Gamma et al, 2000; Cami et al, 
2000; Liechti & Vollenweider, 2001). However, these positive benefits do not appear to be 
consistent in all non-problematic ecstasy users within this programme. In chapters 3, 5 and 6 
non-problematic ecstasy users (including ex-ecstasy users in chapter 5) did not exhibit higher 
positive symptoms than other control groups. This is in agreement with Parrott et al's (2001) 
data for the sociability, positive psychobiology and feeling content with life subscales.
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Though again, comparisons of this nature need to be made with caution, as this study did not 
make the problematic and non-problematic distinction. Additionally, such variations in 
research findings concerning these positive scales may reflect the potential methodological 
problem mentioned earlier, in using additional scales which have not been validated and 
assessed for internal consistency, and which may not (or did not) appear to represent separate 
factors (as previously discussed).
Dose-related effects
Concerning lifetime consumption of ecstasy use; none of the studies within this research 
programme indicated a consistent dose-related effect between any psychopathological 
dimensions; this is inconsistent with most previous research. Parrott, Sisk & Turner (2000) 
demonstrated that heavier ecstasy users (who had used on more than 20 occasions, with a 
mean of 371 occasions) reported significantly higher scores on several dimensions of the 
SCL-90 compared to non-using controls: including somatisation, obsessionality, anxiety, 
hostility, phobic anxiety, paranoid ideation, psychoticism and appetite. Also, Parrott et al 
(2001) found that SCL-90 psychopathology scores increased as the use of psychoactive drugs 
increased, and Milani et al (2000) demonstrated a positive correlation between the amount of 
ecstasy used and reported levels of anxiety, phobic anxiety, psychoticism, MDMA side 
effects and total negative feelings.
Contrary to lifetime consumption levels, the current data on the average dose consumed on 
any one occasion positively correlated with anger, phobic anxiety and sexual dysfunction 
(chapter 3) and obsessive-compulsive, anger, phobic-anxiety and psychoticism scales (chapter 
7). The average dose consumed, negatively correlated with the positive subscales of feeling 
content with life, positive mood and sociability. These findings are consistent with previous 
research. Milani et al (2001) found that perceived problems in 'problematic ecstasy users' 
were related to the number of pills taken in a single occasion. In addition, Schifano et al 
(1998) also found that those consuming larger doses of ecstasy in a single evening, were at a 
higher risk of psychopathological disorders. It therefore appears that it may be the intensity 
of ecstasy dosage which is crucial in the development of psychopathology, rather than total 
ecstasy consumption. However, these possible dose-related effects could reflect 
corresponding increases in polydrug use, as well as ecstasy use, since heavier ecstasy users 
have been shown to display a higher lifetime consumption of other drugs including cannabis,
211
Kirstie Soar Chapter 8
amphetamine, cocaine and LSD (Parrott et al, 2001; Milani et al, 2001), and these drugs alone 
have been associated with psychopathology (Lavik & Onstad, 1986; Newcomb & Bender, 
1986; Newcomb, Scheier & Bentler, 1993; Mass et al, 2001).
OVERVIEW OF COGNITIVE FINDINGS 
Short-term Memory
Within the current research programme short-term memory was measured using two tests: the 
Auditory Verbal Learning Test (AVLT; Rey, 1964) and the story recall component of the 
Rivermead Behavioural Memory Test (Wilson et al, 1991). The AVLT has been extensively 
used to evaluate memory functioning in normal samples and in a variety of clinical samples 
concerning different medical and psychiatric conditions (Lezak, 1995). Both problematic 
ecstasy users (including the individual examined for the case study) and non-problematic 
ecstasy users did not show any signs of impairment on short-term verbal recall memory as 
measured by the AVLT and RBMT story recall (compared to polydrug or drug naive controls) 
in any of the studies. The current findings, concerning short-term verbal recall as measured 
by the AVLT, are inconsistent with the majority of previous research which has demonstrated 
impairments in AVLT scores, for both immediate and delayed recall, in ecstasy users (Fox et 
al, 2001c; Reneman et al, 2000; Reneman et al, 2001). However, others such as Thomasius et 
al (2003), have reported similar AVLT results. Previous research findings on the RBMT 
story recall have been less consistent. Morgan (1999) and Morgan et al (2002) showed 
deficits in story recall in ecstasy users, with similar patterns of ecstasy consumption to those 
in this thesis. However, in agreement with current findings, Thomasius et al (2003) and 
Morgan (1998) did not find evidence for story recall impairments in ecstasy users.
There are no available norms for the RBMT story recall task, but there are a number of 
available norms for the AVLT (Lezak, 1995; chapter 16). However, for the purposes of this 
research, data was compared with norms based on an Australian sample of 20 to 29 year olds 
of average intelligence published by Geffen et al (1990). These norms were preferable for 
comparison compared to other available norms, because they provide data for adults within 
the same age range, similar educational attainment and report the same recall trails as used in 
the current research programme; these are all factors that can potentially account for variances
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in scores on this test (Mitushina, Kyle & D'Elia, 1999). When compared to normative data 
across all trials of the AVLT, all ecstasy using groups appeared to be performing below norms 
(table 38), suggesting that ecstasy users are possibly exhibiting short term verbal recall 
impairments. As mentioned before in the context of the psychopathological findings, this 
brings into question the validity of the polydrug control groups.
When comparing the polydrug controls with the normative data (table 39), this group can be 
seen to be consistently recalling fewer mean words per trial in comparison with normative 
data in all trials and across all studies. Therefore polydrug controls themselves appear to be 
showing signs of memory deficits. However, even when trying to compensate for this 
methodological issue by introducing a new drug-naive control group (see chapter 6), no 
cognitive deficits were evident in any ecstasy using group. The drug naive group did however 
highlight the significantly poor performance displayed by the polydrug controls on delayed 
recall trial. However, even this new drug naive group performed below what would be 
expected compared to a normative data set. Thus, whilst the research programme does not 
provide any direct evidence that ecstasy users are showing signs of short-term verbal memory 
dysfunction, this is possibly due to poor control groups rather than the absence of cognitive 
impairments in ecstasy users.
Executive Functioning
Executive functioning was measured using the original manual version of the Tower of 
London task (Shallice, 1982), which purported to measure strategic aspects of executive 
functioning. Since participants were required to manually rearrange the balls, the task also 
examined psychomotor control. Neither the planning times nor these motor response times 
(represented by 'solution times') were found to differ between ecstasy using groups 
(problematic, non-problematic or ex-ecstasy users), polydrug controls and drug naive 
controls, throughout this research programme. The individual case study, however, did show 
increased motor response times and planning times compared to polydrug controls and both 
non-problematic and problematic ecstasy users. However, this cognitive impairment could, in 
part, have been a consequence of the extensive psychopathological problems displayed in this 
particular individual, rather than just ecstasy use, since many psychiatric disorders can have 
an effect upon cognitive functioning (Velligan et al, 2002; Zilberman et al, 2003).
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Kirstie Soar Chapter 8
That groups of ecstasy users did not display any impairment on the TOL task relative to 
controls, is somewhat inconsistent with previous literature using the same measurement. 
Schifano et al (2001), Milani and Schifano (2000) and Fox et al (2001b) have all shown that 
ecstasy users, with similar levels of ecstasy use to participants in the studies in this thesis, 
perform significantly worse than controls on the manual version of the TOL. Studies which 
have not demonstrated executive deficits in ecstasy users on the TOL task have used the 
computerised versions of the task (Fox et al, 2002 and Morgan, 1998). There is no normative 
data currently available that relates to the manual version of the TOL (there are only 'norms' 
for the computerised CANTAB version), thus no valid comparisons or interpretations can be 
made concerning the general performance of ecstasy users and the validity of the control 
groups. However, the above observations regarding the poorly performing controls are quite 
likely to have affected the outcome of these trials.
Everyday Memory (including cognitive failures)
Everyday memory was measured using the Rivermead Behavioural Memory test, a battery of 
twelve psychological tests which assess the skills necessary for adequate functioning in 
normal life rather than performance on experimental tasks (Wilson et al, 1991). The overall 
profile and screening scores associated with this test battery did not differ between non- and 
problematic ecstasy users, polydrug or drug naive controls, in any of the empirical studies. 
Only the individual, RW, displayed poor performance on everyday memory measured by the 
RBMT. However, looking at the separate components of the RBMT, problematic ecstasy 
users performed poorly on the 'immediate delivery of a message' test compared to non- 
problematic ecstasy users, and 'remembering a first and second name' component compared 
to polydrug controls in the first study (chapter 1). Thus, cognitive impairments in everyday 
memory in ecstasy users is comparable to previous literature (Schifano et al, 1998; Milani and 
Schifano, 2000; Rodgers et al, 2001) but only in those ecstasy users that are defined as 
problematic ecstasy users, not in the non-problematic users. However, as this conclusion is 
based just on the one study here, which employed the full RBMT, these findings should be 
viewed with caution.
The small and limited impairments in everyday memory as measured by the RBMT may be 
due to the lack of sensitivity to the subtle memory deficits thought to be associated with 
ecstasy. The RBMT is designed as a screening instrument to detect brain damage (Wilson et
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al, 1989) and, as such, this particular cognitive test may not be suitable for detecting subtle 
memory deficits, whether due to brain damage or the introduction of a drug or stressor (Wall 
et al, 1994; Wills et al, 2000). One future possibility for objectively assessing everyday 
memory in ecstasy users is to use the Extended Rivermead Behavioural Memory test 
(ERBMT) which doubles the amount of material involved in the assessment, by combining 
material from the different forms of the test. This is thought to increase the sensitivity to 
detect memory problems, by increasing the level of difficulty (Wall et al, 1994).
Self-perceived everyday cognitive performance was measured by the cognitive failures 
dimension of the modified BSI, which consisted of questions concerning the self-perception 
of a variety of cognitive slips over the previous 4 weeks. Problematic ecstasy users reported a 
significantly greater number of cognitive failures compared to drug naive controls, though 
this finding was not consistent throughout the research (only in chapter 7). Non-problematic 
ecstasy users did not report elevated levels of cognitive failures compared to control groups. 
Again, this finding concerning self-perceived cognitive performance in non-problematic 
ecstasy users, appears to conflict with other studies (Rodgers, 2000; Heffernan et al, 2001; 
Fox et al, 2001b), where as the finding in problematic ecstasy users, support these previous 
studies. Again, as mentioned earlier, comparisons of this nature need to be made with caution 
as these previous studies did not make this distinction between problematic and non- 
problematic use.
Prospective Memory
Chapters 5, 6 and 7 failed to show any significant deficits in prospective memory in 
recreational ecstasy users compared to polydrug and drug naive controls. This again, is 
inconsistent with the literature, where prospective memory deficits in recreational ecstasy 
users, compared to polydrug controls, have been demonstrated (Heffernan et al, 2001; 
Rodgers et al, 2001). This discrepancy may possibly be due to the different assessment 
measures used between studies. Prospective memory in the current studies was assessed 
using components taken from the RBMT (e.g. remembering an object and remembering to 
ask for an appointment). The reliability and validity of using these components alone has not 
been established with regard to assessing and measuring prospective functioning. Also, 
scoring these items was based on that used in the RBMT, which is based in turn on the whole 
test battery being utilised, and thus may be an unrepresentative scoring of prospective
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memory alone. Bearing this in mind, it would be more ideal for prospective memory to be 
assessed, as a concept on its own, using a standardised prospective memory questionnaire as 
used in previous studies (i.e. Prospective Memory Questionnaire; Heffernan et al 2001, 
Rogers et al, 2001), but also to develop an objective assessment which is reliable and valid at 
measuring this cognitive function.
Reaction Time
A choice reaction time task was employed in study 1 (chapter 3). Neither ecstasy using 
groups showed any deficits on times compared to one another or the polydrug control group. 
This is consistent with most of the previous literature concerning unimpaired reaction time 
abilities in ecstasy users (Parrott et al, 1998; Rodgers, 2000; Fox et al, 2001b; Semple et al, 
1999). The two previous studies that did demonstrate impaired reaction times in ecstasy 
users, only did so compared to drug-naive controls (Croft et al, 2001) and in very heavy users, 
who had used considerably larger amounts of ecstasy (a mean of 741 tablets; Verkes et al, 
2001) than any ecstasy using group within this research. Thus it appears that this cognitive 
process is relatively intact in ecstasy users and it was for this reason that reaction times were 
not measured in the subsequent studies.
Dose-related effects
According to the current research there were no dose-related effects of ecstasy (with respect 
to lifetime consumption, average dose and largest dose) on measures of reaction time, 
executive functioning, immediate and delayed RBMT story recall and cognitive failures. This 
agrees with the majority of the literature employing these cognitive assessment measures 
(Parrott et al, 1998; Verkes et al 2001; Morgan et al, 1998; Morgan et al, 1999; Thomasius et 
al, 2001).
However, dose-related effects were consistently found in the 'remembering name' task of the 
RBMT (lifetime consumption, average dose and largest dose), immediate AVLT recall 
(average and largest dose) and delayed verbal recall (average and largest dose). These results 
are in line with the psychopathological dose-response effects, it appears that it may be the 
intensity of ecstasy dosage on one or more occasions, rather than total ecstasy use, which is
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crucial to the development of selective cognitive deficits concerning (AVLT assessed) 
immediate and delayed verbal memory.
Methodological issues concerning the variability in cognitive task administration
It has been suggested that inconsistencies between the cognitive findings from this current 
research programme and those in the existing literature may reflect poor control groups in 
these studies for valid statistical comparisons (chapter 6). However, it could also be partially 
due to variation in administration of the cognitive tasks between the procedures used in this 
thesis and previous research studies. It is acknowledged that there is little uniformity in 
administration of the AVLT (Lezak, 1995). Whilst the current studies employed the same 
number of AVLT trials as previous studies (e.g. Reneman et al, 2001 & 2001), there are a 
number of differences in task administration compared to existing literature. One 
inconsistency is the absence of a recognition trial, as reported in the studies by Reneman et al 
(2000 & 2001). Secondly, the interval between trial presentation and delayed recall in each of 
the present studies varied; since the length of delay was dependent on completion of other 
cognitive tasks within that time period. This variation in delay is inconsistent compared to 
previous literature, which has stipulated a specific time period (e.g. 20 minutes in Reneman et 
al (2001) and Thomasius et al (2003), and 30 minutes in Fox et al (2001)).
This latter issue, concerning cognitive activities in the interval period, also varies between 
studies, both within this current research programme and in previous literature. This in itself 
could account for differences in performance (Lezak, 1995). Finally, the time given for 
participants to recall the word lists is not described by researchers in any previous papers 
using this task; nor was it strictly controlled for within the current research programme. 
According to the instructions provided by Rey (1964), the time for word recall should be 60 
seconds for the first trail and 90 seconds for all subsequent trials. Such lack of uniformity in 
procedures could account for some of the variance in the research findings (Lezak, 1995).
Similar arguments can be applied to the atypical RBMT story recall findings, especially 
concerning the delay period. Studies that have shown deficits in ecstasy users have tended to 
use a delay interval of 40-50 minutes, filled with a number of cognitively demanding tasks 
(Morgan, 1999; Morgan et al, 2002). The current research programme used a delay period of 
no more than 20 minutes, similar to the interval time used by Thomasius et al (2003).
219
Kirstie Soar Chapter 8
Finally, it has been stressed that there is a necessity for standardised administration for the 
TOL, as differences in instruction and cueing, influence performance across all levels of 
difficulty on this task (Unterrainer et al, 2003). This is especially the case within this current 
research programme, since the manual TOL was employed, which increases the chances of 
error and variability in administration. This could possibly account for discrepancies in 
findings in executive functioning between this research and previous investigations.
ALTERNATIVE INTERPRETATIONS AND LIMITATIONS
Methodological problems are undoubtedly a very possible candidate for helping explain the 
discrepancies between the thesis findings and the ecstasy literature, as outlined above. In 
particular the issue of the inadequate controls, who were actually appearing to show signs of 
cognitive deficits and elevated psychopathology compared to normative data, questions the 
validity and reliability of these groups for comparisons and interpretations concerning ecstasy 
user's cognitive performance and psychopathological status. However, whilst these 
arguments may account for the inconsistencies in the performance between non-problematic 
ecstasy users and controls, the question still remains as to why problematic ecstasy users are 
showing signs of elevated psychopathology and some selective cognitive dysfunction, even 
compared to non-problematic ecstasy users.
Patterns of ecstasy use
It is difficult to ascertain whether the greater number and severity of psychopathological 
symptoms, and the cognitive deficits in problematic ecstasy users, relative to non-problematic 
ecstasy users, are due to differences in patterns of ecstasy use. From chapter 3, there were no 
significant differences in any patterns of ecstasy use compared to non-problematic ecstasy 
users (i.e. average dose, maximum dose on any one occasion and total lifetime consumption). 
However, chapter 7 indicated that problematic ecstasy users reported a significantly higher 
average dose of 2.89 compared to 1.82 tablets in non-problematic ecstasy users. They also 
reported a significantly higher maximum dose on any one occasion of 6.56 compared to 4.19 
tablets in non-problematic ecstasy users; and a higher lifetime consumption of ecstasy of 
404.61 compared to 117.27.
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When comparing the patterns of ecstasy use of those problematic ecstasy users across the two 
studies, it appears that it may be the intensity and frequency of using ecstasy that may 
contribute to psychopathological symptoms in these ecstasy users. Problematic ecstasy users 
consumed much higher levels of ecstasy in their lifetime (404.61 in chapter 7 and 367.36 in 
chapter 3), compared to non-problematic ecstasy users (263.55 in chapter 3 and 117.27 in 
chapter 7). They had also consumed this higher level of ecstasy in a shorter period of time 
(61.29 months in chapter 3 and 75.02 months in chapter 7) compared to those non- 
problematic ecstasy users in study 1 and study 4 (83.7 months and 87.42 months 
respectively). The issue of intensity of dosing is also consistent with the dose-related effects 
discussed earlier for the psychopathological scores and selective cognitive deficits.
One important methodological limitation concerning the interpretation of differing patterns of 
ecstasy use between groups is that, as with the majority of published studies, it is impossible 
to obtain an objective assessment of MDMA consumption in these ecstasy using groups. The 
research into the long-term effects of recreational ecstasy use is based on the model of 
MDMA-induced serotonergic neurotoxicity. This model assumes that recreational ecstasy 
users are actually consuming doses of MDMA that are actually neurotoxic. However, 
differences in self-report patterns of ecstasy use, between user groups, may not necessarily 
reflect differences in MDMA consumption, since there is no control over MDMA 
administration, nor is there any confirmation of the dose and the purity of MDMA taken.
There is little quality control on the streets regarding the content of ecstasy tablets (see 
Parrott, 2004 for a comprehensive review), with considerable variation in the composition of 
tablets, even with tablets which are physically similar in appearance and have the same brand 
name (Sherlock et al, 1999; Bell et al, 2000). Analyses of tablets sold as ecstasy have shown 
that they do generally contain MDMA, but that levels of the compound vary. Sherlock et al 
(1999) examined 25 tablets handed in under amnesty in the UK and found active doses of 
MDMA to be approximately 80-150mg. Weir (2000) examined a larger sample of 69 tablets 
sold as ecstasy in Europe between 1995 and 1997. Of the 30 that contained MDMA, levels 
ranged from 2mg to 149mg. Some studies have even reported samples of ecstasy tablets with 
MDMA levels as high as 180mg and 200mg (O'Connell & Heffron, 2000 and Christopersen, 
2000, respectively). The most recent study by Palenicek et al (2002) reports levels ranging 
from 30mg to lOOmg of MDMA per tablet.
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Ecstasy tablets have also shown to include analogues of MDMA and other active substances: 
such as MDEA (3,4-methylenedioxy-N-ethylamphetamine), MDA (3,4- 
methlyenedioxyamphetamine), caffeine, amphetamine, methamphethamine, paracetamol, 
ketamine, ephedrine, aspirin, pheneylethylamine dextromethorphan (DXM), 
pseudoephedrine, and salicylates (Schifano, 1998; Sherlock et al, 1999; Weir 2000; Palenicek 
at al, 2002; Baggott et al, 2000). Reports of unusual or unexpected effects from ecstasy 
therefore may be explained by the presence of these other substances in ecstasy tablets. 
Ecstasy tablets are rarely if ever contaminated with toxic impurities (Schifano, 1998; King, 
2000), but approximately 8-10% of drugs sold as ecstasy, contain no active ingredient 
whatsoever (Weir, 2000; Baggott et al 2000). The likelihood of consuming MDMA in an 
ecstasy tablet varies depending on the batches available at that time, size of the sample 
examined and geographical location of where the tablets are obtained (Parrott, 2004). From 
an Italian sample, of at least 20,000 tablets, Schifano (1998) found that 85-90% of tablets 
contained MDMA as the active ingredient. A study from the Czech Republic found that over 
80% of tablets tested contained only MDMA (Palenicek et al, 2002), whereas latest reports 
suggest that non-MDMA tablets are rare, with purity levels between 90 and 100% (Parrott, 
2004).
It is clear that there are uncertainties over the chemical constituents of ecstasy tablets, and 
these may be an important confounding factor when assessing the effects of MDMA-induced 
neurotoxicity and when comparing ecstasy user groups. One can only provide an estimate 
when calculating MDMA intake in human studies, which until recently has been the average 
dose of lOOmg (Bolla et al, 1998; Christopersen, 2000). However, Cole et al (2002) suggest 
evidence that the quality of the ecstasy tablet has actually declined since the beginning of the 
1990's. In their analysis of 80 ecstasy tablets, MDMA content ranged from 20-109mg, but 
the mean content was 60-69mg, much lower than the lOOmg commonly assumed in past 
empirical studies (for example, Bolla et al, 1998). Debate still continues though, since in a 
review of this question, Parrott (2004) argues that since the late 1990's the proportion of 
ecstasy tablets containing active MDMA has actually increased to a comparatively high level 
again. Needless to say, the changes (regardless of whether it is an increase or decrease) in 
MDMA content need to be taken into account when interpreting potential differences in 
patterns of ecstasy use within and between user groups.
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Other drug use
Throughout the research programme all ecstasy using groups reported using significantly 
more, other drugs than polydrug controls. This polydrug use is in line with epidemiological 
findings which suggest that ecstasy users are more likely to be polydrug users (Webb et al, 
1996; Pederson & Skrondal, 1999; Topp et al, 1999; Winstock et al, 2001; Strote et al, 2002; 
Arria et al, 2002). Riley et al (2001) reported that 81% of their sample reported mixing drugs 
and/or alcohol. A majority of ecstasy users (92.1%) report co-administration of cannabis 
(Strote et al, 2002), but ecstasy use also has a high association with other drugs such as 
amphetamine, LSD, amyl/butyl nitrate, cocaine, tobacco and alcohol (Webb et al, 1996; Riley 
at al, 2001; Topp et al, 1999). These drugs alone have been shown to be associated with 
various psychopathological symptoms (Mass et al, 2001; Lavik & Onstad, 1986) and 
cognitive impairments (Horner et al, 1999; Ling et al, 2003; Pope et al, 2003; Pope et al, 2001 
Demir et al, 2000; Blume, 2001; Stein et al, 1997 and Hoff et al, 1996). Polydrug use has also 
been associated with higher ratings of psychopathology (Milani et al 2000; Parrott et al 2000). 
It is thus possible that the psychopathological and cognitive findings in problematic ecstasy 
users within this research may be due to wider polydrug use. However, despite problematic 
ecstasy users reporting significantly more use of most other drugs compared to the polydrug 
controls, they only reported significantly higher levels of LSD and magic mushrooms than 
non-problematic ecstasy users in chapter 7, and Prozac and monthly cannabis use in chapter 3. 
This would seem to undermine the idea that the elevated symptoms in problematic ecstasy 
users are due to differences in levels of other drug consumption.
Another area for consideration is the long-term implications of possible interactions of 
various drugs, when consumed in combination with or directly following and/or preceding 
ecstasy use and whether the use of one drug will enhance the potential toxicity of other drugs 
at a later time. At present little is known of the pharmacological effects of these drug 
interactions and whether they may possibly enhance or protect toxicity. For example, 
amphetamine has been shown to enhance the level of MDMA-induced neurotoxicity 
(O'Loinsigh et al, 2000); whilst alcohol has been shown to have a neuroprotective effect 
against MDMA induced neurotoxicity (Miller & O'Callaghan, 1994). It is likely that 
administering such drugs together produces slightly different effects compared to using 
ecstasy alone. Hernandez-Lopez et al (2002) addressed the combination of MDMA and 
alcohol in a double-blind, double-dummy randomised crossover trial consisting of nine male
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volunteers. MDMA used in combination with alcohol induced longer lasting euphoria and 
well-being than MDMA or alcohol alone, whilst MDMA actually reversed the subjective 
sedation induced by alcohol. Verheyden et al (2003) reported that participants who took 
cannabis, alcohol and cocaine in conjunction with ecstasy reported higher scores on a acute 
positive effects of the drug, suggesting that the subjective pleasurable effects of these drugs 
are additive. Further still, they showed that users who had used cocaine in conjunction with 
their ecstasy use scored higher on the acute negative and positive effects compared to ecstasy 
users that had not used cocaine, whereas those who had used amphetamine and ecstasy 
together reported higher physical effects than those that had not. A more recent study has 
also implicated the additive effect nicotine has on neurocognitive functioning in ecstasy users 
(Friend et al, 2004). These findings may be of possible clinical significance considering that 
these substances are commonly co-administered, and considering that ecstasy users are almost 
exclusively polydrug users. The exploratory findings from study 4 (chapter 7) support this 
claim to some extent, with problematic ecstasy users attributing various problems to various 
drugs and combinations of their drug use, not just ecstasy use. It could also be speculated that 
the intensity of ecstasy use in the problematic group could mean that this group were also 
more likely to have used a number of combinations of drugs in a shorter period of time 
compared to non-problematic ecstasy users, again increasing the possibility of even greater 
neurotoxic injury and subsequent functional consequences. Future studies, comparing ecstasy 
users who use ecstasy alone, with ecstasy users that use it in conjunction with other drugs 
such as alcohol, cannabis, cocaine and amphetamine are needed. Similar questions also need 
to be asked pertaining to their patterns of use, akin to those asked of ecstasy users (e.g. 
average consumption and maximum consumption on each occasion and duration of usage). 
This future study, may shed some light into the clinical implications of drug interactions.
Whilst reported patterns of ecstasy and other drug use is a possible explanation for the 
differences in problematic ecstasy users compared to non-problematic ecstasy users, there are 
important methodological limitations concerning this interpretation. Throughout all the five 
studies, profiles of individual's ecstasy and other drug use was based solely on self-report 
data with no biological assays to verify this data. Self-report data is not always reliable. 
These reports are unlikely to be wholly accurate and may often underestimate or overestimate 
ecstasy consumption, especially considering the variety of chemicals sold under the name of 
ecstasy. They may also under- or overestimate their usage either because of fears about 
confidentiality or to heighten their 'street credibility'. Also, retrospective accounts of drug
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use history rely on memory; both the theoretical model of MDMA toxicity and the evidence 
of cognitive performance in ecstasy polydrug users problematise the reliability and use of 
self-report.
Biochemical markers could have been employed in this research programme in order to verify 
self-report drug use data. Hair analysis has been proposed as a method of providing long- 
term qualitative and quantitative information concerning individuals' retrospective drug use 
(Kikura et al, 1997; Alien & Oliver, 2000). In addition, through using methods such as 
chromatography/mass spectrometry (GC/MS; Alien & Oliver, 2000) or by ion mobility 
spectrometry (IMS; Keller et al 1998) the detection of deposits of MDMA, its metabolites and 
other compounds in the hair shaft can be found, therefore confirming whether MDMA has 
actually been ingested, since not all tablets sold as ecstasy contain the psychoactive ingredient 
MDMA (Weir, 2000; Baggott et al 2000; Parrott, 2004). Kikura et al (1997) detected MDMA 
in all hair samples from 7 individuals who reported that they had used ecstasy and also 
Semple at al (1999) reported that hair analysis generally confirmed the drug history given by 
participants. A recent large-scale study of 110 volunteers that compared drug concentrations 
analysed by GC/MS, with self-reported drug histories showed a concordance rate of greater 
than 50% between self-report drug history levels and levels detected using hair analysis and 
concluded therefore that there is some reliability in self-report data on drug use (Cooper et al, 
2000). However, this still leaves approximately 50% of self-report data that does not match 
with levels detected by hair analysis. Additionally, Cooper et al (2000) failed to find any 
correlation between the reported numbers of ecstasy tablets consumed and the levels detected 
in the hair. Thus, whilst hair analysis may give some objective indication of drug use, it can 
only be used for a medium term of drug usage (e.g. 6-12 months), as measurement of 
previous drug use is solely reliant on hair length, and in addition, consistency and reliability 
of this method has yet to be established.
Perhaps a more immediate application of biochemical assay could be in the process of 
confirming more short-term drug taking and abstinence, in particular, given that the half-life 
of MDMA in animals is between 1 and 2 hours, a 2-week abstinence period prior to cognitive 
and psychopathological assessment was deemed sufficient to rule out any withdrawal or 
possible residual effects of the drug. However, the current research programme failed to 
objectively confirm that individuals were abstinent from ecstasy for two weeks prior to 
cognitive and psychopathological assessment, or even absent from other drugs on the day of
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assessment. Since participants knew that payment was given for completion in all studies 
(with the exception of the last one), it is possible that they avoided being excluded from 
taking part, by fabricating when they had last consumed drugs. To avoid such issues urine 
and/or blood samples need to be used on the days of assessment to confirm the necessary 
period of abstinence/presence from drugs. Urine and blood screens have proved to be 
consistent with self-reported drug histories by Schifano et al (1998) and Sherlock et al (1999) 
reported that 29 of 31 respondents who reported taking ecstasy tablets on the night of the 
study actually had MDMA present in their urine. However, Curran (2000) argues that whilst 
blood and urine screens can detect drugs like cannabis 2 to 3 weeks after use, amphetamines 
such as MDMA can only be detected 24 hours to 48 hours after the last dose. Therefore, 
ideally a combination of hair analysis (assessing drug use in the previous 4 weeks) and urine 
analysis need to be used for verification of self report data and drug abstinence. However, 
there are still limitations with hair analysis verification as mentioned earlier.
Pre-existing Differences
One possible explanation for the emergence of two distinct groups of ecstasy users, may be 
due to pre-existing vulnerabilities in individuals (i.e. in those individuals that report problems 
associated with their ecstasy use). In the current research programme, a greater number of 
problematic ecstasy users (both in chapters 3 and 7) reported previous psychiatric histories 
compared to non-problematic ecstasy users and in, chapter 7, a greater number of them had a 
family history of psychiatric illness. Thus, pre-existing psychiatric differences may have 
contributed to these 'ecstasy-related' problems in one of two ways. Firstly, it may be the case 
that these individuals had a genetic pre-disposition for such psychopathological problems, 
hence the difference in psychiatric history between the two ecstasy using groups. The classic 
diathesis model for mental health, proposes that the combined impact of genetic 
predisposition and an environmental stressor, produces a given negative mental health 
outcome (Gabbard & Goodwin, 1996). In the individuals assessed here, their ecstasy use may 
have constituted this significant external stressor by negatively modulating normal brain 
function. In less vulnerable individuals, ecstasy use alone may not be sufficient for the 
emergence of psychological problems.
Secondly, these problems, regardless of whether they were caused and/or influenced by 
genetic and/or environmental factors, may have existed prior to their ecstasy use. There is the
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possibility that the onset of psychopathological problems may have preceded rather than 
followed initiation of ecstasy and other drug use, and thus was a cause, rather than an effect of 
ecstasy use, since poor premorbid adjustment is associated with increased drug use. The 
retrospective nature of the studies in this research programme and in previous research means 
that this issue has not been addressed. In a prospective-longitudinal study in a non-clinical 
sample, Lieb et al (2002) found that in a majority of cases (88%), ecstasy and other polydrug 
use was actually secondary to the onset of DSM-IV mental disorders and psychological 
problems. These pre-morbid disorders consisted mainly of specific phobia (98.4%), social 
phobia (76.6%), alcohol abuse/dependence (78%), and somatoform conditions (73.2%). In an 
additional prospective-longitudinal study, it was revealed that ecstasy use was secondary to 
the onset of DSM-IV mental disorders in the majority of cases, and the risk of initiation of 
ecstasy use was higher in those individuals who presented themselves with a mental disorder 
at baseline. However, the relationship between drug use and vulnerability to psychopathology 
is not always that simple. Brady et al (1993) reported that whilst females were more likely to 
suffer from depression and other affective disorders prior to their drug use, males were more 
likely to develop depression after the onset of drug use, indicating that psychiatric factors may 
precede or contribute to the initiation of drug use in females, but be more consequential to 
drug use in males. This finding was later supported by Zilberman et al (2003) who reported 
that females where more likely to use drugs as a result of mood and anxiety disorders, 
whereas males were more likely to show psychiatric problems after the onset of drug use. 
Due to the methodological design of the current research programme it is difficult to ascertain 
whether the psychopathology in problematic ecstasy users were primary or secondary to their 
drug use, additionally, gender differences was not the focus of the research.
Similar pre-existing vulnerability factors could account for the differences in cognitive 
abilities between the non-problematic and problematic ecstasy users, though group 
differences for these capacities were weaker and less consistent. It is also possible that the 
selective cognitive deficits presented in the problematic ecstasy users, but not in the non- 
problematic ecstasy users, are actually secondary to their psychopathological problems, rather 
than ecstasy per se. This is of particular salience since the problematic ecstasy users were 
consistently showing signs of elevated depression and anxiety. Depression and anxiety 
disorders both have a potential to effect cognition by producing a slowing of psychomotor 
abilities (Lezak, 1995), a prevailing "frontal" cognitive profile (Goodwin, 1997), deficits on 
the TOL task, visual search task (Beats et al, 1996) and executive functioning (Purcell et al,
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1997) and distractibility and attentional disorders (Eysenck, 1982). Cognitive dysfunction 
itself is part of the DSM-IV diagnostic criteria for depression, anxiety and other axis I and II 
disorders.
These possible arguments may account for the development of problematic ecstasy use. Such 
pre-existing factors could also account or certainly contribute to the patterns of ecstasy use. 
For example, a slightly depressed or anxious individual may need to consume more ecstasy 
tablets in order to achieve the subjective effects similar to those experienced by 'normal' 
individuals and/or part of their ecstasy usage, is a form of self-medication for these pre­ 
existing pathologies. Both these issues may explain the differential patterns of ecstasy usage 
between the problematic and non-problematic ecstasy users in this research.
Previous studies assessing the cognitive and psychopathological effects of ecstasy use have 
not explicitly addressed such premorbid issues, which could potentially limit the 
interpretation of their findings. One of the key challenges for future research is to attempt to 
screen for and control these possible pre-morbid psychological characteristics in ecstasy 
users, before concluding that ecstasy is a primary risk factor for the onset of certain 
psychopathological problems.
Secondary personality traits
Secondary personality differences between non-problematic and problematic ecstasy users 
may also play a role in the discrepancies between the two groups in psychopathology scores 
and cognitive performance. It is well established that childhood problems and personality 
traits such as antisocial behaviours, sensation seeking and impulsivity, are associated with an 
increase risk of experimenting with controlled drugs and developing substance abuse 
problems (Bardo et al, 1996; Hawkins et al, 1992; Zuckerman et al, 1994; Hatzitaskos et al, 
1999; Clark et al, 1998). This would be consistent with studies showing elevated scores on 
trait impulsiveness in ecstasy users compared to controls (Morgan, 1998; Morgan et al, 2002; 
Montgomery & Butler, 200la & b). These secondary personality factors are also associated 
with lower serotonergic functioning (Linnoila et al, 1993; Virkkunen et al, 1995). It may be 
plausible that the problematic ecstasy users within this research programme displayed 
premorbid personality differences compared to non-problematic ecstasy users, which may 
have caused and/or contributed to the development of problems.
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These personality traits alone may account for the psychopathological scores and cognitive 
deficits in the problematic ecstasy users, since many of these personality traits, independent of 
drug use, are also associated with poorer cognitive performance and increased risk of 
developing adult psychopathology (Zuckerman & Neeb, 1979; Hawkins & Trobst, 2000). 
Previous studies on ecstasy users have shown differences in impulsiveness (Morgan et al, 
1998; Parrott, Sisk & Turner, 2000; Montgomery & Butler, 2001a & b), sensation seeking 
(Daumann et al, 2001) and novelty seeking (Dughiero et al, 2001; Montgomery & Butler, 
2001) compared to controls. In many of these studies, ecstasy users have also shown elevated 
levels of psychopathology (Parrot, Sisk & Turner, 2000; Morgan, 1998; Daumann et al, 2001; 
Dugherio et al, 2001). Additionally, in a pharmacological challenge study using d- 
fenfluramine, Gerra et al (1998) actually found correlations between prolactin changes and 
novelty seeking scores in ecstasy users. Laviola et al (1999) reported that both elevated 
novelty seeking scores and an interrupted monoaminergic functioning were both associated 
with adolescent ecstasy use compared to controls, suggesting there may be a premorbid 
condition or personality style/trait involving some 5-HT deficiency in ecstasy users. 
However, again these studies did not define whether the ecstasy users considered themselves 
to be problematic or not; but they highlight that such premorbid states, especially ones that are 
known to be related to low 5-HT function, could contribute to a misleading impression that 
cognitive deficits and increased psychopathology are caused by problematic ecstasy use.
There is support for personality traits interacting with problematic ecstasy use, at some level. 
Fox et al (2001b) examined the differences between self-reported problematic (psychological, 
emotional and somatic problems) and non-problematic ecstasy users in relation to both 
consumption and premorbid life adjustment variables. The problematic ecstasy group had 
significantly higher scores on all scales of the SCL-90 compared to the non-problem group. 
However, their self-perceived problematic use was shown to be unrelated to their drug use but 
instead to negative interpersonal relationships prior to taking the drug and less socially 
orientated motivations for using the drug.
The last empirical study of the current research thesis attempted to explore a potential 
personality indicator of problematic ecstasy use on the basis of attribution and, specifically, 
whether individuals that self-perceived themselves as problematic had a different locus of 
control to those ecstasy users that did not perceive themselves as problematic (chapter 7).
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Despite the fact it has been shown that higher rates of psychopathology are related to an 
external locus of control (Hale & Cochran, 1987), this personality construct was not found to 
be of importance in determining whether individuals reported problems attributable to ecstasy 
use in the current study. However, the fact that a higher percentage of problematic ecstasy 
users reported life changes attributable to ecstasy suggests that some form of attributional 
style may still play some role in problematic ecstasy use.
It therefore appears that in future research, there is a need to incorporate an objective 
assessment of secondary personality factors. Of particular importance is the need to control 
for axis II disorders, such as a personality disorder, as well as axis I disorders, which previous 
research has tended to ignore.
Serotonergic Neurotoxicity
The fundamental underlying assumption in the current and previous research is that 
recreational-ecstasy use causes serotonergic neurotoxicity (see chapter 1 for details) and the 
functional consequences of this neurotoxicity are thought to be in behavioural domains 
influenced by serotonin (see chapter 2 for details). Whilst the problematic ecstasy users are 
displaying evidence of elevated psychopathology and also some cognitive deficits, non- 
problematic users are not. Based on this assumption, it could be suggested, perhaps 
controversially, that the non-problematic ecstasy users have not incurred significant or indeed 
any serotonergic neurotoxic injury whereas the problematic ecstasy users have.
There are arguments, and supportive evidence from both animal and human research, to 
suggest that there may be a critical threshold of serotonergic activity below which functional 
sequalae develops. It is possible that problematic ecstasy users may be more vulnerable to the 
neurotoxicity of ecstasy by virtue of a lower serotonergic 'injury' threshold. Individual 5-HT 
neurons may be more robust in some users and thus this injury threshold is not reached, 
therefore not developing functional problems. Or perhaps, more likely, that some individuals 
have lower levels of 5-HT to begin with and less serotonergic injury is needed to reach this 
critical threshold.
Heuther et al (1997) argues that this threshold is hard to predict from animal models as there 
are a number of important species differences. Even within the same species there are genetic
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differences in individual vulnerabilities (Zhou et al, 1996). Also, the dose of MDMA 
required to cause serotonergic damage, depends on state parameters such as age, health state, 
environmental temperature, environmental surroundings and fluid supply. Bowyer et al 
(1994) and Broening et al (1994 & 1995) showed that if hyperthermia is elicited in animals 
whilst under the influence of MDMA, serotonergic neurotoxicity was enhanced. However, a 
more recent study which assessed both serotonin depletion and behavioural measures 
(anxiety, cognition and depression) at different ambient temperatures at the time of drug 
administration, produced different findings. McGregor et al (2003) showed that, in rats, 
hyperthermia at the time of MDMA administration was not necessary to produce serotonergic 
depletion and subsequent long-term anxiety and depression. In addition, poorer cognition was 
only observed in the rats at the highest ambient temperature. Such inconsistent findings 
continue to fuel the debate concerning whether or not the extent to which human recreational 
ecstasy users 'chill out' whilst on ecstasy, affects neurotoxicity and functional consequences. 
Another important area of inquiry, which may shed light on the inconsistencies in the ambient 
temperature debate concerns the age of initiation of ecstasy use. This factor may also account 
for differences in the problematic and non-problematic ecstasy users within the current 
research.
Newcomb et al (1993) found that whilst teenage polydrug use had few effects on adult mental 
health, specific drug use (for example, cannabis and cocaine use) in adolescence and changes 
in these patterns in young adulthood, predicted later psychopathology. Adolescent onset of 
substance use disorder, compared with adult-onset, resulted in higher rates of depression 
(Clark et al, 1998), and in alcoholics, early-onset alcoholism resulted in more depression and 
anxiety symptoms compared to late onset alcoholism.
Early onset cannabis users, but not late onset users, exhibited significantly longer reaction 
times than controls (Ehrenreich et al, 1999). Also there were differences in cerebral blood 
flow (higher in early-onset; Wilson et al, 2000). However a subsequent study, only found 
differences in early versus late onset cannabis use on verbal IQ but not other areas of 
cognition. This research suggests that early onset of drug use might have the effect of 
disrupting the developmental processes that leads to successful adaptation during 
adolescence, such that adolescent drug use appears to increase the risk of developing drug- 
related problems (Laviola et al, 1999). This inconsistency in age of onset in humans could be 
accounted for by the different drug using populations and the different pharmacological
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actions. However, the discrepancy could also be accounted for by possible age-related 
metabolic differences in individuals and metabolic handling of certain drugs.
Morley-Fletcher (2004) noted that early differences in metabolism of MDMA play a role in 
the behavioural changes associated with the drug and that these effects are detectable at the 
adolescent stage. Differences in MDMA metabolism have also been reported in humans 
(Kreth et al, 2000), as well as animals. Polymorphic enzyme cytochrome P450 2D (CYP2D6) 
is involved in the metabolism of a broad array of drugs. Kreth et al (2000) and Ramamoorthy 
et al (2002) have shown that individuals who lack fully functioning CYP2D have a reduced 
ability to metabolise MDMA. Since unexpected adverse effects of drugs are often related to 
their metabolism, it is possible that the differences in the capacity to metabolise ecstasy, 
specifically MDMA, may determine or modulate inter-individual acute toxic reactions 
(Schifano, 2004) and potentially long-term ecstasy-related neurotoxicity, and have an impact 
on the development of ecstasy-related problems in particular individuals. Thus it could be 
speculated that the problematic ecstasy users within this research programme may, with 
regard to metabolism, have a predisposing genetic risk to the adverse effects of ecstasy.
A number of alternative arguments for the discrepancy in findings between the problematic 
ecstasy and non-problematic ecstasy users within this current research programme have been 
discussed. Whilst these propositions are plausible, suggestions for the differences between 
the two ecstasy using groups may need to be verified with the use of biochemical assays, 
further analyses and additional studies, before any firm conclusions can be drawn. But 
according to these interpretations it does appear that ecstasy use is more toxic and is a higher 
risk factor for the development of adverse psychopathology and cognitive dysfunction in 
some populations of ecstasy users more than others. This may be due to patterns of use, 
predisposing genetic risks, premorbid differences, personality and environmental factors and 
the age of onset; or possible some multi-factorial combination of such influences.
Recruitment Strategies:
Definitions of problematic ecstasy use
Whilst possible accounts have been discussed concerning the differences in non-problematic 
and problematic ecstasy users within the current research programme, there is still the need to
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account for the discrepancies between the current findings and the previous literature on 
ecstasy use, cognition and psychopathology. Methodological issues concerning valid and 
reliable control groups seem to be the likely explanation (as previously addressed), but the 
discrepancy could be accounted for by the differing criteria for inclusion into drug user 
groups. Studies that have demonstrated elevated psychopathology and cognitive deficits in 
ecstasy users compared to polydrug controls (e.g. Dugherio et al, 2001; Daumann et al, 2001, 
Thomasius et al, 2003; Parrott, Sisk and Turner, 2000; Parrott et al, 2001; Morgan et al, 2002; 
Reneman et al, 2001) do not define whether or not the ecstasy users employed in their 
research considered themselves as problematic. Parrott, Sisk and Turner (2000) and Parrott et 
al (2001) did not state any exclusion criteria and there was no objective assessment of 
psychiatric status in the ecstasy users employed in their studies. Morgan et al (2002) did 
exclude participants who reported a psychiatric history, but there was still no objective 
assessment of ecstasy user's psychiatric status at the time the research was conducted. In 
these studies, therefore, it is possible that their samples of ecstasy users could have consisted 
of both problematic and non-problematic ecstasy users, hence it is difficult to address whether 
the research findings concerning the problematic ecstasy users in this current study are 
consistent with that of previous research.
Even within this research programme the inclusion criteria differs between studies for 
'problematic ecstasy users'. In the first study (chapter 3) problematic users were defined as 
recreational users of ecstasy who reported problems which they attributed to past ecstasy use, 
and which had to be clinically defined and/or to interfere with the individual's life to the 
extent that they had sought some form of help. In chapter 7 there was a looser, less stringent 
definition: ecstasy users who reported problems that they attributed to their past ecstasy use. 
Thus, the latter group could have consisted of ecstasy users not defined as problematic ecstasy 
users according to the criteria in chapter 3. This difference may also have accounted for 
differences in scores in problematic ecstasy users between studies. However, when BSI data 
from chapter 7 was analysed using the 'problematic ecstasy user' criteria from the first study 
(chapter 3), the problematic ecstasy users (both help seeking and non-help seeking users) 
were still reporting higher psychopathological scores on a number of subscales (appendix, 
table 39). The only difference appeared with the depression and anxiety subscales, where 
'help seeking' problematic ecstasy users appeared to be reporting higher depressive and 
anxiety symptoms (appendix, table 41). These findings suggest that for ecstasy use to be 
problematic to the user, it is not necessary or crucial for them to have sought help for their
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problems. Individual problematic perceptions and attributions appear to be valid in 
representing whether ecstasy use is problematic or not.
Thus, when comparing the current findings with that of the previous literature it is important 
to bear in mind the inclusion and exclusion criteria for ecstasy users, employed in studies, 
when interpreting their findings. There is also a need within future ecstasy research to be 
clear on the definition of 'problematic' ecstasy use before drawing any conclusions 
concerning ecstasy and the development of clinical problems.
Adequate control groups & recruitment strategies
One of the main issues that has arisen throughout this thesis is the limitation of data 
interpretation due to poor control groups. Initially it was thought that the inconsistent 
findings between non-problematic ecstasy users and polydrug controls were possibly 
confounded by the extent and nature of polydrug use. The study in chapter 6 attempted to 
address the possible role of polydrug use in relation to cognitive and psychopathological 
deficits, in ecstasy and non-ecstasy polydrug users, by including a drug-naive control group. 
However, the inclusion of this fourth experimental group failed to identify any further 
cognitive deficits or psychopathology in the drug using groups. In fact, these drug-naive 
controls were actually showing symptoms relating to phobic anxiety, above levels exhibited 
by polydrug controls, ex-ecstasy and current ecstasy users, which in itself may have impacted 
upon their cognitive performance. It is therefore necessary for a suitable control group to be 
established for adequate comparisons to be made on cognitive and psychopathological 
functioning in drug using groups. Control groups should consist of individuals with similar 
lifestyles and backgrounds to other experimental groups and also be screened for psychiatric 
and premorbid personality disorders using an objective diagnostic tool.
It was observed, during data collection, that the participants who volunteered for these studies 
did so for a variety of (often conflicting) reasons. Like some studies, and more specifically 
case studies, this research relied on participants presenting themselves as problematic ecstasy 
users. Many of those that self-selected themselves in the 'problematic' group, in the first 
study, had a very strong personal interest in the study, perhaps in an attempt to gain 
understanding and insight into the cause of the problems which they attributed to their past 
ecstasy use. This confirms the belief of Cole & Sumnall (2003), who suggested that ecstasy
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research consists of samples of individuals who are coming forward to confirm their fears 
about adverse effects that have been raised in the media profile. However, many (but not all) 
of the current ecstasy users who still advocated ecstasy use, volunteered to take part to try and 
dispel the belief that ecstasy can contribute to cognitive and psychopathological dysfunction. 
Certainly, asking for "non-problematic" ecstasy users could result in attracting ecstasy users 
who are from a very different cohort of users compared to those used in existing studies. 
Regardless of the reason for volunteering, it could be argued that ecstasy users that contribute 
to these studies are highly motivated participants with their own personal agenda for 
contributing to the ecstasy research. In contrast, most of the polydrug and drug-naive controls 
who volunteered, did so more for financial reward. Such variations in motivations for taking 
part in research could possibly have confounding effects on research outcomes and certainly 
warrants further investigation when documenting ecstasy-related effects.
In addition to conflicting motivational issues, the lifestyles of experimental groups differed to 
varying degrees, which could also affect variances in cognitive and psychopathological 
performances. Current ecstasy users are unlikely to have the same lifestyle patterns as non- 
drug using controls or cannabis using controls. They tend to have repeated circadian 
disruption, extended aerobic exercise and altered patterns in appetite, which could all effect or 
contribute to cognitive and affective states (Turner et al, 2000). This differs somewhat to ex- 
ecstasy and problematic ecstasy users, who are no longer, part of that clubbing lifestyle, and 
also to polydrug and drug naive controls. Also, the polydrug and drug-naive controls tended 
to be recruited mainly using the snowball technique rather than through advertisements in 
clubs and clubbing magazines. Using the snowballing technique to recruit participants has the 
obvious potential bias, in that it may limit recruitment of individuals from particular social 
networks and subcultures and in the case of this research predominantly consisted of 
undergraduate students. The work presented here raises the question as to whether research 
should avoid using undergraduate students as a control sample, since their possible lack of 
motivation and interest in the studies may have prevented them from performing to the best of 
their abilities, which could account for the poor cognitive performances throughout this 
research programme.
To avoid the possible motivational and lifestyle confounds raised in using drug-naive or 
polydrug control groups to potentially demonstrate the cognitive and psychopathological 
profiles of ecstasy users, it would be of interest to use a sample of other drug using groups
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e.g. heroin or cocaine users. It has been acknowledged that chronic use of illicit drugs may 
be associated with a more general profile of neuropsychological deficits (Rogers & Robbins, 
2001) and psychopathology. For instance, not only have executive disturbances been found 
in ecstasy users (Morgan, 1998; Bhattachary & Powell, 2001; Verkes et al, 2001; Morgan et 
al, 2002; Fox et al, 2002), but also in cannabis users (Pope et al, 2003), cocaine users (Stein, 
1997; Bolla et al, 1998; Minnes, 1998), and heavy alcohol drinkers (Blume, 2001). However, 
there may be subtle differences between different classes of drugs. For instance, cannabis is 
associated with short term memory deficits on free-recall and learning tasks, as well as 
attentional tasks; cocaine is associated with executive deficits, visuo-spatial abilities, 
psychomotor speed and manual dexterity; and opiates tend to produce marked deficits on 
'frontal' tasks (Rogers & Robbins, 2001). Further work in these directions could lead to 
'profiling' and perhaps an understanding of cognitive and psychopathological deficits unique 
to or exacerbated by ecstasy.
SUMMARY
This chapter has provided an overview of the findings from the current research programme 
in relation to previous literature. It appears that ecstasy users self-select themselves into two 
distinct groups, those that do not perceive themselves to be largely problematic or at least do 
not attribute problems to their past ecstasy use and those that report problems which they 
associate with their ecstasy use. However, the nature and severity of these problems vary 
between individuals, as supported by the cognitive and psychopathological assessment results. 
This chapter has highlighted that problematic ecstasy users, rather than non-problematic 
ecstasy users, reported a number of psychopathological symptoms (in particular elevated 
somatisation, depression and anxiety), and also demonstrated selective cognitive impairments. 
Problematic ecstasy use could be in part due to slight differences in patterns of ecstasy use, 
with the suggestion that the intensity of drug use may contribute to the development of 
psychopathology, although there also appears to be other contributory factors that play a role 
in the emergence of psychopathology, within this sub-sample of ecstasy users (e.g. pre­ 
existing problems, predisposition and environmental factors).
It is suggested that there is some multi-factorial combination of these individual factors which 
influence the extent and nature of the development of a problematic ecstasy profile. This 
proposed model is summarised in the following diagram (diagram 1). It is hypothesised that 
the more contributory factors that are present within an individual, the more likely that
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problematic ecstasy use will develop. For example, an individual who has a strong 
predisposition to psychiatric problems, altered metabolism of MDMA and a lower neurotoxic 
'injury' threshold is more likely to develop problems if they use high amounts of ecstasy on 
each occasion, in conjunction with other drug use. This would then be exacerbated further if 
this drug use occurred in a hot, crowded environment with little fluid and a shortage of sleep.
The proposed model can also account for the inconsistency in psychopathological and 
cognitive deficit research findings between non-problematic ecstasy users from the current 
research thesis and that of previous literature. The model would propose that these 
non-problematic ecstasy users within this thesis, have fewer 'risk' factors present in the 
context of their ecstasy use compared to ecstasy using samples (which may include both 
problem and non-problematic ecstasy users as noted earlier) in other research studies which 
document psychopathological and cognitive differences. The model also shows areas where 
'protective' possibilities exist, in terms of harm reduction 'use advice', particularly if, as is 
perhaps highly likely, it is a combination of factors.
Such harm-reduction advice would be in line with, and in addition to, those strategies that are 
already employed by many ecstasy users (Panagopoulos & Ricciardelli, 2005). In particular 
the model may highlight those individuals that could be more vulnerable to developing 
ecstasy related problems. For example, if there are known mental health problems within an 
individual's family, it would be advisable for that person to avoid using ecstasy as a 
recreational drug as they could have an elevated risk of developing ecstasy-related problems. 
Further still, if individuals know that they are genetically deficient in the hepatic enzyme 
CYP2D6 (the enzyme that regulates MDMA metabolism), they too are more likely to have a 
toxic reaction to ecstasy consumption, as well as the potential for developing longer term 
problems and are advised not to consume the drug. However, if such 'at risk' individuals, and 
indeed the general population of ecstasy users, still choose to use ecstasy, advice on patterns 
and consumption of ecstasy usage could hopefully help reduce the overall risk of developing 
ecstasy related problems. This advice could include guidance on safer dosing: by limiting 
ecstasy binges; ideally only consuming small amounts of ecstasy at any one time; allowing a 
period of at least 2 weeks between ecstasy usage, in order to allow for the acute and sub-acute 
effects to diminish; limiting or avoiding cocktails of drugs, specifically amphetamine and 
cocaine use in conjunction with ecstasy use (since these drugs have shown to enhance 
MDMA neurotoxicity). Additionally, raising awareness of the environment that ecstasy is
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consumed in could potentially reduce the risk of developing ecstasy-related problems. This 
would include appropriate regulation of body temperature, allowing periods of rest in a quiet 
room, not allowing the body to become too hot, maintaining an adequate water supply and 
further avoiding dehydration by avoiding the consumption of alcohol. Further, exerting 
control over other lifestyle factors such as ensuring appropriate sleep and a balanced diet 
could help the body to restore and maintain normal functioning. However, future research 
needs to address and understand the relative weighting of each factor within this model in 
order to provide appropriate and specific 'protective' advice. In addition, such objectives must 
be tempered by the possibility that some risk factors are not easily assessed or knowable, and 
that the possibility of ecstasy as a sole determinant of pathology remains key for some 
individuals.
However, caution needs to be taken when interpreting the specific assessment scores of 
ecstasy users, in this thesis, in relation to other ecstasy using samples, due to the inherent and 
particular methodological issues possibly affecting the studies presented. This mainly 
concerns the validity and reliability of an adequate control group. Opportunities to strengthen 
the research paradigms used within this research thesis concern addressing many of the 
methodological issues raised. In summary, these include:
• Improving recruitment strategies to ensure recruiting control groups which are
appropriately matched to ecstasy using groups, in that they display similar lifestyles, 
sleep and diet patterns and, more importantly, other drug use, so as to achieve greater 
experimental control.
• Focusing further on the different combinations of drug use in conjunction with ecstasy 
use, in order to assess the possible interactions and differences in the long-term effects 
of these combinations, in relation to cognitive and psychopathological indices.
• Use of bio-markers (e.g. urine and hair analysis) to verify drug use in conjunction with 
the self-report data, in order to improve the reliability of type and quantity of different 
drug use.
• Exploring the age of onset of ecstasy use and its potential long-term effects, especially 
in relation to differences in metabolic rates, and subsequent cognitive and 
psychopathological differences.
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• Improving assessment of psychopathological status, and including a more objective 
assessment measure (e.g. DSM IV).
• Improving assessment of cognitive functioning; including an objective measure of 
prospective memory; using a computerised version of the TOL to avoid manual errors 
in presentation and scoring of the test; and possibly use the extended version of the 
RBMT to increase the sensitivity of detecting everyday memory problems.
• Assessment of secondary personality traits, existing psychopathology and possible 
individual predispositions will help us contextualise the effects of ecstasy, but also, 
perhaps, help us to identify probable "at risk" populations of ecstasy users.
However, the issue of causation within this problematic ecstasy/MDMA research area will 
only be truly inferred by conducting a controlled prospective-longitudinal study assessing 
serotonin, secondary personality factors, indices of predisposition, cognitive and behavioural 
functioning in MDMA-naive individuals that are randomly assigned to MDMA or placebo 
conditions. Only then can it be shown that recreational ecstasy use causes neurotoxic injury 
and cognitive and psychological problems, and whether these develop to the extent that they 
become problematic to the user. However, because MDMA has been shown to have 
neurotoxic effects on animal brains after just a single dose (Ricaurte et al, 1988), such studies 
are unlikely to occur. Thus, this further highlights the crucial need for researchers to 
document the conditions under which psychopathology and cognition remain unimpaired in 
ecstasy users, just as it is important to describe the situations where deficits develop. As 
Parrott (2003) argues, researchers who find unimpaired performance profiles should be 
encouraged to submit their findings for publication, and perhaps, in line with this suggestion, 
a function of journal editorship should be to consider the publication of non-findings.
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APPENDIX A
PERSONAL HISTORY
Age___________________ Gender
Age left
Current
education
rating of health
Nationality
Bad Moderate Fine
1 2 3
Good
4
Have you ever been clinically diagnosed (by a Doctor) with any of the 
following?
Anxiety Yes D No D
Depression Yes D No D
OCD (Obsessive Compulsive Disorder) Yes D No D
Schizophrenia or Paranoia Yes D No D
Phobia Yes D No D
Panic attacks Yes D No D
Eating disorders Yes D No D
Alcohol or Drug dependency Yes D No D
Have any member of your immediate family ever been diagnosed (by a Doctor) 
with any of the following?
Anxiety Yes D No D
Depression Yes D No D
OCD (Obsessive Compulsive disorder) Yes D No D
Schizophrenia or Paranoia Yes D No D
Phobia Yes D No D
Panic attacks Yes D No D
Eating disorders Yes D No D
Alcohol or Drug dependency Yes D No D
Have you ever been hospitalised for any brain injury?
Yes D No D 
Are you on any current medication?
Yes D No D 
If yes, what is this medication prescribed for?
DRUG USE QUESTIONNAIRE 
Please answer these as accurately as possible: 
1. ECSTASY/MDMA AND OTHER DRUGS
Which of the following drugs have you taken, and approximately how many 
times?
Ecstasy/MDMA 
Amphetamine 
Cocaine 
Crack
Opiates (Heroin,
morphine)
Cannabis
Benzodiazepines (e.g.
Valium)
LSD
Magic mushrooms
Anabolic steroids
Solvents
Poppers
Ketamine
Prozac
GHB (liquid ecstasy)
No D
No D
No D
No D
No D
NO n
No D
No D
No D
No D
No D
No D
No D
No D
No D
Yes D
Yes D
Yes D
Yes D
Yes D
Yes D
Yes D
Yes D
Yes D
Yes D
Yes D
Yes D
Yes D
Yes D
Yes D
If yes, how many times? 
If yes, how many times? 
If yes, how many times? 
If yes, how many times? 
If yes, how many times?
If yes, how many times? 
If yes, how many times?
If yes, how 
If yes, how 
If yes, how 
If yes, how 
If yes, how 
If yes, how 
If yes, how 
If yes, how
many times? 
many times? 
many times? 
many times? 
many times? 
many times? 
many times? 
many times?
Others (Please specify & indicate how often used, as above):
2. ALCOHOL TOBACCO AND CANNABIS USE
Do you smoke tobacco? No D Yes D
If yes, how many cigarettes do you smoke per day on average?_
Do you drink alcohol? No D Yes D
If yes, how many units of alcohol do you drink in a typical week?_
Do you smoke cannabis? No D Yes D
If yes, how many times do you smoke per month on average?__
APPENDIX B
ECSTASY QUESTIONNAIRE
(Only complete if you have taken ecstasy)
1. When was the first time you took Ecstasy/MDMA?____
2. When did you last take Ecstasy/MDMA?__________
3. How many tablets would you normally take in one occasion?.
4. What is the largest number of tablets you have taken in one occasion?
5. How many ecstasy tablets have you taken in your lifetime?.
6. Have you increased the number of ecstasy tablets you take on each 
occasion?
Yes D No D
7. Has the effect of ecstasy changed, the more you have taken it?
Yes D No D
8. Do you suffer if you go for sometime without taking ecstasy?
Yes D No D
9. Do you need to take ecstasy regularly?
Yes D No D
10. Do you feel you are dependent or addicted to ecstasy in any way?
Yes D No D
11. Do you consider yourself to be a stable user of ecstasy, using
approximately the same amount of tablets on each occasion with regular 
intervals between each occasion?
Yes D No D
12. Do you continue to use ecstasy?
Yes D No D
13. Do you usually take other drugs together with ecstasy?
Yes D No D 
If yes, please indicate which ones: _____________________
14. Do you take any drugs that are supposed to prevent ecstasy side effects?
Yes D No D
APPENDIX C
15.The following are a list of effects that you may have experienced whilst on 
ecstasy. Please indicate whether you ever experienced them and if so how 
much.
Not at all Slightly Moderate Strongly
Confusion/disorientation
Agitation/irritability
Anxiety
Euphoria/extreme happiness
Unresponsiveness
Largely reduced body temperature
Excessive sweating
Large increase in heart rate
Dilated pupils
Nausea/sickness
Unreactive pupils
Flushing
Tremors
Restlessness/hyperactivity
Lack of muscle co-ordination
Uncontrollable muscle spasms/twitching
Muscle stiffness
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
APPENDIX D
16. Has your use of ecstasy led to changes in your experiences of life? Please 
indicate how much the following changes apply to you, some are positive 
changes others are negative.
Increased empathy 
Obsessive Thoughts 
Aggression 
Loss of organis 
Backache 
Breathlessness 
Decrease in def 
Confidence Loss 
Less Sociable 
Mood Swings 
Improved soci 
Depression 
Anxiety 
Paranoia 
Increased feel 
Hallucinations 
Panic attacks 
Phobias
Enhanced sensations 
Sex problems 
General Illness 
Weight Loss 
Sleep Problems 
Spiritual enlight 
Memory Loss 
Concentration Loss 
Decrease in fear 
Motivational Problems
occurring?
Not at all
y 1
1
1
itional skills 1
1
1
nsiveness 1
i 1
1
1
interpersonal functioning 1
1
1
1
js of well being 1
r flashbacks 1
1
1
1
1
1
1
1
jnment 1
1
DSS 1
1
l  1
ch period of your ecstasy use did
i
Slightly
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
these
Moderate
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
changes start
Strongly
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
18. Have any of these changes led you to seek help or advice from a 
professional organisation?
Yes D No D 
If yes, please indicate which of the following you have approached:
GP (Doctor) Yes D No D
Clinical psychologist Yes D No D
Psychiatrist Yes D No D
Drug services/clinic Yes D No D
Other (please specify)____________ Yes D No D
19. Have you been prescribed some form of treatment for these changes?
Yes D No D 
If yes, please indicate:
APPENDIX E
DRUG USE QUESTIONNAIRE
Please answer these as accurately as possible:
1. PAST DRUG USE
Which of the following drugs have you taken, and approximately how many?
Amphetamine
Cocaine
LSD
Magic mushrooms
Poppers
Ketamine
GHB (liquid ecstasy)
Prozac (not prescribed)
Crack
Opiates (e.g. Heroin,
morphine)
Benzodiazepines (e.g.
Valium)
Anabolic steroids
Solvents
Others (Please specify
No D 
No D 
No D 
No D 
No D 
No D 
No D 
No D 
No D 
No D
No D
Yes D 
Yes D 
Yes D 
Yes D 
Yes D 
Yes D 
Yes D 
Yes D 
Yes D 
Yes D
If yes, how many? 
If yes, how many? 
If yes, how many? 
If yes, how many? 
If yes, how many? 
If yes, how many? 
If yes, how many? 
If yes, how many? 
If yes, how many? 
If yes, how many?
Yes D If yes, how many?
No D Yes D If yes, how many? _
No D Yes D If yes, how many? _
& indicate how often used, as above):
2. CANNABISUSE
No D Yes DDo you currently smoke cannabis?
If yes, how many times do you smoke per month on average?
how many years have you smoked for? ________
Yes DHave you smoked cannabis in the past? No D
If yes, how many times did you smoke per month on average?
How many years did you smoke for? ______________
3. CURRENT ALCOHOL AND TOBACCO USE
Do you smoke tobacco? No D Yes D 
If yes, how many cigarettes do you smoke per day on average?.
Do you drink alcohol? No D Yes D 
If yes, how many units of alcohol do you drink in a typical week?.
4. PAST ECSTASY USE (only complete if vou have taken ecstasv)
When was the first time you took Ecstasy/MDMA (year/month)?
When did you last take Ecstasy/MDMA (year/month)?
How many ecstasy tablets have you taken in your lifetime?
Please indicate by circling the appropriate statement, how often, on average, 
you use or did use ecstasy?
Weekly Monthly Every 3 months Yearly
On average, how many tablets would you normally take in one occasion?
What is the largest number of tablets you have taken in one occasion?
Do you continue to use ecstasy? No D Yes D 
If no, please indicate why you stopped:
Have you experienced any problems, which you attribute to your ecstasy use?
No D Yes D
Have any of these problems led you to seek help or advice from a professional 
organisation? No D Yes D
If yes, please indicate which of the following you have approached:
GP (Doctor) Yes D
Clinical psychologist Yes D
Psychiatrist Yes D
Drug services/clinic Yes D
Other (please specify)____________ Yes D
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APPENDIX G
Table 31; Percentages of reported positive and negative life changes in drug-naive controls
and whether thev attributed this change to alcohol
N=lll
Positive life changes
Increased empathy
Decrease in defensiveness
Improved social/interpersonal 
functioning 
Increased feelings of well being
Decrease in fear
Spiritual enlightenment
Enhanced sensations
Negative life changes
Obsessive thoughts
Aggression
Mood swings
Less sociable
Confidence loss
Depression
Anxiety
Paranoia
Hallucinations
Panic attacks
Phobias
Breathlessness
Backache
Sex problems
General illness
Weight loss
Sleep problems
Loss of organisational skills
Motivational problems
Memory loss
Concentration loss
Other non- 
drug factor
19.8
11.7
24.3 
26.1
20.7
18
18
15.3
20.7
28.8
25.2
35.1
25.2
17.1
9
4.5
2.7
9
12.6
28.8
10.8
27
23.4
25.2
12.6
23.4
9
21.6
Alcohol
5.4
6.3
18 
9.9
12.6
0.9
9
4.5
9
4.5
2.7
1.8
6.3
1.8
9
0
0.9
0
1.8
0
0
1.8
0.9
6.3
4.5
5.4
5.4
9
No change 
experienced
74.8
82
57.7 
64
66.7
81.1
73
80.2
70.3
66.7
72.1
63.1
68.5
81.1
88.3
95.5
96.4
91
85.6
71.2
89.2
71.2
75.7
68.5
82.9
71.2
85.6
69.4
which, if anv drills) thev
N=62
Positive life changes
Increased empathy
Decrease in defensiveness
Improved social/interpersonal
functioning
Increased feelings of well
being
Decrease in fear
Spiritual enlightenment
Enhanced sensations
Negative life changes
Obsessive thoughts
Aggression
Mood swings
Less sociable
Confidence loss
Depression
Anxiety
Paranoia
Hallucinations
Panic attacks
Phobias
Breathlessness
Backache
Sex problems
General illness
Weight loss
Sleep problems
Loss of organisational skills
Motivational problems
Memory loss
Concentration loss
attributed this change to
C 0o *^
Lri 4|—
| F?0 •§
24.2
16.1
21
30.6
21
19.4
9.7
21
24.2
32.3
24.2
32.3
27.4
24.2
9.7
6.5
12.9
9.7
27.4
33.9
12.9
32.3
21
32.3
21
29
14.5
22.6
e
1^
3A
Cu
S
0
0
1.6
4.8
1.6
0
1.6
0
0
1.6
0
0
1.6
0
0
1.6
0
0
0
0
0
0
1.6
1.6
1.6
1.6
1.6
3.2
0*
'S3
8u
3.2
4.8
3.2
1.6
0
3.2
3.2
3.2
3.2
1.6
1.6
1.6
1.6
1.6
0
0
0
0
0
0
1.6
0
1.6
1.6
0
0
0
Q
C/3
0
0
0
0
0
1.6
1.6
0
0
0
0
0
0
0
0
1.6
0
0
0
0
0
0
0
0
0
0
0
0
A03ee
5
17.7
21.0
19.4
24.2
9.7
12.9
22.6
12.9
14.5
8.1
12.9
8.1
9.7
14.5
21.0
3.2
8.1
0
12.9
0
1.6
3.2
6.5
8.1
12.9
17.7
16.2
24.2
"3
0^y
^
11.3
17.7
45.2
21.0
32.3
0
9.7
6.5
24.2
16.1
14.5
6.5
11.3
9.7
4.8
3.2
1.6
0
0
0
4.8
9.7
0
3.2
4.8
12.9
12.9
19.4
1 %A •—
3. %•
48.4
48.4
21
24.2
38.7
66.1
58.1
59.7
50
40.3
48.4
53.2
53.2
53.2
66.1
87.1
79
90.3
59.7
66.1
79
56.5
71
54.8
56.5
46.8
3.2
41.9
ecstasy users which, if any drue(s), they attributed
N=62
Positive life changes
Increased empathy
Decrease in defensiveness
Improved social/interpersonal
functioning
Increased feelings of well
being
Decrease in fear
Spiritual enlightenment
Enhanced sensations
Negative life changes
Obsessive thoughts
Aggression
Mood swings
Less sociable
Confidence loss
Depression
Anxiety
Paranoia
Hallucinations
Panic attacks
Phobias
Breathlessness
Backache
Sex problems
General illness
Weight loss
Sleep problems
Loss of organisational skills
Motivational problems
Memory loss
Concentration loss
Other nonOdrug factor
19.4
12.9
12.9
22.6
9.7
11.3
1.6
11.3
4.8
14.5
8.1
16.1
12.9
12.9
1.6
1.6
9.7
8.1
9.7
16.1
8.1
1.6
4.8
6.5
6.5
8.1
1.6
6.5
I
45.2
17.7
35.5
33.9
16.1
27.4
54.8
3.2
4.8
25.8
9.7
4.8
16.1
14.5
11.3
9.7
9.7
0
3.2
9.7
6.5
9.7
19.4
14.5
1.6
1.6
4.8
3.2
Amphetamine
6.5
8.1
17.7
9.7
4.8
3.2
12.9
8.1
4.8
19.4
8.1
4.8
11.3
8.1
9.7
1.6
4.8
0
8.1
3.2
6.5
1.6
22.6
22.6
1.6
1.6
0
3.2
this change to
Cocaine
9.7
6.5
33.9
27.4
21.0
3.2
25.8
16.1
11.3
21.0
8.1
4.8
6.5
11.3
8.1
0
3.2
0
3.2
1.6
3.2
4.8
6.5
19.4
0
0
0
0
Q en
16.1
11.3
6.5
8.1
4.8
27.4
24.2
8.1
0
9.7
4.8
3.2
4.8
6.5
11.3
21.0
4.8
0
0
0
0
0
0
4.8
0
0
0
0
Cannabis
21.0
21.0
19.4
17.7
6.5
22.6
22.6
21.0
0
12.9
22.6
12.9
9.7
22.6
25.8
4.8
8.1
0
11.3
0
0
0
1.6
12.9
16.1
30.6
27.4
19.4
Alcohol
12.9
22.6
43.5
25.8
32.3
8.1
11.3
8.1
32.3
25.8
16.1
9.7
16.1
1.6
3.2
1.6
1.6
1.6
1.6
3.2
14.5
9.7
0
3.2
11.3
6.5
11.3
17.7
No change experienced
29
45.2
17.7
29
46.8
51.6
35.5
43.5
53.2
32.3
41.9
51.6
46.8
35.5
45.2
66.1
77.4
88.7
66.1
71
69.4
74.2
50
40.3
56.5
41.9
40.3
38.7
users which, if any drue(s), thev attributed
N=53
Positive life changes
Increased empathy
Decrease in defensiveness
Improved social/interpersonal
functioning
Increased feelings of well being
Decrease in fear
Spiritual enlightenment
Enhanced sensations
Negative life changes
Obsessive thoughts
Aggression
Mood swings
Less sociable
Confidence loss
Depression
Anxiety
Paranoia
Hallucinations
Panic attacks
Phobias
Breathlessness
Backache
Sex problems
General illness
Weight loss
Sleep problems
Loss of organisational skills
Motivational problems
Memory loss
Concentration loss
an«! o
£§ * 
0 §£
7.5
13.2
22.6
22.6
17
9.4
5.7
1.9
11.3
7.5
5.7
11.3
5.7
9.4
3.8
1.9
7.5
9.4
7.5
15.1
13.2
7.5
7.5
3.8
1.9
5.7
3.8
7.5
>>i
1
45.3
35.8
45.3
35.8
20.8
30.2
56.6
37.7
11.3
54.7
17.0
22.6
62.3
37.7
34.0
24.5
34.0
9.4
17.0
28.3
13.2
39.6
49.1
35.8
18.9
13.2
13.2
17.0
this change to
Amphetamine
7.5
9.4
11.3
11.3
1.9
3.8
20.8
18.9
18.9
28.3
13.2
24.5
28.3
24.5
30.2
3.8
17.0
3.8
17.0
15.1
3.8
20.8
32.1
35.8
5.7
11.3
3.8
9.4
Cocaine
15.1
9.4
18.9
15.1
17.0
3.8
18.9
18.9
17.0
28.3
9.4
15.1
18.9
22.6
20.8
3.8
11.3
3.8
7.5
1.9
11.3
15.1
15.1
20.8
1.9
3.8
1.9
3.8
Q
V3 
J
17.0
13.2
3.8
9.4
7.5
18.9
20.8
20.8
3.8
9.4
5.7
5.7
7.5
9.4
17.0
24.5
5.7
3.8
1.9
0
1.9
9.4
1.9
9.4
0
0
0
1.9
Cannabis
26.4
20.8
17.0
15.1
7.5
24.5
26.4
30.2
3.8
24.5
39.6
24.5
17.0
24.5
49.1
3.8
17.0
3.8
11.3
0
5.7
22.6
5.7
20.8
13.2
32.1
7.5
24.5
Alcohol
13.2
13.2
28.3
20.8
17.0
1.9
11.3
13.2
26.4
24.5
9.4
9.4
22.6
9.4
9.4
3.8
5.7
3.8
0
1.9
5.7
3.8
1.9
15.1
5.7
5.7
1.9
3.8
No change experienced
34
32.1
17.0
28.3
47.2
37.7
24.5
32.1
45.3
15.1
35.8
37.7
17.0
26.4
20.8
52.8
47.2
75.5
52.8
47.2
60.4
43.4
28.3
28.3
41.5
30.2
24.5
17.0
APPENDIX H
Table 40; Locus of Control mean scores (SD) for drug-naiVe, polydrug controls, 
non-problematic ecstasy, problematic ecstasy users and problematic ecstasy users 
who reported seeking help.
N LOC
111 12.44 ±4. 19
Non-ecstasy Polydrug Users ^ 12 65 + 3 87
Non-problematic Ecstasy
users 62 12.56 ±4.08
(E)
Problematic ecstasy users <,, 1 1 56 + 4 19
Problematic ecstasy users,
seeking help 17 10.88 ±4.79
(PE)
0.411 
Group effect (sig.)
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APPENDIX K
Table 42: Ethnic diversity in drug naive, polvdrug controls, non-problematic and
problematic ecstasy users
Caucasian
Asian
Afro-Caribbean
Chinese
Other
^ .. Polydrug Drug naive J ° users
67 47
13 7
9 4
1 1
21 3
Non- 
problematic 
Ecstasy users
59
2
1
0
0
Problematic 
Ecstasy users
50
2
1
0
0
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THE MODIFIED BRIEF SYMPTOM INVENTORY
Below is a list of problems and complaints that people sometimes have. Please read each one carefully. 
After you have done so please circle one of the numbers to the right that best describes HOW MUCH YOU 
HAVE EXPERIENCED THAT FEELING OR COMPLAINT, WHEN NOT UNDER THE EFFECT OF DRUGS. 
IN THE PAST FOUR WEEKS.
WE ARE VERY INTERESTED IN YOUR QUESTIONNAIRE EVEN IF YOU HAVE NEVER TAKEN DRUGS.
Circle only ONE number for each problem and do not skip any items. 
Please see example below before beginning.
EXAMPLE:
IN THE PAST MONTH, WHEN FREE OF DRUGS. HAVE YOU EVER EXPERIENED:
1. Backaches
Not at all A little Bit Moderately Quite a bit Extremely 
0 1 © 3 4
The "2" has been circled, this means that the person had been Moderately bothered by backache in the past 
4 weeks, IN A DRUG FREE SITUATION.
APPENDIX L
IN THE PAST MONTH, WHEN NOT UNDER THE 
EFFECT OF DRUGS, HAVE YOU EVER 
EXPERIENCED:
1. Nervous or shakiness inside
2. Faintness or dizziness
3. Feeling interested in things
4. Feeling comfortable with others
5. The idea that someone else can control your 
thoughts
6. Feeling others are to blame for most of your 
troubles
7. Feeling quick witted
8. Trouble remembering things
9. Increased sexual desire
10. Sleeping well
11. Feeling easily annoyed or irritated
12. Feeling rash or impulsive
13. Pains in heart or chest
14. Feeling afraid of open spaces
15. Thoughts of ending your life
16. Feeling alert and attentive
17. Feeling that most people cannot be trusted
18. Poor appetite
Not at all A Little Bit Moderately Quite a bit Extremely 
01234
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IN THE PAST MONTH, WHEN NOT UNDER THE 
EFFECT OF DRUGS, HAVE YOU EVER 
EXPERIENCED:
19. Having sexual interest and/or pleasure
20. Craving for chocolate
21. Suddenly scared for no reason
22. Temper out bursts that you could not control
23. Feeling satisfied with life
24. Feeling lonely even when you are with other 
people
25. Feeling blocked in getting things done
26. Having good times with friends
27. Decreased sexual desire
28. Feeling lonely
29. Feeling blue
30. Having good appetite
31. Feeling no interest in things
32. Feeling fearful
33. Feeling clear-headed
34. Your feelings being easily hurt
35. Difficulties in planning things
36. Feeling that people are unfriendly or dislike you
37. Feeling in good spirits
Not at all A Little Bit Moderately Quite a bit Extremely 
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IN THE PAST MONTH, WHEN NOT UNDER THE 
EFFECT OF DRUGS, HAVE YOU EVER 
EXPERIENCED:
Not at all A Little Bit Moderately Quite a bit Extremely
38. Feeling inferior to others 01234
39. Nausea or upset stomach 01234
40. Feeling that you are watched or talked about by 0 1 234 
others
41. Trouble falling asleep 01234
42. Feeling non-judgemental of others 01234
43. Having to check and double check what you do 0 1 2 3 4
44. Feeling healthy and proficient 01234
45. Difficulty making decisions 01234
46. Feeling afraid to travel on buses, subways or 0 1 2 3 4 
trains
47. Premature orgasm (premature ejaculation in 01234 
males)
48. Trouble getting your breath 01234
49. Feeling happy 01234
50. Hot or cold spells 01234
51. Having to avoid certain things, places or activities 01234 
because they frighten you
52. Your mind going blank 01234
53. Feeling creative 01234
54. Numbness or tingling in parts of your body 01234
55. Mid-week blues 01234
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IN THE PAST MONTH, WHEN NOT UNDER THE 
EFFECT OF DRUGS, HAVE YOU EVER 
EXPERIENCED:
Not at all A Little Bit Moderately Quite a bit Extremely
56. The idea that you should be punished for your 01234 
sins
57. Delayed orgasm (difficulty in achieving orgasm for 0 1 2 3 4 
females)
58. Feeling hopeless about the future 01234
59. Trouble concentrating 01234
60. Feeling close to others 01234
61. Feeling weak in parts of your body 01234
62. Feeling tense or keyed up 01234
63. Enjoying dancing and/or music 01234
64. Overeating 01234
65. Feeling confident about the future 01234
66. Having urges to beat, injure or harm someone 01234
67. Having mood swings 01234
68. Feeling good about your body 01234
69. Having urges to break or smash things 01234
70. Feeling very self conscious with others 01234
71. Feeling liked by others 01234
72. Physical problems with sex (impotence, genital 01234 
pain)
73. Feeling uneasy in crowds 01234
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IN THE PAST MONTH, WHEN NOT UNDER THE 
EFFECT OF DRUGS, HAVE YOU EVER 
EXPERIENCED:
Not at all A Little Bit Moderately Quite a bit Extremely
74. Feeling tranquil 01234
75. Never feeling close to another person 01234
76. Spells of terror or panic 01234
77. Getting into frequent arguments 01234
78. Having trust in other people 01234
79. Feeling nervous when you are left alone 01234
80. Others not giving you proper credit for your 01234 
achievements
81. Feeling so restless you couldn't sit still 01234
82. Feelings of worthlessness 01234
83. Feeling its wonderful to be alive 01234
84. Feeling that people will take advantage of you if 0 1 2 3 4 
you let them
85. Feeling full of energy 01234
86. Feelings of guilt 01234
87. The idea that something serious is wrong with 01234 
your mind
88. Feeling relaxed 01234
89. Forgetting to do something 01234
90. Feeling easily distracted 01234
91.Trouble making up your mind 01234
92. Forgetting where you had left something 01234
93. Feeling confused 01234
APPENDIX L
Modified Brief Symptom Inventory Subscale Definitions
Somatisation
Distress arising from perceptions of bodily dysfunction e.g. faintness or dizziness, pains in heart or 
chest, hot or cold spells, feeling weak in parts of your body.
Obsessive-compulsive
Thoughts, impulses and actions that are experienced as unremitting and irresistible by the individual 
but ego-alien or unwanted in nature e.g. feeling blocked in getting things done, having to check and 
double check what you do, difficulty making decisions, your mind going blank.
Interpersonal sensitiveness
Focuses on feelings of personal inadequacy and inferiority, particularly in comparison to other 
individuals e.g. your feelings being easily hurt, feeling that people are unfriendly or dislike you, and 
feeling very self conscious with others.
Depression
Feelings of hopelessness and other cognitive somatic correlates of depression e.g. thoughts of 
ending your life, feeling lonely, having no interest in things, feeling worthlessness and hopeless 
about the future.
Anxiety
Behaviours usually associated with high manifest anxiety e.g. nervous or shakiness inside, suddenly 
scared for no reason, feeling tense or keyed up and spells of terror or panic.
Anger/hostility
Anger and hostile behaviour act under the 3 categories; thoughts, feelings and action. E.g. feeling 
easily annoyed or irritated, temper outbursts are uncontrollable, having urges to beat, injure or harm 
someone, and to break or smash things and getting into frequent arguments.
Phobic Anxiety
Consists of fears of a phobic nature orientated towards travel in open spaces, crowds or public 
places and conveyances represented by this dimension. E.g. feeling afraid of open spaces or on the 
street, feeling afraid to travel on buses, subways or trains, having to avoid certain things, places or 
activities because they frighten you, feeling uneasy in crowds and feeling nervous when left alone.
Paranoid ideation
Paranoid phenomena are most effectively conceived as thinking, primary characteristics of paranoid 
thought e.g. feeling others are to blame for most of your troubles, feeling that most people cannot 
be trusted and feeling that you are watched or talked about by others.
Psychoticism
APPENDIX L
Behaviours and thoughts which form broad spectrum psychotic behaviour including, the idea that 
someone else can control your thoughts, feeling lonely even when you are with people, the idea that 
you should be punished for your sins, the idea that something is wrong with your mind.
Negative psychophysiology
Include items such as poor appetite, trouble falling asleep and overeating. 
MDMA side effects
Consists of subjective side effects repeatedly reported by ecstasy users e.g. feeling rash or 
impulsive, craving for chocolate, difficulties in planning things, mid-week blues, having mood 
swings.
Sexual functioning
Focuses on changes in sexual desire and performance e.g. decreased sexual desire, premature 
orgasm, delayed orgasm, and other physical problems with sex (impotence, genital problems).
Cognitive failures
Allows for subjective assessment of everyday cognitive performance e.g. forgetting to do 
something, feeling easily distracted, forgetting where something had been left.
Feeling content with life
Feeling interested in things 
Feeling satisfied with my life 
Feeling in good spirits 
Feeling creative
Feeling confident about the future 
Feeling it's wonderful to be alive
Mood State
Feelings associated with positive and elevated mood e.g. quick wittedness, attentiveness, feeling 
happy, tranquil and relaxed.
Sociability
Behaviour and feelings associated with the ability to socialise effectively with others e.g. feeling 
comfortable with others, having a good time with friends, having trust in other people, and feeling 
liked and being close to others.
Psychobiology
Includes positive psychobiological behaviours, thoughts and feelings e.g. sleeping well, having a 
good appetite, feeling healthy and proficient, feeling good about your body and feeling full of 
energy.
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Psychiatric disorders in Ecstasy (MDMA) users: a literature 
review focusing on personal predisposition and drug history
K. Soar*, J. J. D. Turner and A. C. Parrott
Department of Psychology, University of East London, London, UK
3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) has been implicated in the onset of a number of psychological 
disorders and associated with a number of psychiatric symptoms that have persisted after cessation of the drug. This paper is 
a review of the published psychiatric case studies from the last 10 years involving MDMA. Only 24% of patients had a 
previous psychiatric history and 34% had a psychiatric illness amongst first degree relatives. The percentage of patients 
not having had a personal or family history of psychiatric illness and the temporal relationship between MDMA 
ingestion and the experience of recurring symptoms strongly suggest a causal relationship between the drug and neuro- 
psychiatric manifestations. Further supporting evidence comes from several studies using non-clinical samples. 
Ecstasy users that don't present themselves in healthcare settings as having clinical symptoms have significantly 
higher scores on certain subscales of the SCL-90 compared with Ecstasy-naive controls, with higher pathology 
scores in heavier Ecstasy users. The full-blown psychiatric cases may represent the broad end of this problematic spectrum. 
Copyright £ 2001 John Wiley & Sons, Ltd.
KEY WORDS — Ecstasy; psychopathology; problematic; recreational; polydrug
INTRODUCTION
3,4-methylenedioxymethampethamine (MDMA or 
Ecstasy) is a popular recreational drug, due to the 
easily controllable emotional state it gives. MDMA 
has been associated with a number of psychological 
disorders and psychiatric symptoms, which often per­ 
sist after cessation of the drug; these include panic 
attacks (Whitaker-Azmitia and Aronson, 1989), 
depression (Cohen, 1996), flashbacks (Creighton 
et al., 1991), psychosis (Vaiva et al., 2001), paranoid 
ideation (McGuire and Fahy, 1991) and suicidal 
ideation (Benazzi and Mazzoli, 1991). The fact that 
MDMA is a prominent feature in many reported 
adverse psychiatric cases suggests that MDMA's 
pharmacological properties play a role in the develop­ 
ment of such disorders. The question arises whether 
there is a causal link between Ecstasy use and the
* Correspondence to: K. Soar, Department of Psychology, Uni­ 
versity of East London, Romford Road, London E15 4LZ, UK. Tel: 
+ 44-20-82234556. Fax: +44-20-82234937. 
E-mail: k.soar@uel.ac.uk
Copyright 0 2001 John Wiley & Sons, Ltd.
development of psychiatric disorders or whether 
MDMA exacerbates a predisposed neurological con­ 
dition in individuals. This paper attempts to address 
this question by reviewing all published psychiatric 
cases from the last 10 years where MDMA has been 
the prominent feature and looking at further new 
evidence of clinical symptoms in a non-psychiatric 
population.
PSYCHIATRIC CASES
Numerous case studies where psychiatric symptoms 
have developed where MDMA use has been a promi­ 
nent feature are summarised in Table 1. The adverse 
symptoms, which vary in nature and intensity, are 
most in behavioural domains that are putatively influ­ 
enced by brain serotonin. Of these cases 29% involve 
psychotic symptoms, 26% anxiety and panic attacks, 
26% delusions, hallucinations or visual illusions and a 
further 16% involve some form of depression. The 
varying persistency of the psychiatric disorders sug­ 
gests that Ecstasy can cause long-term neurotoxicity, 
with symptoms evident long after Ecstasy use has been
Accepted 3 October 2001
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discontinued (Cohen, 1996; McCann and Ricaurte, chiatric disturbances prior to MDMA use. The high
1992; Schifano, 1991; Windhaber, et al., 1998). percentage of patients who do not have a personal
It is difficult to draw any conclusions comparing and family history of mental illness and the temporal
Ecstasy use amongst these individuals, due to lack relationship between MDMA ingestion and the
of documentation, but the amounts recorded vary experience of recurring symptoms after additional
greatly from 0.25 tablets (Williams et al., 1993) up Ecstasy consumption strongly suggest a cause and
to 10 tablets per night (McGuire and Fahy, 1991). effect relation in most of the reported cases. 
The duration of usage also varies extensively, from
just the one occasion (Cohen, 1996; Teggin, 1992; NON poYrHTATRTr PASFS Cohen and Cocores 1997; Vaiva et al, 2001; Spatt NON-pSYCHIA™c CASES 
et al., 1997) to 6 years (McGuire and Fahy, 1991). Ecstasy-related psychopathology has not only been 
The majority of patients appear to be male (75%), shown in a clinical population. Recent research sug- 
yet this may reflect the general pattern of drug usage, gests that there may be other Ecstasy users who 
Attention should be drawn to the interpretative dif- experience milder psychiatric disturbances but who 
faculties of these case studies. The anecdotal nature of do not contact health professionals. There is a growing 
case reports makes it difficult to determine the risk to body of evidence for this in studies of recreational 
the average recreational user. There is the suggestion users who don't present themselves to clinicians, gen- 
that the basis of the disorder already existed before eral practitioners or drug services with clinical symp- 
Ecstasy use occurred, since poor premorbid adjust- toms, yet who have significantly higher scores on a 
ment is associated with increased drug use. The mean revised version of the SCL-90 (self-rating clinical 
age of the sample (24 years) is in the age range when symptom questionnaire) than Ecstasy-naive controls, 
the first episode of psychiatric illness is likely to The revised version of the SCL-90 includes 30 extra 
occur. It could also be possible that a genetic predis- questions on various positive moods and life experi- 
position for a neuropsychiatric illness may exist in ences, together with an 'Ecstasy side effects' factor, 
these individuals or that a personal history of psychia- Parrott et al. (2000b) surveyed a group of young 
trie problems increases their likelihood of the devel- people from a small town near Cork, Ireland. All 
opment of Ecstasy-induced disorders. A review of volunteers completed a questionnaire on past drug 
13 case reports by McGuire et al. (1994) reported that use and the SCL-90. Heavy Ecstasy users reported 
a psychiatric illness had occurred among first-degree significantly higher scores on several dimensions of 
relatives of approximately 50% of patients. However, the SCL-90 than the non-Ecstasy users. These 
the current review found that only 24% of patients had included somatisation, obsessionality, anxiety, hosti- 
a previously diagnosed psychiatric illness and that lity, phobic anxiety, paranoid ideation, psychoticism 
only 34% had a family psychiatric history. and appetite. Similar results were found in a large- 
Additional evidence suggesting a relationship scale survey of 768 volunteers from Italy and the 
between Ecstasy use per se and psychiatric problems UK (Parrott et al, 2000a). Using the UEL drug ques- 
are the studies by Series et al. (1994), McGuire et al tionnaire, the researchers placed participants in one of 
(1994) and Milas (2000). They present cases where a six groups, depending on their past drug use: non-drug 
reoccurrence of symptoms occurred after further users; alcohol and tobacco users; cannabis, alcohol 
Ecstasy use. In addition, Creighton et al (1991) and tobacco users; illicit polydrug users, but not of 
reported a patient who was free of psychiatric symp- Ecstasy; light Ecstasy polydrug users; and heavy 
toms for 8 months, but after taking a further 4 doses of Ecstasy (20 + tablets) polydrug users. All participants 
Ecstasy the psychological symptoms returned. The completed the modified version of the SCL-90. There 
individual reported by Cassidy and Ballard were significant differences between non-drug users 
(1994) stated that there was a close relationship and Ecstacy polydrug users on the somatisation, 
between symptom improvement and Ecstasy cessa- obsessive-compulsive, anxiety, anger/hostility, phobic 
tion. Additional support comes from a large-scale anxiety, psychoticism and MDMA side effect scales, 
clinical survey (Schifano et al, 1998), where the The highest pathology scores were found in the heavy 
longer-term polydrug users, who had consumed an Ecstasy polydrug users and to a lesser extent in the 
average of 43 Ecstasy tablets, were found to be at a light Ecstasy polydrug users.
considerably higher risk of developing a psychopatho- It should be emphasised that in these studies 
logical disorder than the patients who took smaller polydrug use was a general characteristic of Ecstasy 
amounts (average = 3). Most importantly, these use. The heavier the Ecstasy use, the heavier the poly- 
patients specifically denied the presence of these psy- drug use. Symptom profiles were similar among the
Copyright © 2001 John Wiley & Sons, Ltd. Hum Psychopharmacol Clin Exp 2001; 16: 641-645.
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polydrug users who hadn't taken Ecstasy, thus the dextromethorpan (DXM), which in high doses can
high pathology scores for the heavy Ecstasy users cause serious adverse reactions, including phencycli-
could simply be a profile of polydrug use in general, dine-like psychosis (Dodds and Reval, 1967). Finally,
Support for this comes from a study by Fox et al. as already mentioned, it is difficult to determine
(2001), which reported that psychological symptoms which, if any, of the previously used drugs are respon-
in such individuals were unrelated to Ecstasy use. This sible for the manifestation of the symptoms, since
study examined the differences between 'self-reported Ecstasy users are almost always polydrug users,
problem' (psychological, emotional and somatic pro- Despite the discrepancies in the research non-
blems) and 'non-problem' Ecstasy users in relation to clinical populations, there is still evidence that
both consumption and premorbid life adjustment vari- MDMA use is significantly related to psychiatric
ables. The problem Ecstasy group had significantly symptoms. Many of the reported symptoms are paral-
higher scores on all scales of the SCL-90, yet lei to the disorders presented in the case studies. It
their self-perceived problematic use was related not may be that in the individual clinical cases the
to their drug use but to negative interpersonal relation- patients' symptoms developed to such an extent that
ships prior to taking the drug and less socially orien- they sought professional help, and thus they are at
tated motivations for using the drug. However, this the broad end of the problematic spectrum, 
study used a relatively small sample of Ecstasy users.
Milani et al. (2000) showed there was a significant fOKrfj TJSTON 
positive correlation between the amount of Ecstasy
pills consumed by polydrug users and their scores Given that the total number of people in Britain who
on the anxiety, phobic anxiety and psychoticism have tried Ecstasy is approximately 5 million, if
scales. Furthermore, in a study by Milani et al. Ecstasy were directly responsible for causing psychia-
(2001) of 234 Ecstasy polydrug users, 'problematic' trie symptoms a greater number of reported psychia-
users had higher pathology scores on several sub- trie cases would be expected. With adverse individual
scales of the SCL-90, compared with the 'non-proble- cases it is more likely that the individual has a
made' users. But their perceived problems were pre-existing vulnerability to psychiatric disturbances
related to the greater lifetime consumption of Ecstasy or low serotonin levels prior to Ecstasy consumption,
and the number of pills taken in a single occasion. However, this review shows that there is some evi-
This suggests that there may certainly be an associa- dence that MDMA may cause psychopathology in
tion between Ecstasy use and psychopathological recreational users. This evidence comes from the
symptoms. What needs to be addressed is whether reports of psychiatric disorders among individuals
the SCL-90 scores of these individuals lie within the who have consumed large quantities of Ecstasy
clinical range. (McGuire and Fahy, 1991; Creighton et al., 1991)
Caution should be taken when interpreting the and from reports of psychological symptoms in
results of these studies, because a number of methodo- Ecstasy users that have not manifested to such a
logical issues need to be addressed. These include degree that they seek professional help,
inadequate sampling techniques through self-referral. The suggestion that the intensity of dosing of
The different sample sizes of the studies also leads to Ecstasy is crucial in the development of psychopathol-
inconsistencies, with small sample sizes having lesser ogy has also been made. Individuals who have taken a
statistical power, which is the case in most MDMA- larger number of MDMA tablets have a higher risk of
related research. Data were reliant on subjective developing psychiatric disorders (Milani et al., 2000;
reports in both the drug use and SCL-90 responses, Schifano et al, 1998) and are more likely to report
which may contain inaccuracies. There is also the having been inpatients (Hammersley et al., 1999).
uncertainty of the pharmacological constituents of Attention should be drawn to the fact that more
the Ecstasy tablets: numerous reports suggest varying often than not recreational Ecstasy users take other
levels of MDMA or related compounds in Ecstasy drugs, such as cannabis, psychostimulants and hallu-
tablets, with some tablets containing other active cinogens. Polydrug use itself may lead to different
ingredients (caffeine, amphetamine) and some con- types of psychobiological problems. Milani et al.
taining none at all (Curran, 2000). Chemical analysis (2000) found a correlation between other drug use
of street Ecstasy has shown that tablets are unlikely to and pathology scores, and Parrott et al. (2000a)
be pure MDMA. Baggott et al. (2000) identified the showed that heavy Ecstasy polydrug users have the
most common drug other than MDMA in highest pathology scores. Because of these constraints
street-bought Ecstasy tablets as the antitussive it may be beneficial to assess the consequences of
Copyright (O 2001 John Wiley & Sons, Ltd. Hum Psychopharmacol Clin Exp 2001; 16: 641-645.
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Ecstasy use within the wider context of recreational 
drug use as a whole.
Ideally a prospective study should be done that 
combines detailed psychiatric and psychological 
assessments with functional neuroimaging techni­ 
ques, to clarify the relationship between the intensity 
of Ecstasy dosing and the resulting psychological 
effects. However, the illegality of Ecstasy use and 
ethical constraints mean that such a study is unlikely.
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PERSISTENT NEUROPSYCHOLOGICAL PROBLEMS AFTER
7 YEARS OF ABSTINENCE FROM RECREATIONAL
ECSTASY (MDMA): A CASE STUDY 1
K. SOAR A C PARROTT H. C. FOX
School, of Psychology Department of Psychology Psychiatry Department University of East London University of Wain Swansea Yalr University
Summary. — This case study concerns a 26 yr.-old male who had consumed i amounts of Ecsrasy seven years previously. He stated that his increasingly intensive use of ecstasy over a 4-yr. period had led to the emergence of multiple psychiatric and psychological problems. Given these problems, he stopped using Ecstasy, but the problems had not resolved despite seven years of abstinence. The neurocognitive pro­ file was very similar to that shown by current heavy Ecstasy users, with deficits in immediate and delayed verbal recall, moderately impaired memory function, but nor mal expressive language ability and perceptual functioning. Extremely high pathology was evident, including depression and phobic anxiety. Severe problems \virh sleep and sex were also reported. Further studies involving larger groups of abstinent former us­ ers are needed; adverse sequelae associated with intensive Ecstasy use may sometimes be enduring.
The recreational use of Ecstasy (MDMA, 3,4-Methylenedioxymetham- phetamine) is associated with a range of psychobiological deficits, including phobic anxiety, impulsivity, depression, psychosis, hostility/aggression, and disorders of sleep (Morgan, 1998; Schifano, De Furia, Forza, Minicuci, & Bricolc, 1998; McGuire, 2000; Parrott, Sisk, & Turner, 2000; Parrott, Milani, Parmar, & Turner, 2001; Soar, Turner, & Parrott, 2001). In neuro­ cognitive terms, deficits in working memory (Wareing, Fisk, & Murphy, 2000; Verkes, Gilsman, Pieters, Schoemaker, Visser, Kuilpers, Pennings, Bruin, Wijngaart, Van Gerven, & Cohen, 2001), episodic memory (Morgan, 1999; Rodgers, 2000), prospective memory (Heffernan, Jarvis, Rodgers, Scho- ley, & Ling, 2001;, and higher executive functioning (Fox, Parrott, & Tur­ ner, 200 Ib; Morgan, McFie, Fleetwood, & Robinson, 2002), have all been re­
ported.
Despite the empirical evidence for neuropsychological problems in rec­ reational users, there has been very little research into whether these deficits remain after abstinence from Ecstasy. Tentative evidence for the persistence of deficits on some aspects of central executive functioning and measures of anxiety has been shown by Wareing, et al. (2000). Morgan, et al. (2002) found that selective cognitive impairments remained after an average of two
'Address correspondence to Kirstie Soar, Department of Psychology, Unisc-rsity of East Lon­ don, Romford Road, l^ndon E15 4LZ, UK or e-mail lk.soar@uel.ac.uk).
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years of abstinence. Evidence for the persistence of depression after an aver­ 
age of 6 mo. of abstinence has also been shown (Machines, Handley, & Har 
ding, 2001). However, we are not aware of any published studies involving a 
longer period of cessation,
CASE STUDY
This paper describes an individual case study (RW) who contacted the 
Recreational Drugs Research Group at the University of East London. He 
described himself as having severe psychobiological problems, which he at­ 
tributed to past Ecstasy use. RW was a 26-yr.-old Caucasian male, who stated 
that he had no history of a closed head injury or psychiatric illness prior to 
his Ecstasy use, although there was a history of anxiety and depression 
amongst first-degree relatives. Between 1991 and 1994, RW reported that he 
had taken around 750 Ecstasy tablets. Initially he took 1-2 tablets on each 
occasion, but this increased to an average of 10 per night, whilst on some 
evenings he would take 25 tablets, stating ''. ,. they were like sweeties (can­ 
dy), I just kept popping them in my mouth one after the other. ...' He stared 
that he felt he needed to take Ecstasy and reported being dependent I Fan- 
sen, 1999) and addicted ro the drug despite not suffering if he went some 
time without taking it. During this 3-yr, period he also reported taking am­ 
phetamine (10 occasionsi, cocaine (25), crack cocaine (6). d-tysergic acid di- 
ethylamide (35), solvents (20), nitrates/poppers <20) and cannabis on a daily 
basis and for a year after the onset of these psychological symptoms.
Over the three years of increasingly intensive Ecstasy use he developed 
escalating problems including depression, suicidal thoughts, visual illusions, 
panic attacks, social phobia, sexual impotence, and severe sleeping prob­ 
lems, which he directly attributed to Ecstasy. Their increasing severity led 
him to cease taking Ecstasy but with no alleviation of these symptoms. He 
therefore approached his local physician, sought advice from a drug clinic, 
and was assessed by a clinical psychologist and a psychiatrist. He was diag­ 
nosed with a constellation of psychiatric disorders including anxiety, depres­ 
sion, phobia disorder, and panic attacks, which were related to his drug de­ 
pendency. Various medications were tried, including fluoxetine, tripfluoper- 
azine (still a current daily medication of 15 mg) and diazepam (used inter­ 
mittently); these latter drugs partially relieved some symptoms, although 
mostly they have remained. Currently, he consumed 18 units 2 of alcohol per 
week and smoked on average 30 cigarettes a day.
FINDINGS 
RW exhibited elevated psychopathological scores on all dimensions of
2A unit of alcohol is 8 grams by weight or lcl/10 ml by \olume, of pure alcohol.
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the Brief Symptom Inventory compared to normal controls, psychiatric in- 
patients, and psychiatric outpatients (Derogatis & Melisaratos, 1983). R\X"s 
psychopathology is consistent with his self-reported depression, suicidal 
thoughts, panic attacks, social phobia, sexual impotence, and sleeping prob­ 
lems (and also apparently with his previous psychiatric reports; however, we 
have no record of these). These high scores were also consistent with previ­ 
ous empirical research findings of elevated psychiatric symptoms on the 
SCL-90, an outpatient psychiatric symptom checklist (Parrott, el at., 2000, 
2001; Dughiero, Schifano, & Forza, 2001; Morgan, et al., 2002).
Cognitively, RW demonstrated poor immediate recall on the Auditory 
Verbal Learning Task compared to normative data (Rey, 1964 > and impair­ 
ments on the Rivermead Behavioural Memory Test on which his total mem­ 
ory score (16) indicated moderately impaired memory function, specifically, 
poor face recognition and borderline performances on immediate article re­ 
call and message delivery (Wilson, Cockbum, Baddeley, & Hiorns, 1991). 
Executive functioning was also assessed using a manual version of the Tower 
of London (Shallice, 1982). The Tower of London planning and solution 
times were compared with data from an earlier study, which used an identi­ 
cal testing procedure. RW exhibited longer planning and solution times for 
all 12 trials, compared to non-Ecstasy controls, a profile of deficits similar to 
those displayed by current heavy Ecstasy users (Fox, et al., 2001b).
DISCUSSION
The ncurocognitive profile, in this case, mirrors the pattern of selective 
impairments exhibited by current Ecstasy-polydrug users, where significant 
deficits in immediate and delayed verbal recall and executive functioning are 
often demonstrated (Fox, Parrott, & Turner, 2001a; Fox, et al., 2001b; Par- 
rott, 2001; Morgan, et al., 2002). Furthermore, RWs neuropsychological 
profile is very similar to that of a group of former Ecstasy users who had 
been abstinent on average two years but still exhibited significantly impaired 
recall on the Rivermead Behavioural Memory test and committed significant­ 
ly more errors in executive functioning, compared to polydrug-usmg con­ 
trols (Morgan, el al., 2002). The elevated psychopatholgy demonstrated by 
RW was also consistent with raised psychiatric profiles demonstrated by cur­ 
rent Ecstasy-polydrug users (Parrott, et al., 2001) and the heightened depres­ 
sion scores of former Ecstasy users (Machines, et al., 2001). These similar 
patterns of neurocognitive deficits and psychobiological problems lend sup­ 
port to the notion that RWs problems are a reflection of intensive past Ec­ 
stasy use. Three similar case studies of severe psychobiological problems in 
very intensive Ecstasy users have been described by Jansen (1999).
Causality between RWs past Ecstasy use and his current neuropsycho­ 
logical status cannot be directly determined, given the design limitation of
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this case study. There is reliance on self-reported data. Also, there are no 
objective measures of neuropsychological status, either prior to, during or di­ 
rectly after the crucial period of intensive Ecstasy usage. RW may also have 
had some premorbid neuropsychological deficits or personality dispositions 
which led him to heavy drug use, or there was some form of cornorbidity. 
Self-reported drug .history is also unverifiable. both in quantity consumed 
and the length of abstinence from drugs, if at all. There is also the poten­ 
tially confounding factor of other psychoactive drug use, both of illicit recrea­ 
tional drugs and of psydhotherapeutic medications. These may have contrib­ 
uted to the neurocognitive and psychiatric symptom profiles (Parrott, et al., 
2001; Curran, 2002: Morgan, et al, 2002).
In light of preliminary observations made in this case study, \\ e argue 
the need for studies where better methodological control could be obtained. 
Larger groups of former users would allow the influence of other psychoac­ 
tive drug use to be statistically assessed. Prospective studies should also be 
undertaken among drug users, when Ecstasy and other drug use could be 
recorded using detailed drug diaries and verified using hair analysis, along 
with objective psychiatric and personality assessment. Such studies could 
answer not only questions about psychoactive drug effects, but also the lon­ 
gevity of neuropsychological effects, independent of premorbid psychiatric 
or personality dispositions.
Important topics for research are the intensity of Ecstasy use and the 
patterns of neurocognitive recovery of time. These factors may all be related. 
Thus, light or intermittent Ecstasy use may lead to minimal drug-related 
problems (Fox, et al., 2001b; Parrott, 2001), whereas intensive Ecstasy usage 
may lead to the most severe problems while on the drug (Jansen, 1999), fol­ 
lowed by minimal recovery afterwards—as illustrated by this case study.
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APPENDIX R
University of 
East London
Participate in Research
complete a psychological 
questionnaire
Contact: Kirstie Soar
GN107
k.soar@uel.ac.uk
x4082
APPENDIX S
UNIVERSITY OF EAST LONDON
APPLICATION FOR APPROVAL OF AN EXPERIMENTAL PROGRAMME INVOLVING HUMAN
SUBJECTS
Please read the Notes for Guidance before completing this form. If necessary, please continue your answers on a 
separate sheet of paper: indicate clearly which question the continuation sheet relates to and ensure that it is 
securely fastened to the application form.
1. Title of the programme:
Long term psychological effects of recreational ecstasy/MDMA use
2. Name of person responsible for the programme: Prof. Andy Parrott 
Status: Reader in Psychology
3. Faculty: Science & Health Department/Unit: Psychology
4. Level of the programme (delete as appropriate):
(a) undergraduate basic
(b) undergraduate project
(c) postgraduate
(d) post-doctoral or staff
5. Number of:
(a) experimenters (approximately): One
(b) subjects (approximately): Sixty
6. Nature of experimenters (delete as appropriate):
(a) staff (b) students (c) others 
If "others" please give full details:
Post graduate Researcher
7. Nature of subjects (general characteristics, e.g. University students, primary school children, etc):
Young people aged 18+ years.
8. Probable duration of the programme: 1 year
from (starting date): April 2001 to (finishing date): April 2002
APPENDIX S
9. Aims of the programme including any hypothesis to be tested:
The study attempts to assess the psychobiological functioning of recreational ecstasy users who complain of 
problems, which that attribute to ecstasy use. There have been numerous reports of individuals that have developed 
chronic problems after the consumption of ecstasy. However, these papers only look at individual cases and don't 
assess the subjects psychiatric history, drug use history and cognitive abilities compared to heavy MDMA users 
who don't complain of problems. This study aims to assess these factors and try's to establish why certain 
individuals develop these problems whilst other heavy MDMA users seem to be void of them. Deficits on selective 
memory and executive functioning tests have been shown in MDMA users. Similar tests will be used to assess 
whether those that report problems have greater deficits in these tasks compared to heavy users with no reported 
problems. This may help to establish whether potential deficits occur as a function of problematic ecstasy use. 
Psychiatric histories and SCL-90 scores will also be compared to assess whether there are certain vulnerability 
factors in developing problems from ecstasy use or whether there a just certain individuals that seek help rather 
than others who are presented with problems but just 'suffer in silence'.
10. Description of the procedures to be used (give sufficient detail for the Committee to be clear 
about what is involved in the programme). Please append to the application form copies of any 
instructional leaflets, letters, questionnaires, forms or other documents which will be issued to 
the subjects:
All participants will be tested individually in a room within the psychology department in the Science and Health 
faculty or in a counselling room at local drug advice centres. Prior to the investigation, all participants will be 
informed of the aims and ethical considerations of the research and requested to sign a consent form (see appendix 1). 
The participant will then be seated at a table in order to fill out a personal history questionnaire and a drug portfolio 
questionnaire (see appendix 2); the NART will then be administered as a general measure of intellectual ability and to 
ensure participants have an adequate knowledge of English. All responses will be taped. The participant will then be 
administered the SCL-90 followed by number of cognitive tasks to complete:
Adult Verbal Learning Test (AVLT): which involves several lists of words being read aloud in order for each 
participant to recall them both immediately and following a period of delay. Again all response will be recorded.
Rivermead Behavioural Memory Test Battery: a highly standardised neurological assessment battery that involves a 
series of short sub-tests used to measure participants" everyday memory. Comprises of paper and pencil tasks.
Tower of London Test (TOP: This task assesses participants planning ability. Participants are requested to move a 
number of coloured balls from a start position to a goal position in a minimal number of moves.
Reaction Time test (RT): A measure of participants processing speed.
Following the completion of these tasks, participants will be asked to expand on three or four answers given in the 
drug history questionnaire. All responses will be recorded. On completion, participants will be debriefed and time is 
given for participants to answer any questions.
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11. Are there potential hazards to the subject(s) in these procedures? \ES/NO 
If yes: (a) what is the nature of the hazard(s)?
(b) what precautions will be taken?
12. Is medical care or after care necessary? YES/M? 
If yes, what provision has been made for this?
13. May these procedures cause discomfort or distress? YES//V0 
If yes, give details including likely duration:
14. (a) Will there be administration of drugs (including alcohol)? YES/M? 
If yes, give details:
(b) Where the procedures involve potential hazards and/or discomfort or distress, please state 
what previous experience you have had in conducting this type of research:
15. (a) How will the subjects' consent be obtained?
Prior to the investigation, the aims and objectives of the study will be explained verbally and in writing. An assigned 
consent form will then be required before procedures are to continue.
(b) What will the subjects be told as to the nature of the experiment?
The nature of the investigation will be fully described, prior to administration.
APPENDIX S
16. (a) Will the subjects be paid? YES/NO
(b) If yes, please give the amount: £ 10.00
(c) If yes, please give full details of the reason for the payment and how the amount given in 16 (a) 
above has been calculated (i.e. what expenses and tune lost is it intended to cover):
Payment is given to reimburse participants for their time and to cover any travel expenses.
17. Are the services of the University Health Service likely to be required during or YES/NO 
after the programme?
If yes, give details:
18. (a) Where will the experiments take place?
In a counselling room/psychology laboratory at the Science and Health faculty, The Green
(b) What equipment (if any) will be used?
A laptop computer containing the Reaction time test, a stopwatch and a small tape recorder.
(c) If equipment is being used is there any risk of accident or injury? If so, what precautions are being 
taken to ensure that should any untoward event happen adequate aid can be given
N/A
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19. Are personal data to be obtained from any of the subjects? YES/NO 
If yes, (a) give details:
Detailed personal history and portfolio of drug use will be obtained. This will include family history of psychiatric 
conditions; subjective reports of any drug induced problems participants feel they have encountered and when these 
occurred. It will also include details of types of drugs taken, quantity of drugs taken and patterns of usage.
(b) state what steps will be taken to protect the confidentiality of the data?
Participants will be allotted a drug sub-code, which will be placed on any paper work containing sensitive data. 
Confidentiality will be ensured to participants and they will be informed that they are under no obligation to give their 
name. They are informed, that the signing of the consent form in no way defines them as either a drug user or non- 
drug user and they are also informed that drug status will not be accessible.
(c) state what will happen to the data once the experimental programme has been 
completed and the results written-up. If the data is to be destroyed how will this be 
done? How will you ensure that the data will be disposed of in such a way that there is 
no risk of its confidentiality being compromised?
All detailed questionnaires and result data will be shredded. Tape recordings will be destroyed. Any other personal 
information will be kept on a computer system with restricted access; by the experimenter only.
20. Will any part of the experimental programme take place in premises outside the YES/NO 
University or will any members of the experimental team be external to the 
University?
If yes, please give full details of the extent to which the participating institution will indemnify the 
experimenters against the consequences of any untoward event:
21. Are there any other matters or details which you consider relevant to the consideration of this 
proposal? If so, please elaborate below:
APPENDIX S
22. DECLARATION
I undertake to abide by accepted ethical principles and appropriate code(s) of practice in carrying out 
this programme.
Personal data will be treated in the strictest confidence and not passed on to others without the written 
consent of the subject.
The nature of the investigation and any possible risks will be fully explained to intending subjects, and 
they will be informed that:
(a) they are in no way obliged to volunteer if there is any personal reason (which they are 
under no obligation to divulge) why they should not participate in the programme; and
(b) they may withdraw from the programme at any time, without disadvantage to 
themselves and without being obliged to give any reason.
NAME OF APPLICANT: Signed: _________________ 
(Person responsible)
Date:
NAME OF HEAD OF DEPARTMENT: Signed:
Date:
UNIVERSITY OF EAST LONDON 
MEMORANDUM
From:
Dept:
Email:
To:
Dept:
Date: 
Subject:
Mrs Sue Green
Quality Assurance, Barking Campus
BKSTAFF1/GREEN2
Professor A C Parrott
Psychology 
The Green
QUALITY
ASSURANCE
16 February 2001 Ref: SLG/ETH/99/83/Soar
University Ethics Committee: Approval of an experimental 
programme involving human subjects: Long term effects of 
recreational ecstasy/MDMA use
cc:
I advise that Members of the University Ethics Committee have now 
approved the above application on the terms previously advised to you, so I 
now write to give formal confirmation of this approval.
Sue Green
fuH'app.mem
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UNIVERSITY OF EAST LONDON
APPLICATION FOR APPROVAL OF AN EXPERIMENTAL PROGRAMME INVOLVING HUMAN
SUBJECTS
Please read the Notes for Guidance before completing this form. If necessary, please continue your answers on a 
separate sheet of paper: indicate clearly which question the continuation sheet relates to and ensure that it is 
securely fastened to the application form.
1. Title of the programme:
Persistent Neuropsychological effects of 'ecstasy' (MDMA), in recreational users.
2. Name of person responsible for the programme: Prof. Andy Parrott 
Status: Reader in Psychology
3. Faculty: Science & Health Department/Unit: Psychology
4. Level of the programme (delete as appropriate):
(a) undergraduate basic
(b) undergraduate project
(c) postgraduate
(d) post-doctoral or staff
5. Number of:
(a) experimenters (approximately): one
(b) subjects (approximately): 45
6. Nature of experimenters (delete as appropriate):
(a) staff (b) students (c) others
If "others" please give full details:
Post graduate Researcher
7. Nature of subjects (general characteristics, e.g. University students, primary school children, etc):
Young people over the age of 18
8. Probable duration of the programme: 3 months
from (starting date): May 2001 (finishing date): Sept 2001
APPENDIX T
9. Aims of the programme including any hypothesis to be tested:
This study attempts to assess the persistent effects of MDMA neurotoxicity and its functional sequel in recreational 
ecstasy users and ex-users. It has been repeatedly shown in animals and now documented in human studies that 
MDMA is a highly selective serotonin neurotoxin. These neurodegenerative effects are long lasting, however recovery 
has been shown in brain areas of some animals. The functional consequence of serotonin neurotoxicity in humans is 
thought to be associated with subtle but significant cognitive deficits, as measured by neuropsychological tests and 
possible psychiatric symptoms. Deficits on selective memory and executive functioning tests have been shown in 
MDMA users along with significant scores on a clinical symptom self-reporting questionnaire. This study aims to test 
whether serotonin recovery occurs in humans as shown in animals, by assessing participant's abilities on certain 
neuropsychological tests. Selective memory tests and executive planning tests will be used to assess whether ex-users 
of ecstasy have a recovery in their ability to complete these tasks compared to current users. SCL-90 scores will also 
be recorded to assess whether ecstasy users exhibit psychiatric symptoms compared to ecstasy naive subjects and 
whether these are persistent symptoms by comparing them with ex-users SCL-90 scores.
10. Description of the procedures to be used (give sufficient detail for the Committee to be clear 
about what is involved in the programme). Please append to the application form copies of any 
instructional leaflets, letters, questionnaires, forms or other documents which will be issued to 
the subjects:
The participant will be tested within the Psychology department in the Science and Health faculty. Prior to the 
investigation, the participants will be informed of the aims and ethical considerations of the study and requested to 
sign a consent form (see appendix 1). The participant will then be seated at a table in order to fill out a personal 
history questionnaire and drug portfolio questionnaire (appendix 2); the NART will then be administered as a general 
measure of intellectual ability. The participant will then be administered the SCL-90 followed by a number of 
cognitive tasks to complete:
Prospective memory tasks: taken from the Rivermead Behavioural Memory test. It involves the participant 
remembering a previously hidden belonging and also to remember to ask for an appointment on the cue of an alarm.
Immediate and delayed memory task: taken from the Rivermead Behavioural Memory Test, which involves a story 
being read aloud in order for the participant to recall it both immediately and following a period of delay.
Reaction Time test (RT): A measure of participants processing speed.
Tower of London Test (TOD: This task assesses the participants planning ability. The participant is requested to 
move a number of coloured balls from a start position to a goal position in a minimal number of moves.
All responses to the NART and cognitive tasks will be tape-recorded. All responses will be recorded. On 
completion, the participants will be debriefed and time is given for him/her to ask any questions.
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11. Are there potential hazards to the subject(s) in these procedures? YES/NO 
If yes: (a) what is the nature of the hazard(s)?
(b) what precautions will be taken?
12. Is medical care or after care necessary? YES/NO 
If yes, what provision has been made for this?
13. May these procedures cause discomfort or distress? YES/NO 
If yes, give details including likely duration:
14. (a) Will there be administration of drugs (including alcohol)? YES/M? 
If yes, give details:
(b) Where the procedures involve potential hazards and/or discomfort or distress, please state 
what previous experience you have had in conducting this type of research:
15. (a) How will the subjects' consent be obtained?
Prior to the investigation, the aims and objectives of the study will be explained verbally and in writing. An assigned 
consent form will then be required before procedures are to continue.
(b) What will the subjects be told as to the nature of the experiment?
The nature of the investigation will be fully described, prior to administration.
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16. (a) Will the subjects be paid? YES/NO
(b) If yes, please give the amount: £
(c) If yes, please give full details of the reason for the payment and how the amount given in 16 (a) 
above has been calculated (i.e. what expenses and tune lost is it intended to cover):
17. Are the services of the University Health Service likely to be required during or YES/M? 
after the programme?
If yes, give details:
18. (a) Where will the experiments take place?
In a counselling room/psychology laboratory at the Science and Health faculty, The Green
(b) What equipment (if any) will be used?
A laptop computer containing the Reaction time test, a stopwatch and a small tape recorder.
(c) If equipment is being used is there any risk of accident or injury? If so, what precautions are being 
taken to ensure that should any untoward event happen adequate aid can be given
N/A
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19. Are personal data to be obtained from any of the subjects? YES/NO 
If yes, (a) give details:
Detailed personal history and portfolio of drug use will be obtained. This will include family history of psychiatric 
conditions; subjective reports of any drug induced problems participants feel they have encountered and when these 
occurred. It will also include details of types of drugs taken, quantity of drugs taken and patterns of usage.
(b) state what steps will be taken to protect the confidentiality of the data?
Confidentiality will be ensured and the participant will be informed that they are under no obligation to give their 
name. They are informed that the signing of the consent form in no way defines them as either a drug user or non- 
drug user.
(c) state what will happen to the data once the experimental programme has been 
completed and the results written-up. If the data is to be destroyed how will this be 
done? How will you ensure that the data will be disposed of in such a way that there is 
no risk of its confidentiality being compromised?
All detailed questionnaires and result data will be shredded. Tape recordings will be destroyed. Any other personal 
information will be kept on a computer system with restricted access; by the experimenter only.
20. Will any part of the experimental programme take place in premises outside the YES/NO 
University or will any members of the experimental team be external to the 
University?
If yes, please give full details of the extent to which the participating institution will indemnify the 
experimenters against the consequences of any untoward event:
21. Are there any other matters or details which you consider relevant to the consideration of this 
proposal? If so, please elaborate below:
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22. DECLARATION
I undertake to abide by accepted ethical principles and appropriate code(s) of practice in carrying out 
this programme.
Personal data will be treated in the strictest confidence and not passed on to others without the written 
consent of the subject.
The nature of the investigation and any possible risks will be fully explained to intending subjects, and 
they will be informed that:
(a) they are in no way obliged to volunteer if there is any personal reason (which they are 
under no obligation to divulge) why they should not participate in the programme; and
(b) they may withdraw from the programme at any time, without disadvantage to 
themselves and without being obliged to give any reason.
NAME OF APPLICANT: Signed: ____________
(Person responsible)
Date:
NAME OF HEAD OF DEPARTMENT: Signed:
Date:
UNIVERSITY OF EAST LONDON
MEMORANDUM
From:
Dept:
Email:
To:
Dept:
Date:
Subject:
Ms MaryamJ Kermani 
Graduate School, Stratford 
maryam@uel.ac.uk
Ms Sue Meade
School of Psychology 
02 November 2001 Ref: SLG/ETH/00/62/0
University Ethics Committee: Approval of an experimental 
programme involving human subjects: Persistent 
Neuropsychological effects of recreational 'ecstasy1 
(MDMA), in recreational users. (K Soar) (Professor Andy 
Parrott)
cc:
I advise that Ivlembers of the University Ethics Committee have now 
approved the above application on: the terms previously advised to you, so I 
now write to givevformal confirmation of this approval.
Mr Woodhouse ; would-write again in approximately six months time to 
monitor progress of the .project.
Marvarri-4 Kertmani
/r
fulTapp-mem
APPENDIX U
UNIVERSITY OF EAST LONDON
APPLICATION FOR APPROVAL OF AN EXPERIMENTAL PROGRAMME INVOLVING HUMAN
SUBJECTS
Please read the Notes for Guidance before completing this form. If necessary, please continue your answers on a 
separate sheet of paper: indicate clearly which question the continuation sheet relates to and ensure that it is 
securely fastened to the application form.
1. Title of the programme:
Personality characteristics of problem versus non-problem ecstasy (MDMA) users.
2. Name of person responsible for the programme: Prof. Andy Parrott 
Status: Reader in Psychology
3. Faculty: Psychology Department/Unit: Psychology
4. Level of the programme (delete as appropriate):
(a) undergraduate basic
(b) undergraduate project
(c) postgraduate
(d) post-doctoral or staff
5. Number of:
(a) experimenters (approximately): One
(b) subjects (approximately): Two hundred
6. Nature of experimenters (delete as appropriate):
(a) staff (b) students (c) others 
If "others" please give full details:
Post graduate Researcher
7. Nature of subjects (general characteristics, e.g. University students, primary school children, etc):
Young people aged 18+ years.
8. Probable duration of the programme: 4 months
from (starting date): July 2002 to (finishing date): Oct 2002
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9. Aims of the programme including any hypothesis to be tested:
There are currently a number of empirical reports demonstrating higher psychological symptoms in ecstasy polydrug users 
compared to polydrug controls (non-ecstasy users) along with a large number of individual case studies highlighting the 
association of ecstasy use and behavioural and psychological disorders. Together this research strongly suggests that ecstasy 
use may contribute or cause psychological problems in the recreational user. However recent literature indicates that there are 
two distinct groups of ecstasy users, those that develop problems attributable to ecstasy use and those that don't despite similar 
patterns of ecstasy use and other drug consumption profiles. It is thought that premorbid personality dimensions may play an 
important role in ecstasy related problems, bearing this is mind, this study attempts to establish whether certain personality 
factors (in this case, locus of control) are important in determining whether ecstasy users have problems which they attribute to 
past ecstasy use. This will be achieved by assessing the problems reported by recreational drug users, in particular, which drug 
they attribute the problems to and whether those that report problems have a greater external locus of control compared to those 
individuals that don't reported any problems.
10. Description of the procedures to be used (give sufficient detail for the Committee to be clear 
about what is involved in the programme). Please append to the application form copies of any 
instructional leaflets, letters, questionnaires, forms or other documents which will be issued to 
the subjects:
Participants will be informed of the aims and ethical considerations of the research and requested to sign a consent form 
[see appendix 1], which is attached to the front of a series of questionnaires, which they are then asked to complete. 
These questionnaires include:
• A personal history questionnaire [appendix 2]
• A drug use questionnaire [appendix 3]
• The Locus of Control Scale (Rotter, 1966) [appendix 4]
• A modified version of the Brief symptom Inventory (BSI), which includes items on sexual dysfunction, positive 
mood, positive psychobiology and cognitive failures [appendix 5]
On completion of these questionnaires, participants are asked to either hand them back to the experimenter or where necessary 
post them to the experimenter in the stamped addressed envelope.
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11. Are there potential hazards to the subject(s) in these procedures' 
If yes: (a) what is the nature of the hazard(s)?
YES/M?
(b) what precautions will be taken?
12. Is medical care or after care necessary?
If yes, what provision has been made for this?
YES/M?
13. May these procedures cause discomfort or distress? 
If yes, give details including likely duration:
YES/M?
14. (a) Will there be administration of drugs (including alcohol)? 
If yes, give details:
YES/M?
(b) Where the procedures involve potential hazards and/or discomfort or distress, please state 
what previous experience you have had in conducting this type of research:
15. (a) How will the subjects' consent be obtained?
Prior to the investigation, the aims and objectives of the study will be explained in writing. An assigned consent form 
will then be required before completion of the questionnaires.
(b) What will the subjects be told as to the nature of the experiment?
The nature of the investigation will be fully described in writing, prior to the completion of the questionnaire
APPENDIX U
16. (a) Will the subjects be paid? YES/M?
(b) If yes, please give the amount:
(c) If yes, please give full details of the reason for the payment and how the amount given in 16 (a) 
above has been calculated (i.e. what expenses and time lost is it intended to cover):
17. Are the services of the University Health Service likely to be required during or YES/M? 
after the programme?
If yes, give details:
18. (a) Where will the experiments take place?
The programme is solely based on a series of questionnaires, which can be completed wherever the participant 
chooses.
(b) What equipment (if any) will be used?
(c) If equipment is being used is there any risk of accident or injury? If so, what precautions are being 
taken to ensure that should any untoward event happen adequate aid can be given
N/A
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19. Are personal data to be obtained from any of the subjects? YES/NO 
If yes, (a) give details:
Detailed personal history and portfolio of drug use will be obtained. This will include family history of psychiatric 
conditions; subjective reports of any drug induced problems participants feel they have encountered and when these 
occurred. It will also include details of types of drugs taken, quantity of drugs taken and patterns of usage. Subjects 
will also be asked to leave a contact e-mail or telephone if they wish to take part in any future studies of this nature.
(b) state what steps will be taken to protect the confidentiality of the data?
Participants will be allotted a drug sub-code, which will be placed on any paper work containing sensitive data. 
Confidentiality will be ensured to participants and they will be informed that they are under no obligation to give their 
name. They are informed that the signing of the consent form in no way defines them as either a drug user or non- 
drug user.
(c) state what will happen to the data once the experimental programme has been 
completed and the results written-up. If the data is to be destroyed how will this be 
done? How will you ensure that the data will be disposed of in such a way that there is 
no risk of its confidentiality being compromised?
All detailed questionnaires and result data will be shredded. Any other personal information will be kept on a 
computer system with restricted access; by the experimenter only.
20. Will any part of the experimental programme take place in premises outside the YES/M> 
University or will any members of the experimental team be external to the 
University?
If yes, please give full details of the extent to which the participating institution will indemnify the 
experimenters against the consequences of any untoward event:
21. Are there any other matters or details which you consider relevant to the consideration of this 
proposal? If so, please elaborate below:
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22. DECLARATION
I undertake to abide by accepted ethical principles and appropriate code(s) of practice in carrying out 
this programme.
Personal data will be treated in the strictest confidence and not passed on to others without the written 
consent of the subject.
The nature of the investigation and any possible risks will be fully explained to intending subjects, and 
they will be informed that:
(a) they are in no way obliged to volunteer if there is any personal reason (which they are 
under no obligation to divulge) why they should not participate in the programme; and
(b) they may withdraw from the programme at any time, without disadvantage to 
themselves and without being obliged to give any reason.
NAME OF APPLICANT: Signed: _________________ 
(Person responsible)
Date:
NAME OF HEAD OF DEPARTMENT: Signed:
Date:
UNIVERSITY OF EAST LONDON
MEMORANDUM
From:
Dept:
Email:
To:
Dept:
Date:
Subject:
Ms MaryamJ Kermani 
Graduate School, Stratford 
maryam@uel.ac.uk
Ms Sue Meade
School of Psychology 
02 November 2001 Ref: SLG/ETH/00/62/0
University Ethics Committee: Approval of an experimental 
programme involving human subjects: Persistent 
Neuropsychological effects of recreational 'ecstasy1 
(MDMA), in recreational users. (K Soar) (Professor Andy 
Parrott)
cc:
I advise that Members of the University Ethics Committee have now 
approved the above application on, ;the terms previously advised to you, so I 
now write to giveVformarconfirmation of this approval.
Mr Woodhouse, would .write again in approximately six months time to 
monitor progress of the project.
MaryarrN Kertmani
full'app.mem
APPENDIX V
Table 43; Chapter 3 - Modified BSI subscale ANCOVA statistics, with age as 
covariant
BSI Subscale
Somatisation
Interpersonal Sensitivity
Depression
Anxiety
Phobic Anxiety
Psychoticism
Main effect
F(2,52) = 6.7 14, p = 0.003
F(2,52) = 6.82, p = 0.002
F(2,52) = 5.66, p = 0.006
F(2,52) = 5.58, p = 0.006
F(2,52) = 7.781, p = 0.001
F(2,52) = 7.737, p = 0.001
Co-variance of age
F(l,53) = 0.178, = 0.254
F(l,53)=1.33,p=0.624
F(l,53) = 0.036, p = 0.850
F(l,53) = 0.942, p = 0.336
F(l,53) = 0.208, p = 0.650
F( 1, 54) = 0.222, p = 0.64
Table 44; Chapter 6 - Modified BSI subscale ANCOVA statistics, with age as 
covariant
BSI Subscale
Somatisation
Interpersonal Sensitivity
Depression
Anxiety
Phobic Anxiety
Psychoticism
MDMA side effects
Cognitive failures
Main effect
F(3,70) = 9.53, p = <0.001
F(3,70) = 5.77, p = 0.001
F(3,70) = 5.77, p =0.001
F(3,70) = 6.14,p=0.001
F(3,70) = 9.56, p < 0.001
F(l,73) = 8.515, p<0.001
F(3,70) = 4.09, p = 0.01
F(3,70) = 5.80, p = 0.001
Co-variance of age
F(l,73)= 1.54, p = 0.219
F(l,73) = 0.75, p = 0.39
F(l,73) = 0.15, p = 0.701
F(l,73)= 1.15, p = 0.286
F(l,73) = 0.007, p = 0.934
F(l,73) = 0.79, p = 0.779
F(l,73) = 0.012, p = 0.914
F(l,73)= 1.45, p = 0.705
APPENDIX X
UNIVERISTY OF EAST LONDON 
STRATFORD CAMPUS
The Principal Investigator
Kirstie Soar
Psychology Department 
(0208 2234556, k.soar@uel.ac.uk)
Project Title
Long term effects of recreational ecstasy/MDMA use.
Project Description
This study is to assessing the long-term effects of to recreational ecstasy use. 
You will be required to complete in a number of questionnaires covering your 
personal history and recreational drug use. You will be administered a self- 
rating questionnaire for positive and negative life experiences and clinical 
symptoms and some cognitive tests which measure memory ability, planning 
ability and also reaction times. Following completion of these tasks you will 
be asked to expand on answers given in the questionnaires and given the 
opportunity to ask any questions.
Confidentiality of the Data
Confidentiality will be ensured and you are under no obligation to give your 
name. Signing the consent form does not define you as a drug user or non- 
drug user.
Disclaimer
You are not obliged to take part in this study and are free to withdraw at any 
time during the tests. Should you choose to withdraw from the programme 
you may do so without disadvantage to yourself and without any obligation to 
give a reason
University Research Ethics Committee
If you have any queries regarding the conduct of the programme in which you are being asked to participate please 
contact the Secretary of the University Research Ethics Committee: Mr DG Woodhouse, Principal Administrative 
Officer for Research, Research Unit, University of East London, Longbridge Road, Dagenham, Essex, RM8 2AS 
(telephone 0208 590 7000 ext. 3006, fax 0208 590 7799, e-mail wdhouse@uel.ac.uk).
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I—————————————————————————————————————
UNIVERSITY OF EAST LONDON 
Consent to Participate in an Experimental Programme
I have read the information leaflet relating to the above programme of 
research in which I have volunteered to participate in. The nature and 
purposes of the research have been explained to me, and I have had an 
opportunity to discuss and ask questions about this. I understand I have been 
asked to fill in a complete personal and drug history questionnaire, a clinical 
symptom inventory and complete a number of cognitive tasks.
I understand that my involvement in this study, and particular data from this 
research, will remain strictly confidential. I am not asked to give my name or 
address rather my details will be distinguished from others by an allotted drug 
sub-code, in order to maintain complete anonymity. Only the researchers 
involved in the study will have access to the data. It has been explained to 
me what will happen to the data once the experimental programme has been 
completed.
I hereby fully and freely consent to participate in this study which has been 
fully explained to me.
Having given this consent I understand that I have the right to withdraw from 
the programme at any time without disadvantage to myself and without being 
obliged to give any reason.
Participant's drug subcode
Participant's signature. 
Date.............................
APPENDIX Y
UNIVERISTY OF EAST LONDON 
STRATFORD CAMPUS
Kirstie Soar
Psychology Department 
(0208 2234556, k.soar@uel.ac.uk)
Project Title
Persistent neuropsychological effects of 'ecstasy1 (MDMA), in recreational
users.
Project Description
This study is to assess the persistent long-term effects of recreational ecstasy 
use. It will involve the completion of a number of questionnaires covering your 
personal history and recreational drug use. Followed by the administration of 
a self-rating questionnaire for positive and negative life experiences and 
clinical symptoms and some cognitive tests, which measure memory ability 
and planning ability. There will also be an opportunity to ask any questions 
regarding the study.
Confidentiality of the Data
Confidentiality will be ensured and you are under no obligation to give your 
name. Signing the consent form does not define you as a drug user or non- 
drug user and will be detached from any other collated data.
Disclaimer
You are not obliged to take part in this study and are free to withdraw at any 
time during the tests.
University Research Ethics Committee
If you have any queries regarding the conduct of the programme in which you are being asked to participate please 
contact the Secretary of the University Research Ethics Committee: Mr DG Woodhouse, (telephone 0208 590 7000 
ext. 3006, fax 0208 590 7799, e-mail wdhouse@uel.ac.uk).
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UNIVERSITY OF EAST LONDON 
Consent to Participate in an Experimental Programme
I have read the information leaflet relating to the above programme of 
research in which I have volunteered to participate in. The nature and 
purposes of the research have been explained to me, and I have had an 
opportunity to discuss and ask questions about this.
I understand that my involvement in this study, and particular data from this 
research, will remain strictly confidential. I am not asked to give my name or 
address, in order to maintain complete anonymity.
I hereby fully and freely consent to participate in this study which has been 
fully explained to me.
Having given this consent I understand that I have the right to withdraw from 
the programme at any time without disadvantage to myself and without being 
obliged to give any reason.
Participant's initials. 
Date........................
APPENDIX Z
UNIVERISTY OF EAST LONDON
Kirstie Soar
Psychology Department 
(0208 2234556, k.soar@uel.ac.uk)
Project Title
Personality characteristics of problem versus non-problem
Ecstasy (MDMA) users.
Project Description
This study is to assess whether there are certain personality factors, which 
are important in determining whether recreational ecstasy users develop long- 
term psychological problems. It will involve the completion of a number of 
questionnaires covering your personal history and recreational drug use; 
problems attributable to certain drug use; clinical symptoms and a personality 
questionnaire which determines whether you attribute control to yourselves or 
to external factors.
Confidentiality of the Data
Confidentiality will be ensured and you are under no obligation to give your 
name. Signing the consent form does not define you as a drug user or non- 
drug user and will be detached from any other collated data.
Disclaimer
You are not obliged to take part in this study and are free to withdraw at any 
time during the tests.
University Research Ethics Committee
If you have any queries regarding the conduct of the programme in which you are being asked to participate please contact the Secretary of the University Research Ethics Committee: Telephone 0208 590 7000 ext. 3006, fax 0208 
590 7799.
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Consent to Participate
The study has been fully explained to me 
I have volunteered to participate
I understand data from this research, will remain strictly 
confidential.
I fully and freely consent to participate in this study
I understand that I have the right to withdraw at any time
Participant's initials.
Date.
